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Abstract
This thesis explores the relationship between the use of antiretroviral therapy (ARVs) 
and drug resistance emergence in HIV-1 infected individuals. It also describes the 
combined impact of treatment use and resistance mutations on virological and 
immunological response in individuals who are under follow-up in one of four trials: 
MaxCminl, MaxCmin2, COLATE or SMART; and three observational studies: 
EuroSIDA, the UK CHIC study and the UK drug resistance database.
The emergence of resistance to an ARV that an individual is receiving may influence 
viral replication rates, which could increase the risk of CD4+T cell count deterioration, 
clinical progression and death, unless changes are made to the treatment regimen. 
Individuals may exhaust all treatment options if large amounts of resistance mutations 
are detected in their viral sub-populations. In the current era, new ARVs are still 
arriving on the market, but resistance to these ARVs is only partially understood. 
Understanding what mutations emerge in individuals who are failing treatment and the 
impact of specific mutations and combinations of mutations on the likelihood of 
responding to future regimens is still essential for being able to administer long-term 
therapy successfully.
Research for this thesis started just after the introduction of ritonavir boosted protease 
inhibitors (Pl/rs). Drug resistance emergence among individuals who experienced 
virological failure on a Pl/r containing regimen is described in detail, and the 
relationship between resistance at baseline and virological response is also quantified. 
Other aspects of drug resistance are investigated, including: the potential benefit of 
harbouring the M184I/V mutation, the impact of resistance on immunological response 
and the relationship between resistance and viral re-suppression rates amongst 
patients who interrupt an NNRTI containing regimen.
This thesis outlines the benefits of resistance testing and highlights some of the key 
issues with interpreting resistance data. Resistance tests are generally performed on a 
selective group of individuals so caution needs to be used when extending the results 
to all HIV-1 infected individuals. Further, consensus sequences are useful for 
indicating resistance that is present in the predominant virus; however, more minor, 
archived, species are not usually identified through this method and these may also be 
an important determinant of therapy response.
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CHAPTER 1: GENERAL INTRODUCTION
1.1. The natural history of HIV-1
The first recognised cases of Acquired Immune Deficiency Syndrome (AIDS) were 
reported in five, previously-healthy, homosexual men in Los Angeles on 5th June 19811. 
All of these men had pneumocystis carinii pneumonia (PCP), a rare lung infection that 
was primarily seen in patients who were receiving immunosuppressive therapy or 
among chronically malnourished patients before the advent of AIDS. Human 
Immunodeficiency Virus (HIV), the virus that causes AIDS, was discovered soon after2'
5
AIDS has killed more than 25 million people since it was first diagnosed and it is 
estimated that, as of November 2007, approximately 33.2 (range: 30.6, 36.1) million 
individuals worldwide were living with HIV, of which 2.5 million (7.5%) were infected in 
20076. Currently there are 15.4 million (46%) women and 2.5 million (7.5%) children 
under the age of 15 years who are living with the virus6. The number of people infected 
with HIV has doubled over the last ten years and since prevalence rates are increasing, 
effective measures to deal with this growing population of HIV infected individuals need 
to be found7.
HIV is a lentivirus which, in turn, is part of a larger group of viruses known as 
retroviruses. HIV takes a long time to produce adverse effects in the body (NB: lenti- 
translates to slow in Latin). HIV can be classed into two strains; HIV-1 and HIV-2. 
Both strains of the virus are thought to have originated from retroviruses found in non­
human primates8. HIV-2 is related to SIVsm, a strain of Simian Immunodeficiency 
Virus found in sooty mangabeys. The more virulent strain, HIV-1, descends from 
SIVcpz9, a retrovirus originally found in the chimpanzee subspecies of pan troglodytes 
troglodytes in Southern Cameroon. In this thesis I will focus on HIV-1 because it is 
more infectious and pathogenic than HIV-2, it progresses at a faster rate and because 
there are many more patients infected with HIV-1, it is a much larger clinical problem.
1.1.1. The immune system
When HIV initially enters the body it starts to infect and cause depletion of CD4+ T 
cells; in particular those located in the gastrointestinal wall. CD4+ T cells are T helper 
cells which communicate the presence of invading pathogens to macrophages and 
dendritic cells, both of which are needed for the body to destroy any invading material 
(in this case HIV), or direct other immune cells to do so. If these cells are not activated, 
the body will not be able to fight infection and HIV will continue to replicate unhindered 
and thus able to deplete the immune system further.
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Although the mechanisms of destruction are not fully understood, it is thought that HIV 
leads to a depletion of CD4+ T cells through the following three methods:
• The presence of HIV leads to increased rates of apoptosis (i.e. cell suicide)
• The CD8 killer cells will recognise and kill the HIV-infected CD4+ T cells
• HIV will also directly kill these cells
Individuals usually develop minor symptoms (e.g. fevers, sweats, malaise, lethargy, 
nausea, myalgia, arthralgia, headaches, sore throat, diarrhoea, generalized 
lymphadenopathy or thrombocytopenia)10 following infection with HIV. Some severe 
symptoms such as gastrointestinal haemorrhage, encephalopathy, pneumonitis, or 
rhabdomyolysis associated with acute renal failure may also occur during this so-called 
acute or primary infection phase, which occurs in the first few weeks following infection. 
In the majority of patients, the more serious, persistent symptoms only appear a 
median of ten years after HIV first enters the body, but it can take more than twenty 
years for some patients to develop major symptoms11'13. This period of asymptomatic 
infection varies according to the individual, from less than two years to more than 25 
years. The asymptomatic period is explained in more detail in section 1.1.3.2.
1.1.2. HIV replication
Once HIV has entered the body, its surface glycoprotein, gp120, binds to the CD4+ 
receptors of host cells where this protein is expressed. In addition, gp120 engages a 
co-receptor on the surface of target cells -  the CCR5 co-receptor on T cells and 
macrophages and the CXCR4 co-receptor on the surface of T cells. The binding 
triggers a conformational change of gp120 that allows fusion of the viral envelope with 
the cell membrane, a process mediated by the viral glycoprotein gp41.
HIV is composed of two copies of positive single-stranded RNA that code for the virus’s 
nine genes13'15. When fusion has occurred, the viral RNA (ribonucleic acid) is released 
into the cell cytoplasm where it undergoes reverse transcription into double-stranded 
DNA (deoxyribonucleic acid). This process is catalyzed by an HIV enzyme called 
reverse transcriptase16'18. The resulting DNA enters the nucleus of the host cell where 
it integrates into the cell genetic material using a viral integrase emzyme17,1920. Once 
viral DNA has integrated into the cell it can remain dormant (i.e. the host cell may be in 
a resting state and not producing any new virions or exhibiting any signs of infection - it 
is latently infected). Since HIV can remain in latently infected cells it may go 
undetected by the immune system for many years21'23.
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The host cell will eventually be activated, resulting in the transcription of viral DNA to 
messenger RNA (mRNA) which is then translated into viral proteins and genomic RNA. 
The viral proteins include polypeptides and the enzyme protease, a protein required to 
cleave other HIV proteins into functional forms. These viral proteins assemble with the 
genomic RNA to form new HIV virions at the cell surface, which are then released into 
the body to infect another cells17:24.
1.1.3. The pathogenesis of infection with HIV
The number of CD4+ T cells and the amount of circulating HIV RNA in plasma (i.e. the 
“viral load”) are the most powerful markers that predict the risk of HIV progression25"28. 
Normal CD4+ T cell counts vary between 500 and 1200 cells/pL in uninfected 
individuals29. In HIV-infected individuals, CD4+ T cell counts fall by approximately 50 to 
80 cells/pL per year30"32. When CD4+ T cell counts fall to below 200 cells/pL the risk of 
developing an AIDS related illness is greatly increased33. AIDS is defined as the 
occurrence of one of a number of different opportunistic infections (Table 1.1.3.1 J34"36.
Table 1.1.3.1 AIDS defining illnesses37
Candidiasis of bronchi, trachea, or lungs 
Candidiasis oesophageal 
Cervical cancer (invasive)
Coccidioidomycosis, disseminated or extrapulmonary 
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal for longer than 1 month 
Cytomegalovirus disease (other than liver, spleen or lymph nodes)
Encephalopathy (HIV-related)
Herpes simplex: chronic ulcer(s) (for more than 1 month); or bronchitis,
pneumonitis or oesophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal (for more than 1 month)
Kaposi's sarcoma
Lymphoma Burkitt's, immunoblastic or primary brain 
Mycobacterium avium complex
Mycobacterium, other species, disseminated or extrapulmonary 
Pneumocystis jiroveci (formerly Pneumocystis carinii)
Pneumonia (recurrent)
Progressive multifocal leukoencephalopathy 
Salmonella septicemia (recurrent)
Toxoplasmosis of the brain 
Tuberculosis
Wasting syndrome due to HIV___________________________________________
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In the 1990s new technologies that were able to measure the amount of plasma HIV 
RNA in HIV infected individuals were introduced. These include the polymerase chain 
reaction (PCR) assay29, the branched DNA (bDNA) assay38 and the nucleic acid 
sequence-based amplification (NASBA) assay39. Initially, the lower limit of 
quantification for these assays ranged between 200 and 500 HIV RNA copies/mL, with 
an upper limit of quantification of between 100,000 and 1,000,000 copies/mL38140. More 
sensitive assays are now available, with a quantification threshold of between 20 and 
50 copies/mL41"44. Below this level, HIV RNA still cannot be reliably quantified.
When HIV RNA testing entered clinical practice, it became possible to describe the 
natural course of HIV by examining HIV RNA levels and CD4+ T cell counts from the 
time of seroconversion to the time of AIDS diagnosis or death45"48. HIV mainly uses 
CD4+ T cells to replicate and, as a result, these cells die or are removed. In contrast, 
the amount of plasma HIV RNA gradually increases with time after seroconversion.
For simplicity, it is sometimes suggested that three different patterns of disease 
progression exist: rapid, intermediate and late progression, as depicted in the cartoon 
in Figure 1.1.3.1. This is broadly the case, but disease progression should really be 
considered to be a continuous spectrum rather than three distinct categories.
Figure 1.1.3.1: Generalized Time Course of HIV Infection and Disease
adapted from the Centers for Disease Control and Prevention, i) Rapid progressors, ii)
Intermediate progressors and iii) Late progressors49
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1.1.3.1. Primary HIV infection
The first stage of HIV infection is known as primary or acute HIV infection (PHI). In the 
first few weeks following infection the virus starts to multiply by infecting and killing the 
T lymphocyte cells, resulting in sharp rises in plasma HIV RNA13 50. This results in a 
decline in the number of CD4+ T cells, which are crucial for maintaining an immune 
response (section 1.1.1)5152. In the gut lymphoid tissue, where most CD4+ T cells live, 
the numbers of CD4+ T cells decrease by > 50% in the initial days following infection53"
55
In PHI, HIV RNA levels can increase to as much as 107 copies/mL before declining to a 
‘set point’2* 49156"58. Since HIV RNA levels are high in this period, and the adaptive 
immune response has still to fully develop, individuals are very infectious, yet not all
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patients display clinical symptoms23159. Although HIV RNA appears to stabilise at a 
lower set-point, replication still continues. The HIV RNA plateau in Figure 1.1.3.1 is not 
related to the absence of virus replication, instead, it demonstrates that the number of 
HIV virions being produced (i.e. the number of newly infected cells) in a given period of 
time is the same as the number of HIV virions being cleared by the immune system. 
This turnover rate will not remain constant indefinitely and HIV RNA levels will start to 
increase again as time progresses. The precise reasons for this are still not known. 
However, it could relate to dimunition of the immune response or to evolution of a virus 
that is better suited to replicate in a wide range of body compartments47 48160.
During PHI there is a decline in CD4+ T cell counts and our bodies start to produce 
antibodies in order to fight the virus. The time that HIV-antibodies are initially produced 
is referred to as seroconversion2*61. The production of antibodies corresponds to a 
decline in the HIV RNA levels, possibly due to an immune response (i.e. there are 
transient increases in CD4+ T cell counts which results in cellular as well as antibody 
responses) or exhaustion of other susceptible cells for HIV to infect.
1.1.3.2. Asymptomatic HIV infection
HIV infected individuals may remain asymptomatic for many years, however, most (and 
perhaps all) patients who are left untreated will eventually experience a progressive 
breakdown of the immune system as a result of their infection1257. When CD4+ T cell 
counts fall too low the body becomes defenceless and vulnerable to infection, so many 
individuals progress to AIDS or death. Although CD4+ T cell counts decline gradually 
over the course of the infection, contrary to expectations, the rate of decline may be 
lower at more advanced stages of the disease rather than more rapid62. The median 
time to development of AIDS after seroconversion is between 10 and 11 years11'13 63. 
The period following seroconversion is referred to as the asymptomatic period because 
patients do not present with significant, HIV-related, clinical symptoms.
1.1.3.3. Symptomatic HIV infection
Currently there are a number of different antiretroviral drugs available to treat HIV 
infection (section 1.2). If HIV infected individuals remain untreated patients may start 
to develop symptoms. Early symptoms include fever, headache, diarrhoea, skin 
rashes, fatigue, weight loss, sweats and oral candidiasis64-68. As the immune system is 
destroyed further, more severe opportunistic infections develop. Once one of the 
conditions in Table 1.1.3.1 has developed the individual is classified as having 
progressed to AIDS. The definition of AIDS was first put forward in 1985; it was next 
revised in 1987 and again in 1993. The 1993 version is the version we currently refer
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to, although there has been a push for this definition to be updated as more information 
has become available on some malignancies, such as anal cancers, that could be 
considered as an AIDS defining event37.
1.1.4. Routes of HIV transmission
HIV can be transmitted through blood, semen, cervico-vaginal secretions and breast 
milk. The most common mode of transmission worldwide is sexual intercourse, even 
though the probability of infection per contact can be as low as one in a thousand69. 
The most efficient mode of transmission is through the transfer of blood. Prior to 1985, 
patients requiring organ or tissue replacement and haemophiliacs requiring Factor VIII, 
a blood coagulant, became infected through receiving blood from infected donors70:71. 
Now regular screening is used to remove HIV infected blood from donations.
HIV can also be passed from mother to child (vertical transmission) either in utero, at 
birth or through breastfeeding. If the mother does not breastfeed, takes anti-HIV 
therapy during pregnancy and opts for a caesarean section delivery, the risk of 
transmission can be reduced to less than 1%^.
1.2. Antiretroviral therapy
After combination antiretroviral therapy (cART) was introduced between 1995 and 
1996, the natural course of HIV changed dramatically in developed countries73'77. For 
many years, there were only three main classes of drugs that were approved by both 
the FDA and the European Medicines Evaluation Agency to treat HIV; where each drug 
class was classified by its mechanism of preventing viral replication. Anti-HIV drugs 
are grouped into nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs or 
NtRTIs), protease inhibitors (Pis) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs)33.
Since 2006, other drugs such as entry inhibitors (including fusion inhibitors, small 
molecule CCR5 inhibitors and CXCR4 inhibitors), integrase inhibitors and maturation 
inhibitors have arrived/or are arriving on the market, and are now more commonly used 
in clinical practice33178. The introduction of new drugs from existing classes, combined 
with the arrival of new drugs from novel treatment classes, means that it will be more 
possible to personalise treatment for each individual. The time of the arrival of these 
new antiretrovirals (ARVs), and the estimated timeline for the availability of all new 
ARVs, is listed in Figure 1.2.1 for each drug class. Since these drugs have recently 
arrived on the market or are yet to be approved, they have not been used widely by the 
patients who are included in this thesis and so are not documented in detail.
23
Figure 1.2.1: Estimated timeline for the availability of new ARVs in all classes
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1.2.1. Nucleoside (and nucleotide) reverse transcriptase inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of drug used as 
anti-HIV therapy. Zidovudine (AZT) was authorised for treating HIV-infected individuals 
in the US in 198779 and since then, six NRTIs have been approved: didanosine (ddl), 
zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (ABC) and emtricitabine 
(FTC), although ddC is no longer commonly used. One nucleotide reverse 
transcriptase inhibitor (NtRTI), tenofovir (TDF) was also approved for treating HIV 
infected individuals80* 1. Table 1.2.1.1 lists all of the NRTIs and NtRTIs licensed for use 
in the US and Europe. NRTIs and NtRTIs tend to be used in a combination with 
another drug from the same class in addition to a third drug from a different class.
NRTIs work by inhibiting the enzyme reverse transcriptase during reverse transcription. 
Following phosphorylation to three-phosphate derivativies, the NRTI binds to the active 
site on the HIV reverse transcriptase enzyme and is incorporated into the HIV proviral 
DNA chain, resulting in chain-termination. The remaining viral RNA is subsequently 
destroyed by other cellular enzymes82183. NtRTIs work in the same way, but, because 
they already carry a phosphate group, they require only two phosphorolations to be 
activated intracellulalry rather than the three that are required by NRTIs 84:85.
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Table 1.2.1.1: Licensed nucleoside and nucleotide reverse transcriptase inhibitors
Brand name Generic name Manufacturer name FDA approval 
date81
Retrovir® Zidovudine GlaxoSmithKline 19 Mar 87
Videx® Didanosine (buffered version) Bristol-Myers Squibb 9 Oct 91
Hivid® Zalcitabine Hoffmann-La Roche 19 Jun 92
Zerit® Stavudine Bristol-Myers Squibb 24 Jun 94
Epivir® Lamivudine GlaxoSmithKline 17 Nov 95
Combivir™ Zidovudine/Lamivudine GlaxoSmithKline 27 Sep 97
Ziagen™ Abacavir GlaxoSmithKline 17 Dec 98
Videx EC® Didanosine (delayed release 
capsules)
Bristol-Myers Squibb 31 Oct 00
Trizivir® Zidovudine/lamivudine/abacavir GlaxoSmithKline 14 Nov 00
Emtriva™ Emtricitabine Gilead Sciences 2 Jul 03
Epzicom™ Abacavir/Lamivudine GlaxoSmithKline 2 Aug 04
Truvada™ T enofovir/Lamivudine Gilead Sciences 2 Aug 04
Viread® Tenofovir Gilead Sciences 26 Oct 01
1.2.2. Protease inhibitors
The introduction of protease inhibitors (Pis) coincided with the use of regimens 
containing three or more ARVs and has consequently changed the course of HIV66. 
Pis act on the virus during the last stage of its reproduction cycle. Pis resemble pieces 
of the protein chain that the viral enzyme protease cleaves. They prevent the enzyme 
from processing the HIV proteins, gag and gag-pol, into the smaller segments required 
by HIV in order to reproduce. The resulting virions are immature and cannot infect 
other cells or replicate87.
Currently there are nine approved Pis: saquinavir (hard and soft gel formulations) 
(SQV), ritonavir (RTV), indinavir (IDV), nelfinavir (NFV), (fos)amprenavir (APV), 
lopinavir (LPV), atazanavir (ATV), tipranavir (TPV) and darunavir (DRV)80181. Table 
1.2.2.1 displays all of the currently licensed Pis and the dates of their approval.
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Table 1.2.2.1: Licensed protease inhibitors
Brand name Generic name Manufacturer name FDA approval 
date81
Invirase® Saquinavir Hoffmann-La Roche 6 Dec 95
Norvir® Ritonavir Abbott Laboratories 1 Mar 96
Crixivan® Indinavir Merck 13 Mar 96
Viracept® Nelfinavir Agouron
Pharmaceuticals
14 Mar 97
Fortovase® Saquinavir (soft gel capsules) Hoffmann-La Roche 7 Nov 97
Agenerase® Amprenavir GlaxoSmithKline 15 Apr 99
Kaletra® Lopinavir/ritonavir Abbott Laboratories 15 Sep 00
Reyataz® Atazanavir Bristol-Myers Squibb 20 Jun 03
Lexiva® Fosamprenavir GlaxoSmithKline 20 Oct 03
Aptivus® Tipranavir Boehringer Ingelheim 22 Jun 05
Prezista® Darunavir Tibotec 23 Jun 06
Since around 2000, small doses of ritonavir have been used in combination with other 
Pis because ritonavir inhibits the CYP3A4 liver enzyme that metabolises away these 
other Pis88. As a result it provides a pharmacologic boosting effect by raising the 
trough levels of the other Pis and by extending their half-lives88. The improved potency 
of the regimen is associated with a reduced risk of resistance emergence (i.e. the 
emergence of mutations that correspond to a decrease in the antiretroviral activity of an 
ARV -  discussed in detail in section 1.6) and generally no substantial increase in 
toxicity89'91, although indinavir boosted with ritonavir has been associated with more 
adverse events than indinavir alone92. The inhibition of the CYP3A4 enzyme can also 
affect (and be affected by) the drug levels of concurrent medication through 
pharmacologic interaction. Therefore, levels of concurrent medication need to be 
adjusted accordingly in order to avoid unnecessary toxicities. This can also affect the 
efficacy and toxicity of the Pis.
Ritonavir-boosted regimens tend to be more potent and simpler, and also avoid the 
food restrictions that are associated with single Pis, so they are now commonly used in 
clinical practice. The first study investigating the use of ritonavir boosting was a Danish 
PI study comparing HIV RNA reductions in patients who received two NRTIs and either
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IDV, RTV or RTV and SQV. They found superior HIV RNA reductions in the RTV/SQV 
arm compared to either the IDV or RTV arm. Although, in this study, RTV was used at 
a 400mg dose instead of the current 100mg dose, so it is likely that it also had some 
activity against HIV and was not just used to boost the level of SQV93.
1.2.3. Non-nucleoside reverse transcriptase inhibitors
Although non-nucleoside reverse transcriptase inhibitors (NNRTIs) work at the same 
stage of HIV replication as NRTIs, they bind to a different site of the reverse 
transcriptase enzyme, causing its allosteric inhibition to prevent conversion of RNA to 
proviral DNA85. The NNRTIs currently approved by the FDA are nevirapine (NVP), 
delavirdine (DLV) and efavirenz (EFV)8081. Table 1.2.3.1 lists all licensed NNRTIs and 
their approval dates. Another NNRTI called loviride was used in clinical practice before 
results from a trial showed its inefficacy in combination with other ARVs94. Similarly, 
trials have shown that delavirdine has no superior efficacy compared to other NNRTIs, 
so the European pharmaceutical licensing authority’s scientific advisory board rejected 
licensing applications for this drug in December 1999. Second generation NNRTIs, 
etravirine (TMC125) and rilpivirine (TMC278), are currently in advanced clinical 
development.
Table 1.2.3.1: Licensed non-nucleoside reverse transcriptase inhibitors
Brand name Generic name Manufacturer name FDA approval date81
Viramune® Nevirapine Boehringer Ingelheim 21 Jun 96
Rescriptor® Delavirdine Pfizer 4 Apr 97
Sustiva™ Efavirenz Bristol Myers-Squibb 17 Sep 98
1.2.4. Entry inhibitors and fusion inhibitors
Entry inhibitors and fusion inhibitors work differently to other classes of drugs because 
they work outside the cell to prevent HIV from entering the host cell in the first place. 
The first fusion inhibitor, enfuvirtide (T-20), is injected. Since it is more complicated to 
use and its complex structure makes it more expensive than other ARVs, it is only used 
in patients with very limited treatment options available. Maraviroc is another entry 
inhibitor that has been approved for treatment in the US and Europe in 2007 (Table 
1.2.4.1)8081.
As we saw in section 1.1.2 the HIV envelope fuses to the membrane of CD4+ T cells 
and allows its genetic material to be absorbed into the cell. HIV uses the gp120 
glycoprotein on its outer surface to bind to the target cell, allowing the gp41 viral protein
27
to embed itself in the cell plasma membrane and mediate fusion. Since entry inhibitors 
competitively bind to the gp41 viral protein, they prevent the creation of an entry pore 
and stop the virus from entering the cell in the first place95196.
Table 1.2.4.1: Licensed entry inhibitors and fusion inhibitors
Brand name Generic
name
Manufacturer name FDA approval 
date81
Fuzeon® Enfuvirtide Hoffmann-La Roche and Trimeris 13 Mar 03
Selzentry or Celsentri Maraviroc Pfizer 24 Apr 07
1.3. T reatment strategies
1.3.1. Monotherapy (1987-1992)
For the first four years of treating HIV the only available drug was an NRTI called 
azidothymidine (AZT), now referred to as zidovudine7* 97. The FDA approved AZT in 
1987 after the results of a clinical trial comparing the 4 months survival rate of AZT with 
placebo were published98. This trial showed a decrease in mortality and a reduction in 
the incidence of opportunistic infections in patients receiving AZT monotherapy. 
Further studies supported a benefit of the drug; therefore, it was approved for use in 
symptomatic patients as early as March IQS?7999100.
It soon became clear that the benefits of this drug were only short-lasting. The largest 
study of AZT monotherapy in asymptomatic individuals, the Concorde study, published 
data showing that AZT monotherapy did not increase the chances of AIDS-free survival 
over the long-term101. Overall, NRTI monotherapy has been shown to reduce the viral 
load by around 0.5 log10 copies/mL for six months and by 0.3 log10 copies/mL for a 
further six months, but after that any further reduction is negligible, due to the 
emergence of resistance (see section 1.6)102.
1.3.2. Dual therapy (1992-1996)
Although NRTI dual therapy was used from 1992, it was not until 1995 that clear 
evidence became available indicating that patients who received dual therapy had a 
slower progression to AIDS and death compared to patients who received 
monotherapy103 104. In contrast, another study examining the benefit of AZT/ddl against 
AZT monotherapy found the dual combinations to only be effective in patients without 
previous exposure to AZT, reflecting the effects of drug resistance and cross­
resistance (section 1.6.2.1)105.
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1.3.3. Combination antiretroviral therapy (cART) (1996-current)
Highly active antiretroviral therapy (HAART) or combination antiretroviral therapy 
(cART) was commonly used after 1996, although a few patients were on triple 
combination regimens prior to this date861106'108. Currently, state-of-the-art cART is 
composed of a combination of at least three ARVs from at least two classes. The 
reason why two drugs are better than one and three are better than two is that drug 
resistant mutants pre-exist within the viral quasispecies (i.e. strains of HIV that contain 
drug resistance mutations -  discussed in more detail in section 1.6). Mutants that are 
resistant to a single drug are fairly common, those resistant to two drugs less common 
and those simultaneously resistant to three drugs are very rare. Therefore, by using 
three drugs to target two different phases of replication, a virus that is resistant to one 
of the three drugs will still be suppressed by the other two drugs. Patients starting 
cART usually initiate a combination of two NRTIs and one NNRTI or one p i109-111.
The era of cART started with the approval of saquinavir, the first PI to enter the market. 
Compared with a dual NRTI containing regimen, a combination of two NRTIs plus 
saquinavir was found to reduce the risk of AIDS and death in both ARV-naive and 
ARV-experienced patients106112. The same patterns were also seen in patients who 
received combinations of NRTIs with all of the new Pis that entered the market113-121. It 
then became common practice to treat patients using at least three ARVs including a 
PI. These regimens are highly potent, but many patients experienced tolerability 
problems, especially to the Pl-component of the regimen115:116 122:123.
An alternative triple class regimen for patients who struggle to deal with the toxicities of 
Pis includes the use of an NNRTI instead of a pi124125. NNRTIs are also useful for 
patients who experience virological problems on their PI and have PI resistance 
mutations, as well mutations to the NRTI components of the regimen, in their virus 
population. Due to the presence of resistance, these patients may have limited 
treatment options available within the classes of ARVs they have already been 
exposed to, so an ARV from a different class may be required instead (section 
1.6) 126’127.
NNRTIs were introduced into cART regimens after it was shown that, when used in 
combination with NRTIs, they were generally more tolerable than Pis and were equally 
as effective at suppressing viral replication. However, this trend was primarily seen in 
ARV-naive patients. When NNRTIs were used in patients who shwoed large amounts 
of resistance mutations to their nucleoside backbone, they continued to experience 
rapid rises in their HIV RNA levels instead of the expected declines. This reflects the
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rapid selection of NNRTI resistant mutants when the NNRTI is not well supported by 
active NRTIs. It was therefore decided to use NNRTIs as first-line therapy instead of 
Pis in order to avoid compromising the use of NNRTIs. As we will see in section 1.6, 
NNRTIs are more affected by resistance emergence than Pis, so if they are used in 
sub-optimal regimens it is likely that resistance mutations will rapidly emerge to the 
NNRTI and any future use of them will be inhibited1281129.
As time progressed, more ARVs were developed in each drug-class, new formulations 
of existing ARVs came out and more novel treatment options were investigated, 
including triple NRTI-containing regimens130*134. This was done to reduce the pill 
burden and increase adherence so that the drug levels remained high and viral 
replication was suppressed135*137. In addition, NRTIs have less of a drug interaction 
with anti-tuberculosis drugs compared to the other classes of ARVs, and since 
tuberculosis is the leading cause of death among HIV infected individuals, maximising 
HIV treatment and TB treatment simultaneously is an important consideration138.
Treatment guidelines exist on when to start therapy, what drugs to start with, when to 
change and what to switch to in the case of therapy failure (see section 1.4.2)33. 
Current guidelines in the UK recommend that patients should start an NNRTI- 
containing regimen with a dual NRTI backbone when they become symptomatic or 
reach a CD4+ T cell count between 200 to 350 cells/pL33109.
1.4. Risk factors for HIV progression
As illustrated in Figure 1.1.3.1 the natural course of HIV varies according to the 
individual. The rate of HIV progression is dependent on certain factors including the 
age at onset of HIV, and gender139:140. In addition to these demographic variables, host 
genetic factors, the level of immune function, co-infections, viral genetics and the 
presence of symptomatic PHI have also been shown to affect the rate of clinical
141-145progression .
Host genetic variability is associated with susceptibility to HIV infection and progression 
to AIDS146 147. HIV enters the cell through an interaction with both the CD4+ T cell and 
a chemokine receptor: CCR5 and CXCR4 are the major chemokine receptors used by 
HIV147. CCR5 is present on a broad range of cells that can also be infected by HIV, but 
CXCR4 is only found on CD4+ T cells. CCR5-strains of HIV target macrophages in 
addition to CD4+ T cells because the envelope proteins of macrophages are configured 
in such a way that they work best using CCR5 as their co-receptors. These strains of 
HIV are called macrophage-tropic and are not able to induce syncytia, hence are also
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termed non-syncytium inducing (NSI) strains. The levels of CCR5 expression are up- 
regulated in chronically HIV infected individuals therefore monitoring levels of CCR5 
could potentially be used in the future as an indicator of disease progression. CXCR4 
containing strains on the other hand are syncytium inducing (SI) and can only target 
CD4+ T cells. Patients infected with CXCR4 strains experience faster declines in CD4+ 
T cells and progress to AIDS and death more rapidly (3- to 5- fold increase) than 
patients infected with CCR5 strains147.
A small fraction of the population carry a mutation on their CCR5 gene called the delta 
32 mutation, which indicates that there is a deletion of a 32 base pair segment. In 
patients who are CCR5A32 homozygous (i.e. they harbour two copies of this deletion 
(+/A32)) there is very strong protection against HIV entry because variants of CCR5 
containing the delta 32 mutation are non-functional146,148,149. Patients who are 
CCR5A32 heterozygous (i.e. they harbour one copy of this deletion (+/A32) and hence 
have lower levels of expression of CCR5) also receive some protection against 
infection with HIV compared to patients who have a CCR5 gene that does not contain 
the CCR5A32 mutation. Patients who are CCR5A32 heterozygous can still become 
infected, but they will show slower disease progression.
In most individuals, CCR5 strains are predominant early on in the infection. As the 
disease progresses, the more aggressive CXCR4 strains become prevalent150. 
However, 50% of individuals who die of AIDS still have CCR5 strains present. It is still 
unclear why there is a switch from CCR5 strains to CXCR4 strains in the dominant 
plasma population. It could potentially be because CXCR4 containing strains deplete 
CD4+ T cell counts and so results in more rapid disease progression, or alternatively, 
CXCR4 strains may only emerge once the immune deterioration has become 
significant. Anti-HIV drugs are also less effective at treating CXCR4 containing strains 
which may explain why they become more prevalent in later stages of the disease147.
1.4.1. Modifiable markers of HIV progression
Although some factors associated with HIV progression are not modifiable, we can 
alter others by using treatment. The most recent CD4+ T cell count (i.e. the absolute 
number of circulating CD4+ T cells), the CD4+ T cell nadir and the slope of CD4+ T cell 
decline have been shown to be powerful predictors of the risk of AIDS and death151'154. 
Since there is large measurement variation of CD4+ T cells, a single determination may 
not accurately reflect the long term risks of the disease and so multiple measurements 
are required before making any changes to the treatment regimen155.
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HIV RNA levels have also been shown to be powerful predictors of disease 
progression26128. Currently, the routine measurement of both HIV RNA and CD4+ T 
cells is employed in the clinical care of HIV-infected individuals. Both markers are used 
in combination with each other to determine when individuals should initiate 
antiretroviral treatment and are also used to assess the short-term and long-term risks 
of disease progression in treated and untreated individuals156.
1.4.2. Virological failure
It is possible to keep the risk of progression to AIDS and death at a minimum by 
changing a patient’s treatment regimen if they do not experience a virological response 
on therapy or if they experience a decline in their CD4+ T cell counts. Historically, the 
primary endpoints of studies were based on clinical events such as AIDS and death, 
but since the introduction of cART, the rates of disease progression have substantially 
fallen, so it is impractical to continue to use these endpoints any longer. CD4+ T cell 
counts and HIV RNA levels are now used as alternative endpoints instead.
There is no set method for assessing virological response over time, but since the main 
aim of therapy is to suppress HIV RNA levels below the level of quantification of the 
assay, virological failure definitions usually encapsulate patients who do not have a 
virological response to treatment initially (i.e. their HIV RNA levels remain above the 
level of quantification of the assay) and patients who initially respond to treatment but 
later experience a virological rebound (i.e. their HIV RNA level falls below the level of 
quantification of the assay and then rebounds above it). If a patient experiences 
virological failure they may wish to switch therapy to a more effective regimen. In early 
virological failure the primary aim of therapy is to achieve re-suppression of HIV RNA, 
usually by substituting one ARV for another ARV33 109.
The prognostic value of CD4+ T cell counts for predicting clinical events has been 
shown to be higher than that of HIV RNA levels in patients receiving therapy, but since 
HIV RNA levels are a better reflection of an early treatment response they are often 
used as the primary outcomes in trials157. In some studies, patients who are receiving 
treatment have a lower risk of clinical progression for a given CD4+ T cell count and 
HIV RNA level compared to patients who are off treatment158,159. This indicates that 
potent antiretroviral therapy may protect against clinical progression beyond the 
protection acquired through lowering HIV RNA levels and increasing CD4+ T cell 
counts. This could be a result of improving overall immunodysfunction, beyond what is 
measured by CD4+ T cell counts, or possibly through the presence of resistance 
mutations (see section 1.6)160,161.
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1.5. Genetic sequencing
The HIV genome is 9749 nucleotides long and the order in which the nucleotides 
appear defines the genetic sequence162. As with all RNA, HIV RNA is a polymer 
containing four different nucleotide bases: two purine bases, adenine (A) and guanine 
(G); and two pyrimidine bases, cytosine (C) and uracil (U). The A, C and G bases are 
the same as those found in DNA, however uracil is different. Instead thymine (T), a 
pyrimidine similar to uracil, is the complementary base to adenine in DNA. The use of 
a single symbol to represent a variety of possible nucleotides at a single position has 
become widespread over the last few years. The symbols R and Y are commonly used 
to designate purines (A or G) and pyrimidines (C or T), respectively.
Genes that code for proteins are composed of nucleotide triplets called codons where 
each protein-coding gene/codon can be translated into one of twenty existing amino 
acids (Table 1.5.1). Each section of the RNA gene encodes for a particular protein that 
is necessary for the life cycle of HIV to continue. The complete set of genes is called 
the genome163.
Table 1.5.1: List of standard amino-acids
Amino Acid 3-Letter 1-Letter Nucleotide triplets
alanine Ala A GCU, GCC, GCA, GCG
arginine Arg R CGU, CGC, CGA, CGG, AGA, AGG
asparagine Asn N AAU, AAC
aspartic acid Asp D GAU, GAC
cysteine Cys C UGU, UGC
glutamic acid Glu E GAA, GAG
glutamine Gin Q CAA, CAG
glycine Gly G GGU, GGC, GGA, GGG
histidine His H CAU, CAC
isoleucine lie I AUU, AUC, AUA
leucine Leu L UUA, UUG, CUU, CUC, CUA, CUG
lysine Lys K AAA, AAG
methionine Met M AUG
phenylalanine Phe F UUU, UUC
proline Pro P CCU, CCC, CCA, CCG
serine Ser S UCU, UCC, UCA, UCG, AGU, AGC
threonine Thr T ACU, ACC, ACA, ACG
tryptophan Trp W UGG
tyrosine Tyr Y UAU, UAC
valine Val V GUU, GUC, GUA, GUG
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1.5.1. The HIV genome
There is huge diversity among HIV genomes, even within an individual164. It is 
therefore stipulated that HIV is a quasi-species of a virus165. Viral quasi-species are 
related but non-identical mutant and recombinant viral genomes that result from 
genetic variation, competition, and selection. The dynamics and structure of RNA 
allows several viral populations to live and replicate in their hosts simultaneously.
The HIV genome contains several genes: some code for structural proteins and others 
are accessory genes that have no structural function166. The three main functional 
regions in HIV are the gag, po/and env (Figure 1.5.1.1). The gag (group-specific 
antigen) and po l (polymerase) genes together are translated into large poly-proteins 
which are cleaved by a virus-encoding protein -  the protease enzyme -  that is 
contained within pol. The gag gene encodes the structural proteins of the virus (i.e. it 
provides the physical infrastructure of the virus and contains the genetic code for 
producing the following four proteins: matrix, capsid, nucleocapsid and p6), the pol 
gene provides the mechanism by which the virus replicates (i.e. it contains the genetic 
code for producing HIV reverse transcriptase, integrase and protease) and the env 
(envelope) gene encodes the glycoproteins, which interact with host cell surface 
receptors and are needed to allow the virus to enter the cell167.
Figure 1.5.1.1: Diagram of the HIV genome
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1.6. Antiretroviral drug resistance
A major barrier to the success of cART is the emergence of drug resistance mutations 
that inhibit the activity of antiretroviral drugs. Since the start of the pandemic, the HIV- 
infected patient population has been exposed to over twenty different ARVs, which has 
led to the emergence of a wide range of drug resistance mutations (i.e. nucleotide 
changes along the genetic sequence that impact on the antiretroviral activity of ARVs). 
Although the mechanism of mutation development differs by drug class and, to some 
extent, by individual drugs, there are some mutations that result in a virus that is better 
able to replicate in the presence of an ARV.
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Mutations that impact on the ability of the virus to replicate in the presence of an ARV 
tend to occur at, or near, the active sites of the enzymes targeted by antiretroviral 
drugs. These are generally along the reverse transcriptase (RT) or protease (PR) 
sections of the pol gene. Some viruses have developed large numbers of ARV-specific 
mutations and consequently patients with these viruses in their viral sub-species have 
limited or no antiretrovirals that are active (or partially active) against viral replication. 
Understanding resistance emergence and how it impacts on the virological profiles for 
patients is crucial for being able to administer successful treatment. It will be the main 
focus of this thesis.
1.6.1. The emergence of resistance
It is estimated that HIV replication in vivo involves the production and clearance of 
approximately one to ten billion viral particles daily, infecting over ten million host cells 
every day if a patient does not receive treatment1681169. As already described in section
1.5.1, the viral population of an HIV infected person is predominantly heterogeneous 
(i.e. the majority of virions differ) and since the transcription of RNA into viral DNA is an 
error prone process that does not contain an inbuilt error checking system to repair any 
errors that arise, genetic mutations will occur during replication131170. A genetic 
mutation is defined as an alteration or mistake in the genetic code171.
In the presence of an ARV and ongoing virus replication, a pre-existing resistant 
mutant can be selected by the drug. If replication under drug pressure continues, the 
mutant will acquire further mutations that increase resistance or alter fitness1721173. 
Thus the process is one of selection and evolution but not creation. These mutations 
are termed drug resistance mutations. A genetic mutation (i.e. a change to a 
nucleotide along the genetic sequence) may result in a change to the amino acid that is 
present at a particular position. In the absence of therapy a particular viral species will 
dominate which is generally referred to as the ‘wild-type’ virus. Throughout this thesis I 
will use the term ‘wild-type’ to refer to viruses that do not contain any drug resistant 
mutations. These viruses are usually present following infection, although the 
transmission of drug-resistant strains has become an increasing problem in recent 
years174"176.
Mutants with resistance to drugs usually have a reduced fitness (i.e. the ability to 
replicate) compared to wild-type viruses. However, mutations that compensate for this 
reduction in fitness often arise in order to allow the virus to replicate at a comparable 
rate to that of wild-type viruses. These mutations are termed compensatory mutations 
and play an important role in resistance development and persistence.
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Patients who are on a failing cART regimen, and have high levels of viral replication, 
have the highest risk of experiencing resistance emergence in their dominant virus 
population. High replication rates mean there is a greater chance of an error occurring, 
and if these patients are also receiving an ARV it is likely that mutations will emerge 
that allow the virus to thrive in the presence of that ARV and be preserved177178. In 
patients who are receiving ARVs, viruses with drug resistant mutations tend to be fitter 
than viruses without those mutations so these mutated viruses will out-grow the less fit, 
wild-type viruses and become dominant.
Patients who are receiving sub-optimal therapy tend to experience rapid increases in 
their HIV RNA levels and resistance emergence. Resistance to a particular ARV tends 
to emerge when both the potency of the ARV and the genetic barrier (i.e. the number of 
mutations that the virus requires to become resistant to that ARV) of the ARV is low. 
The genetic barrier is determined by a number of factors, including the number of 
resistance mutations that are required for loss of activity of an ARV, the level of pre­
existing resistance and the replication rate of the pre-existing resistant viral strains. 
Defining the genetic barrier involves determining the effect of a single mutation and/or 
combination of mutations on the susceptibility of HIV to the ARVs in the regimen.
Monotherapy is a treatment strategy where resistance has been shown to emerge 
easily and rapidly to the ARV received. Monotherapy inhibits certain viruses from 
replicating, however once mutations emerge that are resistant to the ‘monotherapy’ 
drug in question, that drug will no longer be effective at suppressing the virus. As a 
result replication rates will increase, leading to an elevation in viral mutants that are 
resistant to the drug.
Dual therapy increases the genetic barrier of the regimen because, for replication to 
occur effectively, the virus has to have resistance mutations to both drugs in the 
regimen. Since more mutations are generally needed to develop resistance to two 
drugs compared to one, viral load increases are not seen as quickly in these patients 
as in those receiving monotherapy103. Now triple combinations of drugs are used to 
maximise antiretroviral activity and inhibit viral replication; however, adherence rates 
need to be good in order to keep the potency of the regimen high and avoid resistance.
1.6.1.1. Adherence and risk of resistance
Adherence to antiretroviral treatment is one of the most important determinants of 
resistance emergence and therapy success179. Patients who start cART and have 
directly observed therapy (DOT) experience virological suppression rates of up to
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100%180181. Although it is hard to measure adherence in an individual, physicians 
continue to promote the optimal use of drugs by trying to enhance the levels of 
adherence in their patients.
Various different measures of adherence exist (e.g. Medication Event Monitoring 
Systems (MEMS), DOT, physician perception, plasma pharmacokinetic drug levels, 
self-reported and self-administered questionnaires amongst others), yet none of them 
have proved to be wholly reliable182.
If adherence rates are suboptimal the emergence of resistance becomes a major issue 
because there is insufficient drug pressure to prevent replication from occurring183. In 
fact, the relationship between adherence and mutation accumulation has an inverse-u 
shape where low rates of mutation accumulation are seen in patients with low 
adherence levels, due to minimal selection pressure, and low rates of accumulation are 
also seen in patients with high adherence levels, due to suppression of viral replication 
(Figure 1.6.1.1.1 (i)). The rate of mutation accumulation and the magnitude of the 
relationship between adherence and mutation accumulation has been shown to vary 
by drug class (Figure 1.6.1.1.1 (ii))184, however, the same inverse-u shaped 
relationship between adherence levels and resistance accumulation is observed within 
all classes.
Figure 1.6.1.1.1: Resistance-adherence curves183185
i) A cartoon demonstrating the relationship between adherence and resistance
accumulation
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ii) The relationship between adherence and resistance accumulation for patients 
receiving a nelfinavir or lopinavir/r containing regimen (which also contains lamivudine): 
A) primary PI mutations B) secondary PI mutations and C) lamivudine resistance 
mutations
1.6.2. Active drugs and switching
Resistance is the underlying cause of most virological failure (see section 1.4.2) in 
patients who have moderate to high adherence levels and optimal drug 
pharmacokinetic levels. Most patients who initiate a first-line of antiretroviral therapy in 
the absence of transmitted drug resistance have no drug resistant mutations present in 
their quasispecies at a prevalence equal to or above approximately 0.1%, so they 
should have a virus that is susceptible to all of the drugs they are receiving. Patients 
who experience virological rebound on a first-line regimen may have resistance 
mutations in their predominant virus population, to some, or all of the drugs in their 
regimen. It is important to identify these mutations and switch the ARVs that are no 
longer effective to ARVs that are (i.e. active drugs) so that the patient remains on a 
fully suppressive regimen. Since first-line regimens usually include two NRTIs 
(referred to here as background drugs) and either a PI or an NNRTI (referred to here 
as the anchor drug), use of the other anchor drug will not be compromised. Depending 
on the class of ARVs that has been compromised these patients can initiate two 
different NRTIs, because cross-resistance (discussed overleaf) among NRTIs is fairly 
low, and/or an anchor ARV from a class of ARVs that has not been used before. This 
is termed second-line therapy.
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1.6.2.1. Cross-resistance
Drug resistant mutations are not all specific to a particular antiretroviral drug. 
Mutations may emerge that indicate reduced susceptibility to more than one ARV from 
a particular class, including an ARV that a patient has never been exposed to before. 
Although mutations along the RT gene indicate resistance to both NRTIs and NNRTIs 
there is only one mutation that has been identified so far that indicates reduced 
susceptibility to both NRTIs and NNRTIs simultaneously; probably because these 
classes of drugs have different sites of action. The only mutation that is currently 
known to indicate resistance to both NRTIs and NNRTIs is the little studied N348I 
mutation186. Cross-resistance usually occurs within a particular class of drugs and not 
across classes.
Reduced susceptibility to more than one PI is most likely to be associated with an 
amino-acid substitution at one of six different positions along the protease section of 
the pol gene: 10, 46, 54, 82, 84 and 90. Other PI mutations (i.e. D30N, G48V, I50V or 
I50L -  see section 1.6.3.1) are relatively specific for particular Pis and are less likely to 
produce cross-resistance187.
Within-class cross-resistance is a major issue because, even though over twenty 
different ARVs are available for treating HIV, the emergence of a mutation to a 
particular ARV could inhibit the use of other ARVs from within the same class. Cross­
resistance is more likely to happen for NNRTIs than for either NRTIs or Pis. Although 
there is some overlap among mutations for ARVs from within these latter classes, the 
latter classes tend to require several mutations for susceptibility to a drug to be 
compromised. So, the emergence of a single mutation may result in the reduced 
activity of another drug from the same class but it should not compromise the use of 
any other ARV entirely. For example, resistance to 3TC is associated with the reverse 
transcriptase mutation M184V that causes complete cross-resistance to FTC, but has 
no significant resistance effects on other NRTIs and, in fact, increases susceptibility to 
NRTIs such as TDF, ZDV or d4T.
The genetic barrier of first-generation NNRTIs is lower than that of both Pis and NRTIs, 
and, as a result, the emergence of a particular NNRTI mutation may dramatically affect 
the response to other ARVs from within the same class. There are two main pathways 
for developing resistance to NNRTIs, one in which the K103N mutation is present, 
resulting in cross-class resistance to all NNRTIs, and another in which K103N is not 
present, resulting in a variable degrees of cross-class resistance.
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1.6.2.2. Lines of therapy
Although antiretroviral therapy is highly potent and is known to suppress HIV RNA 
replication effectively, there are still some patients who receive treatment but do not 
experience virological suppression. This could relate to the presence of drug 
resistance mutations in their viral populations188.
The emergence of resistance has been shown to limit the long-term duration of 
virological suppression188. If a patient experiences HIV RNA rebound on their first-line 
therapy the chances of achieving virological suppression on a second-line or further 
line regimen are reduced because mutations to some of the drugs in the regimen may 
already be present in the viral sub-species189. It is preferable to use a combination of 
at least three drugs without any overlapping resistance mutations, in any line of 
treatment, to minimize the risk of resistance emergence as much as possible109.
Patients with long-term exposure to a number of different ARVs may have a plethora of 
resistance mutations in their viral sub-species, some of which may not be present in 
the dominant viral species, but present in plasma as low frequency mutants and hidden 
in archived reservoirs of HIV proviral DNA. These mutations could still compromise the 
use of treatment because viruses containing these mutations are likely to become 
dominant under selective pressure from antiretroviral drugs.
In the absence of therapy, wild-type viruses have the highest replication capacity (i.e. 
ability to replicate), so these strains are likely to become dominant if therapy is 
stopped172. Patients with limited treatment options may wish to undergo a treatment 
interruption in order to allow the wild-type strains of HIV to become dominant again so 
that they can temporarily restore susceptibility to some ARVs.
If patients who have predominantly wild-type viral strains resume therapy, they will 
experience noticeable decreases in their HIV RNA levels as the wild-type strains of HIV 
decline, but strains of HIV harbouring resistance mutations will become dominant again 
if they contain a mutation to an ARV that the patient is receiving (Figure 1.6.2.2.1). As 
a result the benefits of treatment interruption are short-lived and the strategy is not 
currently recommended. In the case of repeat virological failure, a patient should 
attempt to switch to an active regimen that suppresses viral replication in the presence 
of all of the mutations they have in their viral strains. Mutations that are present in the 
dominant viral strains should be considered in combination with mutations that are 
present in archived sub-species. Patients who have exhausted most treatment options 
because their viral strains contain too many resistance mutations can be referred to as
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at a ‘salvage’ stage of therapy. The degree of susceptibility that the virus has to a 
treatment regimen is assessed through the use of resistance testing.
Figure 1.6.2.2.1: Resistance and viral load (www.aidsmap.com)
1.6.3. Resistance testing
If a patient experiences virological failure and needs to switch some of the drugs in 
their regimen they may wish to assess what other drugs they have susceptibility to. 
This is done through the use of genotypic and/or phenotypic resistance testing190. By 
using genotypic and/or phenotypic resistance testing it is possible to quantify the 
amount of resistance there is to each ARV individually, and to the regimen as a whole. 
As a result it enables a patient to switch any ARV that is compromised by the presence 
of resistance mutations to an ARV that is not. Although physicians use resistance 
testing to select an active and potent cART regimen for each individual, its use does 
not always correlate to virological response191'195.
1.6.3.1. Genotypic resistance testing
Genotypic resistance testing is used to guide therapy selection by producing lists of the 
type and positioning of each mutation by comparing the genetic code of the sampled 
virus to that of a consensus sequence1931196'198. Consensus sequences vary according 
to the subtype of HIV that the patient is infected with, which has been shown to have 
considerable variation across the world199*202. This thesis includes patients who are 
predominantly infected with subtype B infection and the reference strain commonly 
referred to for subtype B infected patients is HXB2203.
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Genotyping involves sequencing the RT and PR sections of the pol gene, the areas of 
the gene that are targeted by current antiretroviral drugs. It is now also common to 
sequence the gp41 envelope gene in patients receiving enfuvirtide because this area is 
associated with resistance to entry inhibitors204. Genotypic resistance tests look for 
mutations associated with a reduced susceptibility to antiretroviral drugs197;205:206.
Mutations are described by combinations of letters and numbers. The number relates 
to the position of the codon, the initial letter refers to the amino acid that is expected at 
that position in the consensus sequence and the final letter refers to the actual amino 
acid that was found at that position (see Table 1.5.1). For example, the M184V 
mutation is a common mutation associated with resistance to lamivudine. It occurs at 
codon position 184, the expected amino acid at codon 184 is methionine (M) but the 
mutation that is found at that position is valine (V). I will look at the M184V mutation in 
more detail in chapter 6 in this thesis.
All drug resistance mutations contribute towards resistance to antiretroviral drugs to a 
different extent. Some mutations cause resistance to a particular ARV but re-sensitise 
other ARVs207'210, other mutations improve the fitness of the virus under selective 
pressure from ARVs211:212 and some mutations lie along the pathway for developing 
major resistance mutations213. The relationship between mutations and ARVs is 
complex and has resulted in disagreements between experts on how each mutation 
affects response to each ARV. Consequently over twenty different rules-based 
genotypic interpretation systems (GISs) have been proposed214-222. Drug resistance is 
interpreted using one of these systems223. Interpretation systems tend to agree on the 
antiviral response to common resistance mutations, however substantial discordance 
exists in the ascribed levels of resistance to some ARVs and to the regimen itself224-230.
1.6.3.1.1. Genotypic interpretation systems
For a given genotype there is debate on how best to estimate the predicted level of 
activity for each ARV according to the resistance mutations that are identified. A 
number of different GISs are currently used for determining the amount of drug 
resistance to each ARV and guiding therapy changes in patients who are starting a 
new treatment regimen217,220,221 ;225;231;232.
The International AIDS Society (IAS-USA) publishes a list of mutations along the RT, 
PR and envelope genes that are considered to indicate some level of resistance to the 
existing ARVs (appendix I)233. These are split into primary and secondary resistance 
mutations. Primary resistance mutations are generally those that occur first during
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therapy with a non-suppressive regimen and result in a decrease in the sensitivity of 
the virus to the drug in question. Secondary mutations are those that occur over time if 
the virus continues to replicate in the presence of a particular drug (i.e. if a failing 
regimen is not discontinued or switched to an active regimen). All resistance mutations 
are specified for each ARV in the IAS-USA listings so that it is possible to get an overall 
view of how susceptible a virus will be to the regimen a patient is receiving.
Since some mutations are more powerful indicators of resistance than others and some 
mutations indicate hypersusceptibility to certain ARVs but resistance to other ARVs, 
complicated GISs that take into account combinations of mutations have been 
proposed22**221:231. As an example appendix II demonstrates the algorithm for the 
REGA interpretation system. Amino-acid sequences are run through the chosen GIS- 
specific algorithm to produce a score that relates to the degree of resistance a virus 
has to each ARV in the regimen.
Most GISs categorise resistance into three distinct categories (i.e. resistance, 
intermediate resistance or sensitive), however some GISs use a five category system 
instead (i.e. high-level resistance, intermediate resistance, low-level resistance, 
potential low-level resistance and sensitive). Rules exist for condensing down systems 
using five categories to systems containing three categories220. For GISs containing 
three levels of resistance, a score of 0 for an ARV demonstrates full-resistance to that 
ARV, 0.5 indicates intermediate resistance and 1 relates to ARV-sensitivity. A 
genotypic sensitivity score (GSS) can then be generated for the regimen by summing 
the level of resistance shown to each ARV in the proposed regimen218.
Studies have compared how different GISs interpret amino acid substitutions and 
explored how their corresponding interpretations relate to phenotypic drug susceptibility 
and to the clinical activity of ARVs in terms of viral load response228 229. Some GISs are 
rules-based algorithms, updated by experts, which are freely accessible over the 
internet whereas others are costly and the rules are not always specified225. Table 
1.6.3.1.1.1 outlines the GISs that have been proposed for clinical use and undergone 
clinical validation. There is a real need for more information on the prognostic value of 
these tests to determine whether the impact of resistance testing is long-lasting. 
Variability exists in the mechanisms underlying the interpretations, the nature of the 
systems, their intended use and how often they are updated2251234.
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Table 1.6.3.1.1.1: Information on the existing genotypic interpretation systems
GIS Version Manufacturer Date of 
last 
update
Rules-
based
Freely
accessible
For
clinical
use
Undergone
clinical
validation
ANRS 15 Agence Nationale 
de Recherches 
sur le Sida
2007 Yes Yes Yes Yes
Geno2pheno 3.0 German National 
Reference Center 
for Retroviruses
2003 No Yes No Yes
HIV Drug 
Resistance 
Database (HIVdb)
4.3.1 Stanford
University
2007 Yes Yes Yes Yes
Rega Institute 8.0 Rega Expected 
Jan 2008
Yes Yes Yes Yes
VircoTYPE/
VirtualPhenotype
- Tibotec-Virco 2007 No No Yes Yes
HIV-1 GenotypR 
PLUS
- Specialty
Laboratories
2001* Yes No Yes No
TRUGENE HIV-1 
genotyping test
12.0 Siemens 2007 Yes No Yes Yes
Retrogram 1.6 Virology networks 2002* Yes No Yes Yes
ViroSeq HIV 
genotyping system
2 Celera 
Diagnostics/Abbo 
tt Laboratories
2000* Yes No Yes No
GeneSeq 3 Monogram
Biosciences
2003 Yes No Yes No
GenoSure - LabCorp and 
Virco
2004* Yes No Yes No
DMC 3 Detroit Medical 
Center
2004 Yes Yes No Yes
CHL 5.0 Centre 
Hospitalier de 
Luxembourg
2005 Yes No No Yes
Quest-Stanford - Quest
diagnostics
2005 Yes No Yes Yes
GAV/USP 4 Grupo de 
Aconselhamento 
Virologico, Sao 
Paulo University
2006 Yes No No Yes
Therapy Edge 3.2 Advanced
Biological
Laboratories
2005 No No Yes Yes
Los Alamos ? Los Alamos 
National 
Laboratory
2005* No Yes No No
DR SEQAN 1.1 Menendez-Arias 2006 Yes Yes Yes Yes
RCG Resistance
collaborative
group
2000 Yes Yes No Yes
Viradapt - 1999 Yes No No Yes
AntiRetroScan 1.5.1 University of 
Siena
2004 No No No No
IAS-USA - IAS-USA 2007 Yes Yes No Yes
* These systems are regularly updated, but no information is available on when the updates occur
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Mutations associated with resistance to protease inhibitors were initially selected for 
unboosted Pis for every GIS. Due to the potency of ritonavir-boosted Pis (Pl/rs) and 
because Pis are now more commonly used in their boosted form, these GISs may 
require alternative or more sensitive interpretations for ritonavir-boosted regimens. 
Some GISs have already been updated to account for the use of ritonavir-boosting but 
others still have not. Although the ascribed levels of resistance to a Pl/r, calculated 
using a GIS that has yet to be updated for the use of ritonavir boosting, still correlates 
with the activity of the Pl/r if it is used in its boosted form198, most discordance between 
GISs still occurs amongst Pis230. Since limited information exists on the prognostic 
value of GISs, particularly for Pl/rs, I investigated concordance between ascribed Pl/r 
resistance levels using four freely available GISs and related the resulting 
interpretations to virological response using trial data and longitudinal data. These 
analyses are described in detail in chapter 4 and chapter 5 of this thesis.
1.6.3.2. Phenotypic resistance testing
Phenotypic resistance assays measure the amount of a drug that is needed to inhibit 
replication of a viral isolate in vitro by either 50% or 90% relative to a control virus. 
This is referred to as the inhibitory concentration (IC) and the measurement of interest 
is the IC50 or IC90, respectively235. The phenotypic assays currently in routine use are 
based on the production of a recombinant virus containing the patient-derived HIV 
genetic region of interest (e.g., RT and protease) amplified by PCR and inserted into a 
defective laboratory vector to produce a complete virus particle. The virus is then 
grown in the presence of escalating concentrations of drugs.
The growth rate of the cultured HIV is compared to that of wild-type virus and the fold 
change in the amount of drug required to suppress replication is reported. If larger 
quantities of drug are needed to suppress the virus than what is required for the wild- 
type virus, reduced susceptibility is present. If the reduction in susceptibility exceeds a 
threshold value (see below), the viral isolate is called resistant to the drug examined. 
For example, if the cultured sample grows ten times as much as the wild-type virus 
under the same amount of drug concentration then the cultured sample is estimated to 
be ten-fold resistant to that drug. In other words, the susceptibility of the virus to that 
drug is ten times lower than wild-type virus or ten times the amount of drug is required 
to prevent replication to the same extent236. Although phenotypic resistance testing 
accurately reflects drug susceptibility in vitro, the in vivo activity may differ because 
other biological factors that influence response to therapy are not taken into 
consideration.
45
Technical cut-off levels are selected on the basis of the assay's reproducibility when a 
single wild-type reference virus is tested repeatedly. The output obtained from using 
these assays is usually reported as a low-, medium- or high-level resistance score. 
Since resistance levels obtained through this method do not correlate precisely with 
virological response in vivo the clinical relevance of these cut-off levels is questionable. 
Biological cut-offs are an improvement over technical cut-offs and are used to 
determine the level of phenotypic resistance that is considered significant for a certain 
ARV. Biological cut-offs rely on data derived through testing a large number of viral 
isolates from ARV naive patients in vitro, thus representing the range of natural 
variation in susceptibility among different virus strains. Clinical cut-offs, on the other 
hand, are calculated from assessing the level of resistance that impacts on clinical 
responses in vivo. Phenotypic assays use a variety of different cut-off levels to reflect 
susceptibility, reporting any isolate that exceeds a specific cut-off level as having 
resistance. Although the latter seem great, they also have important limitations: they 
reflect the specific characteristics of the population from which they have been derived 
and are clearly influenced by the activity of other drugs in the regimen.
1.6.3.3. A comparison of genotypic and phenotypic resistance testing
Both phenotypic and genotypic resistance tests have their strengths and 
weaknesses237. Phenotypic resistance tests report levels of drug susceptibility, taking 
into account all mutations, and are therefore apparently easier to interpret and apply 
than genotypic tests. However, they also have their limitations: for shifts in phenotypic 
susceptibility to become evident, a significant proportion of the viral quasispecies must 
be resistant to the drug in question. Phenotypic assays also have lower sensitivity 
than genotypic tests as they are unable to detect the effect of mutations that cause 
small changes in the viral quasi-species, but predict impaired virological responses in 
vivo (e.g., T215 revertants). Other limitations of phenotypic resistance testing are that: 
interpretation of low levels of phenotypic resistance is difficult, because even small 
shifts have been associated with reduced responses in vivo (e.g., 1.4 fold for TDF); 
and the decision on what cut-off to use for interpretation is questionable. Further, they 
cost about £400 per test and it takes over a month to process the results. Although, 
there is work being done to lower the cost of phenotypic resistance testing and improve 
the turnaround time238.
Genotyping, on the other hand, costs between £150 and £300 per test and results from 
these come back in about two weeks190:237. Genotypic tests report the exact mutations 
that sire present in the virus rather than providing a low-, medium- or high-level 
resistance output, although these genotypic resistance mutations still need to be
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translated into a genotypic resistance score in order to help the physician understand 
the relationship between resistance and potential response to therapy.
Much discussion has focused on the relative strengths and weaknesses of genotypic 
and phenotypic resistance testing. However, studies to date, have not sufficiently 
assessed the predictive value and relative merits of both tests192:195:239, although most 
available evidence favours genotyping. Genotypic changes can be present several 
months before phenotypic changes, and because results are technically and 
economically more accessible, genotyping is generally preferred to phenotyping in 
detecting transmitted resistance and in early virological failure, whereas phenotypic 
resistance tests may be helpful in patients with complex resistance patterns190.
1.6.4. Mechanisms of resistance to NRTIs
There are two distinct mechanisms for developing resistance to NRTIs: the first is 
through drug discrimination and the second by pyrophosphorolysis. Drug discrimination 
is most common and arises due to the occurrence of mutations at or near the binding 
site of the RT enzyme that lead to a decrease in drug binding. For example, viral 
strains that contain L74V, Q151M or M184V genotypic mutations (all NRTI mutations, 
see section 1.6.3.1) inhibit drug activity by discriminating against the drug in favour of 
the natural substrate (i.e. the enzymes that contain these mutations will select for the 
natural substrate rather than the nucleoside analogue) and so will be able to replicate 
in the presence of an NRTI240:241.
Pyrophosphorolysis, on the other hand, involves the actual removal of the incorporated 
triphosphate NRTI-derivative from the viral DNA chain using adenosine 5'-triphosphate 
(ATP), or less commonly, pyrophosphate, as an acceptor. Reverse transcription starts 
with the nucleoside triphosphate, the active drug in the cell, which is incorporated into 
the viral DNA chain extending and lengthening the chain, liberating a free 
pyrophosphate so that it can continue to grow. Nucleoside analogues work by 
incorporating themselves into the chain and prematurely terminating the DNA chain. In 
pyrophosphorolysis a mutation arises that enables the enzyme to remove the chain- 
terminating nucleoside (i.e. the nucleoside analogue) and unblock the primer, and as a 
result the reverse transcriptase is able to resume its elongation activity. 
Pyrophosphorolysis occurs relatively slowly, but its impact is significant as it results 
from the occurrence of thymidine analogue mutations (TAMs) which confer cross­
resistance to almost all the nucleoside analogues.
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TAMs are mutations that occur in the RT region of the pol gene, and are typically 
selected by AZT and d4T242. There are two distinct pathways to developing TAMs, 
either through the TAM1 pathway (including the 41L, 21OW or 215Y mutations) or 
through the TAM2 pathway (including the 67N, 70R, T215F or 219E/Q mutations)243' 
246. The pathway chosen is driven by the NRTI the patient is using, as well as other 
undetermined factors247.
1.6.5. The rate of emergence of resistance and temporal trends
Resistance mutations may arise in the dominant virus population of an individual as a 
result of a viral drift (i.e. a nucleotide change in the predominant virus), or possibly, and 
more realistically, as a result of a viral shift (i.e. a change in the dominant virus to a 
virus from a different viral quasi-species). At the first onset of resistance this is 
assumed to be the same. The time to the detection of a drug resistant mutation, under 
drug selection pressure, varies according to the individual.
Factors that contribute to the speed of resistance emergence include the mutation 
frequency at the time of treatment initiation (i.e. mutations that are present in major 
populations and in the more minor sub-species), the extent of virus replication and the 
fitness of the mutant (i.e. the ability of the virus to replicate and infect new cells), the 
viral fidelity (i.e. the probability of new mutations emerging in each replication round) 
and the magnitude of drug selection pressure.
It can take a matter of weeks for a mutation to become dominant within the 
quasispecies. For example, the M184I/V mutation can emerge in two weeks if a 
patient is failing lamivudine monotherapy. Other mutations, such as the K65R mutation 
along the RT gene, tend to emerge more slowly during treatment with a failing ddl, 
ABC or TDF containing regimen. Genotypes, phenotypes and the time to the 
emergence of some mutations are outlined in Table 1.6.5.1.
Different methods have been used to explore the temporal trends in the prevalence of 
resistance in HIV infected individuals248. Data from the UK Collaborative Group on HIV 
drug resistance suggests that, in ARV treated patients, the prevalence rates of 
resistance to one, two or three classes of drugs remains constant over time if rates are 
calculated using one resistance test per patient, and the mutations that are present in 
that test are investigated as a proportion of all of the tests performed. Resistance to an 
entire class of drugs is considered to be the emergence of at least one major mutation 
associated with reduced susceptibility to a drug in the class. Resistance to only one
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class of drugs has been high since 1998 (>70%) whereas resistance to all three 
classes of drugs has stayed reasonably low (<20%) (Figure 1.6.5.1).
Table 1.6.5.1: Time to resistance emergence after monotherapy with specific ARVs249
Y181C /I, Y188C . G 190A -
Figure 1.6.5.1: Prevalence of resistance over time: cross sectional approach. 
Among treated patients undergoing resistance testing250
LONDON]urn*
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Figure 1.6.5.2: Prevalence of resistance over time: including archived mutations 
Cumulative prevalence of resistance: accounting for archived resistance mutations250
When the UK Collaborative Group on HIV drug resistance modelled the cumulative 
prevalence of resistance over time instead, to take into account archived resistance 
mutations, they found an increasing number of previously treated patients with major 
resistance mutations to all three classes of drugs. In 1998 less than 4% of patients 
exhibited resistance to either one, two or three classes of ARVs, and by 2002 17% of 
patients had resistance to £1 class of ARVs and 4% had resistance to all three 
classes; however these temporal increases appear to have levelled off since 2000 
(Figure 1.6.5.2). Mutations were only identified for patients with resistance testing 
performed. Since the majority of treated patients will have effective suppression of 
viral replication, they will have an undetectable HIV RNA level and so will not have 
resistance testing performed, even if a resistance mutation is present in their viral sub­
species. As a result these prevalence rates may be under-estimations.
1.6.5.1. Accumulation of new resistance while on therapy
The prevalence of drug resistance to each drug class appears to have plateaued or 
even declined in ARV-experienced patients since 1999250251. This corresponds to the 
proportion of patients who have experienced virological failure to each of the three 
main drug classes over the same time period252. The availability of a large number of 
more convenient NRTIs as well as the wide use of Pl/rs could partially explain why 
prevalence rates of resistance have stopped increasing, although resistance 
emergence is still a problem and patients who have mutations in their viral sub-species 
may continue to experience more emergence of resistance. Of note, much resistance
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was accumulated at the time of mono- and dual therapy, but since these regimens are 
no longer recommended, accumulation of resistance due to these treatment strategies 
should no longer a problem.
It is estimated that around 85% of patients who are failing a cART regimen have 
evidence of at least one resistance mutation in their viral sub-species253:254. Among 
patients on potent cART with detectable viraemia, in whom resistance mutations were 
detected by population sequencing, the incidence of acquiring new mutations was 
shown to be approximately 1.61 (95% Cl: 1.36 to 1.90) mutations per person-years 
follow-up254. In all patients who are starting therapy, the rate of aquiring new mutations 
in regions that are sequenced routinely, is likely to be slow to start off with because the 
selection of initial mutations may be difficult. Once initial mutations have emerged to 
the regimen, the virus will be more susceptible to the emergence of new mutations, so 
these will occur more easily and the rate of accumulating new mutations is likely to 
increase. However, once the virus has become highly mutated, resistance 
accumulation rates will slow down again, because only a finite number of mutations 
can emerge.
In patients who were kept on the same virologically failing regimen for a median of six 
months in EuroSIDA, there was considerable accumulation of drug resistance 
mutations, particularly in patients who had low levels of resistance to the failing 
regimen initially: thymidine analogue mutations emerged in the predominant virus 
population of 25% of patients, NNRTI mutations emerged in the predominant virus 
population of 12% of patients and PI mutations emerged in the predominant virus of 
46% of patients253. The majority of these patients (92%) were on a failing Pl-containing 
regimen at the time of the analysis. Compared to this study, a study by Maggiolo et al 
included more patients who continued on a failing NNRTI-containing regimen and so 
fewer PI mutations were acquired: new resistance mutations emerged in 37.5% 
patients overall; primary RT mutations emerged in the predominant virus of 21.9%; and 
PR mutations emerged in the predominant virus of 14.3%255.
As already detailed in 1.6.5, resistance mutations arise at different rates depending on 
other influential factors. Predictors of resistance emergence include the plasma HIV 
RNA level, the HIV RNA slope and the number and type of mutation detected in the 
initial resistance test. In patients who were failing a PI containing regimen and have 
resistance mutations to each class of drugs they were receiving, new major protease 
inhibitor mutations emerged more rapidly than new TAMs when the M184V mutation 
was present. There was no significant difference in the emergence of TAMs and major
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protease inhibitor mutations if lamivudine was not part of the thymidine analogue 
regimen (i.e. the M184V mutation was not present), because of the antagonistic effect 
of M184I/V on the emergence of TAMs256.
Little is known about the emergence of new resistance mutations to Pis in patients who
are receiving a ritonavir-boosted PI containing regimen. Resistance mutations to
unboosted Pis generally emerge more quickly than to NRTIs, but slower than to
NNRTIs (Table 1.6.5.1). In the current era of ritonavir-boosted regimens it will be
interesting to see whether the same types of resistance mutations emerge and whether
they emerge at the same rate. This will be discussed in more detail in chapter 3248;25°- 
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1.6.6. Phylogenetic analysis
Phylogenetic analysis was originally developed by biological systematists to 
reconstruct evolutionary genealogies of species based on genetic similarities262. In 
HIV, phylogeny is used to identify clusters of genetically similar viral strains, where 
clusters are depicted in a hierarchical branching diagram called a phylogenetic tree263. 
Phylogenetic trees are initially created through multiple-sequence-alignment where 
each sequence of interest is aligned to other sequences of interest. Pairwise distances 
(i.e. the number of nucleotide differences) are then calculated between sequences and 
these are displayed in an un-rooted tree by using neighbour-joining (NJ) distance 
methods26* 265. Boot-strapping is then used to determine the level of support for each 
branch of the tree, based on the data at hand. Boot-strapping generates new trees 
using the same methods as above, but through comparing sequences where 
nucleotides have been removed at random positions along the nucleotide sequence. 
This uses sampling with replacement and is repeated a large number of times (usually 
500-1000) so that many permuted alignments are produced. For each alignment a new 
tree is generated and a consensus tree is subsequently created from the large set of 
trees. The consensus tree consists of groups that occur most frequently in the set of 
trees. It is possible to root the tree by comparing all sequences to a consensus 
sequence (e.g. by including HXB2 in the initial comparisons).
All sequences that are genetically close irradiate from the same node, and the distance 
from the node of the branch indicates the difference in nucleotide bases between 
sequences forming a cluster. Each branch of the tree represents an individual RNA 
sequence and all sequences that are considered to be descendants of a common 
ancestor group together to form a cluster or, when describing HIV subtypes, a 
clade26* 265. Sequences within each clade are genetically similar to every other
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sequence in the same clade. Different approaches are used to determine the most 
likely tree topology and branch lengths266"269.
Progressive sequence alignment is used to produce a phylogenetic tree by 
incorporating new sequences into the calculated alignment according to the order of 
the genetic distance between them. Phylogenetic methods such as parsimony based 
analysis (i.e. a method of identifying the phylogenetic trees that require the smallest 
number of evolutionary events to explain the observed sequence data) and maximum 
likelihood methods (i.e. a substitution model that is used to assess the probability of a 
particular mutation occurring) are used to estimate the likelihood of each nucleotide 
substitution occurring and consequently determine the tree topology and branch 
lengths. In this thesis I will use phylogenetic analysis to compare nucleotide sequences 
along the reverse transcriptase (RT) and along the protease genes because these are 
two areas that are targeted by ARVs.
1.6.7. Resistance testing guidelines
The European HIV Drug Resistance Panel has provided updated guidelines on 
practical issues associated with resistance testing since 200119°. Their 
recommendations include details on when to perform resistance tests, which test to 
use and how best to implement the results. This was last updated in October 2004 
after a push for more hypersusceptibility mutations to be included190.
The panel recommend resistance testing for the following indications:
1. Antiretroviral-naive patients with acute or recent HIV infection
2. At therapy failure, including suboptimal treatment response when an ARV 
change is required
3. Pregnant HIV infected women and paediatric patients with detectable viral load, 
when treatment initiation or change is considered
4. For genotype source patients who are to receive post-exposure prophylaxis 
(PEP).
Resistance testing should also be considered for all ARV-nai've patients who are 
starting therapy. By following guidelines on when to perform resistance testing in 
patients who are experiencing virological failure it is possible to switch some ARVs 
from a failing treatment regimen to other active ARVs with the intention of suppressing 
viral replication.
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1.6.8. Benefits associated with the emergence of resistance
Contrary to expectations, the emergence of mutations may have less of a negative 
effect than anticipated, at least over the short term, although compensation can still 
occur over time. Some mutations that indicate resistance to one ARV have been 
associated with hypersensitivity to other ARVs within the same class270. Other 
mutations may affect the fitness of the virus and impact on the viral replication capacity. 
For example, evidence from in vitro experiments suggests that viruses containing the 
M184V mutation have a lower fitness (i.e. the ability of the virus to replicate and infect 
new cells) and increased fidelity (i.e. a lower probability of the emergence of new 
mutations per replication round) compared to wild-type viruses271'278.
In the E-184V study, patients with limited treatment options performed better if the 
M184V mutation was continuously detected through the use of population sequencing 
during a structured treatment interruption (STI -  see section 1.6.9.2)279. However, it is 
still unknown whether, in the era of cART, it is beneficial to preserve this mutation. By 
lowering the viral replication capacity and increasing the fidelity of the dominant virus, 
other mutations may emerge at a slower rate and so the activity of other drugs in the 
regimen may be preserved for longer280. In the E-184V study, 3TC preserved the 
M184V mutation as well as other pre-existing mutations, probably due to linkage on the 
same genome with M184V. Thus a virus with reduced replication capacity was 
maintained in this study. Under drug selection pressure from other drugs in a regimen, 
this may not be the case. I will investigate the benefit of preserving the M184V 
mutation in the dominant virus population of patients who are failing a 3TC containing 
regimen, in chapter 6, using data from a clinical trial.
1.6.8.1. Fitness and replication capacity
The presence of resistance mutations may cause a virus to have a reduced capacity 
for inducing CD4+ T cell count declines because it may not be able to infect the T 
lymphocyte cells as efficiently281. A reduction in viral fitness associated with viruses 
containing resistance mutations has been shown previously281'286, but this reduced 
fitness may act entirely through a reduction in the viral load and not impact on CD4+ T 
cell counts287. In both patients on ARVs and patients off ARVs there is a trend for more 
favourable (or less unfavourable) CD4+ T cell count changes in patients with lower viral 
loads.
In chapter 7 I use data from patients who are followed up longitudinally throughout 
Europe and have an ongoing viral load > 500 cps/mL in order to assess whether the 
level of resistance present (i.e. specific mutations and classes of mutations) is
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associated with CD4+ T cell count changes, independent of the viral load level and the 
use of ARVs.
1.6.9. Consequences of resistance emergence: salvage treatment
Although over twenty ARVs are currently approved by the FDA, most of them come 
from just three drug classes and consequently have overlapping resistance profiles80181. 
Patients can exhaust all treatment options if too many resistance mutations emerge in 
their viral quasispecies, because ARVs from any one class, or in combination with each 
other, will no longer be effective25* 2611288. New strategies aimed at patients in need of 
salvage therapy have been investigated, yet it is still a problem with 4% of patients in 
the UK showing resistance to all three major classes of ARVs (Figure 1.6.5.2)250.
Patients with high levels of resistance can still benefit from the continued use of a 
failing drug. This is because not every strain of HIV will be resistant to the drug, so the 
drug may still suppress replication to a certain extent. If no active treatment options 
are available the patient may benefit from recycling or continuing to use old drugs. 
Alternatively they could undergo a structured treatment interruption, initiate mega- 
HAART or enrol into an expanded access program for new drugs33110. However, the 
discontinuation of all drugs is increasingly discouraged as it may result in rapid 
immunologic and clinical progression1721173. These issues are discussed below.
1.6.9.1. Continued use or recycling of old drugs
Patients with limited treatment options available may continue to receive their current 
cART regimen even if they experience persistently detectable viraemia. By remaining 
on the same regimen it may be possible to partially control viral replication and remain 
immunologically stable289. Some ARVs continue to exert antiviral activity against 
viruses containing drug resistance mutations; this is true for some Pis due to their high 
genetic barrier and also for some NRTIs279 290'292. Data have also shown, in vitro and to 
a less extent in vivo, that drug resistance mutations may reduce the ability of HIV to 
replicate efficiently (i.e. it has a reduced replication capacity or fitness), therefore 
recycling or rotating ARVs in an attempt to reduce viral fitness could be a treatment 
strategy. Although this needs to be carried out with caution in order to avoid the 
emergence of mutations to drugs that still might be partially active.
If the patient remains on a virologically failing regimen there is risk that more mutations 
will emerge to the existing regimen and this could further compromise future regimens. 
On the other hand, if the patient switches to another regimen containing only one active 
drug, the patient will essentially experience functional monotherapy and risks
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resistance emerging to the active drug thereby inhibiting its future use. Remaining on 
a failing regimen is currently considered advisable if the patient does not have the 
potential of at least two fully active ARVs, the regimen is easy to take and has minimal 
side-effects. The selection of the regimen must be done with care otherwise mutation 
development will compromise rather than enhance current and future treatment 
options.
1.6.9.2. Structured Treatment Interruptions (STI)
Patients may want a break from treatment for several reasons. They may want a break 
from the undesirable side-effects that many patients experience while on treatment, or 
they may experience treatment fatigue, regardless of tolerability. One strategy is to 
undertake an STI as a way to postpone their next regimen until the majority virus has 
reverted back to wild-type. In the absence of treatment the fittest virus will become 
dominant and since wild-type viruses are fittest, it was hypothesized that interrupting 
therapy could expand future treatment options for patients in need of salvage therapy.
In the CPCR064 study that was performed on 270 patients infected with multidrug- 
resistant HIV, STIs were associated with greater progression of disease and did not 
confer immunologic or virological benefits or improve the overall quality of life. In 
addition, the SMART study showed that STIs can actually be harmful in the long term, 
with patients who discontinued treatment having a 2.6 (1.9 to 3.7) higher hazard of 
progressing to AIDS or death compared to patients who remained on treatment 
throughout the period293. After the results of SMART entered the public domain more 
patients who needed to discontinue therapy for any reason started reducing treatment 
down to either monotherapy or simple uncomplicated regimens, rather than terminating 
treatment altogether293. Although STIs did not confer progression of disease or 
virological benefits in patients with multiple failures and multi-drug resistance in 
SMART, they had a prolonged negative impact on CD4+ T cell count recovery294.
NNRTIs have a prolonged half-life compared to ARVs from other classes, so there is a 
concern that an interruption from a suppressive NNRTI regimen may result in 
prolonged exposure to an unprotected NNRTI, leading to a risk of viraemia and 
resistance as a consequence. Since NNRTIs have longer half-lives than most ARVs 
from other classes and a low genetic barrier (i.e. only one mutation is required in order 
to confer high-level drug resistance), they need to be stopped earlier than the other 
ARVs in the regimen to avoid the potential for NNRTI monotherapy295.
Limited data are available on the best way to stop an NNRTI-containing regimen in 
order to avoid effective monotherapy and the potential emergence of drug resistance. I
56
investigate the emergence of drug resistance according to one of three methods used 
to interrupt an NNRTI-containing regimen for patients randomised to the 
discontinuation arm of the SMART study, a large trial that assessed the impact of 
treatment interruptions, in chapter 8. I summarize the impact the three interruption 
strategies had on the likelihood of re-suppressing HIV RNA in the eight months 
following the re-start of treatment, and explore the risk of resistance emergence two 
months after the treatment interruption, in patients who were virologically suppressed 
on an NNRTI-containing regimen and interrupted it as part of SMART.
1.6.9.3. Mega-HAART and ARV-switching in patients on salvage therapy
Drug combinations that use five or more ARVs are also used in patients on salvage 
therapy. This is termed mega-HAART and can consist of as many as up to nine drugs, 
but is often associated with intolerable side-effects and the potential for significant drug 
interactions296. Patients receiving mega-HAART should have therapeutic drug 
monitoring (TDM) to ensure their drug levels are optimal because safety is a big 
concern. This strategy has led to undetectable viral loads over the long-term in highly 
selected patients on salvage therapy296"298.
Patients who continue to experience rising viral loads on mega-HAART or patients who 
are unable to participate in clinical trials because they have no treatment options 
available may consider using new drugs by enrolling into expanded access 
programmes. Ideally new drugs should be used in combination with other active drugs 
for the best results, but some patients may not have the capacity to wait for more drugs 
to become available because their risk of disease progression or death is too high.
1.7. Project objectives and layout of the thesis
The main aim of this thesis is to investigate the clinical impact of resistance testing in 
four randomised controlled trials (RCTs), two cohort studies and a resistance database.
I will initially examine different aspects of resistance emergence using trial data and 
then extend these analyses to patients from the cohort studies.
In particular, the aims of this project are:
i) To explore the emergence of resistance among patients experiencing 
virological failure on a ritonavir-boosted PI
ii) To examine the prognostic value of four freely available genotypic interpretation 
systems for predicting viral load outcome
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iii) To use phylogenetic analysis to examine the relationship between nucleotide
distances, treatment use and virological response for patients in whom the 
M184V mutation is present in the dominant viral population.
iv) To explore the association between the presence of resistance mutations and
CD4+ T cell count change in patients who are receiving antiretrovirals and have 
ongoing viraemia.
v) To assess the impact of different strategies for interrupting an NNRTI on the
likelihood of viral re-suppression in the eight months after therapy is re-started
vi) To investigate the emergence of drug resistance mutations over two months of
follow-up, according to the method of interrupting an NNRTI for patients 
randomised to a large clinical trial
All of the analyses are based on data from four clinical trials (SMART, MaxCminl, 
MaxCmin2 and COLATE) and two large clinical observational databases (EuroSIDA 
and the UK CHIC study with its links to the UK HIV Drug Resistance Database that is 
co-ordinated by the Collaborative Group on HIV Drug Resistance). Since resistance 
testing is dependent on viral load levels (i.e. they are usually performed in patients with 
an HIV RNA > 1000 copies/mL) and is conducted on a selective group of individuals, 
the randomised nature of the trials will not ensure balances between the groups that 
will be compared throughout this thesis. However, patients in the trials are followed up 
frequently and as a result will have a more data available than patients in the 
observational studies. In the observational studies, patients will generally be 
representative of those seen in routine clinical practice. Since the patients who come 
from the observational studies have more irregular follow-up compared to the trial 
patients, data will be more sparse and resistance testing more infrequent. The 
availability of samples for resistance testing varies according to the study. This is 
described in more detail in Chapter 2.
58
CHAPTER 2: INTRODUCTION TO THE DATA
2. Introduction
This thesis includes data from four clinical trials (MaxCminl, MaxCmin2, COLATE and 
SMART) and three observational databases. The observational data come from two 
large multicentre clinical cohort studies: EuroSIDA and the UK CHIC study, where the 
clinical data in the UK CHIC study can be linked to resistance data from the UK HIV 
Drug Resistance Database. Since this thesis explores the relationship between clinical 
variables and different aspects of resistance emergence I have only included patients 
who contributed data to both the UK CHIC study and the UK HIV Drug Resistance 
Database and not patients who were recruited to either of these cohorts alone. In this 
chapter I will describe all of the seven studies that contribute patients to this thesis, with 
special consideration given to how patients were recruited and how data were 
collected.
2.1. Randomised Controlled Trials
2.1.1. The MaxCmin trials
The MaxCmin trials were the first two open-labelled, multicentre phase IV trials to 
perform head-to-head safety and efficacy comparisons between different ritonavir 
boosted PI containing regimens. MaxCminl compared the safety and efficacy of 
ritonavir-boosted saquinavir (SQV/r) against ritonavir-boosted indinavir (IDV/r) and 
MaxCmin2 compared the safety and efficacy of SQV/r against ritonavir-boosted 
lopinavir (LPV/r) over 48 weeks follow-up in HIV-infected adults2" 1300.
2.1.1.1. Patients and methods
Between September 2000 and April 2001 sites in Argentina, Austria, Belgium, 
Denmark, France, Germany, Greece, Italy, Norway, Portugal, Switzerland, Spain, 
Sweden, the Netherlands, the UK and the USA were invited to enrol patients into 
MaxCminl. Patients were randomised 1:1 to IDV/r (800/100 mg bid) or to SQV/r 
(1000/100 mg bid). MaxCmin2 opened enrolment in May 2001 and randomised 
patients 1:1 to LPV/r (400/100 mg bid) or to SQV/r (1000/100 mg bid) until recruitment 
ended in December 2001. Both trials were financially supported by Roche 
Pharmaceutical Ltd.
2.1.1.2. Randomisation
Randomisation was carried out centrally; treatment was open label and patients were 
informed of their randomised treatment at or prior to their baseline visit. Randomisation 
was stratified by region and according to whether a patient was PI-naTve or Pl- 
experienced prior to study entry.
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2.1.1.3. Sample size and analysis
The MaxCmin trials were powered to show equivalence between study arms with an 
80% chance that the 95% confidence interval for the difference in treatment failure 
rates would exclude a difference greater than 15% in either direction over 48 weeks 
follow-up. Treatment failure was considered to be observed virological failure (section
2.1.1.5.1), withdrawal of consent for participation in the study, loss to follow-up or 
death. This was based on a sample size of 150 per arm and an underlying failure rate 
of 20% in both arms.
Per protocol, the primary population for analysis was the intention-to-treat/exposed 
(ITT/e) population including all randomised patients who had taken at least one dose of 
their assigned treatment301. In this analysis, any patient who stopped a component of 
their treatment regimen was not considered to be a failure at the time of stopping, even 
if they stopped the randomised Pl/r. Instead they were considered to be a success 
until they experienced the event of interest (i.e. treatment failure) or they were 
censored at 48 weeks if they did not. The protocol also stipulated an ITT/e/stopping = 
failure analysis where discontinuation of the assigned Pl/r component was considered 
to constitute failure. In both analyses, patients who withdrew consent to participate in 
the study, were lost to follow-up or died were also defined as having experienced 
failure. Exploratory on treatment (OT) efficacy and safety analyses were performed in 
accordance with CPMP guidelines regarding analysis of equivalence trials302.
2.1.1.4. Protocol design
The protocols for both trials had the following identical inclusion and exclusion criteria:
Inclusion criteria:
1. Male or female, > 18 years of age.
2. HIV-1 infected as documented by a licensed HIV-1 antibody ELISA.
3. Women of childbearing potential with a negative serum pregnancy test (beta-HCG) 
within 28 days of trial baseline.
4. Ability to understand and provide written informed consent to participate in the trial.
5. Clinical laboratory values considered not clinically significant - for the potential 
response to the planned new regimen - in the opinion of the investigator.
6. Fulfilment of at least one of the following five criteria, provided that either of the 
boosted Pl-regimens studied in the trial were judged to be of benefit to the person 
(see criteria # 7):
(i) Being protease inhibitor (PI)-naTve
(ii) Being Pl-experienced with a viral load a: 400 copies/mL
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Being Pl-experienced with a viral load < 400 copies/mL and:
(iii) Experiencing adherence problems either before or currently on an 
ongoing unboosted PI-containing regimen (irrespective of type and dosing 
schedule of the PI) and/or
(iv) Experiencing current toxicity to the Pl-component of an unboosted Pl- 
containing regimen (other than to any of the study Pis) and/or
(v) Experiencing typical ritonavir adverse events (i.e. loose stool or peripheral 
dysastesia) on a ritonavir (dose no less than 300 mg bid) boosted double 
Pl-containing regimen (regardless of type and dosing schedule of other 
PI)
7. For all five sub-criteria listed under inclusion criterion #6, the a priori probability of 
responding to each study PI, as judged by the investigator, had to be equal. The 
judgment had to take into account the factors mentioned below, all of which would 
preclude enrolment:
i) Prior dose-limiting toxicity to any of the study Pis (irrespective of dosing)
ii) Prior switch away from a regimen that included one but not the other study 
PI because of virological failure, except if resistance testing at time of 
failure did not show evidence of selective resistance development (not 
applicable for 6(i))
Exclusion Criteria
A patient was not eligible for inclusion in the MaxCmin trials if any of the following
criteria applied:
1. Patients whom in the investigator’s opinion were unlikely to complete the 48-week 
trial period.
2. Patients with current alcohol or illicit drug use which, in the opinion of the 
investigator, could interfere with the patients’ ability to comply with the dosing 
schedule and protocol evaluations.
3. Patients on concomitant medications which, in the opinion of the investigator and 
according to drug product labelling, would result in clinically significant interactions 
with any of the Pl/rs assessed in this trial
4. Patients who were pregnant or breast feeding
5. Patients who had renal failure requiring dialysis
6. Patients suffering from a serious medical condition, including one or more AIDS 
defining events, which in the opinion of the investigator, could compromise the 
safety of the patient.
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2.1.1.5. Background therapy
Patients had to be given a potent background regimen containing at least two non-PIs 
in addition to their Pl/r component. The choice of the non-PI background therapy had 
to be made by the treating physician at each of the trial sites prior to the time of 
randomisation. The aim of treatment was to reduce HIV RNA to undetectable levels 
without prematurely terminating treatment for toxicity or non-adherence. Only locally 
approved ARVs could be used in combination with the randomised Pl/r component. 
Patients were not permitted to receive other Pis than those assigned by randomisation.
Patients were allowed to discontinue the Pl/r component if they experienced treatment 
limiting adverse events or virological failure (section 2.1.1.5.1). Where appropriate 
(e.g. exposure related toxicity or failure potentially due to low exposure) investigators 
were permitted to adjust the dose or the formulation of the randomised PI so that 
patients could continue on trial treatment. The baseline drug regimen was to be 
continued for the duration of the trial period (i.e. 48 weeks). Where needed, other 
ARVs could be discontinued and replaced in case of treatment limiting adverse events, 
virological failure, immunologic failure or clinical failure (i.e. the development of a new 
AIDS defining event (Table 1.1.3.1) or a relapse of a previously successfully treated 
AIDS-defining event) due to the other ARVs, within the first 24 weeks of the study. 
From Week 24 onwards other ARVs could be changed at the discretion of the 
investigator.
2.1.1.5.1. Virological failure
In MaxCminl, virological failure was considered to be:
• For patients entering the study with a viral load <200 copies/mL, an HIV RNA 
value (confirmed) £200 copies/mL
• For patients entering the study with a viral load £200 copies/mL:
1. any rise in HIV RNA £ 0.5 logs (confirmed) and / or
2. a viral load (confirmed) of:
£ 50,000 more than 5 weeks after baseline
£5000 " 14
£ 200 " 27
In MaxCmin2 virological failure was considered to be:
• For patients entering the study with a viral load <200 copies/mL, an HIV RNA 
value (confirmed) £200 copies/mL
• For patients entering the study with a viral load £200 copies/mL:
1. any rise in HIV RNA of £ 0.5 logs (confirmed) and / or
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2. a viral load (confirmed) of:
at Week 4: < 0.5 log reduction from baseline if > 200 at Week 4 
at Week 12: < 1.0 log reduction from baseline if > 200 at Week 12 
at Week 24: an HIV RNA £ 200 copies/mL
2.1.1.5.2. Immunological failure
In both of the MaxCmin studies immunological failure was considered to be:
• Compared with baseline, a decrease in CD4+ T cell counts of > 50% on two
consecutive occasions at least one week apart, providing that the baseline 
CD4+ T cell count was > 150 cells/pL.
• For patients with baseline CD4+ T cell count of 100 to 150 cells/pL, a follow-up 
CD4+ T cell count < 50 cells/pL
• For patients with baseline CD4+ T cell count < 100 cells/pL a follow-up CD4+ T 
cell count < 25 cells/pL
2.1.1.6. Follow-up
Consenting patients were screened in the 28 days prior to the first dose of the study 
drug. Following randomisation, eligible patients were informed of their treatment 
assignment and re-attended the clinic for the baseline assessments (Day 1). Baseline 
data was collected on medical history, demographics and clinical and laboratory 
parameters (appendix III). Data on clinical evaluation, safety, HIV RNA levels and 
CD4+ T cell counts were collected at follow-up visits which occurred after 4, 12, 24, 36 
and 48 weeks (Table 2.1.1.6.1).
Table 2.1.1.6.1: Clinical Evaluations in the MaxCmin Trials
Evaluation Day Week
Screening Baseline 4 12 24 36 48
Informed consent X
Entry criteria X
Demography X
CDC classification X
Height X
Weight X X X X X X
Concurrent medications X X X X X X
HIV-associated conditions X X X X X X
Adverse and serious adverse events X X X X X X
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2.1.1.7. Data collection
Since all of the Pl/r regimens were b.i.d, plasma was collected for pharmacokinetic 
(PK) drug concentration analysis at weeks 4 and 48, as close to 12 hours (range: 11 to 
13 hours) post-dose as possible to obtain the Cmin (i.e. the minimum plasma drug level 
in a patient). If the drug was taken less than one hour before the PK measurement 
was recorded, it was presumed that the most recent dose had yet to "kick in" and that 
the PK measurement actually referred to the dose that was taken prior to it, so 12 
hours was added to the time period (e.g. blood taken at 0.5 hrs after the last dose was 
recorded as 12.5 hours since the "real" last dose). Samples collected one to six hours 
post-dosing, and samples collected more than 13 hours post dosing, were considered 
unusable and not included in any analysis due to the large concentration variability in 
this time interval. Using regression analysis, it was assumed that there was a stable 
log-linear period of decline in the PK levels for samples collected between six and 11 
hours post-dose. Separate models were created for each Pl/r to estimate the Cmin at 
12 hours post-dose for each individual. These were adjusted for the period (i.e. week 4 
or week 48), and the amount of time between the dose and the PK measurement.
At baseline and at each of the follow-up visits, four 1 ml_ vials of plasma were collected 
and stored locally at minus 70° C for resistance testing. Samples were then shipped to 
a central repository at the Copenhagen HIV Programme (CHIP) where each sample 
was uniquely identified in a freezer log. Patients underwent genotypic resistance 
testing if they had a baseline HIV RNA >500 copies/mL or they experienced virological 
failure (section 2.1.1.5.1) and had HIV RNA >500 copies/mL. Patients underwent 
phenotypic resistance testing if they were PI experienced at baseline, had an HIV RNA 
>1000 copies/mL and had baseline genotypic resistance data available. Phenotypic 
resistance data was only performed on samples at baseline. Patients were selected for 
both genotypic and phenotypic resistance testing retrospectively.
Samples of interest were shipped on dry ice, in batches, to a central testing facility for 
protease gene sequencing. For MaxCminl the testing facility was the International 
Clinical Virology Centre (ICVC, UK), and for MaxCmin2 it was Advanced Biological 
Laboratories (ABL, Luxembourg). ABL has developed a strong focus on HIV drug 
resistance, mainly on algorithm-based genotype interpretation systems, the 
management of sequence and complex integrated clinico-virological databases, and on 
more advanced genetic analysis tools such as virus subtype characterization.
The MaxCmin resistance data that was obtained at baseline and during follow-up was 
combined with baseline clinical and demographic data (Table 2.1.1.7.1) in order to
64
explore resistance emergence in detail, and to assess the impact of mutations on 
virological response.
Table 2.1.1.7.1: Data included in this thesis from the MaxCmin studies
Baseline data:
Demographic: Gender
Race
Date of birth 
Mode of HIV infection 
Region of origin
Body Mass Index (weight and height information is collected 
separately)
Clinical: Date of HIV diagnosis
Stage of HIV infection according to CDC classification
Date and diagnosis of any HIV-related diseases (CDC category
Bor C)
Laboratory markers: Dates and values of current CD4+ lymphocyte counts and any 
values recorded in the year proceeding baseline 
Date and value of CD4+ nadir
Date and value of current and past plasma viral load 
measurements
Treatment information: Type and duration of all prior ARVs and dates of starting new 
medication: NRTIs: AZT, ddl, 3TC, ddC, d4T, ABC, combivir 
and trizivir; NNRTIs: NVP, DLV, EFV; Pis: SQV (hard gel 
formulation), SQV (soft gel formulation), IDV, RTV (<400 
mg/dose), RTV (£400 mg/dose), NFV, APV, LPV
Other data: Cmin levels at week 4 and week 48 (i.e. drug concentrations in 
each patient 12 hours after taking the Pl/r)
Resistance data: Date of baseline resistance test and nucleotide sequence 
obtained
Date of resistance test at the time of failure and nucleotide 
sequence obtained
Genotypic data: mutations in the dominant viral species, 
including data on the gene location (i.e. RT or PR), the codon 
position, the amino acid present at a particular position, and 
information on whether the mutation is present in a mixture or on 
its own. Flags were used to highlight any major mutations 
(using the most up-to-date IAS-USA listings) and compensatory 
mutations.
Phenotypic data: the fold change in ARV required to suppress 
replication compared to wild-type, for all available ARVs
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2.1.2. The COLATE Study
COLATE (Continuation of LAmivudine Treatment in Europe) was a randomised trial to 
address whether the continued use of 3TC in patients experiencing virological failure 
on a 3TC-containing cART regimen could be virologically beneficial. As described in 
section 1.6.8 it is postulated that viruses containing the M184V mutation have a lower 
fitness and increased fidelity compared to wild-type viruses. Since use of 3TC 
preserves the M184V mutation it was hypothesised that continued use of lamivudine 
could lead to suppressed rates of viral replication in patients who were failing 
treatment. Patients in COLATE were randomised (1:1) to discontinue or continue 3TC 
in addition to receiving the most effective cART regimen available (appendix V). 
COLATE was a phase IV, open-label, multi-centre clinical trial conducted at twenty 
sites in twelve countries in accordance with the Helsinki II Declaration, the Good 
Clinical Practice guidelines (ICH-GCP Guideline (CPMP/ICH/135/95))280. Local 
independent Ethics Committees approved the protocol. The first patient was enrolled 
on 28th May 1999 and, after recommendation from the DSMB, recruitment was stopped 
prematurely on 15th May 2002 because there was slow recruitment to the trial. 
Recruitment was almost complete at the time that the study was stopped and every 
attempt was made to follow all enrolled patients for the entire 48 weeks.
2.1.2.1. Patients and methods
HIV positive patients were eligible at screening if they were receiving a failing 3TC 
containing regimen, had plasma viral load >1000 copies/mL in addition to a 
documented history of viral load values <500 copies/mL for at least one month whilst 
taking 3TC, were £18 years old, were not pregnant or breastfeeding and did not have a 
serious medical condition. In addition, all laboratory values had to be without potential 
adverse clinical significance as per the treating physician’s judgement.
2.1.2.2. Randomisation
At screening, patients were divided into two strata: stratum A contained patients who 
experienced virological failure on their first-line 3TC-containing cART regimen; and 
stratum B contained patients who were failing a later cART regimen that contained 
3TC. At screening the treating physician planned a new three-drug cART regimen, 
which did not include 3TC, but to which 3TC could be added depending on the 
outcome of randomisation. After the new cART regimen was planned, patients were 
randomised (1:1) to either: switch to the planned new regimen and discontinue 3TC or 
switch to the planned new regimen and continue 3TC (150mg twice daily). 
Randomisation was performed centrally and stratified for strata, country and planned 
ddl use in the new regimen. Patients could not receive ABC or ddC in their new
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regimen because the M184V mutation is known to confer low level cross-resistance to 
both of these drugs303.
Patients were allowed to switch one or more of the antiretroviral drugs in their regimen, 
including the 3TC component, in the case of treatment-limiting adverse events. All 
ARVs other than 3TC could be switched in the case of virological failure (section
2.1.2.2.1), immunological failure (using the same definition as the MaxCmin trials -  
section 2.1.1.5.2) or clinical failure (i.e. the development of a new AIDS defining event 
or relapse of a previously successfully treated AIDS-defining event).
2.1.2.2.1. Virological failure
In the COLATE study, virological failure was considered to be:
• From Week 4 and thereafter, a confirmed decrease in HIV RNA of < 0.5 log10 
compared to baseline HIV RNA
OR
• A confirmed increase in HIV RNA of > 1 logi0 compared with nadir HIV RNA,
In both cases the HIV RNA that constituted virological failure had to be >1000 
copies/mL. The assessment of virological failure had to be based on two consecutive 
measurements performed at least one week apart, and could not be taken during an 
intercurrent illness or in the four weeks following an immunisation.
2.1.2.3. Sample size
The initial sample size calculations were performed to investigate whether continued 
use of 3TC was superior at reducing HIV RNA compared to discontinuation of 3TC. 
The trial was powered to detect a difference in HIV RNA reduction of at least 0.5 log10 
copies/mL between treatment arms within each stratum using an average-area-under- 
the-curve-minus-baseline (AAUCMB) approach to estimate HIV RNA declines over 48 
weeks of follow-up280. It was determined that the trial should randomise (1:1) 160 
patients into two treatment arms, assuming 90% power and a significance level of 0.05.
After an unscheduled interim analysis, the DSMB recommended that recruitment 
should be stopped early because recruitment to the study was slow, but follow-up on 
patients already recruited should be continued. For this interim analysis the Peto 
method of repeated significance testing was used to test for treatment difference, with 
a p-value of <0.001 considered significant. A total of 136 patients were recruited (71 in 
the discontinuation arm and 65 in the continuation arm).
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2.1.2.4. Follow-up
Out of 136 patients who were randomised, we have follow-up data on 131 (96.3%), 129 
(94.9%), 124 (91.2%), 125 (91.9%), 120 (88.2%) and 122 (89.7%) patients at baseline, 
weeks 4, 12, 24, 36 and 48 respectively. During follow-up, the following procedures 
were performed at each visit: clinical evaluation, blood safety analyses, viral load and 
CD4+ count (Table 2.1.2.4.1).
Table 2.1.2.4.1: Clinical Evaluations in COLATE
Evaluation Day Week
Screening Baseline 4 12 24 36 48
Informed consent X
Entry criteria X
Demography X
CDC classification X
Height X
Weight X X X X X X
Concurrent medications X X X X X X
HIV-associated conditions X X X X X X
Adverse and serious adverse events X X X X X X
2.1.2.5. Data collection
In COLATE, genotypic resistance data were available at baseline and at all time points 
during follow-up if a patient had an HIV RNA >500 copies/mL. Plasma was collected 
and stored at the specific time point so that it could be used for retrospective evaluation 
of genotypic and phenotypic resistance patterns. Plasma was also used for quality 
assurance of the HIV RNA measurements that were performed, real-time, at the sites. 
All follow-up resistance tests were paired with resistance data that were recorded at 
baseline and these were matched to baseline demographic data (Table 2.1.2.5.1) in 
order to investigate factors contributing to resistance evolution.
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Table 2.1.2.5.1: Data included in this thesis from the COLATE study
Baseline data:
Demographic: Gender
Race
Date of birth 
Mode of HIV infection 
Region of origin
Body Mass Index (weight and height information is 
collected separately)
Clinical: Date of HIV diagnosis
Stage of HIV infection according to CDC classification 
Date and diagnosis of any HIV-related diseases (CDC 
category B or C)
Laboratory markers: Dates and values of current CD4+ T cell counts and any 
values recorded in the year proceeding baseline 
Date and value of CD4+ nadir
Date and value of current and past plasma viral load 
measurements
Treatment information: Type and duration of all prior ARVs and dates of starting 
new medication:
NRTIs: AZT, ddl, 3TC, ddC, d4T, ABC, combivir and 
trizivir
NNRTIs: NVP, DLV, EFV
Pis: SQV, IDV, RTV (<400 mg/dose), RTV (s>400 
mg/dose), NFV, APV, LPV
Other data: Strata
Resistance data: Date of baseline resistance test and nucleotide sequence 
obtained
Date of follow-up resistance test and nucleotide sequence 
obtained
Genotypic data: mutations that are present in the dominant 
viral species, including data on the gene location (i.e. RT 
or PR), the codon position, the amino acid present at a 
particular position, and information on whether the 
mutation is present in a mixture or on its own. Flags were 
used to highlight any major mutations (using the most up- 
to-date IAS-USA listings) and compensatory mutations.
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2.1.3. The SMART Study
Although the implementation of antiretroviral treatment guidelines has resulted in 
substantial declines in morbidity and mortality over the years76, the effectiveness of 
cART has been shown to wane over time due to the emergence of HIV drug resistance 
and because of toxicities associated with ARVs and their impact on adherence304. 
Many asymptomatic patients are not at an immediate risk of developing serious 
opportunistic diseases, especially if they have suppressed rates of viral replication, so 
they may wish to undergo a treatment interruption. Other reasons why patients may 
wish to undergo a treatment interruption are discussed in section 1.6.9.2. This 
motivated a comparison of two strategies: one which conserved treatment options by 
interrupting their use while the risk of opportunistic disease was low; and one which 
aimed to consistently sustain virological suppression (i.e. an HIV RNA < 50 copies/mL) 
without a break from therapy.
The SMART trial (Strategies for Management of AntiRetroviral Therapy) was a large 
international study designed to examine the impact of intermittent cART treatment in 
HIV-infected individuals. SMART was supposed to run for over nine years, but it was 
stopped in January 2006 after only two years of follow-up in some patients. This was 
decided after an elevated risk of clinical progression was seen in patients who 
interrupted treatment.
2.1.3.1. Patients and methods
HIV infected patients were eligible for recruitment into SMART if they were £13 years 
old, were not pregnant or breastfeeding and did not plan to become pregnant over the 
course of follow-up, had a CD4+ T cell count >350 cells/pL, were receiving ARVs and 
were willing to initiate, modify or stop ARVs depending on the outcome of 
randomisation. Patients who were not receiving ARVs at randomisation were required 
to use them immediately if they were randomised to the VS arm of SMART, and were 
required to postpone using them until after their CD4+ T cell count fell below 250 
cells/pL if they were randomised to the DC arm of SMART.
The study was opened for enrolment in the US and Australia in January 2002 and in 
April 2004 additional sites in Europe, Asia, South and North America began. The 
purpose of the SMART study was to compare the long-term clinical consequences of 
two strategies of antiretroviral management: drug conservation (DC) vs. viral 
suppression (VS). Enrolment was stopped prematurely on 11th January 2006 because 
patients in the DC arm had twice the risk of disease progression (i.e. the development
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of clinical AIDS or death) compared to patients in the VS arm. When enrolment was 
stopped, 5,472 patients had been enrolled from 318 sites on six continents.
2.1.3.2. Randomisation
In SMART, patients were randomised (1:1) to either the drug conservation (DC) group 
or the viral suppression (VS) group. Randomisation was performed centrally and 
stratified for clinical site. Randomisation schedules were generated to ensure that 
there were an approximately equal number of individuals in each treatment arm at each 
site. The DC strategy aimed to conserve drugs through episodic use of ARVs for the 
minimum time to maintain CD4+ T cell counts >250 cells/pL. Patients in the DC arm 
were required to re-initiate therapy once their CD4+ T cell count fell below 250 cells/pL. 
The VS strategy was aimed at suppressing HIV RNA levels as much as possible, 
immediately following randomization and throughout follow-up, irrespective of the CD4+ 
T cell count. Patients in the VS arm were expected to undergo a treatment change 
whenever appropriate in order to keep the HIV RNA below the limit of detection. The 
primary endpoint of the SMART study was clinical HIV-related disease progression or 
death.
2.1.3.3. Sample size
It was determined that the trial should randomise (1:1) 6000 patients into two treatment 
arms, assuming 80% power, a significance level of 0.05 and an annual loss-to-follow- 
up rate of 2%. The trial was powered to detect a 20% difference in the risk of HIV 
progression or death between treatment arms, assuming that disease progression 
would account for 70% of the end-points and death the other 30%. The sample size of 
6000 was calculated after varying the assumptions for the expected cumulative rate of 
disease progression in the control arm (i.e. the viral suppression arm) -  see Table
2.1.3.3.1.
Table 2.1.3.3.1: Sample size considerations for the SMART study
S a m p le  S ize R e q u ire d  fo r  th e  S M A R T  S tu d y :
In flu e n c e  of H y p o th e s iz e d  T re a tm e u t  D iffe re n c e  
(exp ressed  as a h a z a rd  ra t io )  an d  C o n tro l G ro u p  E v e n t R a te *  
(expressed  as c u m u la tiv e  p e rc e n t a fte r  5 y e a rs )
C u m u la t iv e  5 -Y e a r  E v e n t R a tes
H a z a r d  R a tio 7 .5 °  o
".600
5.400
3.400
1 0 °  o
5. SCO 
4.100
0.85
o.so
0." 5
: assum es increasing hazard after year 2: 5-year enrollm ent; 6 years m inim um  
follow -up; 2% loss-to-follow -up per year
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2.1.3.4. Follow-up
Patients were to be seen at 1, 2, 4, 6, 8,10 and 12 months following randomisation and 
every 4 months thereafter for follow-up data collection visits. During follow-up the 
following procedures were to be performed at each visit: clinical evaluation, blood 
safety analyses, viral load and CD4+ count (Table 2.1.3.4.1).
Table 2.1.3.4.1: Clinical Evaluations in SMART
Evaluation Screening
visit*
Follow-up visits to year 1 
(months)
Follow 
visits, y« 
to 9 (ev 
mont
r-up 
jars 2 
ery 4 
is)
1 2 4 6 8 10 12 4 8 12
Informed consent X
Entry criteria X
Demography X
CDC classification X
Any supplemental diagnoses X X X X X X X X X X X
Height X X X X X X X X X X X
Weight X X X X X X X X X X X
Concurrent medications X X X X X X X X X X X
HIV-associated conditions X X X X X X X X X X X
Adverse and serious 
adverse events
X X X X X X X X X X X
* Within 45 days before randomisation
2.1.3.5. Data collection
To evaluate whether resistance emergence was reduced in the DC arm compared to 
the VS arm in the SMART trial, plasma samples were collected at baseline and at 
various time points during follow-up when a patient had HIV RNA >1000 copies/mL or 
when the site chose to perform a resistance test (Table 2.1.3.5.1). Resistance testing 
was recommended for all patients who had to undergo a treatment change. Plasma 
was collected and stored at the corresponding time points so that it could be used for 
retrospective evaluation of genotypic resistance patterns. Resistance testing was 
performed on site, and repeated centrally where necessary.
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If antiretroviral therapy is discontinued for a prolonged period of time the selective 
pressure for the emergence of resistant strains associated with the treatment regimen 
will be removed. In addition, any individual who defers therapy will not be at risk of 
mutations emerging because there will be a lack of selective pressure. As a result we 
would expect to see fewer mutations emerging in patients randomised to the DC arm of 
SMART compared to the VS arm.
Table 2.1.3.5.1: Data included in this thesis from the SMART study
Baseline data:
Demographic: Gender
Race
Date of birth 
Mode of HIV infection 
Body Mass Index
Clinical: Date and diagnosis of any HIV-related diseases (CDC 
category B or C)
Laboratory markers: Date and value of CD4+ lymphocyte counts 
Date and value of CD4+ nadir 
Date and value of plasma viral load
Treatment information: Type and duration of all prior medications:
NRTIs: AZT, ddl, 3TC, FTC, ddC, d4T, ABC, TDF, combivir 
and trizivir; NNRTIs: NVP, DLV, EFV; Pis: SQV (hard gel 
formulation), SQV (soft gel formulation), IDV, RTV (<400 
mg/dose), RTV (£400 mg/dose), NFV, AMP, LPV, ATV, 
TPV; Other: T-20
Resistance data: Date of baseline resistance test and nucleotide sequence 
obtained
Date of follow-up resistance test and nucleotide sequence 
obtained
Genotypic data: mutations that are present in the dominant 
viral species, including data on the gene location (i.e. RT or 
PR), the codon position, the amino acid present at a 
particular position, and information on whether the mutation 
is present in a mixture or on its own. Flags were used to 
highlight any major mutations (using the most up-to-date 
IAS-USA listings) and compensatory mutations.
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2.2. THE COHORT STUDIES
2.2.1. EuroSIDA
Some of the data analysed in this thesis come from the EuroSIDA study, a prospective 
observational cohort of 14262 patients with HIV infection (January 2008). EuroSIDA is 
one of the largest international cohort studies, so far spanning 93 centres across 31 
European countries, Israel and Argentina.
2.2.1.1. Study design
EuroSIDA was initiated as a prospective observational cohort study as a follow-up 
study to the AIDS in Europe study, after marked differences in survival across Europe 
were demonstrated305. EuroSIDA began enrolment in May 1994 and includes 
information on patients in the pre-cART era, the early cART era and now some of the 
same patients are still under follow-up in the late-cART era. It is guided by a Steering 
Committee consisting of different regional representatives. EuroSIDA is sponsored by 
the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th 
Framework (QLK2-2000-00773) and the 6th Framework (LSHP-CT-2006-018632) 
programs. Current support also includes unrestricted grants by Bristol-Myers Squibb, 
GlaxoSmithKline, Roche, Gilead, Pfizer, Merck and Co., Tibotec and Boehringer- 
Ingelheim. The participation of centres from Switzerland was supported by a grant 
from the Swiss Federal Office for Education and Science. It is co-ordinated by CHIP, 
Copenhagen, Denmark, receives statistical support from the statistical centre at the 
Royal Free and University College Medical School, London and receives virological 
support from two virology laboratory groups, one based in London, UK and the other in 
Badalona, Spain. Permission to perform any analyses on EuroSIDA data is given by a 
Scientific Committee containing epidemiologists, clinicians and statisticians.
2.2.1.2. Patients and methods
To date, EuroSIDA has enrolled seven cohorts of consecutive HIV infected patients, 
aged 16 years or over, with consecutive, pre-booked clinic appointments in one of 93 
clinical centres across 31 European countries, Israel and Argentina. Patients are 
enrolled until a predefined number are attained from each centre. Cohort I recruited 
3116 patients from May 1994; Cohort II enrolled 1365 patients from November 1995; 
Cohort III, 2841 patients from February 1997; Cohort IV, 1225 patients from January 
1999; Cohort V, 1223 patients from November 2001; Cohort VI, 2121 from November 
2003; and Cohort VII, 2419 from January 2006. For cohorts l-lll, eligible patients were 
those with a CD4+ T cell count <500 cells/pL in the previous four months. The CD4+ T 
cell count restriction was removed for the later cohorts.
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2.2.1.3. Follow-up data collection
Information is collected from patient charts and by patient interview onto a standardized 
data collection form at the first visit (baseline) and every six months thereafter. At 
baseline, clinical and laboratory markers such as haemoglobin, platelets, leukocytes, 
total lymphocyte counts, absolute and percent CD4+ count, plasma HIV RNA and AST 
and ALT levels are measured and the following demographic variables collected: date 
of birth, gender, race, country of origin, and transmission category. HIV infection is 
confirmed by a positive HIV-antibody test result. At each visit, details on all CD4+ T cell 
counts and HIV RNA levels measured since the last follow-up are collected. The dates 
of starting and stopping each antiretroviral and each prophylactic drug are recorded. 
Dates of diagnoses of all AIDS-defining illnesses are recorded, including re-current or 
new events made subsequent to the initial diagnosis, using the 1993 clinical definition 
of AIDS from the Centers for Disease Control37.
The database is updated every six months, unless a patient experiences a clinical 
event, hospitalisation, treatment initiation or interruption, or death - in which case this 
information is recorded as soon after the event as possible. Members of the co­
ordinating office visit all centres to facilitate correct patient selection and to verify 
accurate data collection, through regular monitoring according to a set of standard 
operating procedures.
Plasma is collected and stored at least every six months for resistance testing; patients 
generally undergo genotypic resistance testing when they initiate a new regimen or 
prior to initiation of their first cART regimen. The EuroSIDA virology group is 
coordinated by Dr. Bonaventura Clotet and contains other ad hoc virologists from 
participating sites in the EuroSIDA Study. The intention of the virology group is to 
investigate the clinical and virological efficacy of different therapeutic strategies and to 
reduce morbidity and mortality related to HIV infection by using antiretroviral 
combinations that are able to control plasma viral replication. The group utilises several 
techniques directed to the evaluation of genotypic and phenotypic resistance, and they 
also analyse the behaviour and replication capacity of viruses harbouring one or 
several mutations in the RT and PR genes.
This thesis concentrates on the data items collected up to April 2007 shown in Table 
2.2.1.3.1.
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Table 2.2.1.3.1: Data included in this thesis from the EuroSIDA study
Baseline data:
Demographic: Gender
Race
Date of birth 
Mode of HIV infection 
Region of origin 
Body Mass Index
Clinical: Date of HIV diagnosis
Stage of HIV infection according to CDC classification 
Date and diagnosis of any HIV-related diseases (CDC 
category B or C)
Laboratory markers: Date and value of CD4+ lymphocyte counts 
Date and value of CD4+ nadir 
Date and value of plasma viral load
Treatment information: Type and duration of all medications used:
NRTIs: AZT, ddl, 3TC, FTC, ddC, d4T, ABC, TDF, 
combivir and trizivir 
NNRTIs: NVP, DLV, EFV
Pis: SQV (hard gel formulation), SQV (soft gel 
formulation), IDV, RTV, NFV, AMP, LPV, ATV, TPV 
Other: T-20
Resistance data: Date of baseline resistance test and nucleotide sequence 
obtained
Date of follow-up resistance test and nucleotide sequence 
obtained
Genotypic data: mutations that are present in the dominant 
viral species, including data on the gene location (i.e. RT 
or PR), the codon position, the amino acid present at a 
particular position, and information on whether the 
mutation is present in a mixture or on its own. Flags were 
used to highlight any major mutations (using the most up- 
to-date IAS-USA listings) and compensatory mutations.
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2.2.2. The UK CHIC study
The UK Collaborative HIV Cohort study (The UK CHIC study) is a collaboration of ten 
of the largest HIV clinics in the UK. Eight of these centres are situated in London 
(Chelsea and Westminster, King's College Hospital, Mortimer Market Centre, St. 
Mary's Hospital, The Royal Free Hospital, Barts and the London NHS trust, Homerton 
and North Middlesex), one in Brighton (Brighton and Sussex University Hospital) and 
one in Edinburgh (Edinburgh hospital). Currently the UK CHIC database contains 
information on 29,055 HIV-infected patients in the UK.
2.2.2.1. Study design
The study began in 2001 with the aim of establishing a large clinical follow-up study of 
HIV infected patients in the UK. Routinely collected data on patients attending one of 
the ten clinical HIV centres after 1 January 1996 were retrospectively and prospectively 
merged into a single database.
The ongoing objectives of CHIC are to: monitor and describe changes over time in the 
frequency of AIDS-defining illnesses and survival; describe the uptake of and response 
to cART and; identify factors associated with virological and immunological response to 
cART. Since the number of new infections in the cohort reflects new infections in the 
UK, and there have been an increasing number of women and heterosexuals recruited 
to the study in recent years, the UK CHIC population is generally representative of all 
HIV-infected patients seen for care in the UK. Since it is crucial to examine the impact 
of resistance (both transmitted and that acquired whilst on treatment) on virological 
response, links between the UK CHIC study and the UK Collaborative Group on HIV 
Drug Resistance are essential. The UK CHIC study is closely linked to the UK HIV 
Drug Resistance Database, a database set up in 2001 in order to collect information on 
all routinely performed resistance tests in the UK (see section 2.3.1).
2.2.2.2. Patients and methods
HIV positive patients, aged 16 years or older, who attended at least one of the 
participating centres in 1996 or thereafter, were included in the UK CHIC study. 
Patients may have attended more than one centre for care so could have duplicate 
records between centres. All patients were matched on the basis of their soundex 
code, date of birth in addition to other clinical information and all likely duplicates were 
flagged. These were electronically and manually checked and if a patient was 
identified as a duplicate, one composite record for this patient was included in the UK 
CHIC database. Other methods to identify potential duplicates were also employed306.
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2.2.2.3. Data collection
Loss-to-follow-up rates in the UK CHIC study are kept as low as possible over time, 
nonetheless some patients become lost. Death registers from the Office for National 
Statistics (ONS) for England and Wales, and the General Registrar Office for Scotland 
(GRO) are used to ascertain whether patients are reported to have died, and if so, the 
database is updated with this information and each centre is informed of the death.
Each centre provides electronically formatted data in specified data sets: demographic 
information; AIDS diagnoses and deaths; laboratory data (absolute and percent CD4+ 
counts, HIV RNA levels, haemoglobin, platelets etc) and antiretroviral treatment history 
(start and stop dates as well as reasons for stopping treatment and treatment-limiting 
toxicities). Clinical data and treatment data are updated annually at all of the centres.
2.3. OTHER DATABASES
2.3.1. The UK Collaborative Group on HIV Drug Resistance
The UK Collaborative Group on HIV Drug Resistance is a collaboration between 
laboratories performing HIV resistance tests in the UK, clinical sites using resistance 
testing, academic specialists in HIV drug resistance, the MRC Clinical Trials Unit, UCL 
Centre for Virology, the UK CHIC study, the Health Protection Agency and the 
Department of Health. Understanding HIV drug resistance in the clinical setting helps 
to improve clinical management of HIV-infected patients, and since HIV resistance is a 
complex field, involving a number of different mutations at a number of different sites all 
with different prevalence rates, combining resistance data from different sources is 
important to increase the number of mutations that can be investigated.
There is a high level of overlap between the UK CHIC centres and the centres who 
contribute data to the UK HIV Drug Resistance Database. Collaborators come from 
the following centres: the Royal Infirmary of Edinburgh; Gartnavel General Hospital; the 
Health Protection Agency; Guy’s and St. Thomas’ NHS Foundation Trust; Brighton and 
Sussex University Hospital; King’s College Hospital; the Royal Free Hospital; 
Southmead Hospital; Leeds Teaching Hospital; St. Marys Hospital; University of 
Edinburgh; St. Bartholemews Hospital; Chelsea & Westminster Hospital; Manchester 
Royal Infirmary; and Mortimer Market Centre. Data collection is co-ordinated by the 
MRC Clinical Trials Unit.
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2.3.1.1. Study design -  The HIV Drug Resistance Database
The collaboration began in 2001, alongside the UK CHIC study, with the aim of 
establishing a large HIV drug resistance database containing sequence data on 
resistance tests performed as part of routine clinical care in the UK. This database 
contains the results of over 30,000 resistance tests from approximately 21,000 
patients. There are a total of 6195 (21.3%) patients in the UK CHIC study who have 
resistance data in the UK HIV Resistance Database
The objectives of the collaboration are to use data from the HIV Drug Resistance 
Database to: estimate the prevalence of drug resistance in recent and untreated 
infections within the UK and describe changes over time; to describe the pattern of 
drug resistance in patients failing therapy; and to assess the effect of specific mutations 
(in the context of specific drug regimens) on virological response. The collaboration is 
currently funded by the Department of Health to provide surveillance data on the extent 
of HIV drug resistance in treated and untreated patients.
2.3.1.2. Patients and methods
Approximately 80% of all routine resistance tests performed in the UK are included in 
the HIV Drug Resistance Database.
2.3.1.3. Data collection
All laboratories provide the results of the resistance tests (as full nucleotide sequences) 
performed in the previous calendar year for all of their patients. Sequences are 
processed via programs developed by Stanford University and adapted by the Centre 
for Virology, UCL In brief, each input nucleotide sequence is aligned to an amino acid 
reference sequence (i.e. HXB2 -  consensus B subtype). The inferred mutations are 
then fed into Stanford’s HIVDB algorithm, which is a set of rules for determining the 
relative resistance to all available antiretrovirals220. Along with each resistance test 
result (genotypic result and sequence data where available), data are collected on 
patient demographics, clinical details, antiretroviral treatment history and laboratory 
markers at the time of the resistance test.
The clinical information that can be linked to this resistance data is obtained from the 
UK CHIC study, and from the UK Register of HIV Seroconverters. A collaboration 
between the UK CHIC study and the UK Collaborative Group on HIV Drug Resistance 
was set up to monitor the incidence of resistance over time in relation to the treatment 
received, and to examine the impact of resistance (both transmitted and that acquired 
whilst on treatment) on virological response. There is substantial overlap between
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patients in the two databases, and thus the clinical information is co-ordinated between 
the two studies. This thesis concentrates on the data items from the UK CHIC study 
and from the UK Resistance Database shown in Table 2.3.1.3.1.
Table 2.3.1.3.1: Combined data from the UK CHIC and the UK Resistance Database
Baseline data:
Demographic: Gender
Race
Date of birth
Clinical: Stage of HIV infection according to CDC classification 
Date and diagnosis of any HIV-related diseases
Laboratory markers: Date and value of CD4+ lymphocyte counts 
Date and value of CD4+ nadir 
Date and value of plasma viral load
Treatment information: Type and duration of all medications used:
NRTIs: AZT, ddl, 3TC, FTC, ddC, d4T, ABC, TDF, 
combivir and trizivir 
NNRTIs: NVP, DLV, EFV
Pis: SQV, IDV, RTV (<400 mg/dose), RTV (>400 
mg/dose), NFV, AMP, LPV, ATV, TPV 
Other: T-20
Resistance data: Date of baseline resistance test and nucleotide sequence 
obtained
Date of follow-up resistance test and nucleotide sequence 
obtained
Genotypic data: mutations that are present in the dominant 
viral species, including data on the gene location (i.e. RT 
or PR), the codon position, the amino acid present at a 
particular position, and information on whether the 
mutation is present in a mixture or on its own. Flags were 
used to highlight any major mutations (using the most up- 
to-date IAS-USA listings) and compensatory mutations.
CHAPTER 3: ACCUMULATION OF NEW PI-SPECIFIC MUTATIONS IN
PATIENTS ON Pl/rs
3. Introduction
Even though resistance mutations for unboosted Pis were widely documented at the 
time of performing the analysis described in this chapter, there was little information on 
resistance among patients receiving a ritonavir-boosted protease inhibitor (Pl/r)307'309. 
Resistance mutations may evolve at different rates in patients treated with boosted Pis 
compared to those treated with unboosted Pis, so the rates of occurrence of protease 
mutations and their impact on virological response may need to be updated for patients 
receiving a Pl/r. Updating the interpretation systems to account for the use of ritonavir- 
boosting may be an important consideration for the older Pis, such as indinavir and 
saquinavir, both of which were initially used in their unboosted form but are now more 
commonly boosted with ritonavir. However, the main Pis that are currently prescribed 
include lopinavir and darunavir -  both of which are, and have always been, combined 
with low-dose ritonavir. Therefore, updating the systems to account for the use of 
ritonavir boosting is less of an issue in the current era. Since many of the boosted Pis 
share the same characteristics as each other, much of the information we can obtain 
from exploring these older Pl/rs may still be relevant for the newer Pl/rs.
In general, patients receiving a Pl/r experience less resistance evolution in their viral 
populations to those receiving an NNRTI because of the higher genetic barrier of Pl/rs 
(section 1.6.2)310. In a study by Phillips et al, the risk of a PI mutation emerging in the 
viral populations of patients starting a Pl/r containing regimen was significantly lower 
than the risk of an NNRTI mutation emerging in the viral populations of those starting 
an NNRTI-containing regimen (relative hazard 0.31, 95% Cl: 0.15 to 0.61)311. 
However, new protease mutations were shown to emerge more rapidly than TAMs in 
adherent patients who remained on stable treatment with a thymidine analogue and/or 
protease inhibitor after the onset of virologic failure -  which may also relate to the 
genetic barrier of these classes of drugs256.
3.1. Aims of the chapter
In this chapter I will identify predictors of the risk of virological failure in patients 
receiving a Pl/r containing regimen. I will then examine the presence of primary PI 
mutations in the predominant virus of patients at the time of virological failure, and 
explore the emergence of Pl-mutations in the predominant virus of patients who 
experience virological failure whilst on a Pl/r. To do this, I focus on new mutations that 
occur along the protease (PR) section of the pol gene in the predominant viral
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population of patients enrolled into three 48-week, international, multi-centre, clinical 
trials (MaxCminl, MaxCmin2 and COLATE).
3.2. Literature review
As described in section 1.6.5.1 the rate of acquiring new drug resistance mutations 
varies according to the individual (i.e. age, adherence levels, history of exposure to 
ARVs, HIV RNA levels and the number of resistance mutations already present in the 
virus are contributing factors). Some factors, such as adherence rates, can be 
modified in order to reduce the amount of resistance, but drug resistance mutations 
can still emerge over time even if a patient has perfect adherence312. Although it is 
unlikely that resistance mutations will emerge in the virus population of patients who 
start cART with £3 active drugs, accumulation of resistance can occur in the case of 
sub-optimal therapy.
The emergence of resistance to HIV drugs essentially depends on:
i) The extent of viral replication (i.e. the replication capacity of the virus581170:313:314, 
the viral fidelity and HIV RNA levels581315)
ii) The drug levels of the ARVs in the regimen (including adherence rates179 and 
pharmacological factors that determine drug absorption rates314) and
iii) The genetic barrier (including the number of mutations that are already present 
in the virus and the number of mutations that are required in order for the virus 
to become more resistant to an ARV or to a regimen).
The rate of acquiring new mutations increases with the number of mutations that are 
already present in the virus1831316. However, a ceiling effect exists because only a finite 
number of mutations can emerge. Once all possible mutations have emerged no new 
mutations can arise because the resistant genotype is already present in the virus 
population. If a patient changes an ARV in their regimen, some mutations may 
disappear from the predominant virus (i.e. they are archived in more minor sub­
species), and other mutations may appear because there is a change in the dominant 
virus due to the drug selection pressure. Not all changes that occur to the virus will 
necessarily be to a more resistant virus179.
Patients with ongoing viraemia, who are on a stable antiretroviral regimen, are likely to 
have drug resistance mutations in their predominant virus populations. In these 
patients the incidence rate of acquiring new drug resistant mutations has been shown 
to vary between 0.5 to 3.5 new mutations per person-years of follow-up254:288:312:317. In 
a recent analysis conducted on patients from the Swiss HIV cohort study who were
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virologically failing a cART regimen, resistance mutations were found in the viral 
populations of 84% (95% Cl: 75% to 92%) of patients failing a PI, 30% (95% Cl: 12% to 
54%) of patients failing a Pl/r, and 66% (95% Cl: 49% to 80%) of patients failing an 
NNRTI, demonstrating differences in the rate of accumulating new mutations between 
regimens318. Low levels of resistance have been identified in the virus populations of 
patients who are failing the newer Pl/rs (tipranavir or darunavir), and also among those 
failing the older Pis (saquinavir/r, indinavir/r and lopinavir/r) when used in their boosted 
form319*323.
In a study looking at resistance among patients who were failing a saquinavir/r 
containing regimen, two out of eight patients had a virus in which a new PR mutation 
emerged over 4.8 person-years of follow-up (i.e. 0.4 new mutations per person-years of 
follow-up)319. Overall, in the viral populations of patients receiving one of the three 
Pl/rs investigated in this chapter (i.e. saquinavir/r, indinavir/r or lopinavir/r) the rate of 
accumulating new PR mutations has been estimated to vary from 0.0 to 1.4 new PR 
mutations per person-years of follow-up. The most common PR resistance mutations 
to occur in patients who failed a Pl/r containing regimen were at codon positions 10, 36 
or 84 for saquinavir/r; 46 or 84 for indinavir/r; and 32, 33, 35, 46, 63 or 82 for 
lopinavir/r2581310:319:320;324.
3.3. Methods
3.3.1. Chapter description
The analysis in this chapter investigates the presence of mutations at virological failure 
and mutations that emerge along the PR section of the HIV pol gene, because this is 
the area targeted by Pl/rs. The mutations of interest are primary PI mutations, as listed 
in the IAS-USA 2006 drug resistance guidelines233, as well as all other PR mutations. 
In Pl-experienced patients, the PR section of the pol gene was sequenced at baseline 
(i.e. the time the Pl/r was started) and at the time of failure to identify new mutations 
that emerged during follow-up, possibly due to the failing Pl/r.
Pl-nai've patients have a virus that exhibits a higher genetic barrier to Pis than Pl- 
experienced patients, because they will generally have fewer mutations in their virus 
population at the start of the PI (i.e. usually no primary PI mutations) and hence more 
PR mutations will be required in order to confer resistance to any particular PI. In Pl- 
naive patients without a baseline resistance test I assumed there were no drug 
resistant mutations present in their virus at baseline and that all PR mutations observed 
at failure arose during follow-up. Since the risk of transmitting Pl-resistance is low, this 
is a reasonable assumption to make176;325:326.
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The approach used to detect mutations in the virus populations of these patients does 
not capture all of the PR mutations in the more minor sub-species, and it does not 
account for shifts in the circulating virus when a new cART regimen is initiated (i.e. a 
change in the dominant viral sub-species after a new regimen is started). However, it 
can still be used to examine resistance emergence in the dominant viral species to 
some extent. Since the emergence of new mutations can influence the subsequent 
choice of therapy and consequently have an effect on clinical progression in patients 
who are failing therapy, it is necessary to examine all mutational changes that occur to 
the virus190,327.
3.3.2. The MaxCmin trials
This analysis investigates resistance emergence in MaxCminl, MaxCmin2 and 
COLATE combined. Combination of the two MaxCmin trial populations is justified 
because the studies had identical inclusion/exclusion criteria, the same enrolment 
procedures, the same data collection instruments and similar analytical methods2991300. 
Similarly, data collection and follow-up visits occurred at the same time points in the 
MaxCmin and COLATE trials, so patients from COLATE were included in these 
comparisons to increase numbers. The definitions of virological failure vary between 
the three trials and are outlined in 2.1.1.5.1 and 2.1.2.2.1.
To enable us to explore patients who experienced virological failure using a consistent 
definition of failure among the MaxCmin trials I re-ran the MaxCmin2 definition of failure 
on the combined trials population.
In MaxCmin2, virological failure was considered to be:
• For patients entering the study with a viral load <200 copies/mL, an HIV RNA 
value (confirmed) £200 copies/mL
• For patients entering the study with a viral load £200 copies/mL:
1. any rise in HIV RNA of £ 0.5 logs (confirmed) and / or
2. a viral load (confirmed) of:
at Week 4: < 0.5 log reduction from baseline if > 200 at Week 4 
at Week 12: < 1.0 log reduction from baseline if > 200 at Week 12 
at Week 24: an HIV RNA £ 200 copies/mL
MaxCminl and MaxCmin2 together represent a case series of 630 patients taking 
cART. More than 300 patients received a bi-daily (b.i.d) SQV/r regimen and the 
remaining MaxCmin patients received either IDV/r or LPV/r.
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3.3.3. The COLATE trial
Patients in COLATE who started a Pl/r that was used in either of the MaxCmin studies 
(i.e. SQV/r, IDV/r or LPV/r) were included in these comparisons. Even though 
COLATE patients had different entry criteria to MaxCmin patients280, including 
additional patients in this chapter increases the power of our analysis. Furthermore, 
there was already a large amount of heterogeneity among patients in the MaxCmin 
trials, so combining all three trial populations provides us with more power to identify 
factors associated with more rapid resistance accumulation in a more heterogeneous 
sample.
Patients in COLATE are followed up as frequently as MaxCmin patients (i.e. at 
baseline, and after 4, 12, 24, 36 and 48 weeks of follow-up) but they have more 
resistance data available than patients in the MaxCmin trials. In COLATE, resistance 
tests were performed whenever a patient had an HIV RNA > 500 copies/mL whereas in 
the MaxCmin studies, resistance tests were only performed at baseline and at the time 
of virological failure (if HIV RNA > 500 copies/mL). I re-ran the MaxCmin2 definition of 
failure on the COLATE patients and considered the resistance test taken closest to the 
time of failure to reflect the actual resistance profile at the time of failure. All three trials 
included patients who were ARV-experienced, Pl-experienced as well as ARV-nai've.
3.3.4. Treatment failure
Protocol-defined treatment failure was the primary outcome of the MaxCmin trials. This 
definition included observed virological failure, withdrawing consent, loss to follow-up 
and death. In this chapter I focus solely on patients who experienced observed 
virological failure because most of these patients will have paired resistance tests -  at 
baseline and at the time of failure (see 3.3.2). So a caveat of interpretation is that this 
chapter only investigates accumulation of resistance in the viral populations of patients 
with detectable viral load at baseline and at some point in follow-up (i.e. at failure) and 
not in all patients who started a Pl/r.
3.3.5. Mutation emergence:
Mutation emergence is considered to be the emergence of one or more new mutations 
in the PR gene between baseline and the time of virological failure (defined in one of 
the below three ways). Mutations that were categorised as being part of a mixture 
originally, that emerged as a full mutation or were observed as being part of another 
mixture at the time of failure, were not considered as evolution.
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Primary PI mutations are defined by the IAS-USA Drug Resistance Mutations Group 
(September 2006)233 as one or more of: D30N, V32I, L33F, M46I/L, I47A/V, G48V, 
I50L/V, I54LVM, L76V, V82A/F/LT/S, 184V, N88S and L90M.
Pi-specific mutations -  mutations in bold reflect primary mutations to the Pl/r in 
question, those not in bold reflect secondary PI mutations.
IDV/r mutations are defined by the IAS-USA Drug Resistance Mutations Group 
(September 2006)233 as one or more of: L10I/R/V, K20M/R, L24I, V32I, M36I, M46I/L, 
154V, A71V/T, G73S/A, V77I, V82A/F/T, 184V, and L90M.
SQV/r mutations are defined by the IAS-USA Drug Resistance Mutations Group 
(September 2006)233 as one or more of: L10I/R/V, L24I, G48V, I54V/L, I62V, A71V/T, 
G73S, V77I, V82A/F/T/S, I84V, and L90M.
LPV/r mutations are defined by the IAS-USA Drug Resistance Mutations Group 
(September 2006)233 as one or more of: L10F/I/R/V, K20M/R, L24I, V32I, L33F, M46I/L, 
I47V/A, 150V, F53L, I54V/LWM/T/S, L63P, A71V/T, G73S, V82A/F/T/S, I84V, and 
L90M.
Any PR mutation
The emergence of a PR mutation is defined to be the emergence of a new amino-acid 
at any of the entire list of PR codons sequenced, compared to the amino-acids seen in 
the baseline sequence (i.e. any amino-acid change from HXB2 that was not seen at 
baseline). The HIV protease is a 99 amino-acid peptide, so if a patient had a virus that 
contained the same amino-acids, aligned in the same way as HXB2 at baseline, that 
patient’s virus could undergo a maximum of 99 mutational changes between baseline 
and virological failure, although not all changes would result in a functional virus.
3.3.6. Laboratory methods
For this analysis, samples were extracted from the central plasma repository based on 
the following criteria. Baseline samples were sequenced if the viral load was 
detectable above >500 copies/mL. Samples at the time of virological failure were 
taken as close as possible to the time of virological failure in the MaxCmin studies (if 
HIV RNA >500 copies/mL), although the original definitions of virological failure did 
differ between trials. In COLATE, samples were extracted for resistance testing 
whenever HIV RNA was >500 copies/mL. Samples from patients fulfilling one or both 
of these criteria were selected for further analysis.
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These samples were shipped on dry ice, in batches, to a central testing facility for 
protease gene sequencing. For MaxCminl and COLATE the testing facility was the 
International Clinical Virology Centre (ICVC, UK), and for MaxCmin2 it was Advanced 
Biological Laboratories (ABL, Luxembourg). Nucleotide sequences in each database 
were collected, quality assured and translated to the corresponding amino acid 
sequence.
3.3.7. Statistical analysis
The primary objective of this analysis was to summarise the new primary PI mutations 
that emerged at the time of virological failure and to investigate factors associated with 
resistance emergence. I included all patients who started a Pl/r in any of the three 
trials and investigated factors associated with virological failure using logistic 
regression analysis. The subgroup of patients who experienced virological failure and 
had resistance tests available was then identified in order to investigate resistance 
emergence in the predominant virus of patients who were failing a Pl/r containing 
regimen.
Among patients with resistance data, chi-squared and Fisher’s exact tests were used to 
compare categorical variables at baseline between patients receiving each Pl/r. 
Continuous variables were analysed using analysis of variance analysis (ANOVA) or 
Kruskal-Wallis tests depending on the distribution. Logistic regression analysis 
(unadjusted and multivariable) was performed to investigate predictors of virological 
failure and predictors of resistance emergence (appendix IV). All non-co-linear 
variables that were significant at the 20% level in the unadjusted analysis were retained 
for inclusion in the final multivariable models. All statistical analyses were performed 
using STATA (StataCorp. 2001. Stata Statistical Software: Version 9.2, College 
Station, Texas, USA).
3.4. Results
3.4.1. Patient flow and disposition
There were 799 patients who were enrolled into the three trials (324 in MaxCminl, 339 
in MaxCmin2 and 136 in COLATE). A total of 663 patients were enrolled into the 
MaxCmin trials and of these 630 initiated a Pl/r. The other 33 patients did not initiate 
their randomised Pl/r and were not included in the comparisons. In COLATE, there 
were 38 patients who received IDV/r, 16 who received SQV/r and 28 who received 
LPV/r. Overall, a total of 712 patients initiated a Pl/r in the three trials: 196 (27.5%) 
patients initiated IDV/r, 325 (45.6%) received SQV/r and 191 (26.8%) received LPV/r 
(Figure 3.4.1.1).
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Figure 3.4.1.1: Disposition of patients in this chapter
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sample only
N=2
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available at 
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Resistance tests 
available at 
baseline and failure 
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Pl-naive with failure 
sample only
N=1
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N=4
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treatment
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Patients receiving Indinavir/r (N=196)
MaxCmin patients receiving indinavir/r (N=158) 
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MaxCmin patients receiving lopinavir/r (N=163) 
COLATE patients receiving lopinavir/r (N=28)
Patients receiving saqulnavir/r (N=325)
MaxCmin patients receiving saquinavir/r (N=309) 
COLATE patients receiving saquinavir/r (ISM 6)
Of the 712 patients who started a Pl/r in any of the trials: 562 (78.9%) were male, 349 
(49.0%) were infected through homosexual contact and 246 (34.6%) through heterosexual 
contact, 564 (79.2%) were white and 220 (30.9%) had a CDC stage C disease at baseline. 
The majority of patients were ARV-experienced at baseline (N=530, 74.4%), but fewer 
were Pl-experienced (N=420, 59.0%). Pl-experienced patients had been exposed to a 
median (IQR) of one (one to two) Pis prior to entry, for a median (IQR) duration of 3.2 (1.8 
to 4.3) years. At baseline the median (IQR) HIV RNA was 4.9 (4.3 to 5.5 log10 cps/mL) for 
Pl-naive patients and 3.2 (1.7 to 4.5 log10 cps/mL) for Pl-experienced patients. Overall, 
the median (IQR) CD4+ T cell count was 268 (125 to 431 cells/pL).
A total of 146 patients experienced virological failure in the combined trials using the 
MaxCmin2 definition of failure (54 in MaxCminl, 70 in MaxCmin2 and 22 in COLATE). In 
unadjusted logistic regression analysis, the specific Pl/r used was not associated with 
virological failure. After adjustment, in a multivariable logistic regression analysis, there 
was still no association with the Pl/r, but there was a strong association between the use 
of ARVs prior to study entry and the odds of virological failure (odds ratio: 4.73 for patients 
with previous ARV exposure compared to those who are ARV-naive; 95% Cl: 2.73 to 8.20, 
p<0.0001) and between the baseline HIV RNA level and the odds of virological failure (OR: 
1.69 per log10 cps/mL higher; 95% Cl: 1.41 to 2.03, p<0.0001). Other predictors of 
virological failure are outlined in Table 3.4.1.1.
It was not possible to include all patients who failed their Pl/r in the analyses investigating 
the emergence of resistance mutations. Ten (6.8%) patients had an HIV RNA < 500 
copies/mL at baseline so did not have a baseline resistance test available. In 23 of the 
remaining 136 (16.9%) patients, a lack of ability to amplify and sequence the protease 
gene meant that the baseline resistance test was not available and in 38 of the remaining 
113 (33.6%) cases it was not possible to amplify and sequence the protease gene at 
failure.
So, of the 146 patients who experienced virological failure, 75 (51.3%) had genotypic 
resistance tests (IDV/r: N=21; SQV/r: N=36; LPV/r: N=18) at both baseline and at the time 
of failure and an additional seven patients were PI-naTve at baseline and had a failure 
resistance test only (IDV/r: N=2; SQV/r: N=4; LPV/r: N=1, Figure 3.4.1.1). The seven Pl- 
nai've patients who only had a resistance test at the time of failure were assumed to have 
a virus that did not contain any mutations at baseline. These patients were combined with 
the 75 patients with paired resistance tests to give a total study population of 82.
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Table 3.4.1.1: Virological failure according to baseline characteristics 
The odds of experiencing virological failure, for all three trials combined
Baseline parameter
Unadjusted 
analysis 
Odds ratio 
(95% Cl)
P-value Multivariable 
analysis 
Odds ratio 
(95% Cl)
P-value
Pl/r:
IDV/r
LPV/r
SQV/r
Ref
0.79 (0.48,1.31) 
1.01 (0.65, 1.55)
0.55
Ref
0.64 (0.37,1.11) 
0.99 (0.62, 1.58)
0.17
ARV naive (experienced vs naive) 2.22 (1.36,3.62) 0.0007 4.73 (2.73,8.20) <0.0001
PI-naive (experienced vs naive) 1.61 (1.09,2.36) 0.02 - -
Gender (female vs male) 1.12 (0.72,1.74) 0.61 - -
Age (per 5 years older) 0.95 (0.86,1.05) 0.29 - -
Race:
White
Black
Other/unknown
Ref
1.95 (1.23,3.09) 
1.06 (0.48,2.36)
0.02
Ref
1.69 (0.97,2.94) 
0.66 (0.26,1.64)
0.08
HIV exposure group:
Homo-/bisexual
IVDU
Haemophiliac/transfusion
Heterosexual
Other/unknown
Ref
2.19 (1.18,4.06) 
1.34 (0.43,4.15) 
1.69 (1.12,2.54) 
2.14 (0.97,4.70)
0.03
Ref
1.93 (0.98,3.80) 
1.33 (0.40,4.47) 
1.28 (0.78,2.10) 
1.79 (0.75,4.27)
0.34
CDC, cat. C (Y vs N) 1.53 (1.04,2.23) 0.03 1.70 (1.11,2.60) 0.01
HIV RNA (per log10 cps/mL higher) 1.36 (1.19,1.56) <0.0001 1.69 (1.41,2.03) <0.0001
CD4+ count (per 100 cells/pL higher) 0.90 (0.82,0.98) 0.01 1.02 (0.91,1.14) 0.76
CD4+ nadir (per 100 cells/pL higher) 0.99 (0.86,1.14) 0.93 - -
BMI (per 5 kg/m2 higher) 0.98 (0.78, 1.25) 0.89 - -
I assumed that Pl-naive patients without a baseline resistance test had a virus without any
baseline mutations in the analysis investigating Pl-specific mutations and in the analysis 
investigating primary PI mutations because the prevalence of transmitted PI resistance is 
low. However, these patients were excluded from the analysis investigating the 
emergence of any new PR-mutation (i.e. not only IAS-USA mutations) due to a high 
prevalence of naturally occurring polymorphisms.
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3.4.2. Baseline characteristics
Of the 82 patients with a resistance test at virological failure, 14 (17.1%) were ARV naive 
at baseline, 16 (19.5%) PI naive but ARV experienced and 52 (63.4%) were Pl- 
experienced (Table 3.4.2.1). The 52 Pl-experienced patients had been exposed to a 
median (IQR) of two (one to three) Pis prior to entry, for a median (IQR) duration of 3.0 
(1.0 to 4.4) years. Evidence of PI failure in the year preceding baseline (i.e. HIV RNA 
£400 cps/mL) was found in 39 (75.0%) of the 52 Pl-experienced patients.
Table 3.4.2.1: Baseline characteristics of the patients included in the analysis
Baseline parameter IDV/r
N=23
SQV/r
N=40
LPV/r
N=19
Antiretroviral naive No. (%)
PI-naive
Pl-experienced with
Viral load £400 copies/m L 
Viral load <400 copies/mL
3 (13.0%) 
5(21.7%)
15 (65.2%) 
0 (0.0%)
10 (25.0%) 
8 (20.0%)
20 (50.0%) 
2 (5.0%)
1 (5.3%)
3 (15.8%)
15 (79.0%) 
0 (0.0%)
Of PI-experience patients, the no. (%) with Pl- 
failure in the year before entry
9 (60.0%) 19 (86.4%) 11 (73.3%)
CDC, cat. C No. (%) 10 (43.5%) 14 (35.0%) 9 (47.4%)
HIV RNA (c/mL log10) Median (IQR) 4.3 (3.5, 5.1) 4.7 (4.0, 5.2) 4.6 (4.0, 5.3)
CD4+ (cells/pL)* Median (IQR) 260 (115, 379) 236 (104, 334) 233 (32, 359)
CD4+ nadir (cells/pL) Median (IQR) 107 (43, 170) 99 (31,227) 47 (20, 180)
Age Median (IQR) 40 (30,42) 39 (32,49) 41 (38,45)
Gender No. Male (%) 16 (69.6%) 32 (80.0%) 17(89.5%)
HIV exposure group No. (%)
Homo-/bisexual
IVDU
Haemophilia/transfusion
Heterosexual
Other/unknown
9(39.1%) 
2 (8.7%)
1 (4.4%) 
9(39.1%)
2 (8.7%)
18 (45.0%) 
3 (7.5%)
0 (0.0%) 
18(45.0%) 
1 (2.5%)
5 (26.3%) 
3 (15.8%) 
1 (5.3%) 
10 (52.6%) 
0 (0.0%)
Race No. (%)
White
Black
Other/unknown
18 (78.3%) 
4 (17.4%) 
1 (4.4%)
26 (65.0%) 
11 (27.5%) 
3 (7.5%)
11 (57.9%) 
8 (42.1%) 
0 (0 .0%)
BMI* Median (IQR) 23.9 (20.8,26.5) 23.4 (20.6,26.8) 23.8 (22.3,25.1)
PI Cmin level at week 4 Median ng/mL (IQR) 1924 (579, 3482) 1161 (424, 1831) 4684 (891, 7296)
Ritonavir Cmin at week 4* Median ng/mL (IQR) 1356 (365,1719) 348 (142,955) 217 (39,301)
* Variables followed by a star indicate missing measurements.
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Baseline resistance profiles are only summarised for the 75 patients who have baseline 
resistance data available. At baseline, 24 (32.0%) patients with a resistance test had a 
virus containing a primary PI mutation and 73 (97.3%) had a virus containing an amino- 
acid change from HXB2 (Table 3.4.2.2).
Table 3.4.2.2: Baseline resistance patterns of patients with baseline resistance tests
Baseline resistance:
IDV/r
N=21
SQV/r
N=36
LPV/r
N=18
Primary PI mutations at baseline, (No. (%)) None
1-2
>2
14 (66.7%) 
3 (14.3%) 
4(19.1%)
26 (72.2%) 
6 (16.7%) 
4 (11.1%)
11 (61.1%) 
4 (22.2%) 
3 (16.7%)
Baseline PR differences from HXB2, (No. (%)) None
1-3
4-6
7-9
>9
1 (4.8%) 
9 (42.9%) 
5 (23.8%) 
3 (14.3%) 
3 (14.3%)
1 (2.8%) 
19 (52.8%) 
8 (22.2%) 
7(19.4%) 
1 (2.8%)
0 (0.0%) 
7 (38.9%) 
4 (22.2%)
3 (16.7%)
4 (22.2%)
Phenotypic sensitivity to indinavir* 
Median tC^foldt (IQR)
1.0 (1.0, 1.5)
Phenotypic sensitivity to saquinavir* 
Median ICsofold? (IQR)
1.0 (1.0, 1.8)
Phenotypic sensitivity to lopinavir* 
Median ICsofold? (IQR)
1.2 (1.0, 2.0)
Phenotypic sensitivity to ritonavir* 
Median IC50 fold T (IQR)
1.0 (1.0, 2.0) 1.0 (1.0, 2.4) 1.8 (1.0, 3.0)
*Missing for patients in COLATE and patients in the MaxCmin studies without phenotyping, only 
available for 57 out of 75 (76.0%) patients.
3.4.3. Follow-up characteristics
Among the 82 patients with paired resistance data at baseline and at virological failure, 59 
(71.9%) were still on their baseline Pl/r (i.e. their trial Pl/r) at the time of failure. There 
were 63 (76.8%) patients who were receiving a Pl/r (not necessarily the trial Pl/r) at the 
time of failure and eight patients (9.8%) who were off antiretrovirals completely (IDV/r: 
N=4; SQV/r: N=4), yet this was still considered to be virological failure. The remaining 11 
patients had switched to a non-PI/r containing regimen before virological failure. The 
median (IQR) time from baseline to virological failure was 24 (12 to 33) weeks.
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Overall, the presence of primary PI mutations was relatively uncommon at the time of 
virological failure: 23 (28.1%) patients had a primary PI mutation and 80 (97.6%) patients 
had a PR difference from HXB2 in their predominant virus population at failure (Table
3.4.3.1). Among the 30 patients who were Pl-naive at baseline, two (6.7%) had a virus in 
which a primary PI mutation was detected and 29 (96.7%) had a virus in which a PR 
difference from HXB2 was detected, at failure. In contrast, among the 52 patients who 
were Pl-experienced at baseline, 21 (40.4%) had a virus in which a primary PI mutation 
was detected and 51 (98.1%) had a virus in which a difference from HXB2 was detected at 
the time of failure.
Table 3.4.3.1: Follow-up characteristics
Follow-up parameter:
IDV/r
N=23
SQV/r
N=40
LPV/r
N=19
Time from baseline to virological failure Med wks (IQR) 25 (13, 46) 24 (12, 30) 23 (11,25)
On baseline treatment at therapy failure No. (%) 16 (69.6%) 25 (62.5%) 18 (94.7%)
Primary PI mutations at therapy failure: (No. (%)) None
1-2
>2
19 (82.6%) 
0 (0.0%) 
4(17.4%)
28 (70.0%) 
8 (20.0%) 
4 (10.0%)
12 (63.2%) 
4(21.1%) 
3 (15.8%)
Any PR difference from HXB2: (No. (%))
None
1-3
4-6
7-9
>9
1 (4.4%) 
11 (47.8%) 
7 (30.4%)
1 (4.4%)
3 (13.0%)
1 (2.5%) 
21 (53.5%) 
10 (25.0%) 
4 (10.0%) 
4 (10.0%)
0 (0.0%) 
6(31.6%) 
6 (31.6%) 
2 (10.5%) 
5 (26.3%)
3.4.4. Emergence of primary PI mutations between baseline and failure
Of the 75 individuals who had their virus sequenced at both baseline and virological 
failure, there were 14 (18.7%) who experienced a change to their primary PI resistance 
profile. In five cases the change was from a virus, in which a primary PI mutation was 
detected at baseline, to a virus in which a primary PI mutation could not be detected at the 
time of failure, using population sequencing. This was regarded as a matter of de­
selection. De-selection can occur because most of the patients changed their whole 
antiretroviral regimen at baseline. So, mutations that occurred due to drug pressure from 
a previous regimen may no longer be detected because the drug pressure corresponding 
to the baseline mutations will have been removed. All five of these patients were Pl- 
experienced prior to entry. Three of the five (60.0%) were still on their baseline Pl/r at the 
time of failure, suggesting that de-selection of these mutations due to lack of pressure may 
not apply in all cases.
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From the seven Pl-naive patients with a resistance test at failure only, there was one 
(14.3%) who had a virus in which a primary PI mutation was detected (assumed not to 
have been present at baseline). Overall, there were a total of 15 (18.3%) patients who 
experienced changes to the primary resistance mutations in the dominant virus population 
and 9 (11.0%) who showed emergence of a new primary PI resistance mutation (Table
3.4.4.1).
Table 3.4.4.1: Individuals who experienced a change to their primary PI mutations
Patient
Primary PI mutations New
mutations
gained
Mutations
lost
Pl-nafve
at
baseline
On BL-PI/r 
at failure
On a PI 
at 
failureBaseline Failure
IDV/r
1500004 M46I; V82L; 
L90M
M46I; V82L; 
L90M
No Yes Yes
2004112 M46I M46I No No No
2012105 D30N;
L90L/M
D30D/N; I54I/L; 
L90L/M
I54I/L No No Yes
8000001 M46I; N88S M46I; N88S No Yes Yes
SQV/r
1100213 L90M 184V; L90M; I84V No Yes Yes
1111203 M46I/M; 
I84I/V; L90M
184V; L90M M46I/M No Yes Yes
1213214 M46I/M; V82A; 
L90M;
M46I/M;
V82A;
L90M
No Yes Yes
1224202* L90L/M L90LVM Yes Yes Yes
1503115 V82A; V82A; I84I/V; I84I/V No Yes Yes
1503202 D30D/N;
M46I/M;
L90L/M;
D30D/N;
M46I/M;
L90L7M
No No No
3003102 D30N; M46I; D30N; M46I; 
I84V;
I84V No Yes Yes
5502102 M46I/M; M46I/M Yes No No
8500102 M46I/M;
G48V;
V82A/V;
L90L/M;
M46I/M; G48V;
V82A;
184V; L90L7M;
I84V No Yes Yes
LPV/r
2500061 M46I/M;
V82A/V;
L90M
M46I/M; 
V82A/S; L90M
No Yes Yes
2500063 M46I; 184V; 
L90M
M46I; L76V/L; 
184V; L90M
L76V/L No Yes Yes
* Pl-naive at baseline with a failure sample only.
• Bl-PI/r refers to the Pl/r received at baseline
3.4.4.1. New primary PI mutations
Patients included in these analyses have a cumulative follow-up time of 36.9 person years 
between baseline and the time of virological failure. Over this time period, 11 new primary
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PI mutations emerged and ten primary PI mutations disappeared from the dominant virus 
populations of these patients. This translates to an acquisition rate of 0.30 (0.12 to 0.47) 
new primary PI mutations per person-years follow-up and a de-selection rate of 0.27 (0.10 
to 0.44) primary PI mutations per person-years follow-up. These figures should be 
interpreted with caution because some mutations may actually be present in the viral 
subspecies at baseline, but remain undetected because resistance testing methods do not 
always capture every mutation in the virus populations, especially those that are present in 
low levels.
Out of the nine patients in whom a new primary PI mutation emerged in their dominant 
virus population, seven (77.8%) were exposed to Pis prior to baseline and six had primary 
PI mutations in their predominant virus at baseline (Table 3.4.4.1). Among the new 
primary PI mutations that emerged at time of failure, emergence at codon 84 was the most 
frequently observed (Figure 3.4.4.1.1).
Figure 3.4.4.1.1: Emergence of mutations at each codon for patients with a virus that 
acquired a primary PI mutation
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3.4.4.2. Treatment use at virological failure
Seven of the nine (77.8%) patients who experienced emergence of a new primary PI 
mutation, remained on their Pl/r at the time of failure (IDV/r: N=0 (0.0%); SQV/r: N=6 
(85.7%); LPV/r: N=1 (100%)). Similarly, 52 of the 73 (71.2%) patients who did not 
experience primary PI mutation emergence in their viral populations were on their Pl/r at 
the time of failure (IDV/r: N=16 (72.7%); SQV/r: N=19 (57.6%); LPV/r: N=17 (94.4%)). The
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proportion of individuals who experienced primary PI mutation emergence in their viral 
populations, among those receiving their Pl/r at time of failure, was 11.9% (7 out of 59).
3.4.4.3. Predictors of primary PI mutation emergence
To identify factors associated with the emergence of a new primary PI mutation a logistic 
regression model was used. All variables that were associated with the emergence of a 
new primary PI mutation were identified using the 20% level of significance because of the 
small numbers. These variables were then entered into a multivariable model and 
retained in the model if they were still significant (p<0.20) after adjustment (Table
3.4.4.3.1). Since logistic regression models are not very stable if there are few events, the 
results of this model should also be interpreted with caution.
Marginally more patients who received SQV/r or LPV/r acquired a new primary Pl-mutation 
in their predominant virus, compared to patients who received IDV/r; albeit this trend was 
not significant. Plasma PI levels and plasma ritonavir levels four weeks after Pl/r initiation 
were not significant predictors of the emergence of a new primary PI mutation in 
unadjusted analysis. PI naivety was not protective against primary PI mutation emergence 
either (data not shown). After adjustment, the presence of primary PI mutations at 
baseline was the only predictor of the emergence of new primary PI mutations.
Table 3.4.4.3.1: Baseline predictors of a new primary PI mutation emerging
Unadjusted 
analysis 
OR (95% Cl)
P-value Multivariable 
analysis 
OR (95% Cl)
P-value
Treatment:
IDV/r
SQV/r
LPV/r
Ref
4.67 (0.54,40.61) 
1.22 (0.07,20.94)
0.16 Ref
7.11 (0.60,84.88) 
3.39 (0.14,80.90)
0.19
Primary PI mutations 
present (Yes vs No)
4.10 
(1.60, 10.50)
0.003 3.70 
(1.21, 11.28)
0.02
Baseline HIV RNA level
(per 1 log10 higher)
0.64 
(0.32, 1.27)
0.20 0.79 
(0.29, 2.19)
0.65
Baseline CD4+ T cell count
(per 100 cell higher)
1.24 
(0.93, 1.66)
0.14 1.17 
(0.74, 1.86)
0.51
Nadir CD4+ T cell count
(per 100 cell higher)
1.19 
(0.81, 1.75)
0.37 - -
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3.4.5. Additional analyses
3.4.5.1. Mutations associated with resistance to the baseline Pl/r
Pl-specific resistance mutations were identified from the IAS-USA (Sept 2006) mutation 
lists and are defined in section 3.3.5. Of the 82 individuals who were included in these 
comparisons, 25 (30.5%) had a virus that underwent a change to their Pl-specific 
resistance profile (i.e. either a Pl-specific mutation emerged or disappeared from the 
predominant virus). In 15 (18.3%) of these patients a new Pl-specific resistance mutation 
emerged in the dominant virus population (Table 3.4.5.1.1). All of these patients were still 
on their baseline Pl/r when they experienced virological failure. Since 59 patients overall 
were on their baseline Pl/r at the time of virological failure, the proportion of individuals in 
whom a Pl-specific mutation emerged whilst receiving a Pl/r was 25.4% (i.e. 15 out of 59).
Table 3.4.5.1.1: PI specific mutations
Patient
Mutations to the baseline Pl/r New
mutations
gained
Mutations
lost
Pl-naive 
at BL
On BL- 
Pl/r at 
failure
On a 
Plat 
failureBaseline Failure
IDV/r
1500004 M46I, A71T, 
V77I, L90M;
M36I M36I M46I,
A71T,
V77I,
L90M;
No Yes Yes
1501002 L10V, M36I L10I, M36I No Yes Yes
1501003 L10L7V L10LVV No Yes Yes
2004112 L10L/V, 
M36I, M46I
M36I L10L7V,
M46I
No No No
2012105 A71V, 
V77V/I, 
L90L7M
V77I, L90LVM A71V No No Yes
2500059 L10I, 154V, 
A71V, 
G73G/S, 
184V, L90M
A71V, 184V, 
L90M
L10I, 154V, 
G73G/S,
No Yes Yes
8000001 L10V, 
K20R, M36I, 
M46I
M36I L10V,
K20R,
M46I
No Yes Yes
SQV/r
1100213 I62I/V,
L90M
A71V, 184V, 
L90M
A71V, 184V I62I/V No Yes Yes
1111203 L10F/I/L,
I62I/V,
A71A/V,
V77I/V,
I84I/V,
L90L/M
162V, A71V, 
G73S, V77I, 
184V, L90M
G73S L10F/I/L No Yes Yes
1213214 I62I/V L10I, 154V, 162V, 
A71V, G73S, 
V77I/V, 182A, 
L90M
L10I, 154V, 
A71V, 
G73S, 
V77I/V, 
I82A, L90M
No Yes Yes
1224202 - L90L/M L90L/M Yes Yes Yes
1501103 V77I L10V, 162V L10V, I62V V77I No Yes Yes
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Patient
Mutations to the baseline Pl/r New
mutations
gained
Mutations
lost
Pl-naive 
at BL
On BL- 
Pl/r at 
failure
On a 
Plat 
failureBaseline Failure
SQV/r
1503115 L10I, L24I,
154V, I62I/V, 
A71A/I/WT, 
V77I, V82A
L10I, L24I, 154V, 
I62I/V,
A71 A/l/V/T, V77I, 
V82A, I84I/V
I84I/V No Yes Yes
1503202 I62V,
L90L/M
I62I/V L90L/M No No No
1504102 L10I/L,
154V, L90M
154V, L90M L10I/L No Yes Yes
3003102 L10I/V,
A71A/V
V77I/V
L10V, A71V, 
I84V
I84V V77I/V No Yes Yes
8500102 G48V,
I54I/V,
V77I/V,
V82A/V,
L90L/M
L10I, G48V, 
I54I/V, V77I/V, 
V82A, I84I/V, 
L90L/M
L10I, I84I/V No Yes Yes
LPV/r
1101203 L10I,
K20K/M,
154V, A71V, 
V82A, L90M
L10I, I54V, A71V, 
V82A, L90M
K20K/M No Yes Yes
1401209 L10I, K20R, 
M46I, 154V, 
V82A
L10I/V, K20R, 
L24I/L, M46I,
154V, V82A
L24I/L No Yes Yes
2000215 L63P L63P Yes Yes Yes
2500054 L10I, L24I, 
M46I, 
F53F/L,
154V, V82A
L10I/F, K20R, 
L24I, M46I, F53L, 
154V, V82A
K20R No Yes Yes
2500061 L1 OF, 
M46I/M,
154V, L63P, 
A71A/V, 
V82A/V, 
L90M
L10F, K20R, 
M46I/M, 154V, 
L63P, A71V, 
V82A/S, L90M
K20R No Yes Yes
2500063 L10I, M46I, 
L63P, A71V, 
G73S, 184V, 
L90M
L10I, M46I, 154V, 
L63P, A71V, 
G73S, 184V, 
L90M
I54V No Yes Yes
6500201 L63P L63P Yes Yes Yes
8500058 L10I/IW,
M46I,
F53F/L,
154V, L63P, 
A71V, 
V82A, L90M
L10I/L, M46I, 
F53F/L, 154V, 
L63P, A71V, 
V82A, L90M
No Yes Yes
* Mutations in bold reflect primary Pl-specific mutations (not all primary PI mutai 
Mutations not in bold refer to secondary Pl-specific mutations.
ions).
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3.4.5.2. The rate of acquisition of new Pl-specific mutations 
(i.e. mutations associated with resistance to the baseline Pl/r)
During follow-up, 24 new Pl-specific mutations emerged in the dominant virus of 15 
patients (1 IDV-specific mutation over 12 person years of follow-up; 17 SQV-specific 
mutations over 17.7 person years of follow-up; and 6 LPV-specific mutations over 7.2 
person years of follow-up). This translates to an overall acquisition rate (95% Cl) of 0.65 
(0.39 to 0.91) new Pl-specific mutations per person-years follow-up. Patients who 
received SQV/r had the fastest acquisition rate (0.96 (0.50 to 1.41) new SQV-specific 
mutations per person-years follow-up) and patients who received IDV/r the slowest (0.08 
(0.00 to 0.25) new IDV-specific mutations per person-years follow-up). Patients who 
received LPV/r had an acquisition rate of 0.83 (0.17 to 1.50) new LPV-specific mutations 
per person-years follow-up.
For the 15 patients in whom a Pl-specific mutation emerged, 12 (80.0%) were exposed to 
Pis prior to baseline and ten (66.7%) had a primary PI mutation in their dominant virus at 
baseline. The most common site for SQV-specific mutations was at codon 84 (N=4), for 
LPV-specific mutations it was at codons 20 (N=2) and 63 (N=2) and only one IDV-specific 
mutation emerged and this was at codon 36 (Figure 3.4.5.2.1).
Figure 3.4.5.2.1: Mutational emergence at each codon, for patients with a virus that 
acquired a Pl-specific mutation
IDV/r (N=1) SQV/r (N=8) LPV/r (N=6)
c  5
9
1
i  3 
!■
i: i
10 20 24 36 54 71 73 77 82 84 90
Codon Position
Of note, in three (50.0%) of the six patients who failed an IDV/r containing regimen, who 
no longer had indinavir-specific mutations in their predominant virus, one of the mutations 
that was no longer detectable was a primary indinavir-specific mutation (i.e. the M46I 
mutation in all cases). Only two primary mutations to the Pl/r in question emerged in the 
dominant viral species overall; and both of these were seen in patients treated with SQV/r 
(i.e. the L90M mutation in both cases). The other 22 mutations that emerged were all 
secondary PI mutations (for the Pl/r the patient was receiving).
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10 24 54 62 71 73 77 82 84 90
Codon Position
10 20 24 54 63 71 73 82 84 90
Codon Position
3.4.5.3. Predictors of Pl-specific mutation emergence
To identify factors associated with the emergence of a new Pl-specific mutation, a logistic 
regression model was used. Since more Pl-specific mutations emerged in the dominant 
virus of these patients than primary PI mutations, results from this logistic regression 
analysis will be more robust than the model in 3.4.4.3. The odds of a Pl-specific mutation 
emerging in the predominant virus population was lowest for patients who received IDV/r 
and highest for patients who received LPV/r (Table 3.4.5.3.1). Patients who were Pl- 
experienced prior to entry were at marginally higher odds of experiencing Pl-specific 
mutation emergence in their viral population, but after adjustment for the presence of 
primary PI mutations at baseline, this trend reversed and was not significant. In this 
analysis, the presence of primary PI mutations at baseline was the strongest predictor of a 
Pl-specific mutation emerging.
Table 3.4.5.3.1: Baseline predictors of the emergence of a Pl-s pecific mutation
Unadjusted analysis 
OR (95% CO
P-value Multivariable analysis 
OR (95% Cl)
P-value
Treatment:
IDV/r
SQV/r
LPV/r
0.18 (0.02,1.56) 
Ref
1.85 (0.53,6.38)
0.05 0.11 (0.01,1.10) 
Ref
2.10 (0.48,9.16)
0.02
Pl-experienced at baseline
(Yes vs No)
2.70 
(0.70, 10.48)
0.15 0.42 
(0.05, 3.22)
0.40
AIDS at baseline
(Yes vs No)
1.38 
(0.45, 4.26)
0.58 - -
Primary PI mutations 
present (Yes vs No)
7.57 
(2.23, 25.76)
0.001 12.86 
(2.13, 77.74)
0.005
Baseline HIV RNA level
(per 1 log10 higher)
0.65 
(0.37, 1.16)
0.14 0.54 
(0.26, 1.13)
0.10
Baseline CD4* T cell count
(per 100 cell higher)
1.03 
(0.79, 1.35)
0.82 - -
Nadir CD4+ T cell count
(per 100 cell higher)
0.85 
(0.53, 1.36)
0.50 - -
3.4.5.4. The emergence of any PR mutation from baseline
This analysis was restricted to patients with both baseline and failure resistance tests and 
did not include patients with resistance tests at the time of failure only, due to the unknown 
prevalence of naturally occurring polymorphisms. Of the 75 individuals with baseline and 
failure genotyping, there were 46 (61.3%) who experienced a change in their predominant 
virus populations (i.e. any change to an amino-acid in any position); 33 (44.0%) of these 
patients had a virus in which the change was from a baseline amino-acid that was 
expected according to HXB2 to a follow-up amino-acid that was not (Table 3.4.5.4.1).
100
Table 3.4.5.4.1: Emergence of any PR mutation from baseline
Patient
Any PR mutation from baseline New
mutations
gained
Mutations
lost
Pl- 
naTve 
at BL
On BL- 
Pl/r at 
failure
On a 
Plat 
failureBaseline Failure
IDV/r
1000103 113V, S37N, 164V, 
V77I, L90FL
113V, S37N, 164V, 
V77I
L90FL Yes Yes Yes
1100102 T12N, S37D, K43R, 
L63P, L89LM
T12N, S37D, 
K43R, L63P
L89LM No No No
1500003 V3I, 113V, 115V, 
M36I, S37DN, 
K43R, 162V, L63P
V3I, T12ST, I13IV, 
I15IV, M36I, 
S37DN, K43R, 
I62V, L63P
T12ST No Yes Yes
1500004 V3I, T12AT, S37N, 
M46I, Q58E, L63P, 
A71T, V77I, V82L, 
L90M
V3I, 113V, 115V, 
M36I, S37D, 
K43R, I62V, L63P
113V, 115V, 
M36I, 
K43R, 162V
T12AT, 
M46I, Q58E, 
A71T, V77I, 
V82L, L90M
No Yes Yes
1501002 V3I, L10V, 113V, 
G16EG, E35D, 
M36I, S37N, R41K, 
R57K, L63PS, 
H69K, L89M
V3I, L10I, 113V, 
G16E, E35D, 
M36I, S37N, 
R41K, R57K, 
L63S, H69K, L89M
No Yes Yes
1501003 V3I, L10LV, T12A, 
K14KR, S37N, 
R41K, L63P, I93L
V3I, T12A, S37N, 
R41K, L63P, I93L
L10LV,
K14KR
No Yes Yes
1501008 V3I, M36I, S37D, 
Q61H, H69HQ, 
I72IV
V3I, 1151V, M36I, 
S37D, Q61H, 
I72IMV
I15IV H69HQ No Yes Yes
1503101 L10IL, K20R, V32I, 
E35D, M36I, S37D, 
M46I, I47V, K55R, 
Q58E, I62IV, L63P, 
V82A, I93L
L10IL, K20R, V32I, 
E35D, M36I, 
S37D, M46I, I47V, 
K55R, Q58E, 
L63P, V82A, I93L
I62IV No Yes Yes
2004112 L10LV, 113V, 115V, 
E35D, M36I, S37N, 
R41K, M46I, R57K, 
H69K, L89T
113V, 115V, E35D, 
M36I, S37N, 
R41K, R57K, 
H69K, L89M
L10LV, M46I No No No
2012105 113V, K14R, 115V, 
K20T, D30N, S37N, 
L63P, I66FI, A71V, 
I72V, V75IV, V77IV, 
N88D, L90LM
D30DN, S37N, 
R41K, I54IL, I62V, 
L63P, V77I, V82IV, 
N88D, L90LM, 
I93L
R41K, 
I54IL, I62V, 
V82IV, I93L
113V, K14R, 
115V, K20T, 
I66FI, A71V, 
I72V, V75IV
No No Yes
2012115 S37N, L63P, I72IV, 
V77IV, I93L
S37N, L63P, 
V77IV, I93L
I72IV Yes No No
2500059 V3I, L10I, 113V, 
L19I, E21DE, L33F, 
E35D, S37D, I54V, 
D60E, 162V, L63P, 
I66F, A71V, I72L, 
G73GS, 184V, L90M
V3I, L10F, 113V, 
L19I, E21D, L33F, 
E35D, S37DE, 
I54A, D60E, 162V, 
L63P, I66F, A71V, 
I72L, 184V, L90M
G73GS No Yes Yes
8000001 V3I, L10V, 113V, 
K20R, E35D, M36I, 
S37D, R41K, M46I, 
R57K, H69K, N88S, 
L89M
V3I, T12AT, L19I, 
M36I, S37N, 
R41K, Q61HQ, 
L63S, H69K, 
L89M, I93L
T12AT, 
L19I, 
Q61 HQ, 
L63S, I93L
L10V, 113V, 
K20R, 
E35D, M46I, 
R57K, N88S
No Yes Yes
8500101 113V, 115V, K20R, 
M36I, S37N, R41K, 
H69K, L89M, I93L
113V, 115V, K20R, 
M36I, S37N, 
R41K, H69K, 
K70KR, L89M, 
I93L
K70KR Yes Yes Yes
8500106 S37N, L63P, V77I, 
I93L
S37N, L63P, 
I64IM, I72IV, V77I, 
I93L
I64IM, I72IV Yes No No
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Patient
Any PR mutation from baseline New
mutations
gained
Mutations
lost
PI- 
nai've 
at BL
On BL- 
Pl/r at 
failure
On a 
Plat 
failureBaseline Failure
SQV/r
1100116 115V, K20R, M36I, 
S37D, R41K, 
K45KR, R57K, 
(361N, L63T, I72IT, 
I93L
115V, K20R, M36I, 
S37D, R41K, 
K45KR, R57K, 
061N, L63T, I93L
I72IT No No No
1100213 V3I, 113V, 115V, 
K20T, E35D, M36I, 
S37N, R41K, R57K, 
D60E, Q61D, I62IV, 
L90M, I93L
V3I, 113V, 115V, 
K20T, E35D, M36I, 
S37N, R41K, 
R57K, D60E, 
061D, A71V, 184V, 
L90M, I93L
A71V, 184V I62IV No Yes Yes
1102208 V3I, L10IL, E35D, 
M36I, S37N, R41K, 
K45KR, R57K, 
Q61N, L63FLPS, 
I64L, I93L
Q2P, V3I, L10I, 
E35D M36I, S37N, 
R41K, K45KR, 
R57K, 061N, 
L63FS, I64L, I93L
Q2P Yes No No
1110212 V3I, L10LV, 115V, 
E35D, M36I, S37N, 
P39Q, R41K, R57K, 
D60E, 061D, I62IV
V3I, T4NT 
L10LV, 115V, 
E35D, M36I, S37N, 
P39Q, R41K, 
R57K, D60E, 
061D, I62IV
T4NT Yes Yes Yes
1111203 V3I, L10FIL, K14KR, 
I15LV, G16AG, 
K20KT, S37N, 
M46IM, I62IV, L63P, 
A71AV, V77IV, 
I84IV, I85IV, L90LM, 
I93IL
V3I, L1 OF, K14KR, 
115V, G16A, K20T, 
S37N, 162V, L63P, 
A71V, G73S, V77I, 
184V, 185V, L90M, 
I93L
G73S M46IM No Yes Yes
1111204 E35D, M36I, S37N, 
R41K, K45R, R57K, 
061S, I93L
V3I, E35D, M36I, 
S37N, R41K, 
K45R, R57K, 
061S, I93L
V3I No Yes Yes
1205102 L19Q, D25DN, 
S37CS, L63P, 
V77IV
L19Q, S37C, 
L63P, V77IV
D25DN No Yes Yes
1208204 V3, T4PT, S37N, 
R41KR, K43KR, 
L63LP, 164V
V3I, S37N, R41K, 
K43KR, L63P, 
I64V
T4PT Yes No No
1213208 V3I, S37N, L63P, 
H69HQ
V3I, S37N, R41KR, 
L63P
R41KR H69HQ No No No
1213214 V3I, S37N, K45R, 
I62IV, L63P, K70R, 
I72E
V3I, L10I, (131V, 
L19IL, S37N, 
K45R, M46IM,
154V, 061KQR, 
I62V, L63P, K70R, 
A71V, I72E, G73S, 
V77IV, V82A, 
L90M
L10I, I13IV, 
L19IL, 
M46IM, 
I54V, 
061 KQR, 
A71V, 
G73S, 
V77IV, 
V82A, 
L90M
No Yes Yes
1225205 V3I, S37N, L63A, 
E65DE
V3I, P9PS, 
I13ILPT, S37N, 
L63A, E65DE
P9PS, 
113ILPT
Yes Yes Yes
1501103 S37N, V77I L10V, K14R, 115V, 
E35D, S37N, I62V, 
L63P
L10V, 
K14R, 115V, 
E35D, I62V, 
L63P
V77I No Yes Yes
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Patient
Any PR mutation from baseline New
mutations
gained
Mutations
lost
PI- 
nai've 
at BL
On BL- 
Pl/r at 
failure
On a 
Plat 
failureBaseline Failure
SQV/r
1503002 V3I.T12S, 115V, 
L19T, M36I, S37N, 
R41K, 061E, L63P, 
H69K, V82I, L89M, 
I93L
V3I, T12S, 115V, 
L19T, M36I, S37N, 
R41K, K45KR, 
061EQ, L63P, 
H69K, V82I, L89M, 
I93L
K45KR No Yes Yes
1503115 L10I, L24I, S37T, 
R41K, 154V, I62IV, 
L63P, A71AITV, 
V77I, V82A, I93L
L10I, L24I, S37T, 
R41K, F53FL,
154V, I62IV, L63P, 
A71AITV, V77I, 
V82A, I84IV, I93L
F53FL,
I84IV
No Yes Yes
1503202 V3I, K20KT, D30DN, 
E35D, M36I, S37N, 
R41K, M46IM, I62V, 
L63P, T74ST, 
N88DN, L90LM
V3I, E35D, M36I, 
S37N, R41K, 
I62IV, L63P, I72IT
I72IT K20KT,
D30DN,
M46IM,
T74ST,
N88DN,
L90LM
No No No
1504102 L10IL, 115V, S37N, 
M46I, 154V, K55R, 
L63P, G73T, V82C, 
L90M
115V, S37N, M46I, 
F53L, 154V, K55R, 
L63P, G73T, 
V82C, L90M
F53L L10IL No Yes Yes
1504104 T12S, 113V, L19I, 
S37N, L63P, I64V, 
Q92K
T12ST, 113V, 
I15IV, L19IM, 
S37N, R41KR, 
K43KR, L63P, 
164V, Q92K
I15IV,
R41KR,
K43KR
No No No
3003102 L10IV, D30N, S37N, 
M46I, L63PQ, I64V, 
E65D, A71AV, 
V75IV, V77IV, 
N88D, I93L
L10V, D30N, 
S37N, M46I, L63Q, 
164V, E65D, A71V, 
T74P, 184V, N88D, 
I93L
T74P, 184V V75IV,
V77IV
No Yes Yes
5502102 L10I, T12RT, 113V, 
M36I, S37N, R41K, 
L63T, 164V, E65D
L10I, T12RT, 113V, 
M36I, S37N, R41K, 
M46IM, L63T,
164V, E65D
M46IM Yes No No
8500102 S37N, M46IM, 
G48V, I54IV, 164V, 
T74AT, V77IV, 
V82AV, L90LM
L10I, M36IM, 
S37N, M46IM, 
G48V, I54IV, 164V, 
T74AITV, V77IV, 
V82A, I84IV, 
L90LM
L10I,
M36IM,
I84IV
No Yes Yes
LPV/r
1101203 V3I, L10I, K20KM, 
E35D, M36I, S37N, 
R41K, 154V, R57K 
061N, L63S, I64L 
A71V, V82A, L90M, 
I93L
V3I, L10I, E35D, 
M36I, S37N, R41K, 
154V, R57K, 061N, 
L63S, I64L, A71V, 
V82A, L90M, I93L
K20KM No Yes Yes
1102207 V3I, L10I, 115V 
K20R E35D, M36I, 
S37N, R41K, 154V, 
R57K, Q61N, 
L63LP, I72T, 
T74AT, V82A
V3I, L10I, 115V 
K20R, E35D, M36I, 
S37N R41K 
K43KR, 154V, 
R57K, 061N, 
L63P, I72T, 
T74AT, V82A
K43KR No Yes Yes
1213202 V3I, L10I, 113V, 
L19I, S37N, L63P, 
H69Q, A71T
V3I, L10I, 113V, 
L19I, T26ST, 
T31AT, S37N, 
L63P, H69QA71T
T26ST,
T31AT
Yes Yes Yes
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Patient
Any PR mutation from baseline New
mutations
gained
Mutations
lost
Pl- 
naive 
at BL
On BL- 
Pl/r at 
failure
On a 
Plat 
failureBaseline Failure
LPV/r
1213209 R41K, L63P, I64L, 
V77I
V3I, E35DE, R41K, 
L63P, I64L, V77I
V3I, E35DE No Yes Yes
1219201 V3I, M36I, S37D, 
R57K, D60E, L63P, 
C67CW
V3I, M36I, S37D, 
R57K, D60E, L63P
C67CW No No No
1401209 V3I, L10I, 113V, 
K20R, M36I, S37N, 
R41K, M46I, I54V, 
I62V, L63T, I64V, 
E65D, V82A
V3I, L10IV I13IV, 
K20R, L24IL, M36I, 
S37N, R41K, M46I, 
154V, I62V, L63T,
164V, E65D, V82A, 
I93L
L24IL, I93L No Yes Yes
1501006 V3I.T12I, E35D, 
R41K, I62M, L63P, 
A71V, I93L
V3I, T12AITV, 
L19IL, E35D, 
R41K, I62IMV, 
L63P, A71AV, I93L
L19IL No Yes Yes
2000215 V3I, 113V, E35D, 
M36I, S37N, R41K, 
R57K, H69K, L89M
V3I, 113V, E35D, 
M36I, S37DN, 
R41K, R57K, 
L63P, H69K, L89M
L63P Yes Yes Yes
2500054 V3I, L10I, 115V, 
L24I, E35D, M36V, 
S37N, K43T, M46I, 
F53FL, 154V, K55R, 
I62V, L63A, I64V, 
V82A
V3I, L10FI, 115V, 
K20R, L24I, E35D, 
M36V, S37N, 
K43T, M46I, F53L, 
I54V, K55R, I62V, 
L63A, I64V, V82A
K20R No Yes Yes
2500061 V3I, L10F, L33IL, 
E35DE, M36IM, 
S37N, R41K, 
M46IM, I54V, 
K55KN, D60E, I62V, 
L63P, A71AV, 
V82AV, L90M, I93IL
V3I, L10F, K20R, 
E35D, M36I, S37N, 
R41K, M46IM,
154V, K55N, D60E, 
162V, L63P, A71V, 
V82AS, L90M, 
I93L
K20R L33IL No Yes Yes
2500063 V3I, L10I, 115V, 
K20T, M46I, Q58E, 
162V, L63P, A71V, 
I72IL, G73S, V77I,
184V, 185V, L90M, 
I93L
V3I, L10I, 115V, 
K20T, E34EK, 
M46I, I54V, Q58E, 
162V, L63P, A71V, 
I72L, G73S, 
L76LV, V77I, I84V, 
185V, L90M, I93L
E34EK, 
154 V, 
L76LV
No Yes Yes
Overall, there were a mean (95% Cl) 2.19 (1.69 to 2.69) PR amino-acid changes per 
person-years follow-up between the virus that was sampled at baseline and the virus that 
was sampled at failure. The viral population of patients who received IDV/r underwent 
1.76 (0.99 to 2.53) PR changes per person-years follow-up, in patients who received 
SQV/r there were 2.53 (1.74 to 3.31) PR changes per person-years follow-up and in 
patients who received LPV/r there were 2.14 (1.02 to 3.27) new PR changes per person- 
years follow-up.
For the 33 patients, in whom a PR amino-acid change occurred between baseline and 
virological failure, the most common sites for these changes were at codons 15 and 84 
(Figure 3.4.5.4.1).
Figure 3.4.5.4.1: Mutational emergence at each codon, for patients with a virus in which a 
PR change occurred from HXB2
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3.5. Discussion
3.5.1. Summary of main results
This analysis examines the emergence of mutations along the PR section of the pol gene 
in the predominant viral species of patients enrolled into the MaxCmin or COLATE trials. I 
explored resistance emergence in the predominant virus of patients who experienced 
virological failure, regardless of whether they remained on a Pl/r or not. On reflection, 
restricting the analysis to patients who were on a Pl/r at the time of failure would have 
been a better approach to examine resistance emergence to a Pl/r containing regimen. 
However, this would have resulted in a reduction in numbers. So, to retain power, as many 
patients as possible were included in these comparisons, including those who were on and 
those who were off therapy at the time of failure. Although not all patients were on a 
regimen containing a Pl/r when they experienced virological failure, the majority of patients 
were (i.e. 76.8%), so most of the drug mutations that emerged in this analysis are likely to 
result from the failing Pl/r component of the regimen.
Our primary analysis concerns the prevalence and emergence of primary PI resistance 
mutations at the time of failure, defined according to the September 2006 IAS-USA
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resistance tables233. There were 23 out of 82 (28.1%) patients who had a virus containing 
a primary PI mutation at the time of virological failure. Differences existed according to 
prior PI use: two of 30 (6.7%) patients who were Pl-nai've at baseline and 21 of 52 (40.4%) 
patients who were Pl-experienced at baseline had a virus containing a primary PI mutation 
at the time of failure.
Out of the 82 patients who experienced virological failure and had resistance tests 
available at both baseline and failure, there were only nine (11.0%) who had a virus in 
which a new primary PI mutation emerged over 36.9 person years of follow-up. The odds 
of acquiring a new primary PI mutation was 3.7 fold (95% Cl: 1.2 to 11.3) higher if the virus 
that was sampled at baseline already contained a primary PI mutation, which is consistent 
with other studies253125*30* 327.
3.5.2. Interpretation of results
One possible explanation is that when a patient starts a Pl/r for the first time their genetic 
barrier to Pis is high. However, once a mutation to the Pl/r has emerged, the barrier to 
developing new mutations decreases allowing further accumulation of mutations. In 
addition, patients who have viral strains that already contain PI mutations are more likely 
to be incompletely adherent patients (i.e. previous low levels of adherence may explain 
why the mutation appeared in the first place); this may explain further why mutations are 
more likely to emerge in the predominant virus of these patients compared to those in 
which no mutations were present in their sampled virus at baseline.
Although new primary PI mutations were seen in the virus populations of some patients at 
the time of failure -  most of whom were still receiving their Pl/r at failure -  it is not possible 
to assume these mutations occurred solely due to the selection pressure exerted by the 
Pl/r. However, such a causal link is likely and plausible. Of note, new mutations at codon 
84 prevailed in the virus populations of patients who were using SQV/r, and since this 
mutation is known to be associated with a reduced response to unboosted SQV22*328 it is 
also likely to arise and have an association with virological failure in patients who are 
treated sub-optimally with SQV/r.
I performed several other analyses to capture all of the changes along the PR section of 
the pol gene. Overall, I found an acquisition rate of 0.30 (0.12 to 0.47) new primary PI 
mutations per person-years follow-up, 0.65 (0.39 to 0.91) new Pl-specific mutations per 
person-years follow-up and 2.19 (1.69 to 2.69) new PR amino-acid changes per person-
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years follow-up. Analysis of a subgroup of patients who remained on their Pl/r at the time 
of failure found comparably low rates of new mutations emerging from baseline in all of the 
analyses. Other studies looking at the accumulation of new PR mutations found similar 
event rates254:258:288:317 and similar mutations were identified in the virus populations of 
patients failing one of the three Pl/rs investigated in this analysis309:329:33°. Most of the 
published information on genotypic resistance associated with Pl/rs is derived from studies 
using each PI without ritonavir boosting, although recently, more information on virological 
response amongst patients receiving a ritonavir-boosted regimen has been 
published21*331-335.
In 15 out of 82 (18.3%) patients, the virus that was sampled at failure contained a Pl- 
specific mutation that was not seen at baseline: nine (60%) patients had a virus in which a 
primary Pl-mutation emerged (including primary PI mutations other than those to the Pl/r in 
question) and the six remaining patients had a virus in which only secondary Pl-mutations 
emerged. In addition, 33 out of 75 (44.0%) patients had a virus that underwent any 
change to the PR section of the pol gene between baseline and failure.
This analysis provides a heterogeneous picture of mutations that occur as a result of 
treatment with a Pl/r. All of the mutations that occurred as a result of LPV/r containing 
regimens have previously been associated with resistance to LPV/r. A small proportion of 
mutations that arose in the viral populations of patients receiving IDV/r or SQV/r are not 
known to be associated with the corresponding Pl/r (i.e. at codons 12, 15, 62 or 93 for 
IDV/r; and at codons 13, 15, 41 or 53 for SQV/r). These mutations may augment 
resistance to the PI, or represent compensatory mutations which restore virus fitness.
Longer follow-up of patients who are failing a Pl/r containing regimen should indicate 
whether these mutations are actually associated with virological failure themselves or 
whether they are on the pathway for developing other resistance mutations. However, this 
may not be possible because it is advisable to change regimens if a patient is failing 
therapy in order to stop the emergence of mutations. So, in vitro studies may help to 
elucidate their role in PI resistance instead. Heterogeneity in the amino-acid changes 
identified along the PR section of the pol gene could arise because of the low signal to 
noise ratio (i.e. a large number of codons were sequenced using various approaches), and 
because these analyses are lacking in power. Thus, it is not possible to say for certainty 
that these mutations emerged as a result of the Pl/r the patient was receiving.
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3.5.3. Limitations of the analysis
This analysis was based on 82 of the 146 patients who had observed virological failure in 
the three trials combined. The reason for excluding some patients was either lack of 
available sample or lack of ability to amplify and sequence the protease gene. This 
possibly introduced selection bias by excluding patients who had low levels of HIV RNA 
either at baseline and/or failure. However, baseline characteristics such as previous 
treatment exposure were balanced between patients who were included in these 
comparisons compared to those excluded (data not shown).
New PI mutations associated with reduced viral efficacy were acquired in patients who 
received all three Pl/rs, but this analysis was substantially under-powered to identify any 
clinically meaningful differences in the rate of mutation emergence. In order to maximize 
the sample size to assess the objective of this analysis, I merged data from three 
independent trials and included patients with genotypic data at time of failure but no 
baseline samples as long as they had not received a PI prior to baseline. It is important to 
underline that by doing so, I assumed that in the seven patients without prior exposure 
there were no PR mutations present in their virus at baseline.
This assumption is reasonable because primary PI mutations are rarely transmitted and 
are rarely developed spontaneously2481250,3361337. However, these patients had never been 
exposed to Pis before the trial, so would therefore be expected to respond favourably to a 
Pl/r containing regimen. Since they failed treatment, resistance that has not been 
accounted for in these comparisons may actually be present at baseline. After excluding 
patients who were Pl-nalve from the analysis, the proportion of patients in whom a primary 
PI mutation emerged was 14% and therefore comparable to the 11% if all patients are 
studied together.
Since this analysis was performed on combined data from the three trials I re-ran the 
MaxCmin2 definition of virological failure on patients in MaxCminl and COLATE to 
produce ‘new’ dates of virological failure. Although there was no difference in the new 
dates of virological failure for the majority of patients in MaxCminl (78.6%) and for the 
majority of patients in COLATE (81.1%), the new dates did differ in some patients (from 12 
weeks before to 14 weeks after in MaxCminl and from 6 weeks before to 19 weeks after 
in COLATE). Of note, four patients in COLATE were considered to have experienced 
virological failure using the new MaxCmin2 definition of failure when they did not satisfy 
the original COLATE definition of virological failure.
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Resistance data from patients who are failing a Pl/r containing regimen allows us to 
identify mutations that arise under selection pressure from a failing a Pl/r. Since clinicians 
are likely to switch a patient from a failing Pl/r regimen to an active regimen as soon as 
they experience virological failure, these types of data are fairly uncommon. To allow us to 
investigate resistance emergence in patients on a Pl/r I combined data from the three trials 
because, even though the study methodology differed slightly between studies, 
combination of the three trials increases the number of patients who could be included in 
this analysis.
Combining the three trials could theoretically represent a methodological problem because 
they were set up to answer different questions and are conducted in different ways. 
However, all three trials were conducted between 1999 and 2002 so treatment approaches 
were likely to be similar in each trial, especially with regard to using a ritonavir-boosted PI 
containing regimen because they had just been introduced into clinical practice. 
Furthermore, all definitions of virological failure that were used in the trials incorporate 
information on the baseline HIV RNA levels and the expected response to therapy at 
specific time points over follow-up. These patients should have good suppression over the 
first 24 weeks because they are recruited on the basis that they will respond favourably to 
the drug, and since the purpose of this analysis was not to compare the groups but to 
collect resistance data on patients who experience virological failure, it is assumed that it 
does not constitute a significant methodological issue to merge these data.
3.5.4. Conclusion
New treatment strategies should be intensively studied and all available resistance data on 
mutations leading to changes in virological resistance patterns for a particular ARV should 
be investigated. Combining patients from MaxCminl, MaxCmin2 and COLATE meant it 
was possible to examine resistance evolution in the viral populations of patients receiving 
Pl/rs in some detail. The results of the multivariable logistic regression analyses suggest 
that patients who have a virus that contains no primary resistance mutations at baseline 
are less likely to experience primary resistance emergence in their virus populations. This 
supports evidence suggesting that the longer one has been treated with a Pl/r the greater 
the risk of virological resistance emerging288. This trend was found to be independent to 
the drug concentrations in these patients. However, patients with both drug concentration 
data and resistance data available had drug concentrations that were well above the level 
required to inhibit HIV replication by more than 90%.
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In conclusion, the emergence of new primary PI resistance mutations along the PR section 
of the pol gene was demonstrated in 11 % of patients who virologically failed a regimen 
containing a Pl/r. Existence of resistance mutations at the start of the Pl/r predicted an 
increased risk of new mutations emerging.
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CHAPTER 4: THE ABILITY OF FOUR GISs TO PREDICT VIRAL LOAD
RESPONSE TO RITONAVIR-BOOSTED PIS. USING TRIAL DATA 
4. Introduction
In chapter 3 I investigated the emergence of newly detected PR mutations in the dominant 
virus of patients who were failing a Pl/r containing regimen. Although there was a low rate 
of mutations emerging (i.e. an acquisition rate of 0.30 (95% Cl: 0.12 to 0.47) new primary 
PI mutations per person-years follow-up), primary PI mutations still emerged in the 
dominant virus of 11.0% of patients. Most of the patients in the trials had a virus with only 
a few protease mutations at the time of starting a Pl/r (i.e. trial baseline); therefore, their 
virus should have been sensitive to the drugs that were in the regimen, especially the Pl/r 
component. If the virus is sensitive to therapy, these patients are not expected to 
experience high levels of resistance emergence in their virus populations because viral 
replication should be kept under control.
The short term response to therapy has been associated with longer term response317:338 
so it is worthwhile identifying if any mutation in the dominant virus at baseline can predict 
short term viral load changes in order to maximise the overall longer term response. The 
dominant virus in a patient is unlikely to change much over the first few weeks following 
treatment initiation, so any viral load changes that occur during this interval are likely to be 
related to mutations that are present in the virus at baseline. If viral load changes are 
studied at a later time point it is likely that, under drug selection pressure, changes will 
have occurred within the viral subspecies. As a result, any changes in HIV RNA levels 
may be due to the emergence of new resistance mutations rather than mutations that were 
present in the virus at baseline (Figure 1.6.2.2.1). In this chapter I examine HIV RNA 
declines at two early time points to identify whether baseline mutations can predict early 
virological response as an indicator of the potential success of therapy.
4.1. Aims of the chapter
Rules-based genotypic interpretation systems (GISs) take into account a large number of 
different mutations and assign them all a weight, depending on whether they are detected 
alongside other mutations. As a result they predict varying degrees of susceptibility the 
virus has to the regimen a patient is receiving. In this chapter I will explore the differences 
between four freely available GISs in their ascribed levels of resistance to a Pl/r and 
examine whether these interpretational differences impact on the ability of each system to
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predict short term virological response (appendix V)339. This analysis was performed using 
data from the three randomised controlled trials (MaxCminl, MaxCmin2 and COLATE).
4.2. Literature review
As described in section 1.6.3.1, genotypic resistance testing is used to guide therapy 
selection by producing lists of the type and positioning of each mutation in the sampled 
virus193:197:198. Studies exploring the relationship between resistance and response to 
therapy have so far been limited by a low prevalence of mutations or inadequate data on 
virological response, because extremely large data sets are required in order to produce 
reliable results. As a result, there are disagreements between experts on how each 
mutation affects response to each ARV and consequently over twenty rules-based GISs 
have been proposed21^ 221.
Differences between GISs have been illustrated previously22®1229134^ 341. They tend to agree 
on the level of resistance inferred by the common resistance mutations, especially if the 
patient is receiving an ARV that is compromised by the emergence of a single mutation in 
the virus (e.g. 3TC and the M184V mutation). Conversely, high levels of discordance exist 
between GISs if the virus requires complex mutational patterns for the ARV to be 
compromised by the presence of resistance, (e.g. zidovudine, didanosine, stavudine and 
abacavir)22*2251227'230.
This is also true for protease inhibitors (Pis) where disagreements cannot be attributed to 
the presence of a single mutation or specific mutational pattern229. For example, 
resistance to darunavir/r is considered to be a problem if at least 4 mutations emerge 
among: V III,  V32I, L33F, 147V, 150V, I54L/M, G73S, L76V, 184V, L89V using the ANRS 
GIS, and cannot be attributed to the emergence of any one mutation specifically.
Ritonavir is currently used in low doses to boost levels of other Pis. Due to the potency of 
these combinations, ritonavir-boosted Pis (Pl/rs) may require alternative or more sensitive 
interpretations to those for unboosted Pis, although the current systems have also been 
shown to apply to Pl/rs198. Some GISs have been updated to account for the use of 
ritonavir-boosting, but still most discordance between GISs occurs amongst Pis230.
Individual mutations and resistance to the overall regimen, as illustrated by a genotypic 
sensitivity score (GSS), have been shown to be associated with HIV RNA declines at 
various time-points198:218:34°. Since limited information exists on the prognostic value of
GISs for Pl/rs I investigated concordance between ascribed Pl/r (IDV/r, LPV/r and SQV/r) 
resistance levels using four freely available GISs and related the resulting interpretations 
to virological response after 4 and 12 weeks of follow-up. Although most of the Pl/rs 
studied in this chapter (i.e. SQV/r and IDV/r) are less frequently used nowadays, they were 
commonly used at the time of performing the analysis described here.
4.3. Methods
Current treatment guidelines identify week 12 as the optimal time point for assessing 
virological responses to a new combination regimen342. Since the week 12 viral load 
response has been shown to reflect long-term success this was chosen as the time point 
for this chapter343. I also wanted to see whether there were differences in HIV RNA 
change according to the ascribed Pl/r resistance levels at an earlier time point. If 
differences are noticeable at an earlier stage then changes can be made to the regimen to 
ensure patients receive the maximum benefit from their treatment without risk of further 
resistance emergence in their virus population.
Since the trials have viral load data at four weeks follow-up, I also investigated the 
relationship between GISs and HIV RNA decline after four weeks follow-up. To identify 
the additional effect of other drugs in the regimen (i.e. other than the Pl/r) on viral load 
response I assigned a GSS to the rest of the regimen and explored the relationship 
between this GSS and viral load response at both time points.
4.3.1. The trials
Between May 1999 and May 2002, 799 HIV infected patients were enrolled into the three 
48-week, multi-centre trials (MaxCminl (N=324), MaxCmin2 (N=339) and COLATE 
(N=136)). Patients in COLATE who were receiving a Pl/r (i.e. SQV/r, IDV/r or LPV/r) were 
combined with MaxCmin patients to maximise numbers for these comparisons.
4.3.2. Genotypic interpretation systems
Genotypes were provided as amino acid substitutions (full or as mixtures) from a reference 
clade B strain (i.e. HXB2) for both the RT and protease genes. The amount of resistance 
was quantified by running the amino-acid sequences through the following GISs: ANRS 
(version 13)215; DMC (October 2004)217; REGA (version 6.4)221; and Stanford (version 
4.2.0)220 to produce a score for each ARV in the regimen relating to whether a patient had 
a virus showing resistance, intermediate resistance or sensitivity to that drug (see
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1.6.3.1.1). These four GISs were chosen because they are rules-based, updated regularly 
(usually annually), freely available and possible to programme. Rules for these GISs are 
presented as tables listing mutations that confer possible genotypic resistance to ARVs.
All of the GISs were created from data based on genotype-to-phenotype correlations, with 
a small part based on genotype-to-viral-load-response.
The ANRS algorithm was created by the French ANRS (Agence Nationale de Recherches 
sur le Sida) AC11 resistance group in 2002 in order to help physicians select the most 
effective treatment regimen for a patient. The rules of the current version are almost 
exclusively based on data examining statistically significant correlations between drug 
resistance mutations and virological outcomes from a large database of patients failing 
antiretroviral therapy.
The REGA Institute GIS, Leuven, is a rules-based system based on published evidence 
and expert interpretation, and has a particular focus on the impact of drug resistance on 
the response to ARVs. They also use data from in vitro genotypic and phenotypic studies. 
The first REGA GIS was created in January 2000, which was clinically validated in a 
cohort of patients on salvage therapy, where the three month virological response was 
used as the outcome variable.
The DMC GIS is another rules-based GIS and was created in 2000344 by the Detroit 
Medical Centre. All three GISs provide a three-level resistance output (i.e. resistance, 
intermediate resistance or sensitive) for each ARV according to the mutations that are 
present in the virus. DMC resistance algorithms were not available for Pl/rs so 
interpretations for the unboosted PI were used instead.
The Stanford GIS is another resistance algorithm that was made available online in 
September 2000. This GIS usually provides the inferred resistance level as a continuous 
output which is then translated into a 5-level resistance score: susceptible (score 0 to 9); 
potential low-level resistance (score 10 to 14); low-level resistance (score 15 to 29); 
intermediate resistance (score 30 to 59); or high-level resistance (score £60). Resistance 
levels ascribed by Stanford were reduced from a 5-level system to a 3-level system using 
the recommended method: an overall score of 0 to 14 represents susceptibility, 15 to 59 
intermediate resistance and £60 high-level resistance.
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A GSS was generated for the background regimen by summing the level of resistance to 
each ARV in the regimen other than the Pl/r (see 1.6.3.1.1). Separate GSSs were 
calculated using each of the four GISs. Resistance to ritonavir was not included in this 
calculation since it was not administered in therapeutic doses. I programmed each GIS 
in Stata (version 8.2) and cross-checked the programming with a colleague (Alessandro 
Cozzi Lepri) in SAS (version 8.2). Final checks were made by running 5% of the 
sequences through the online Stanford resistance programme345 and cross-checking the 
inferred resistance levels with the levels that I obtained using my programmes.
4.3.3. Laboratory methods
Plasma samples were used for sequencing if baseline HIV RNA >500 copies/mL. HIV 
RNA was quantified using the Roche Ultrasensitive Amplicor HIV-1 Monitor Assay (Roche 
Molecular Systems, Alameda, California)41 and the Chiron branched chain (bDNA) assay 
(Chiron Corp., Emeryville, California)38.
Different sequencing procedures were used for each study (see section 3.3.6). Virus 
sequencing was performed centrally (Advanced Biological Laboratories, Luxembourg) in 
batches using cryopreserved plasma samples in MaxCmin2 and COLATE. Sequence 
data for the reverse transcriptase (RT) and protease (PR) reading frames (i.e: PR amino 
acid positions 1 to 99 and RT positions 1 to 335) were obtained by extracting HIV RNA 
from 500 pi plasma using the NucliSens isolation kit. Through nested PCR amplification, a 
1.8-kb amplicon encompassing the protease and the first 1005 nucleotides of the RT gene 
was generated, spanning a total of 1302 nucleotides. Purified amplicons were sequenced 
using the ABI Prism BigDye terminator cycle sequencing kit and the resulting nucleotide 
sequences were translated into amino acids. Sample mix-up or lab-contaminated samples 
were identified by generating phylogenetic trees.
In MaxCminl, virological sequencing was performed at the International Clinical Virology 
Center (High Wycombe, UK) where they used the QIAamp kit for RNA extraction from 
plasma (Qiagen, Barcelona, Spain) according to the manufacturer’s instructions.
Sequence data for the RT (positions 1 to 335) and PR (positions 1 to 99) genes were 
obtained using Trugene HIV-1 Genotyping Kit and OpenGene DNA Sequencing System 
(Visible Genetics, Barcelona, Spain).
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4.3.4. Statistical analysis
All patients who initiated a Pl/r, had HIV RNA data available at four and 12 weeks of 
follow-up and had a genotypic resistance test available at baseline were included in these 
comparisons. Concordance in the ascribed Pl/r resistance levels at baseline was 
evaluated between GISs using kappa statistics346. A kappa >0.8 reflects very good 
concordance, 0.6<kappa£0.8 good concordance, 0.4<kappa£0.6 moderate concordance, 
0.2<kappa£0.4 fair concordance and kappa £0.2 poor concordance or no relationship.
Censored linear regression analysis was used to relate Pl/r resistance levels to HIV RNA 
reductions from baseline after 4 and 12 weeks of follow-up. I assumed there was a linear 
relationship between the change in HIV RNA and sensitivity to the Pl/r in question (i.e. the 
difference in change in HIV RNA between resistant and intermediate viruses is the same 
as the difference in change in HIV RNA between intermediate and sensitive viruses). This 
was performed after evaluating the relationship between the decline in HIV RNA levels and 
the degree of resistance, classified as a three-level categorical variable (i.e. resistant, 
intermediate resistance and sensitivity). Since the initial analysis indicated a linear 
relationship across categories, the relationship between the change in HIV RNA and 
sensitivity to the Pl/r was modelled as a linear relationship throughout this chapter.
Patients with missing HIV RNA data at either the 4- or 12- week time point had their HIV 
RNA level estimated through linear interpolation if they had data available at both the 
preceding and following visits. The most commonly used HIV RNA assay has a lower limit 
of quantification of 50 copies/mL therefore it was not possible to estimate exact HIV RNA 
declines for patients with an HIV RNA <50 copies/mL. Factors associated with HIV RNA 
change were identified through censored linear regression analysis (appendix IV) to take 
into account the partial observation of the extent of viral load reduction due to this 
censoring347. All variables associated with HIV RNA decline in unadjusted analysis were 
entered into separate multivariable models for each GIS. Each multivariable model was 
adjusted for the GSS to the rest of the regimen calculated using the same GIS. Statistical 
analyses were performed using STATA.
4.4. Results
4.4.1. Patient characteristics
Seven-hundred-and-twelve of the 799 (89.1%) patients who were enrolled in the trials 
initiated a Pl/r. Overall, 657 of 712 (92.3%) patients had HIV RNA values available at four
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and 12 weeks of follow-up and of these 368 (56.0%) had a baseline resistance test in the 
three weeks prior to baseline. These 368 patients started one of the following single Pl/rs 
(as opposed to double-boosted Pl/rs): IDV/r (N=89, 24%); LPV/r (N=126, 34%); and SQV/r 
(N=153, 42%). The baseline characteristics for these patients are shown in Table 4.4.1.1.
Patients were primarily male (75%), white (73%), were a median age of 39 years (IQR: 34 
to 46 years) and 29% had an AIDS defining event prior to entry. There were 201 (55%) 
patients who were Pl-experienced prior to entry. Median CD4+ cell counts were 223 (IQR: 
100 to 360) cells/pL and median HIV RNA levels were 4.7 (IQR: 3.9 to 5.2) log™ 
copies/mL.
Table 4.4.1.1: Baseline characteristics for the 368 patients from the trials
Baseline parameter IDV/r LPV/r SQV/r Total
(N=89) (N=126) (N=153) (N=368)
Gender No. Male, (%) 61 (69) 95 (75) 121 (79) 277 (75)
Age Med (IQR) 39 (32, 47) 40 (35,46) 38 (35,45) 39 (34,46)
Antiretroviral naive N, (%) 8 (9) 40 (32) 38 (25) 86 (23)
PI-naive N, (%) 26 (29) 15 (12) 40 (26) 81 (22)
Pl-experienced N, (%) 55 (62) 71 (56) 75 (49) 201 (55)
CDC, cat. C N, (%) 23 (26) 43 (34) 41 (27) 107 (29)
HIV RNA (cps/mL log10) Med (IQR) 4.4 (3.8, 5.1) 4.8 (4.0, 5.3) ^4.7 (4.0, 5.2) 4.7 (3.9, 5.2)
CD4+ (cells/pL)* Med (IQR) 249 (119, 364) 214 (82, 388) 217(71,319) 223 (100, 360)
CD4+ nadir (cells/pL) Med (IQR) 138 (55, 224) 108 (35, 199) 102 (33, 224) 110 (39, 215)
HIV exposure group N, (%)
Homosexual/bisexual 39 (44) 55 (44) 63 (41) 157 (43)
IVDU 5 (6) 9 (7) 18 (12) 32 (9)
Heterosexual 34 (38) 52 (41) 60 (39) 146 (40)
Other/unknown 11 (12) 10 (8) 12 (8) 33 (9)
Race N, (%)
White 65 (73) 91 (75) 114 (72) 270 (73)
Black 20 (22) 26 (21) 29 (19) 75 (20)
Other/unknown 4 (5) 9 (4) 10 (9) 23 (7)
Any major NRTI mutation* N, (%) 55 (62) 65 (52) 69 (45) 189 (51)
Any NNRTI mutation* N, (%) 17 (19) 35 (28) 41 (27) 93 (25)
Any primary PI mutation* N, (%) 28 (31) 35 (28) 29 (19) 92 (25)
* Refers to any major mutation as defined in the IAS-USA 2006 tables
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Overall 189 (51%), 93 (25%) and 92 (25%) patients had a virus with a major resistance 
mutation to an NRTI, NNRTI or PI, respectively233. Patients started a variable number of 
ARVs in addition to the Pl/r, with the majority (80%) starting two other ARVs.
4.4.2. Concordance of the interpretation of genotypic data by all GISs
At baseline there were 367 patients who received an NRTI, 35 who received an NNRTI 
and 368 who received a Pl/r. Using the IAS-USA (Sept 2006)233 mutations guidelines to 
crudely examine the prevalence of mutations to the baseline regimen, 151 (41%) patients 
were estimated to have a virus containing a reverse transcriptase (RT)-mutation to an 
NRTI they were receiving at baseline, 4 (11%) patients had a virus containing an RT- 
mutation to an NNRTI they were receiving at baseline and 41 (11%) patients had a virus 
containing a primary Pl-resistance mutation to a Pl/r they were receiving at baseline (N=12 
(14%), N=19 (15%) and N=10 (7%) patients on IDV/r, LPV/r and SQV/r, respectively).
Using the REGA GIS (version. 6.4) to estimate the prevalence of baseline resistance, 
there were 42 (11 %) patients with a virus that was deemed to have full or intermediate 
resistance to the baseline Pl/r (N=15 (17%), N=16 (13%) and N=11 (7%) patients who 
were receiving IDV/r, LPV/r and SQV/r, respectively). These resistance levels are similar 
to the levels of major IAS-USA PI mutations described above. ANRS (version 13) 
calculated comparable levels of resistance to REGA but both DMC (October 2004) and 
Stanford (version 4.2.0) predicted nearly double the number of patients with a virus 
exhibiting full or intermediate resistance to their baseline Pl/r (Table 4.4.2.1).
Table 4.4.2.1: Patients with a virus exhibiting full resistance, intermediate resistance or 
sensitivity to the Pl/r according to each GIS
Interpretation System IDV/r
(N=89)
LPV/r
(N=126)
SQV/r
(N=153)
Total
(N=368)
ANRS
No. (%) with resistance to the Pl/r (R/l/S)*
18/0/71
(20/0/80)
3/11/112
(2/9/89)
6/0/147
(4/0/96)
27/11/330
(7/3/90)
REGA
No. (%) with resistance to the Pl/r (R/l/S)*
9/6/74
(10/7/83)
3/13/110
(3/10/87)
6/5/142
(4/3/93)
18/24/326
(4/7/89)
DMC
No. (%) with resistance to the Pl/r (R/l/S)*
11/22/56 
(12/25/63)
10/13/103
(8/10/82)
12/9/132
(8/6/86)
33/44/291
(9/12/79)
Stanford
No. (%) with resistance to the Pl/r (R/l/S)*
7/11/71
(8/12/80)
5/24/97
(4/19/77)
5/14/134
(3/9/88)
17/49/302
(5/13/82)
* R/l/S -  Full resistance/intermediate resistance/sensitivity to the Pl/r
118
When I examined concordance between interpretations using the REGA and ANRS GISs, 
complete concordance was identified in the ascribed level of resistance to the Pl/r in 349 
(94.8%) cases (i.e. 16 were deemed to have full resistance, 11 intermediate resistance 
and 322 sensitivity using both systems). The interpretations differed for the other 19 
(5.2%) isolates using these systems.
Overall concordance between GISs was moderate. There was complete concordance in 
the predicted level of resistance to IDV/r, LPV/r and SQV/r between all four GISs for 61 
(69%), 102 (81%) and 134 (88%) of the isolates, respectively. Kappas between GISs 
ranged from 0.37 to 0.75 for IDV/r; 0.46 to 0.93 for LPV/r; and 0.38 to 0.68 for SQV/r 
(Table 4.4.2.2).
Table 4.4.2.2: Kappas values to illustrate concordance between GISs
Bold reflects concordance among the whole group; italics reflect concordance among Pl-
experienced patients only
REGA DMC Stanford
IDV/r ANRS 
REGA 
DMC
0.68 0.43 0.64
0.64 0.49 0.60 
0.37 0.75 
0.43 0.73 
0.46
0.54
LPV/r ANRS 
REGA 
DMC
0.93 0.46 0.57
0.92 0.40 0.52 
0.54 0.64 
0.48 0.59 
0.66
0.60
SQV/r ANRS 
REGA 
DMC
0.51 0.42 0.38
0.52 0.50 0.41 
0.56 0.68 
0.65 0.69 
0.64 
0.71
Poor k ^0.2; Fair 0 .21< k <0 .40; Moderate 0.41< k <0.60; Good 0 .61<k ^0.80 and Very Good k >0.80
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Concordance between the DMC GIS and the other GISs increased among a sub-group of 
patients who were Pl-experienced at baseline. All of these GISs were originally designed 
for Pl-experienced patients (i.e. those with more Pl-mutations in their viral populations) so 
we may expect to find improved concordance in this subgroup of patients. Overall, similar 
kappas were identified in Pl-experienced patients compared to the combined population of 
Pl-experienced and Pl-nai’ve patients: kappas ranged from 0.43 to 0.73 for IDV/r; 0.40 to 
0.92 for LPV/r; and 0.41 to 0.71 for SQV/r (Table 4.4.2.2).
Through detailed examination of the GISs it is possible to identify mutations that are 
predictors of resistance with certain GISs but not with others. Figure 4.4.2.1 crudely 
shows the codons that cause discordance between GISs for each drug class. Although 
ANRS considers 25 codons in the protease gene to be associated with resistance to a Pl/r 
in this analysis (i.e. three more mutations than any other GIS), it estimates that fewer 
patients have a virus that shows full or intermediate resistance to their Pl/r compared to 
the other GISs. This is because mutations occurring at these codons are either infrequent 
or need to be considered in combination with other mutations to infer resistance using 
ANRS.
Figure 4.4.2.1: Mutational discrepancies between GISs, by drug class
Mutations in the reverse transcriptase (RT) gene associated with resistance to NRTIs
41 44 62 65 67 69 70 74 75 77 100 115 116 118 151 181 184 210 215 219 333
(S) (D,S)<S) (S) (S) (D.R.S) (S) (S,D)
Mutations in the reverse transcriptase (RT) gene associated with resistance to NNRTIs:
98 100 101 103 106 108 179 181 188 190 225 221 230 236 238 318
<d!r,S) <D,R,S) <D,R,S) (S) <D,R,S) (S) <D,S)
Mutations in the protease (PRO) gene associated with resistance to a Pl/r in these
analyses:
10 16 20 24 32 36 46 47 48 50 53 54 71 73 7 7 82 84 85 38 89 90  93
! ! , , J J ! | | ! p -  j j----------- ,------------------p -
(A.S) (A,R,S) (A) (A) (R) (A)(A)(A,D,S)(R) (A.D.R) (A)(D.R,S) (R) (D)
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Figure 4.4.2.2 shows there is a high level of discordance when examining interpretations 
for each Pl/r separately. DMC predicts significantly higher levels of resistance to IDV/r and 
SQV/r than any other GIS. This is primarily driven by the presence of the I93L protease 
mutation, which occurs in 146 (40%) of our patients but is not considered to have an effect 
on resistance using any GIS other than DMC.
Figure 4.4.2.2: Mutational discrepancies between GISs, by Pl/r
M utations in the protease gene associated with resistance to indinavir/r:
10 20 24 32 33 36 46  47 48 53 54 63 66 71 73 77 82 84 88 39 90 93
1
(D.R.S)
....5 ................  ! .. "T.........-f........ "............?........r.............
(A,D,S) <R) (D.S)(D,R,S)(S) (S) (R)
............f...................1......T...
(A,D) (D.R.S) (R)
. — ( 
(D )
Mutations in the protease gene associated with resistance to lopinavir/r:
10 20 24 32 33 36 46 4  7 48 50 53 54 63 71 82 84 9 0
*'f  1H ' i 1 i | r "J ■ 1 1
(A,D,S)(A,R,S)(D,S) (D,R,S)(A.R,S) <A,D,S)
..... r.... ...... . ~
(S ,R )
Mutations in the protease gene associated with resistance to saquinavir/r:
10 20 24 32 36 46 4 7  4  8  53 54  62 63 71 73 77 82 84 88 9 0  93
t !--------- 1--------- 1-----------1---- !------- ------- r~—i-------- i j 1------1--------1------------1----------------r
(D.R.S) (D.R.S) (A.S) (S) (D,S) (R,S) (S) (S)(D,R,S)(A)(S) (D,R,S)(D,R,S)(D) (S) (D)
Legend: These figures shows every codon along the protease section of the pol gene that, if a mutation 
from HXB2 is present, is considered to contribute to resistance using one of the four GISs. Mutations in 
bold are considered to contribute to resistance for all four GISs. Mutations not in bold only appear on the 
GIS listed below the mutation. A=ANRS, D=DMC, R=REGA, S=Stanford
4.4.3. Relationship between Pl/r resistance and GSS to rest of the regimen
Next I examined the relationship between sensitivity to the Pl/r and sensitivity to the 
background regimen to assess whether patients with a high degree of viral sensitivity to 
their Pl/r also had a high GSS. There were 260 (71%), 241 (65%), 246 (67%) and 231 
(63%) patients who had a virus that deemed to be susceptible to £2 ARVs in their 
background regimen (i.e. ARVs other than the Pl/r) using ANRS, REGA, DMC and 
Stanford, respectively.
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For all of the GISs, there was an increasing amount of sensitivity to the ARVs in the 
background regimen with increasing levels of sensitivity to the Pl/r. Using the REGA GIS, 
the mean (95% Cl) GSS to the rest of the regimen was 0.9 (0.5 to 1.3) for patients who 
had a virus that showed resistance to the Pl/r at baseline, 1.2 (0.9 to 1.6) for patients who 
had a virus that showed intermediate baseline resistance and 1.7 (1.7 to 1.8) for patients 
who had a virus that showed sensitivity to the Pl/r (Table 4.4.3.1).
Table 4.4.3.1: The GSS to the rest of the regimen according to Pl/r resistance levels
Mean (95% CO GSS to the rest of the regimen
ANRS resistance levels
Resistance 1.4 (1.0, 1.7)
Intermediate resistance 1.3 (0.8, 1.7)
Sensitivity 1.8 (1.7, 1.8)
REGA resistance levels
Resistance 0.9 (0.5, 1.3)
Intermediate resistance 1.2 (0.9, 1.6)
Sensitivity 1.7 (1.7, 1.8)
DMC resistance levels
Resistance 0.9 (0.6, 1.2)
Intermediate resistance 1.3 (1.1, 1.6)
Sensitivity 1.7 (1.7, 1.8)
Stanford resistance levels
Resistance 0.8 (0.4, 1.2)
Intermediate resistance 1.2 (1.0, 1.4)
Sensitivity 1.7 (1.7, 1.8)
This trend is expected because patients in the trials had varied entry criteria, including 
patients who were ARV-nai’ve or Pl-nai've prior to entry. Patients with a virus that showed 
resistance mutations at baseline are likely to be patients with high degrees of exposure to 
ARVs prior to the start of the trial and, therefore, they may show mutations along both the 
protease and RT sections of the gene. ARV-na'ive patients will only show mutations if they 
were infected with a strain of HIV carrying resistance mutations and therefore they are 
likely to show few mutations in their viral sub-species and have sensitivity to both the Pl/r 
and the background components of their regimens at baseline.
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4.4.4. Prognostic value of GISs for predicting viral load decline at week 4
The median (IQR) baseline HIV RNA level was 4.7 (3.9 to 5.2) log™ copies/mL (3.5 (3.1 to 
4.6) log10 for patients who had a virus that showed resistance to the Pl/r at baseline, 4.1 
(3.4 to 4.9) log™ for patients who had a virus that showed intermediate resistance at 
baseline and 4.7 (4.0 to 5.3) log™ for patients who had a virus that showed sensitivity to 
the Pl/r at baseline, according to the REGA GIS).
HIV RNA declined by a median (IQR) 1.8 (1.2 to 2.3) log™ copies/mL by week 4. This was 
similar for patients receiving each Pl/r: 1.7 (0.8 to 2.2) log™ copies/mL (IDV/r), 1.8 (1.3 to 
2.3) log™ copies/mL (LPV/r) and 1.8 (1.2 to 2.3) log™ copies/mL (SQV/r). There were 14 
(16%), 14 (11%) and 17 (11%) patients who received IDV/r, LPV/r and SQV/r, 
respectively, who had an HIV RNA recorded as <50 copies/mL in whom the reduction in 
HIV RNA levels were censored in the regression analysis.
In unadjusted analyses, the level of resistance to the Pl/r (all Pl/rs combined) was related 
to HIV RNA reductions using all of the GISs (P<0.10 in all cases): all GISs showed greater 
HIV RNA reductions with increased sensitivity to the Pl/r. For example, patients with a 
virus that was considered to be resistant to the Pl/r using the REGA GIS experienced a 
mean (95% Cl) 1.4 (0.9 to 1.8) log™ decline; patients harbouring a virus that showed 
intermediate resistance had a mean 1.6 (1.2 to 2.0) log™ decline; and patients with a virus 
that showed sensitivity to the Pl/r had a 1.8 (1.7 to 1.9) log™ copies/mL decline.
Due to the strong association between the GSS to the rest of the regimen and Pl/r 
sensitivity, the GSS to the rest of the regimen may confound the relationship between Pl/r 
sensitivity and HIV RNA change. After adjustment for the Pl/r used, HIV RNA at baseline 
and the GSS to the rest of the regimen (using the same GIS that was used to calculate 
resistance to the Pl/r) none of the GISs remained predictive of HIV RNA change to week 4 
when looking at the level of resistance to the Pl/r (Table 4.4.4.1). From a model including 
the REGA GIS, patients who had a virus that showed sensitivity to the Pl/r experienced a 
0.12 greater log™ reduction in HIV RNA between baseline and week 4 compared to 
patients who had a virus that exhibited full resistance, but this trend no longer reached 
statistical significance. The main factor confounding the association between Pl/r 
resistance levels and virological response was the baseline HIV RNA level. This is 
because Pl-nai've patients (i.e. those with few resistance mutations in their predominant 
viral species) are also likely to be those with higher baseline HIV RNA levels. In a model
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including the REGA GIS there was a 0.34 (0.23 to 0.46) log10 larger reduction in HIV RNA 
from baseline for every log™ higher baseline HIV RNA (p<0.001).
Similar patterns are seen when a GSS is calculated for the whole regimen (i.e. 
incorporating the level of resistance to the Pl/r into the sensitivity score) to those seen 
when looking at the level of resistance to the Pl/r alone. After adjustment for the baseline 
HIV RNA level all associations become non-significant (data not shown).
Table 4.4.4.1: Differences in HIV RNA change (AVL: BL to week 4) for each GIS 
According to the Pl/r resistance level and number of active ARVs in the regimen
Interpretation System Unadjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value
ANRS
Pl/r resistance (R -> I -> S) 0.19 (0.01,0.38) 0.04 0.04 (-0.13,0.22) 0.63
GSS to the rest of the regimen
For every additional active ARV 0.10 (-0.06,0.25) 0.21 -0.04 (-0.18,0.10) 0.59
REGA
Pl/r resistance (R I -> S) 0.20 (-0.01,0.40) 0.06 0.06 (-0.14,0.26) 0.54
GSS to the rest of the regimen
For every additional active ARV 0.11 (-0.03,0.25) 0.14 -0.04 (-0.18,0.10) 0.55
DMC
Pl/r resistance (R -> I -> S) 0.18 (0.03,0.34) 0.02 0.08 (-0.07,0.24) 0.29
GSS to the rest of the regimen
For every additional active ARV 0.10 (-0.03,0.23) 0.15 -0.05 (-0.19,0.08) 0.44
Stanford
Pl/r resistance (R -> I -> S) 0.21 (0.02,0.40) 0.03 0.07 (-0.12,0.27) 0.48
GSS to the rest of the regimen
For every additional active ARV 0.11 (-0.04,0.25) 0.15 -0.06 (-0.21,0.09) 0.43
• Coefficients for Pl/r resistance represent the average change in HIV RNA per increase in the 
level of sensitivity to the Pl/r (i.e. from resistant to intermediate to sensitive viruses). 
Therefore patients with a virus that is sensitive to the Pl/r have a 0.04x2=0.08 greater log10 
reduction from baseline to week 4 than patients with a virus resistant to the Pl/r using the 
ANRS GIS (i.e. a difference of 0.04 log10 between resistant and intermediate and another 
0.04 log10 between intermediate and sensitive)
• Coefficients for the number of active drugs in the rest of the regimen represent the average 
change in HIV RNA reduction for each additional active drug in the regimen
• Adjustments were made for the Pl/r used and baseline HIV RNA levels
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4.4.5. Prognostic value of GISs for predicting viral load decline at week 12
By week 12 the median (IQR) HIV RNA level was 2.0 (1.7 to 2.8) log10 copies/mL and the 
median (IQR) HIV RNA reduction from baseline to week 12 was 2.3 (1.4 to 3.0) log10 
copies/mL, which was greater than at week 4. These reductions were similar for all Pl/rs: 
2.2 (1.3 to 2.9) log10 copies/mL (IDV/r), 2.4 (1.4 to 3.1) log10 cps/mL (LPV/r) and 2.3 (1.2 to 
3.0) logi0 copies/mL (SQV/r). There were 40 (48%), 47 (37%) and 61 (43%) patients who 
received IDV/r, LPV/r and SQV/r, respectively, who had an undetectable HIV RNA (<50 
copies/mL) whose observations have been censored in the censored regression analysis.
Table 4.4.5.1 shows that week 12 HIV RNA reductions were crudely associated with Pl/r 
resistance levels (p<0.0001) for all of the GISs and for the number of other active drugs in 
the regimen (p<0.01). All of the GISs showed greater HIV RNA reductions with increasing 
sensitivity to the Pl/r and with an increasing number of other active drugs in the regimen. 
Patients with a virus considered to be resistant to the Pl/r, using the REGA GIS, 
experienced a mean (95% Cl) 1.6 (0.8 to 2.4) log10 decline to week 12, patients harbouring 
a virus with intermediate resistance had a mean 1.9 (1.2 to 2.6) log10 decline and patients 
with a sensitive virus had a 2.8 (2.6 to 3.0) logi0 copies/mL decline.
In a multivariable analysis, adjusted for baseline HIV RNA levels, the Pl/r used and the 
GSS to the rest of the regimen (using the same GIS that was used to calculate the level of 
resistance to Pl/r), all of the GISs still showed significantly greater HIV RNA reductions as 
sensitivity to the Pl/r increased (Table 4.4.5.1). Baseline HIV RNA levels also confounded 
the association between Pl/r resistance and HIV RNA changes in this comparison, 
however, adjustment for the baseline HIV RNA did not remove the association between 
Pl/r sensitivity and HIV RNA changes.
In a multivariable model including the REGA GIS there was a 0.57 (0.37 to 0.77) log10, 
p<0.0001, larger reduction in HIV RNA from baseline for every log™ higher baseline HIV 
RNA. From the model including the REGA GIS, patients with a virus that showed 
sensitivity to the Pl/r had a 0.82 greater log™ reduction between baseline and week 12 
compared to patients with a virus that showed full resistance. The number of other active 
drugs in the regimen did not predict response further for any GIS after adjustments.
When the level of resistance to the Pl/r was incorporated into an overall genotypic 
sensitivity score, there was a 0.13 (-0.03 to 0.29) greater log™ reduction from baseline to 
week 12 for each unit higher GSS score calculated with ANRS, a 0.10 (-0.04 to 0.25)
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greater log10 reduction per unit higher GSS score using REGA, a 0.12 (-0.01 to 0.25) 
greater log10 reduction per unit higher GSS score using DMC and a 0.13 (-0.02 to 0.28) 
greater log™ reduction per unit higher GSS score using Stanford, after adjustment for the 
baseline HIV RNA levels and the Pl/r used.
Table 4.4.5.1: Differences in HIV RNA change (AVL: BL to week 12) for each GIS 
According to the Pl/r resistance level and number of active ARVs in the regimen
Interpretation System Unadjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log™ cps/mL)
P-value
ANRS
Pl/r resistance (R -> I -> S) 0.60 (0.27,0.93) <0.0001 0.37 (0.05,0.68) 0.02
GSS to the rest of the regimen
For every additional active ARV 0.40 (0.12,0.68) 0.006 0.11 (-0.14,0.37) 0.38
REGA
Pl/r resistance (R -> I -> S) 0.69 (0.32, 1.06) <0.0001 0.41 (0.06,0.77) 0.02
GSS to the rest of the regimen
For every additional active ARV 0.36 (0.09,0.63) 0.008 0.04 (-0.22,0.29) 0.78
DMC
Pl/r resistance (R -> I -» S) 0.62 (0.34,0.91) <0.0001 0.42 (0.14,0.70) 0.004
GSS to the rest of the regimen
For every additional active ARV 0.37 (0.12,0.62) 0.004 0.01 (-0.23,0.26) 0.91
Stanford
Pl/r resistance (R I -> S) 0.81 (0.47,1.15) <0.0001 0.49 (0.14,0.83) 0.006
GSS to the rest of the regimen
For every additional active ARV 0.43 (0.16,0.70) 0.002 0.04 (-0.23,0.30) 0.78
• Coefficients are interpreted in the same way as in Table 4.4.4.1
• Adjustments were made for the Pl/r used and baseline HIV RNA levels
Although the GSS to the rest of the regimen was not related to virological response at 
week 4 or week 12 for any of the GISs, there were still differences between GISs in the 
magnitude of their predicted effects (Table 4.4.4.1 and Table 4.4.5.1). At week 4 there 
was a trend for smaller HIV RNA reductions with an increasing GSS to the rest of the 
regimen after adjustment. Conversely there was a trend for greater HIV RNA reductions 
with increasing GSS to the rest of the regimen by week 12. At week 12 each GIS showed 
greater HIV RNA declines with increasing Pl/r sensitivity and with increasing GSS to the
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rest of the regimen, although sensitivity to the Pl/r was more strongly related to HIV RNA 
decline. This is illustrated using the REGA GIS in Figure 4.4.5.1.
Figure 4.4.5.1: HIV RNA declines at week 12, using the REGA GIS 
According to Pl/r resistance levels and the GSS to the rest of the regimen
GSS to the rest of the regimen (REGA) 
0 0.5 to 1.5 >2
Q_Oo
d>o -0.5
<Dc
<Dt/>
CO
J 3
Q
-2.5
COsz0
<
:z : cr1>
-3.5 -  --------------
- • PI sensitivity PI intermediate resistance PI resistance
Number of patients:
PI resistance 3 11 4
PI intermediate resistance 3 14 7
PI sensitivity 13 83 230
4.4.6. Using a fixed GIS to calculate the GSS to the rest of the regimen
Each GIS varies in the way it relates resistance mutations to each ARV, which has 
resulted in differences between their predicted Pl/r resistance levels and their inferred 
levels of resistance to the other ARVs in the regimen. So far I have adjusted each Pl/r 
model for resistance to the background regimen ascribed by the corresponding GIS. To 
reduce the noise generated by these background variations I decided to examine the 
relationship between Pl/r resistance levels and virological response after 12 weeks of 
follow-up, after adjusting for a fixed GSS to the background regimen whilst varying the 
system used for the Pl/r. An analysis adjusted for the REGA GIS rather than each 
corresponding GIS, in addition to baseline HIV RNA levels and the Pl/r used, does not 
substantially affect the magnitude of the overall estimates (Table 4.4.6.1).
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Table 4.4.6.1: Differences in HIV RNA change (AVL: BL to week 12) for each GIS:
adjusted for the REGA GSS
Interpretation System Adjusted Analysis
Additional HIV RNA reduction per higher 
level of sensitivity (logi0 cps/mL)
P-value
ANRS
Pl/r resistance (R -> I -> S) 0.37 (0.05,0.70) 0.02
GSS to the rest of the regimen 
(REGA)
For every additional active ARV
0.04 (-0.22,0.29) 0.77
REGA
Pl/r resistance (R -> I -> S) 0.41 (0.06,0.77) 0.02
GSS to the rest of the regimen 
(REGA)
For every additional active ARV
0.04 (-0.22,0.29) 0.78
DMC
Pl/r resistance (R -> I -> S) 0.43 (0.15, 0.71) 0.003
GSS to the rest of the regimen 
(REGA)
For every additional active ARV
0.00 (-0.26,0.25) 0.98
Stanford
Pl/r resistance (R -> I -> S) 0.51 (0.16,0.86) 0.004
GSS to the rest of the regimen 
(REGA)
For every additional active ARV
-0.01 (-0.27,0.25) 0.92
• Coefficients are interpreted in the same way as in Table 4.4.4.1
• Adjustments were made for the Pl/r used and baseline HIV RNA levels
4.4.7. Sensitivity analysis excluding Pl-naive patients
Since the GISs were created using resistance data from drug-experienced patients I 
repeated this analysis on a subgroup of 201 Pl-experienced patients to see whether our 
results were consistent with those in this population. Pl-experienced patients display 
higher levels of baseline resistance in their virus than Pl-naive patients; however, there 
was still one (1 %) Pl-nai've patient who had a virus with a resistance mutation to the Pl/r 
they received at baseline. Conversely, 40 (20%) Pl-experienced patients had a virus with 
a major IAS-USA Pl-resistance mutation to a Pl/r they were receiving at baseline. There 
were 117 (58%), 106 (53%), 108 (54%) and 99 (59%) patients with a virus that was 
susceptible to £2 ARVs in their background regimen using ANRS, REGA, DMC and 
Stanford, respectively. Although Pl-experienced patients had higher average levels of 
resistance in their virus to all of the ARVs they were receiving at baseline compared to 
those in our previous analyses, these comparisons were performed on a reduced number 
of patients and therefore they have limited power.
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Overall, the magnitude of the difference in HIV RNA reductions between the ascribed Pl/r 
resistance levels for each GIS was similar to the comparisons including both Pl- 
experienced and Pl-naive patients. However, these differences no longer reached 
statistical significance (Table 4.4.7.1).
Table 4.4.7.1: Differences in HIV RNA change (AVL: BL to week 12) for each GIS: Pl- 
experienced patients
Interpretation System Unadjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value
ANRS
Pl/r resistance (R -> I S) 0.40 (0.04,0.76) 0.03 0.30 (-0.04,0.64) 0.08
GSS to the rest of the regimen
For every additional active ARV 0.32 (-0.02,0.65) 0.06 0.07 (-0.23,0.38) 0.63
REGA
Pl/r resistance (R -> I -> S) 0.46 (0.06,0.87) 0.03 0.30 (-0.08,0.69) 0.13
GSS to the rest of the regimen
For every additional active ARV 0.24 (-0.09,0.57) 0.15 -0.04 (-0.35,0.27) 0.78
DMC
Pl/r resistance (R -> I -> S) 0.46 (0.13,0.79) 0.007 0.31 (-0.02,0.64) 0.07
GSS to the rest of the regimen
For every additional active ARV 0.32 (0.01,0.63) 0.04 0.00 (-0.31,0.31) 0.99
Stanford
Pl/r resistance (R -> I -> S) 0.60 (0.21,0.98) 0.003 0.33 (-0.06,0.73) 0.10
GSS to the rest of the regimen
For every additional active ARV 0.36 (0.02,0.70) 0.04 0.00 (-0.33,0.34) 0.98
• Coefficients are interpreted in the same way as in Table 4.4.4.1
4.4.8. Other mutations and virological response at week 4 and week 12
Although there is an issue of multiple testing, I then looked at the relationship between 
individual protease mutations (according to the IAS-USA 2006 guidelines233) and HIV RNA 
response at both time points to see if these trends can be attributed to the presence of any 
specific mutation. In this comparison I found strong associations between mutations at 
positions 10, 24, 46, 47, 54, 82 and 90 with HIV RNA declines (Table 4.4.8.1). The 
presence of these mutations was associated with smaller decreases in HIV RNA, but 
prevalence rates of these mutations were still low in the virus populations of these 
patients. After adjustment for baseline HIV RNA, many of these trends disappeared.
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Table 4.4.8.1: Relationship between individual PR mutations and viral load change
Predicts week 4 response Predicts week 12 response
Mutation
Present
Unadjusted
Analysis
Additional 
HIV RNA 
reduction 
(logio cps/mL)
P-
value
Adjusted
Analysis
Additional HIV 
RNA 
reduction 
(logio cps/mL)
P-
value
Unadjusted
Analysis
Additional HIV 
RNA 
reduction 
(logio cps/mL)
P-
value
Adjusted
Analysis
Additional 
HIV RNA 
reduction 
(logio cps/mL)
P-
vaiue
IAS-USA mutations
L1OF/I/R/V -0.10 
(-0.33, 0.13)
0.38 - -0.52 
(-0.82, -0.21)
0.001 -0.38 
(-0.64, -0.12)
0.004
K20R/M/I/L/T -0.17 
(-0.44 0.10)
0.22 - -0.23 
(-0.59 0.14)
0.23 "
L24I -1.12 
(-2.18, -0.07)
0.03 - -1.80 
(-3.22, -0.39)
0.01 ” “
D30N -0.30 
(-0.66, 0.06)
0.10 - -0.36 
(-0.85, 0.13)
0.15 ‘
V32I -0.97 
(-2.03, 0.08)
0.07 - -1.19
(-2.61,0.23)
0.10 "
L33I/F 0.61 
(-0.15, 1.37)
0.11 0.67 
(-0.01, 1.35)
0.05 0.29 
(-0.73, 1.31)
0.57
M36I/L/V -0.02 
(-0.22, 0.18)
0.85 - -0.09 
(-0.36, 0.19)
0.53 ■
M46I/L -0.23 
(-0.55, 0.09)
0.17 - -0.79 
(-1.22, -0.36)
<0.001 -0.33 
(-0.70, 0.05)
0.09
147 A/V -1.17 
(-2.47, 0.12)
0.08 - -1.73 
(-3.47, 0.00)
0.05 -1.26
(-2.71,0.19)
0.09
G48V -0.18 
(-1.60, 1.25)
0.81 - -0.78 
(-2.69, 1.13)
0.42 *
F53L -0.19
(-1.11,0.73)
0.69 - -0.41 
(-1.65, 0.83)
0.51 -
I54V/L/A/M/T/S -0.19 
(-0.57, 0.19)
0.33 - -0.64 
(-1.15, 0.13)
0.02 *
L63A/P -0.06 
(-0.26, 0.14)
0.58 - 0.02 
(-0.25, 0.30)
0.86
A71V/T 0.01 
(-0.24, 0.26)
0.93 - -0.31 
(-0.65, 0.03)
0.07
G73C/S/T/A 0.11 
(-0.56, 0.77)
0.75 - 0.24 
(-0.66, 1.13)
0.61 -
V77I 0.05 
(-0.16, 0.27)
0.63 - 0.04 
(-0.33, 0.26)
0.82
V82A/F/T/S -0.30 
(-0.67, 0.08)
0.12 - -0.71 
(-1.21, -0.22)
0.005 -
I84V/A/C -0.09 
(-0.73, 0.55)
0.77 - -0.46 
(-1.32, 0.39)
0.29
N88D/S -0.18 
(-0.60, 0.24)
0.40 - -0.41 
(-0.98, 0.16)
0.16
L90M -0.23 
(-0.55, 0.08)
0.14 - -0.73 
(-1.15, -0.30)
0.001 -0.38 
(-0.74, -0.02)
0.04
Other PR mutations (found in >5% of patients)
S37D -0.13 
(-0.43, 0.16)
0.37 - -0.45 
(-0.85, -0.04)
0.03 -0.36 
(-0.69, -0.02)
0.04
• Mutations in bold indicate primary PI mutations to one of the three randomised Pis
according to the IAS-USA mutational lists233 
• Analyses are adjusted for the Pl/r received and baseline HIV RNA
I then identified other protease mutations that were not included in any of the GISs, but 
were observed in the sampled virus of > 5% of our patients: Table 4.4.8.1 shows that the
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only additional mutation associated with virological response was the S37D mutation.
Since the number of patients who had a virus containing each mutation was small, 1 
investigated the combined number of protease mutations (including mutations listed in the 
IAS-USA guidelines in addition to the S37D mutation) to see whether an accumulation of 
mutations has a significant effect on HIV RNA reduction.
The number of PI mutations did not have a predictive effect on HIV RNA change after four 
weeks of follow-up (at week four there was a 0.01 (-0.06 to 0.08) log10 cps/mL greater 
reduction in HIV RNA for each additional PI mutation, p=0.83), but there was a strong 
effect after 12 weeks (at week 12 there was a -0.19 (-0.06 to -0.31) log10 copies/mL greater 
reduction i(i.e. a smaller reduction) in HIV RNA for each additional PI mutation, p=0.004), 
after adjustment.
4.5. Discussion
4.5.1. Summary of main results
Drug resistant HIV can adversely impact on virological and clinical outcomes in both 
treated and untreated individuals196:348:349. ARV-experienced patients may have resistance 
from a previous regimen whereas untreated individuals may be infected with a virus that 
already contains mutations. Genotyping tells us the genetic code of the virus, which is 
conveyed for analysis in the form of a list of mutations that are present in the majority virus 
of a patient, so they can be translated into a sensitivity score using a GIS.
In this analysis I compared four GISs, using data from three trials, where each GIS 
contained three resistance levels (i.e. resistant, intermediate resistance or sensitive). 
Randomisation in randomised controlled trials (RCTs) ensures there are no systematic 
differences between treatment arms apart from the treatment received, so any differences 
observed in the outcome can be attributed to the treatment specifically350. However, any 
balances stemming from the randomised nature of the trials do not extend to patients with 
resistance testing. Moderate concordance was seen between GISs in their predicted 
levels of resistance to a Pl/r (kappas ranged from 0.37 to 0.75 for IDV/r; 0.46 to 0.93 for 
LPV/r; and 0.38 to 0.68 for SQV/r).
I then examined whether any interpretational differences impacted on the ability of each 
system to predict short term virological response. In this comparison none of the GISs 
were associated with significantly greater HIV RNA reductions as sensitivity to the Pl/r
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increased after four weeks of follow-up, but after 12 weeks the ascribed level of sensitivity 
to the Pl/r was related to HIV RNA change for all of the GISs. From the model including 
the REGA GIS, patients who had a virus that showed sensitivity to the Pl/r had a 0.82 
greater log10 reduction between baseline and week 12 compared to patients who had a 
virus that showed full resistance, p=0.02. The GSS to the rest of the regimen was not 
associated with virological response at either time point.
4.5.2. Comparison with other studies
Other studies that have evaluated concordance performed their analysis on more GISs, 
investigated a larger number of ARVs or compared GISs containing additional levels of 
resistance, which resulted in more discordance overall2281229. Ravela et al investigated 
concordance between ANRS, REGA, Stanford and Visible Genetics (VGI) and found 
discordance between 33.6% of interpretations, mainly driven by the NRTIs. Amongst the 
Pl/rs, they found similar kappas for IDV/r (from 0.61 (REGA vs Stanford) to 0.80 (REGA vs 
ANRS)), lower kappas for LPV/r (from 0.40 (ANRS vs Stanford) to 0.67 (REGA vs ANRS)), 
but higher kappas for SQV/r (from 0.63 (REGA vs Stanford) to 0.77 (ANRS vs Stanford))230 
compared to this study. However, they defined discordance as one GIS assigning a 
resistant score and another a sensitive score. If a patient showed intermediate viral 
resistance they were considered neutral and no discordance between either resistant or 
sensitive strains was noted. This re-categorisation would lead to larger kappa values in 
the Ravela study compared to ours.
The Ravela comparison uses GISs that have since been updated to account for the latest 
developments in research and, in some cases, to account for the use of ritonavir boosting. 
Originally GISs were created from the same data, some with overlapping expert 
interpreters, so interpretations were comparable. As time progressed more drugs entered 
the market, more resistance mutations were identified and opinions on what mutations 
contributed towards resistance started to diverge. In addition only some GISs took 
account of the clinically derived GSSs that were published in recent years (i.e. those that 
looked at viral load response)330:333:351:352. ARVs are now used more frequently so there 
has been more of a consensus on what mutations indicate resistance. There has also 
been a concerted effort to improve agreement between GISs. This converging of opinions 
could have resulted in higher kappa values in our study, but that was not the case either.
Our analysis includes the DMC GIS, the system that caused most of the disagreements 
between GISs. Removing DMC from the comparisons increases our overall concordance
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to 89%, bringing our findings closer to the Ravela study. If I consider ‘intermediate 
resistance’ to be consistent with either sensitive or resistant interpretations then 
concordance increases further to >98%. The higher concordance found when our 
comparisons are identical to the Ravela comparisons may reflect a converging of opinions 
regarding resistance within experts. This is especially true for LPV/r which has become 
more widely used since the Ravela study, possibly reflected by the larger kappa values in 
our comparisons. The lower concordance for SQV/r in our analysis may reflect uncertainty 
on how to interpret the impact of ritonavir boosting on resistance.
In a recent study by Maillard et al, the GSSs as defined by Stanford and ANRS were 
predictive of the 24-week virological response to LPV/r in an ARV-experienced 
population353. Since virological outcomes are pivotal for testing the clinical use of GISs I 
examined the relationship between Pl/r resistance levels and HIV RNA change at two time 
points: week four and week 12. In these analyses, differences in HIV RNA reductions 
between ascribed resistance levels did not become apparent until week 12. The majority 
of patients in these comparisons initiated a completely new regimen at baseline so the 
majority virus should have been susceptible to most of the ARVs in the regimen. As a 
result, it may take longer than four weeks for the impact of baseline mutations on viral 
replication to become apparent. Since HIV RNA does not decline linearly with time, in fact 
it starts to increase in some patients on salvage therapy after 4 weeks of follow-up, it 
would be useful to reach a consensus on when to expect a virological response193.
HIV RNA was reduced by 1.8 (1.2 to 2.3) and 2.3 (1.4 to 3.0) log copies/mL from baseline 
after 4 and 12 weeks, respectively. These reductions are larger than in other studies 
comparing GISs for predicting viral load decline193 1971354, but these other studies were 
conducted on patients who were receiving salvage therapy and were less likely to 
experience large reductions. The HIV RNA reductions are greater in this analysis because 
this population contains more varied patients, including patients who were naive to ARV 
therapy, failing a first-line regimen or failing a later regimen. When I examined HIV RNA 
declines at week 12 according to previous PI exposure, HIV RNA was reduced by 2.7 (2.0 
to 3.2) and 1.9 (1.0 to 2.7) log copies/mL from baseline among patients who were Pl-nai've 
and those who were Pl-experienced, respectively.
4.5.3. Interpretation of results
Although each GIS considers different mutations to be relevant for each ARV (Figure 
4.4.2.1 and Figure 4.4.2.2), they all predicted virological response to a similar extent.
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None of the GISs showed significantly greater HIV RNA reductions as sensitivity to the Pl/r 
increased by four weeks of follow-up, but after 12 weeks the ascribed level of sensitivity to 
the Pl/r was related to HIV RNA change for all of the GISs. In multivariable analyses the 
GSS to the rest of the regimen was not associated with virological response at either time 
point, although at week 12 there was a trend for greater reductions with an increasing 
number of active drugs in the background regimen. These results are consistent with a 
study by Miller et al and a recent study by Rhee et al where resistance to a Pl/r was shown 
to be a stronger predictor for virological failure at week 24 than NRTI resistance or NNRTI 
resistance2971355.
On the other hand, De Luca et al found that the GSS to the whole regimen (including the 
Pl/r) did not predict response to a Pl/r-containing regimen354, but the independent effect of 
Pl/r sensitivity may have been overshadowed by sensitivity to the rest of the regimen in 
that study since the regimen was studied as a whole rather than Pl/rs separately. This is 
similar to the findings of this study when I combined the Pl/r resistance levels with the GSS 
for the rest of the regimen, after adjustment for the baseline HIV RNA.
Although the current GISs are able to identify differences in viral load response according 
to their ascribed Pl/r resistance levels, patients with a virus that was deemed to be fully 
resistant to the Pl/r still experienced large HIV RNA reductions (i.e. a reduction of >1 log10 
copies/mL). Pl/rs may exert antiviral effects in the presence of resistance; however, this 
observation is probably, in part, due to susceptibility to the nucleoside backbone. Using 
the REGA GIS, the mean (95% Cl) GSS to the rest of the regimen for patients with a virus 
that was considered to be resistant to the Pl/r was 0.9 (0.5 to 1.3), N=18. Indeed, if a 
patient had a high GSS to the other drugs in their regimen they still experienced large HIV 
RNA reductions despite the presence of Pl/r resistance (Figure 4.4.5.1), but this trend was 
only seen in a small number of patients (N=4). Patients with a virus that was fully resistant 
to all ARVs in their regimen (i.e. the background ARVs and the Pl/r) only experienced 
small HIV RNA declines consistent with the predicted activity of the regimen.
In our analysis >70% of patients had a virus that was susceptible to the Pl/r they were 
receiving at baseline. In these patients the GSS to the rest of the regimen was not an 
important determinant of HIV RNA decline, probably because sensitivity to the Pl/r was the 
major factor influencing response. Even though GISs vary on what resistance mutations 
they consider to be important, as reflected by the low-to-moderate kappa values, the 
relationship between resistance and HIV RNA change for each GIS illustrates that GISs
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effectively discriminate viruses according to sensitivity to Pl/rs. This is somewhat 
surprising considering that the DMC GIS had not yet been updated to take into account 
ritonavir-boosting.
I assessed the relationship between individual mutations and virological response for all 
mutations that were included in any of the GISs. The presence of these mutations was 
associated with a poorer virological response in most cases; however, not all associations 
were significant, possibly because some mutations were too infrequent to quantify their 
effects accurately. At week 4 no other protease mutations than those included in the GISs 
were related to virological response, but by week 12 the S37D mutation was significantly 
associated with a poorer response in both unadjusted and adjusted analysis (Table
4.4.8.1).
Marcelin et al found a strong association between the decrease in HIV RNA and the 
number of mutations observed at codons 24, 62, 82, 84 and 90 for SQV/r330. In this 
analysis I found mutations at positions 10, 24, 46, 47, 54, 82 and 90 to be significantly 
associated with response. Since there were a limited number of people who had a virus 
containing each mutation, I investigated a combination of protease mutations (i.e. the total 
number of IAS-USA protease mutations plus the S37D mutation) to see whether 
accumulation of mutations had a significant effect on HIV RNA reduction. The overall 
number of protease mutations was significantly associated with response at week 12, but 
not at week 4. This is consistent with other studies where the number of protease 
mutations has been associated with response to PI/rS330;335;356.
4.5.4. Limitations of analysis
This analysis has several limitations: I do not have a measure of adherence in these 
patients and since the predictive ability of the GISs is stronger in adherent patients354 non­
adherence could dilute the strength of association between each GIS and response. 
Pharmacokinetic analysis after four weeks of follow-up revealed high PI PK drug levels in 
the majority of patients in these trials (Table 3.4.2.1), reflecting good adherence overall; 
however, adherence rates are known to diminish with time on a regimen357. I examined 
virological response after 4 and 12 weeks follow-up and found a stronger association 
between the Pl/r resistance levels and the 12 week HIV RNA decline compared to week 4. 
This indicates continuously high levels of adherence in these patients. Another limitation 
is that a large proportion of our study population is Pl-naive and will respond to therapy 
differently to Pl-experienced patients. This analysis probably should have been restricted
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to Pl-experienced patients because the GISs were created from data derived from patients 
who were receiving Pis and are designed for use in Pl-experienced patients. However, 
when I repeated the analysis in the subgroup of Pl-experienced patients I found similar 
trends.
A wider limitation of genotypic resistance testing concerns the practical implications of 
dealing with consensus sequences rather than clones (i.e. a procedure of obtaining the 
sequences of a single cloned viral genome rather than the consensus sequences derived 
from multiple genomes). Use of consensus sequencing produces a consensus sequence 
from the dominant quasi-species in circulation; therefore some of the clinically significant 
resistant mutations present at baseline, at levels below 20 to 25% of the virus population, 
may be missed. This could also be a problem with clones unless a large enough number 
of clones from different PCR reactions are sequenced. The presence of low-frequency or 
archived species is a major problem with building GISs in general.
Treatment success beyond the first few weeks of the start of a regimen is likely to be 
influenced by the low frequency viral populations and therefore these may need to be 
incorporated into a GIS in the future if sufficiently sensitive resistance testing approaches 
can be developed (e.g. using ultrasentive detection methods for resistance for low 
frequency mutations and testing PBMC as well as plasma for archived resistance). 
Alternatively, another resistance test could be performed after four weeks of follow-up 
when the minority species has had more chance to replicate. A more simple approach to 
maximise the benefit of GISs is to combine resistance history and treatment history into 
the interpretation system223. It may be necessary to consider all previous causes of 
treatment failure in order to optimise treatment. This is currently done in routine clinical 
practice.
4.5.5. Conclusion
To conclude, differences exist between GISs in their ascribed levels of resistance to a Pl/r; 
however, the level of disagreement for predicting short-term HIV RNA change is relatively 
minor. Although patients with a virus that is deemed to be sensitive to the drugs in their 
regimen experience the largest HIV RNA declines for all of the interpretation systems, 
GISs still need further refinement to improve discrimination and concordance. 
Observational data from cohort studies will enable us to repeat these analyses on the 
newer Pl/rs (i.e. atazanavir, darunavir, tipranavir and fos-amprenavir) to see whether the 
same trends are seen in patients receiving these drugs.
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CHAPTER 5: THE ABILITY OF FOUR GISs TO PREDICT VIRAL LOAD
RESPONSE TO RITONAVIR-BOOSTED PIS. USING OBSERVATIONAL DATA 
5. Introduction
Data from observational studies differ to data from randomised controlled trials (RCTs) in 
many ways. The main advantage of RCTs is that they remove bias from treatment 
comparisons and ensure comparable groups at study entry. A major advantage of 
observational studies is that they best reflect what happens in clinical practice3501358. In the 
previous chapter I compared the prognostic value of four GISs for predicting viral load 
response to three Pl/rs using data from three RCTs. RCTs include pre-scheduled follow- 
up visits and, as a result, the HIV RNA declines seen in the trials may not reflect those 
seen in clinical practice. The ascribed Pl/r resistance levels were related to virological 
response after 12 weeks of follow-up, but not after four weeks. A key limitation of the 
results in the last chapter was that only a low number of patients had a virus containing 
resistance mutations at baseline.
5.1. Aims of the chapter
To increase the number of patients who could be included in these comparisons I repeated 
the 12 week analysis on patients from EuroSIDA to see whether the same patterns are 
observed in patients who are followed up less frequently, due to the nature of the study. If 
no major differences are observed, it will be possible to combine datasets and increase the 
overall power of these comparisons. As a result, I will refer back to the previous chapter 
throughout the results section of this chapter. This chapter examines whether GISs can 
predict viral load response to a Pl/r containing regimen in both an observational study 
(EuroSIDA) and the trials, combined.
5.2. Literature review
In the previous chapter, the resistance data from the trials can be considered to be 
pseudo-observational because the balances stemming from the randomised nature of the 
trials do not extend to patients with resistance testing. So, repeating this analysis on 
observational data is unlikely to amount in additional bias. In an observational setting, it is 
likely that systematic differences exist between the groups being compared and, even 
though variations between known factors can be adjusted for in a multivariable analysis, it 
is not always possible to account for any unknown or unmeasured confounding factors359'
362
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There are some advantages to analysing observational data: patients are usually 
representative of those seen in routine clinical practice so they reflect what happens in real 
clinical situations363'365. In addition, patient characteristics are monitored over a longer 
period of time than in most trials, so observational data also enable us to investigate the 
long term response to treatment. Although follow-up is longer in observational studies 
than in trials, patients are usually not followed up as frequently or regularly. This can 
result in differences between observational studies and trials in their reported incidence 
and prevalence rates of virological and immunological events366-369.
Irregular follow-up visits also pose a problem for choosing a time point to best measure 
virological response to a regimen because, even though linear interpolation or other 
methods can be used to account for missing measurements at various time points3661370'376, 
they may not accurately reflect the actual viral load values at these different times. In the 
MaxCmin and COLATE trials, the clinical visits were scheduled after four and 12 weeks 
and then at 12 week intervals thereafter. This analysis investigates the virological 
response after 12 weeks of follow-up (range: 4 to 24 weeks) for patients who started a Pl/r 
containing regimen in EuroSIDA, because Pl/r resistance levels were more powerful at 
predicting the response at week 12 compared to week 4 in the previous chapter.
5.3. Methods
Since these data are observational there were no restrictive entry criteria for inclusion in 
the study, so patients are likely to have more heterogeneous characteristics (i.e. the 
number and type of background ARVs is likely to be more varied and patients are likely to 
have a virus that shows a larger degree of resistance to all of the ARVs in their regimen) 
than the trial patients. Repeating the analysis on patients who have a virus that contains a 
higher level of resistance will provide more power to determine whether there are real 
differences in viral load response according to the ascribed Pl/r resistance levels and 
whether differences do, in fact, exist between GISs.
Repeating this analysis on observational data also meant it was possible to include more 
up-to-date regimens. This analysis involves a greater number of Pl/rs than in the previous 
chapter, some of which have recently entered the market. Patients in EuroSIDA who 
started APV/r, ATV/r, IDV/r, LPV/r or SQV/r were included in these comparisons.
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5.3.1. EuroSIDA
Details of EuroSIDA have been described in section 2.2.1. At each visit, all CD4+ T cell 
counts and HIV RNA levels taken since the last follow-up visit were collected and dates of 
starting and stopping each ARV were recorded. Out of the 11928 patients with available 
clinical data when the database was closed for analysis, in July 2005, there were 3893 
(32.6%) who had ever started a Pl/r.
5.3.2. Virological response
Since HIV RNA measurements are taken less frequently in observational studies 
compared to the trials I considered any HIV RNA value recorded in the three months prior 
to and up to one week after starting a Pl/r to correspond to the baseline HIV RNA level. 
The HIV RNA value that was recorded closest to baseline was considered to be the 
baseline HIV RNA as long as it was measured before Pl/r initiation. For seven patients, no 
HIV RNA data was recorded in the three months preceding the start of a Pl/r, but was 
available in the week after. Since HIV RNA is likely to change in the week following 
initiation of a new regimen, the HIV RNA measured in the week following initiation was 
taken as the baseline HIV RNA, under the assumption that it was actually taken before the 
start of the regimen, but the dates of entry were inaccurate in the database.
HIV RNA response was measured 12 weeks (range: 4 to 24 weeks) after Pl/r initiation. If 
a patient had more than one HIV RNA measurement in the follow-up window then the 
value taken closest to 12 weeks was included in this analysis.
Since resistance testing is unlikely to coincide with the date that the Pl/r was started, the 
latest resistance test taken in the year prior to starting a Pl/r was included as the baseline 
resistance test in this analysis. A sensitivity analysis was performed where this restriction 
was reduced to six months.
5.3.3. Laboratory methods
In EuroSIDA, virological sequencing was either performed at the IrsiCaixa Foundation 
(Badalona, Spain) or at the International Clinical Virology Center, depending on the time of 
the resistance test (section 2.2.1.3). Sample mix-up or lab-contaminated samples were 
identified by generating phylogenetic trees.
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5.3.4. Genotypic interpretation systems
Genotypes were provided as amino acid substitutions from HXB2 and the GISs used to 
ascribe resistance levels were the same as in 4.3.2
5.3.5. Statistical analysis
Concordance between ascribed Pl/r resistance levels for each GIS was evaluated using 
kappa statistics in the same way as 4.3.4. I related these ascribed Pl/r resistance levels to 
HIV RNA reductions from baseline after 12 weeks follow-up. In EuroSIDA the most 
commonly used HIV RNA assay has a lower limit of quantification of 50 copies/mL; 
however, some sites use a more sensitive HIV RNA assay that can quantify virus below 
that threshold. In these cases I modelled the full HIV RNA reductions and did not consider 
the patient to have a censored HIV RNA measurement. All variables associated with HIV 
RNA decline in an unadjusted censored regression analysis were entered into separate 
multivariable models for each GIS. Each multivariable model is adjusted for the GSS to 
the rest of the regimen calculated using the same GIS.
5.4. Results
5.4.1. Patient characteristics
Out of the 11928 patients who were enrolled into EuroSIDA, there were 4968 (42%) 
patients who had plasma samples stored for genotypic resistance testing at some point 
during follow-up. Overall, 3893 patients received a Pl/r and of these, 475 (12%) had a 
resistance test in the year prior to Pl/r initiation. A total of 418 of 475 (88%) patients had 
HIV RNA values available at baseline (-3 months to +1 week) and 376 (79%) also had HIV 
RNA values available between 4 and 24 weeks after starting the Pl/r. The 376 patients 
who were included in these comparisons started one of the following single Pl/rs (Table
5.4.1.1): APV/r (N=28, 7%), ATV/r (N=29, 8%), IDV/r (N=55, 15%), LPV/r (N=231, 61%) 
and SQV/r (N=33, 9%). Of these, 301 (80%) patients were Pl-experienced and the other 
75 (20%) were Pl-nai've.
Patients were primarily male (77%) and were a median age of 41 years (IQR: 37 to 48 
years). Patients in EuroSIDA had been infected with HIV for longer than those in the trials: 
more patients had an AIDS defining event (34% versus 29%) and a greater number had 
been exposed to Pis prior to entry (80% versus 55%). This wider treatment use resulted in 
patients having their HIV-infection more under control, as reflected by the higher CD4+ cell 
counts and lower HIV RNA levels. Median CD4+ cell counts and HIV RNA levels in the
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EuroSIDA population were 260 (IQR: 160 to 406) cells/pL and 4.0 (IQR: 3.2 to 4.9) log10 
cps/mL, respectively, whereas in the trials the equivalent baseline CD4+ cell counts and 
HIV RNA levels were 223 (IQR: 100 to 360) cells/pL and 4.7 (IQR: 3.9 to 5.2) log10 cps/mL, 
respectively.
Table 5.4.1.1: Baseline characteristics for the 376 patients in EuroSIDA
Baseline parameter
APV/r
N=28
ATV/r
N=29
IDV/r
N=55
LPV/r
N=231
SQV/r
N=33
Gender No. Male, (%) 24 (86) 17 (59) 50 (91) 179 (77) 21 (63)
Age Med yrs (IQR) 39 41 40 42 41
(35, 49) (35, 44) (35, 42) (38, 49) (36, 47)
Antiretroviral naive N, (%) 0 (0) 0 (0) 7 (13) 7 (3) 9 (27)
Pl-nai've N, (%) 0 (0) 5 (17) 12 (22) 29 (13) 6 (18)
Pl-experienced N, (%) 28 (100) 24 (83) 36 (65) 195 (84) 18 (55)
CDC, cat. C N, (%) 16 (57) 6 (21) 19 (35) 77 (33) 8 (24)
Calendar year of starting the May 00 Aug 04 Apr 00 Aug 02 Jun 00
Pl/r Med month, yr (IQR) Dec 99, Jan 02 Oct 03, Sep 04 Jul 99, Jan 01 May 01, Oct 03 Jun 99, Jem 01
HIV RNA (cps/mL log10) 4.0 4.2 4.3 4.0 3.7
Med (IQR) (3.5, 5.0) (2.8, 5.0) (3.2, 4.8) (3.2, 4.9) (3.1, 4.9)
CD4+ (106/l)* 198 317 255 260 249
Med (IQR) (72, 357) (174,435) (170, 392) (153, 410) (192, 406)
CD4+ nadir (106/l) 20 116 150 81 143
Med (IQR) (9,77) (30, 160) (69, 224) (26, 180) (85, 202)
HIV exposure group N, (%) 
Homosexual/bisexual 14 (50) 15 (52) 29 (53) 112 (48) 14 (42)
IVDU 6 (21) 6 (21) 10 (18) 43 (19) 7 (21)
Heterosexual 4 (14) 8 (28) 14 (25) 61 (26) 9 (27)
Other/unknown 4 (14) 0 (0) 2 (4) 15 (6) 3 (9)
Race N, (%) 
White 24 (86) 20 (69) 46 (84) 187 (81) 25 (76)
Black 1 (4) 2 (7) 4 (7) 16 (7) 3 (9)
Other/unknown 3 (11) 7 (24) 5 (9) 28 (12) 5 (15)
Any NRTI mutation* N, (%) 27 (96) 19 (66) 35 (64) 189 (82) 18 (55)
Any NNRTI mutation* N, (%) 17 (61) 21 (72) 18 (33) 106 (46) 7 (21)
Any primary PI mutation* N (%) 24 (86) 9 (31) 17 (31) 121 (52) 10 (30)
* Refers to any major mutation as defined in the IAS-USA 2006 tables233
Overall, 288 (77%), 169 (45%) and 181 (48%) patients had a virus showing a major IAS- 
USA resistance mutation (Sept 2006)233 to an NRTI, NNRTI or PI, respectively. Patients 
started a variable number of ARVs in addition to the Pl/r component of the regimen, with 
the majority (N=231, 61%) starting two other ARVs. There were 35 (9%) patients who 
received fewer than two background ARVs and the remaining 110 (29%) patients received 
£3 background ARVS.
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5.4.2. Concordance of the interpretation of genotypic data by all GISs
At baseline, 363 patients received an NRTI, 100 received an NNRTI and 376 received a 
Pl/r. There were 220 (61 %) patients with a virus that showed an IAS-USA (Sept 2006)233 
resistance mutation to one of their baseline NRTIs, 27 (27%) with a virus that showed a 
resistance mutation to a baseline NNRTI and 92 (24%) with a virus that showed a major 
resistance mutation to a baseline Pl/r. These levels of resistance are higher than those 
seen in the trials where there were 151 (41%), 4 (11%) and 41 (11%) patients with a virus 
that showed a major resistance mutation to an NRTI, NNRTI or PI they were receiving at 
baseline, respectively.
Using the REGA GIS (version 6.4), there were 68 (18%) patients with a virus that showed 
full or intermediate resistance to the Pl/r they were receiving at baseline (N=9 (32%), N=2 
(7%), N=10 (18%), N=44 (19%) and N=3 (9%) patients on APV/r, ATV/r, IDV/r, LPV/r and 
SQV/r, respectively). In the same way as for the trial data ANRS (version 13) calculated 
comparable levels of resistance to REGA (version 6.4) but both DMC (October 2004) and 
Stanford (version 4.2.0) predicted over double the number of patients with a virus 
exhibiting full or intermediate resistance to their baseline Pl/r. This comparison involves a 
greater number of Pl/rs than in the previous chapter. Large differences occur between 
GISs in the ascribed level of resistance to the newer Pl/rs, although recently there is a 
growing consensus on which mutations indicate resistance to these drugs. The 
breakdown of resistance by Pl/r and GIS is shown in Table 5.4.2.1.
Table 5.4.2.1: Patients with a virus exhibiting full or intermediate baseline resistance to 
the Pl/r according to each GIS
I Genotypic Interpretation System
T  ANRS DMC REGA Stanford
I N (%) N (%) N (%) N (%)
Pl/r
APV/r (N=28) 3 (11) 17 (61) 9 (32) 23 (82)
ATV/r (N=29) 2 (7) 9 (31) 2 (7) 8 (28)
IDV/r (N=55) 14 (25) 16 (29) 10 (18) 12 (22)
LPV/r (N=231) 31 (13) 80 (35) 44 (19) 96 (42)
SQV/r (N=33) 2 (6) 9 (27) . 3 (9) 7 (21)
Any Pl/r (N=376) I 52 (14) 131 (35) 68 (18) 146 (39)
Overall concordance between GISs on the predicted level of resistance to the combined 
Pl/rs was low-to-moderate. Kappas ranged from 0.01 to 0.38 for APV/r; 0.31 to 1.00 for 
ATV/r; 0.48 to 0.79 for IDV/r; 0.34 to 0.77 for LPV/r; and 0.30 to 0.57 for SQV/r (Table
5.4.2.2).
142
Table 5.4.2.2: Kappa values to illustrate concordance between GISs
REGA DMC Stanford
APV/r ANRS 0.18 0.17 0.08
REGA - 0.06 0.01
DMC - - 0.38
ATV/r ANRS 1.00 0.31 0.35
REGA - 0.31 0.35
DMC - - 0.92
IDV/r ANRS 0.65 0.48 0.68
REGA - 0.67 0.79
DMC - - 0.52
LPV/r ANRS 0.77 0.36 0.34
REGA - 0.50 0.48
DMC - - 0.65
SQV/r ANRS 0.57 0.31 0.30
REGA - 0.35 0.45
DMC - - 0.47
Poor k <0.2; Fair 0.21< k<0.40; Moderate 0.41< k <0.60; Good 0.61£ k < 0.80 and Very Good k >0.80
You will recall that Figure 4.4.2.2 illustrates the codon positions that cause discordance 
between resistance levels for IDV/r, SQV/r and LPV/r. Figure 5.4.2.1 shows that there is 
also a high level of discordance between GISs when examining interpretations for APV/r 
and ATV/r separately. The GISs vary on what codons and what amino acid substitutions 
they consider to be associated with resistance to each Pl/r and they also account for the 
mutations differently, by assigning them different weights. This has not been accounted 
for in these figures.
Figure 5.4.2.1: Mutational discrepancies between GISs: for APV/r and ATV/r
M utations in the protease gene associated with resistance to am prenavir/r:
10  20  24 32 33 35 36 41 46 4 7 4c 5 0  53 54  63 . 71 73 7 7 8  2  84  , 8 90
 I 14-----,----4— I  ~1 f 1 ~V '  V  "* ! —--T F 1----—r—*- —“ —I   T • 1
(S ) (R .S ) (A ) (D ,S )(A )  (D ,R .S )  (D ,S )  (S )  < A ,S )(D ,S ) (S ) (D ) (S ) < D ,R ,S )
M utations in the protease gene associated with resistance to atazanavir/r:
10 16 20 24 32 33 36 4^ 4 6  47 48 50  53 54 60 63 71 73 77 82 84  85 88 90
 1——i----- 1-----1------- 1 1------ 1------ 1-------- 1----- 1-------1 !------ 1----1------ 1-----1----- r " 1...... . .... i— ' i   J
(A,R,S)( A,S)(R,S)(R,S) {R,S)( A,R, S)(R,S)(R) (S) (R,S) (S)(D,R,S)( A) (S) (R,S)(R,S) (R)(D,R,S) (A )(D ,R ,S )
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5.4.3. Prognostic value of GISs for predicting viral load decline
The median (IQR) baseline HIV RNA was 4.0 (3.2 to 4.9) and after a median 13 (IQR: 9 to 
17) weeks from the start of a Pl/r containing regimen this was reduced by a mean 1.8 
(95% Cl: 1.7 to 1.9) log10 cps/mL. This reduction is smaller than that seen in the trials, 
presumably because more patients in EuroSIDA had a virus with resistance mutations to 
their ARVs, so it is expected that their virus would not be as susceptible to treatment.
The HIV RNA reduction was similar for patients using each Pl/r: 1.5 (0.9 to 2.0) log10 
(APV/r); 1.9 (1.3 to 2.4) log10 cps/mL (ATV/r); 1.6 (1.3 to 2.0) log10 cps/mL (IDV/r); 1.9 (1.7 
to 2.1) log10 (LPV/r); and 1.7 (1.3 to 2.2) log10 (SQV/r); (p=0.42 from a censored regression 
analysis). There were 88 (23%) patients with an HIV RNA recorded as 50 cps/mL in 
whom the reduction was censored in the regression analysis (4 (14%), 7 (24%), 7 (13%), 
63 (27%) and 7 (21%) patients receiving APV/r, ATV/r, IDV/r, LPV/r or SQV/r, 
respectively).
In unadjusted analysis, the level of resistance to the Pl/r (all Pl/rs combined) was 
significantly related to HIV RNA reductions for all GISs (p^0.01). The GSS to the rest of 
the regimen did not predict virological response using either the ANRS GIS or the REGA 
GIS (Table 5.4.3.1). There was a trend towards a relationship between the GSS to the 
rest of the regimen with viral load response for both DMC and Stanford, but these trends 
went in the opposite direction to what was expected. For the DMC GIS there was a -0.11 
(-0.26 to 0.02) larger decline from baseline in HIV RNA for each additional active drug a 
patient had in their background regimen (i.e. a smaller decline). Similarly, for the Stanford 
GIS there was a -0.13 (-0.28 to 0.02) larger decline in HIV RNA from baseline for every 
additional active drug a patient had in their background regimen.
After adjustment for baseline HIV RNA levels, the Pl/r used, the time between baseline 
and follow-up HIV RNA measurements and also for the time between baseline resistance 
test and the date of Pl/r initiation, all GISs still showed significantly greater reductions as 
sensitivity to the Pl/r increased. The GSS to the rest of the regimen did not predict 
response further (Table 5.4.3.1). Patients with a virus that was ascribed to be sensitive to 
the Pl/r were predicted to have a 0.72 greater log10 reduction between baseline and week 
12 compared to patients with a virus harbouring full resistance. This difference in the 
magnitude of effect sizes is comparable to the patterns we saw in the trials where there 
was predicted to be a 0.82 greater log10 reduction between baseline and week 12 for
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patients with a virus that showed sensitivity to the Pl/r compared to patients with a virus 
exhibiting full resistance.
Table 5.4.3.1: Differences in HIV RNA change (AVL: BL to week 12) for each GIS 
According to the Pl/r resistance level and number of active ARVs in the regimen
Interpretation System Unadjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value
ANRS
Pl/r resistance (R -> I -> S) 0.34 (0.11,0.58) 0.003 0.36 (0.15,0.56) 0.001
GSS to the rest of the regimen
For every additional active ARV -0.02 (-0.16,0.12) 0.78 0.04 (-0.08,0.16) 0.56
REGA
Pl/r resistance (R I -> S) 0.37 (0.13,0.60) 0.003 0.36 (0.15,0.58) 0.001
GSS to the rest of the regimen
For every additional active ARV -0.04 (-0.19,0.11) 0.58 0.04 (-0.09,0.18) 0.53
DMC
Pl/r resistance (R -> I -> S) 0.30 (0.12,0.47) 0.001 0.22 (0.06,0.38) 0.008
GSS to the rest of the regimen
For every additional active ARV -0.11 (-0.26,0.02) 0.10 -0.05 (-0.18,0.08) 0.45
Stanford
Pl/r resistance (R -> I -> S) 0.42 (0.20,0.63) <0.0001 0.42 (0.21,0.63) <0.0001
GSS to the rest of the regimen
For every additional active ARV -0.13 (-0.28,0.02) 0.09 0.05 (-0.09,0.19) 0.51
• Coefficients are interpreted in the same way as in Table 4.4.4.1
• Adjustments were made for baseline HIV RNA levels, the Pl/r used, the time between 
baseline and follow-up HIV RNA measurements and also for the time between baseline 
resistance test and the date of Pl/r initiation
The results of the multivariable model including the REGA GIS show: a 0.52 (0.41 to 0.63) 
logio larger reduction in HIV RNA from baseline for every log10 higher baseline HIV RNA 
(p<0.0001); a 0.02 (0.00 to 0.04) log10 larger reduction in HIV RNA from baseline for every 
week longer between the baseline and the follow-up HIV RNA measurements (p=0.06); 
and a -0.006 (-0.014 to 0.003) log10 smaller reduction in HIV RNA from baseline for every 
additional week prior to baseline that the resistance test occurred on (p=0.20). Similar 
results were seen in multivariable models including all of the other GISs (data not shown).
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5.4.4. Investigating each Pl/r separately
I investigated HIV RNA reductions according to the level of resistance to each Pl/r 
separately to see whether the above trends were driven by a specific Pl/r. Even though 
individual comparisons in each treatment arm resulted in reduced power, the levels of 
resistance to ATV/r, LPV/r and to SQV/r were significantly associated with virological 
response for each GIS: with more viral sensitivity related to larger HIV RNA reductions 
(p<0.01). The same trends were not seen in the subgroups of patients receiving IDV/r or 
APV/r. For APV/r this could be partly due to small numbers. This is illustrated using the 
REGA GIS in Table 5.4.4.1.
Table 5.4.4.1: Differences in HIV RNA change (AVL: BL to week 12): for each Pl/r 
Using the REGA interpretation system
Interpretation System Unadjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction per 
higher level of 
sensitivity 
(log10 cps/mL)
P-value
APV/r resistance (R I -> S) 0.42 (-0.55, 1.40) 0.38 0.65 (-0.36, 1.66) 0.20
GSS to the rest of the regimen
For every additional active ARV 0.46 (-0.29, 1.21) 0.22 0.62 (-0.18,1.42) 0.12
ATV/r resistance (R -> I S) 0.88 (-0.04,1.81) 0.06 1.22 (0.42,2.02) 0.004
GSS to the rest of the regimen
For every additional active ARV -0.47 (-1.56,0.61) 0.38 -0.56 (-1.42,0.29) 0.19
IDV/r resistance (R -> I -> S) -0.33 (-0.91,0.24) 0.25 -0.17 (-0.61,0.28) 0.46
GSS to the rest of the regimen
For every additional active ARV -0.04 (-0.67,0.59) 0.90 -0.11 (-0.58,0.37) 0.65
LPV/r resistance (R -> I -> S) 0.45 (0.15,0.75) 0.003 0.48 (0.21,0.75) <0.0001
GSS to the rest of the regimen
For every additional active ARV 0.02 (-0.25,0.30) 0.87 0.13 (-0.10,0.37) 0.27
SQV/r resistance (R I -> S) 1.09 (0.23,1.96) 0.02 0.95 (0.25, 1.64) 0.009
GSS to the rest of the regimen
For every additional active ARV 0.10 (-0.63,0.82) 0.78 -0.29 (-0.81,0.23) 0.27
• Coefficients are interpreted in the same way as in Table 4.4.4.1
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5.4.5. The combined trials/EuroSIDA dataset
Although EuroSIDA contained a more treatment experienced population compared to the 
trials, separate analysis of the two datasets provided consistent results. Therefore, I 
merged the datasets to improve power because the frequency of resistance to the Pl/r in 
each study individually was relatively low. To my knowledge this is the largest combined 
database of patients receiving a Pl/r in which it is possible to examine the relationship 
between ascribed resistance levels and viral load outcome.
In this comparison I also investigated the GSS to the rest of the regimen as a categorical 
variable with three categories (i.e. no other active drugs; 0.5 to 1.5 other active drugs; and 
£2 other active drugs) instead of as a continuous variable. This was because I wanted to 
distinguish between patients who had a virus that showed resistance to all of their 
background drugs from patients who had a virus that showed susceptibility to all of their 
background drugs.
The median (IQR) baseline HIV RNA was 4.4 (3.5 to 5.1) log10 copies/mL, after a median 
(IQR) 12 (9 to 13) weeks from the start of a Pl/r containing regimen this was reduced by a 
mean (95% Cl) 2.2 (2.1 to 2.3) log10 copies/mL. The level of resistance to the Pl/r (all Pl/rs 
combined) was related to HIV RNA reductions for all GISs (p<0.0001).
After adjusting for the baseline HIV RNA level, the Pl/r used, the time between baseline 
and follow-up HIV RNA measurement and the GSS to the rest of the regimen (calculated 
using the same GIS that was used to calculate the level of Pl/r resistance), all GISs still 
showed significantly greater reductions as sensitivity to the Pl/r increased. Patients with a 
virus that showed sensitivity to the Pl/r experience a 0.82 greater log™ reduction between 
baseline and week 12 compared to patients with a virus exhibiting full resistance using the 
REGA GIS (Table 5.4.5.1).
When I included the GSS to the rest of the regimen in the model as a categorical variable 
instead of as a continuous variable I found that differences existed between GISs. The 
resistance levels ascribed by two GISs were significantly related to HIV RNA declines. 
There was a trend for greater HIV RNA reductions with increasing Pl/r sensitivity and with 
increasing GSS to the rest of the regimen in both unadjusted and adjusted analysis for 
REGA and ANRS (Table 5.4.5.1).
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Table 5.4.5.1: Differences in change (AVL: BL to week 12), for the trials and EuroSIDA 
combined
Interpretation System Unadjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction per higher 
level of sensitivity 
(log10 cps/mL)
P-vaiue
ANRS
Pl/r resistance (R -> I -> S) 0.49 (0.29,0.68) <0.0001 0.39 (0.22,0.56) <0.0001
GSS to the rest of the regimen
0
0.5 to 1.5 
>2
Ref
0.33 (-0.15,0.82) 
0.66 (0.21, 1.11)
0.003 Ref
0.46 (0.05,0.87) 
0.49 (0.11,0.86)
0.04
REGA
Pl/r resistance (R -> I -> S) 0.56 (0.35,0.76) <0.0001 0.41 (0.23,0.59) <0.0001
GSS to the rest of the regimen
0
0.5 to 1.5 
£2
Ref
0.25 (-0.23,0.73) 
0.59 (0.13,1.06)
0.004 Ref
0.39 (-0.01,0.79) 
0.45 (0.06,0.83)
0.07
DMC
Pl/r resistance (R -> I -> S) 0.49 (0.33,0.65) <0.0001 0.33 (0.19,0.47) <0.0001
GSS to the rest of the regimen
0
0.5 to 1.5 
£2
Ref
-0.15 (-0.62,0.32) 
0.10 (-0.34,0.53)
0.20 Ref
-0.02 (-0.41,0.37) 
-0.01 (-0.37,0.35)
0.99
Stanford
Pl/r resistance (R -> I -> S) 0.67 (0.49,0.86) <0.0001 0.46 (0.29,0.63) <0.0001
GSS to the rest of the regimen
0
0.5 to 1.5 
£2
Ref
0.12 (-0.43,0.67) 
0.23 (-0.30,0.75)
0.55 Ref
0.20 (-0.25,0.65) 
0.18 (-0.25,0.61)
0.67
• Coefficients are interpreted in the same way as in Table 4.4.4.1
• Adjustments are made for the Pl/r used, baseline HIV RNA and the time between Pl/r initiation and 
follow-up HIV RNA measurement
For both of these GISs, the relationship between the GSS to the rest of the regimen and 
HIV RNA declines was driven by patients who had a virus exhibiting full resistance to all of 
the other drugs in the regimen compared to those with a virus that showed susceptibility to 
at least one drug. Neither DMC nor Stanford showed a relationship between the GSS to 
the rest of the regimen and HIV RNA response.
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5.4.6. Investigating other mutations and virological response
I then looked at the relationship between individual protease mutations (according to the 
IAS-USA September 2006 guidelines233) and viral load response in EuroSIDA, to see 
whether the same mutations predicted response as I found in the trial data (section 4.4.8). 
In contrast to the comparisons performed in the trials, the presence of the F53L mutation 
was associated with a worse virological response, and the 147A/V mutation was not related 
to HIV RNA decline in either unadjusted or adjusted analysis. This is somewhat surprising 
given the impact of I47A on LPV/r, for example. To assess whether the effect was masked 
by the fact that the two mutations 147V and I47A were considered together in Table 
5.4.6.1,1 investigated the relationship between each mutation and HIV RNA reductions 
separately. No relationship was identified in either of these analyses (data not shown). 
Mutations at positions 10, 46, 54, 82 and 90 were consistently associated with smaller HIV 
RNA declines (Table 4.4.8.1 and Table 5.4.6.1).
Table 5.4.6.1: Relationship between individual mutations and virological response
Mutation
Present
Unadjusted Analysis
Additional HIV RNA 
reduction with presence 
of mutation 
(log10 cps/mL)
P-value Adjusted Analysis
Additional HIV RNA 
reduction with presence 
of mutation 
(log10 cps/mL)
P-value
L1OF/I/R/V -0.35 (-0.64, -0.04) 0.03 -0.34 (-0.60, -0.07) 0.01
K20R/M/I/L/T -0.15 (-0.51, 0.22) 0.43 - -
L24I -0.52 (-1.27, 0.24) 0.18 - -
D30N 0.05 (-0.50, 0.59) 0.87 - -
V32I -0.10 (-1.12, 0.92) 0.84 - -
L33I/F -0.18 (-0.83, 0.47) 0.58 - -
M36I/L/V 0.10 (-0.21, 0.40) 0.54 - -
R41K -0.15 (-2.78, 2.48) 0.91 - -
M46I/L -0.37 (-0.70, -0.04) 0.03 -0.38 (-0.68, -0.09) 0.01
I47A/V 0.34 (-0.88, 1.56) 0.58 - -
G48V 0.05 (-0.77, 0.86) 0.91 - -
150 L/V 0.45 (-2.18, 3.08) 0.74 - -
F53L -0.78 (-1.42, -0.14) 0.02 -0.68 (-1.24, -0.13) 0.02
I54V/L/A/M/T/S -0.57 (-0.98, -0.16) 0.007 -0.62 (-0.98, -0.26) 0.001
L63A/P -0.21 (-0.51, 0.08) 0.15 -0.24 (-0.49, 0.01) 0.06
A71V/T -0.39 (-0.69, -0.09) 0.01 -0.42 (-0.68, -0.16) 0.002
G73C/S/T/A -0.39 (-0.86, 0.09) 0.11 - -
V77I -0.13 (-0.43, 0.18) 0.42 - -
V82A/F/T/S -0.65 (-1.02, -0.27) 0.001 -0.52 (-0.84, -0.19) 0.002
I84V/A/C -0.33 (-0.75, 0.09) 0.13 -0.39 (-0.76, -0.03) 0.04
N88D/S 0.21 (-0.37, 0.79) 0.48 - -
L90M -0.58 (-0.89, -0.27) <0.0001 -0.56 (-0.83, -0.29) <0.0001
* Analyses are adjusted for the Pl/r received and baseline HIV RNA
• Mutations in bold indicate primary PI mutations to one of the five randomised Pis
according to the IAS-USA mutational lists233
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I combined the EuroSIDA and trials datasets and investigated HIV RNA reductions 
according to the overall number of IAS-USA September 2006 primary PI mutations in the 
virus. In unadjusted analysis there was a -0.14 (-0.18 to -0.10) log10 cps/mL larger HIV 
RNA reduction (i.e. a smaller reduction) for each additional primary PI mutation present, 
p<0.0001. After adjustment for the baseline HIV RNA and the Pl/r used there was a -0.11 
(-0.15 to -0.07) log10 cps/mL smaller reduction over 12 weeks of follow-up for each 
additional primary PI mutation, p<0.0001.
5.5. Discussion
In this chapter I compared the ascribed levels of resistance to five Pl/rs using four GISs 
and evaluated the relationship between resistance and viral load response using data from 
the EuroSIDA study. Patients in EuroSIDA are more representative of HIV infected 
patients than those in the trials because they have less restrictive entry and follow-up 
procedures. In this comparison, patients had more exposure to ARVs prior to the start of a 
Pl/r and consequently had more resistance mutations in their virus at baseline compared 
to the trial patients.
5.5.1. Summary of main results
When I evaluated concordance between GISs I found similar levels of concordance (i.e. 
low-to-moderate) between ascribed Pl/r resistance levels in EuroSIDA and in the trials. In 
EuroSIDA kappas ranged from 0.01 to 0.38 for APV/r; 0.31 to 1.00 for ATV/r; 0.48 to 0.79 
for IDV/r; 0.34 to 0.77 for LPV/r; and 0.30 to 0.57 for SQV/r. In the trials, kappas ranged 
from 0.37 to 0.75 for IDV/r; 0.46 to 0.93 for LPV/r; and 0.38 to 0.68 for SQV/r. In 
EuroSIDA the kappa statistics for IDV/r were slightly higher whereas, in contrast, they 
were moderately lower for SQV/r and LPV/r compared to those seen in the trials. This 
indicates that there is more of a consensus between GISs on mutations that confer 
resistance to IDV/r, because the EuroSIDA comparisons are conducted on isolates 
containing a greater number of mutations overall. However, variations on the weight 
assigned to these mutations exist for both LPV/r and SQV/r. It may be better to consider 
the number in addition to the type of protease mutations for these Pl/rs rather than 
individual mutations specifically. For example, the total number of IAS-USA mutations 
could be considered where primary and secondary mutations are both assigned a different 
weight.
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I also found high levels of discordance for APV/r (i.e. low kappa values), which could result 
from the use of different formulations of amprenavir when each GIS was initially created 
(i.e. amprenavir boosted with ritonavir, amprenavir alone or fosamprenavir). Different 
formulations may lead to different rates of non-compliance and to disagreements between 
experts on the degree of resistance inferred by each mutation. There is a consensus on 
whether most mutations affect susceptibility to APV/r, but the weight attributed to each 
mutation differs according to the GIS. These differences resulted in high levels of 
discordance between GISs. More genotype-to-viral-load-response data, on a larger group 
of patients receiving APV/r, would improve these comparisons.
There are minor differences between GISs in the way they assign resistance levels (i.e. 
the presence of the L10F mutation when combined with other mutations may indicate high- 
level resistance using one GIS but using another GIS it may only correlate to intermediate 
resistance). To see if these differences in ascribed resistance levels impacted on the viral 
load response I related baseline resistance levels to the 12 week HIV RNA decline. HIV 
RNA was reduced by 1.8 (1.7 to 1.9) log cps/mL a median of 13 (IQR: 9 to 17) weeks after 
starting a Pl/r. This reduction is smaller than the HIV RNA decline seen in the trials 
because EuroSIDA patients had a virus with more resistance to the ARVs in their regimen 
and are therefore not expected to respond as well. In addition, they started their Pl/r with 
a lower HIV RNA so they have less scope for large reductions. EuroSIDA patients are 
also followed less intensively (i.e. this HIV RNA value is likely to be recorded at the first 
visit after starting the Pl/r in EuroSIDA whereas in the trials patients will have been 
followed up at week four as well as at week 12). As a result, early increases in HIV RNA 
that would require treatment changes may be missed or only identified at a later stage in 
EuroSIDA. Due to this delay in response times the virological profiles in observational 
studies may be worse.
Although EuroSIDA patients have a larger number of resistance mutations in their 
predominant virus at the start of a Pl/r compared to patients in the trials, some of these 
patients will have had a resistance test performed before starting a new regimen. It is 
therefore unlikely that they will have been assigned an ARV which they will be resistant to. 
As a result fairly low levels of resistance were still seen at Pl/r initiation in EuroSIDA.
In both unadjusted and adjusted analysis, the level of resistance to the Pl/r was 
significantly related to HIV RNA declines, and all of the GISs predicted HIV RNA declines 
to a similar extent. The relationships between Pl/r resistance levels and HIV RNA declines
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in EuroSIDA were more significant, but of a similar magnitude, to those observed in the 
trials. This could be because there was a higher amount of baseline resistance seen in 
patients in EuroSIDA therefore more power to identify any differences if they did exist.
To see whether the relationship between Pl/r resistance levels and viral load reductions 
was driven by a specific Pl/r, I quantified the relationship between Pl/r resistance levels 
and HIV RNA changes for each Pl/r individually. Although this resulted in comparisons on 
a smaller number of patients and therefore less power to show any differences, resistance 
levels to ATV/r, LPV/r and to SQV/r were significantly associated with viral load changes 
for every GIS. The magnitude of the effect (i.e. the reduction in HIV RNA from baseline) 
differed significantly between Pl/rs: from a 0.96 log10 cps/mL greater reduction in patients 
with a virus that was ascribed to be sensitive to LPV/r compared to patients with a virus 
ascribed to be resistant to LPV/r to a 2.44 log10 cps/mL greater reduction in patients with a 
virus ascribed to be sensitive to ATV/r compared to patients with a virus ascribed to be 
resistant to ATV/r, using the REGA GIS. This illustrates that the GISs are able to 
discriminate between patients who have a virus that contains Pl/r resistance mutations and 
are not expected to have favourable HIV RNA reductions from baseline, and patients who 
have a virus that exhibits sensitivity to the Pl/r and are expected to respond well to the Pl/r. 
However, since these analyses were performed on a sub-group of patients, the differences 
in coefficient estimates between Pl/rs may not actually reflect those that would be seen in 
clinical practice.
5.5.2. Interpretation of results
Although GISs do effectively predict differences in HIV RNA declines according to the 
ascribed resistance category, these trends are not seen for all of the Pl/rs separately 
(Table 5.4.4.1). The lack of a difference for APV/r and IDV/r could be due to the small 
numbers, but it could also be because only a few specific primary PI mutations are thought 
to indicate resistance to these Pl/rs. Instead, resistance may need to be thought of as a 
continuum (including a wider variety of mutations) rather than as a binary variable 
according to the presence or absence of a specific mutation. Most of the existing GISs 
include all mutations they consider to confer resistance in their algorithms, in order to 
calculate the overall resistance score for each drug. However, many less frequently 
occurring mutations may be overlooked, or have unknown impact because they are less 
common and/or less well studied. These mutations may be on the pathway for the 
emergence of further resistance. The resistance output for the Stanford GIS is actually 
provided as a continuous score that accounts for every possible PR mutation, but it is
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rarely used on a continuous level in clinical practice. Furthermore, the Stanford GIS does 
not account for combinations of mutations but only specific mutations individually. Some 
mutations may need to be assigned different weights if they are present alongside other 
resistance mutations.
5.5.3. The combined dataset
I combined EuroSIDA data with the trial data to increase the number of patients in whom I 
could investigate the GSS to the rest of the regimen in more detail. Yet still, in this 
combined study population there were low prevalence rates of some mutations. Although 
the prognostic effect of the GSS to the rest of the regimen partly disappeared after 
adjustment for the Pl/r resistance level, baseline HIV RNA and the time between Pl/r 
initiation and follow-up HIV RNA measurement, there was a trend for greater HIV RNA 
declines if the virus also showed some activity to the background regimen compared to 
patients who had a virus that showed no activity to their background ARVs. This trend 
was not seen for DMC or Stanford where no relationship between the number of active 
background ARVs and viral load response was seen. In all of these comparisons, Pl/r 
sensitivity was much more predictive of HIV RNA declines than the GSS to the rest of the 
regimen. This may be because the main drug in the regimen (i.e. the Pl/r) is more potent 
than the background drugs and is required (to a greater extent than the background drugs) 
to maximise virological suppression.
I then repeated the analysis in 4.4.8, exploring the relationship between individual 
mutations and viral load response in the EuroSIDA population. The presence of mutations 
at positions 10, 46, 54, 82 and 90 were associated with smaller HIV RNA declines in both 
EuroSIDA and the trials, even after adjustment for the Pl/r used. I then looked at primary 
protease mutations as a continuum (in all of the studies combined) and, consistent with 
other studies, I found that the number of protease mutations was significantly associated 
with response3301335*356. There was a 0.11 (0.07 to 0.15) log10 cps/mL smaller HIV RNA 
reduction over follow-up for each additional primary PI mutation, p<0.0001.
5.5.4. Other resistance approaches
Various alternative approaches for quantifying the effect of resistance have been 
suggested. Marcelin etal proposed integrating the ARV-specific drug levels with the 
genotypic resistance score to quantify the combined effect of drug exposure and viral
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susceptibility. The ratio of the PI Cmin to the number of baseline PI mutations was shown 
to predict virological response significantly for a number of different ARVs33013771378. 
Resistance levels derived using other bioinformatic approaches, some of which employ the 
use of fuzzy logic (a mathematical approach used to represent knowledge affected by 
uncertainty), have also been related to viral load response2161379. Machine learning 
techniques have also been employed, such as support vector machines (SVMs), artificial 
neural networks (ANNs), super-learner prediction algorithms in addition to other genotypic 
resistance algorithms. Some of their resulting interpretations have been related to viral 
load response380-383.
SVMs are a set of supervised learning methods that are used to classify isolates as being 
resistant or sensitive to a particular ARV. SVMs attach a weight to each point mutation so 
they capture all resistance mutations in the overall sequence background and not just 
mutations that are linked to a few prominent sequence positions. SVMs have been shown 
to reliably predict phenotypes from genotypes for most of the existing ARVs3841385, but 
limited data are available showing the value of these interpretations for predicting viral load 
response.
On reflection, mutations that are present in low level resistant strains are likely to become 
dominant again if a drug that selects for these mutations is re-started. In this analysis, the 
majority of patients started a new Pl/r containing regimen at baseline, so low-level 
resistant strains may start to outgrow the virus that was dominant at baseline if the patient 
fails to suppress replication on the new regimen. As a result, a method that takes into 
account archived mutations or mutations that are present in low levels may be a better 
indication of the baseline resistance profiles of patients in these comparisons.
ANNs or neural networks (NNs) are mathematical or computational models that are based 
on biological neural networks. In the Copenhagen HIV Programme (CHIP), we have 
recently used ANNs to identify resistance patterns in 1507 matched phenotypic and 
genotypic resistance pairs that were obtained from the Stanford HIV-DB database. We 
used these data to train and validate ANNs to reliably predict susceptibility to 16 ARVs 
using knowledge of the physiochemical descriptors of the amino acid mutations in the 
complete enzyme’s primary structure for the RT- and PR- gene, rather than only 
examining a subset of mutations. Now we plan to use these ANNs to see if we can model 
the complex relationship between resistance mutations and viral load response in patients 
from EuroSIDA and from the trials combined. If these ANNs are shown to be clinically 
useful for predicting viral load outcome in patients, they will be implemented as tools on
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the world wide web to provide a rapid and free alternative to both virtual and real 
phenotypic testing as well as genotypic testing (J Kjaer et al: resubmitted to HIV medicine).
5.5.5. Conclusion
To conclude, differences were observed between GISs using both trial data and 
observational data as illustrated in this subgroup of EuroSIDA study participants and in the 
previous chapter looking at trial patients. Although differences exist in the resistance 
levels ascribed by each GIS, the GISs were comparable in the extent to which they 
predicted virological response after 12 weeks of follow-up.
By combining study populations I was able to increase power and investigate the 
relationship between GIS resistance levels, both to the Pl/r and to the other ARVs in the 
regimen, and virological response in more detail. In this analysis there was a trend for 
greater HIV RNA reductions with increasing Pl/r sensitivity and with increasing GSS to the 
rest of the regimen for the ANRS and REGA GISs. For these GISs, the relationship 
between the GSS and HIV RNA decline was driven by patients who had a virus that did 
not show sensitivity to any other drugs in the regimen compared to those who had a virus 
that showed sensitivity to at least one other drug. All of these GISs need to be refined 
further to enable them to predict HIV RNA changes more efficiently and eventually a 
consensus on what resistance mutations contribute to viral load response may be 
reached.
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CHAPTER 6: EVOLUTIONARY DISTANCES IN COLATE
6. Introduction
In chapter 3, I investigated the emergence of drug resistance mutations between baseline 
and the time of virological failure by identifying all new mutations that emerged in the 
predominant virus of patients treated with a Pl/r. In chapters 4 and 5, I compared the 
ascribed Pl/r resistance levels at baseline, generated with each of four genotypic 
interpretation systems (GISs), for predicting viral load response to a Pl/r containing 
regimen. In these chapters, there was moderate concordance between GISs on how best 
to interpret genotypic data for Pl/rs, and a trend towards larger viral load declines with 
increasing sensitivity to the Pl/r. When I investigated the prognosis of a genotypic 
sensitivity score (GSS) to the other drugs in the regimen for predicting viral load response, 
I found a weaker association for all GISs. Since the level of resistance to the Pl/r is a 
stronger predictor of viral load response than the GSS to the other drugs in the regimen, 
measuring the level of viral susceptibility to a regimen by summing the predicted levels of 
susceptibility to each of the component drugs may not yet be a reliable approach for 
quantifying resistance for the whole regimen.
Phytogeny aims to provide us with an understanding of the molecular changes that 
influence viral evolution and gives us a more precise picture of how the virus evolves in 
general (both under pressure from, and in absence of, ARVs) (section 1.6.6). 
Phylogenetic analysis involves the collection of information on specific nucleotide changes 
rather than solely looking at changes to the nucleotide-triplet encoded amino acids. Data 
are available at the nucleotide level in all of the studies in this thesis, so it would be 
possible to calculate crude distances between sequences to estimate molecular changes 
on a nucleotide level. However, PAUP (Phylogenetic Analysis Using Parsimony)263 is an 
alternative approach that can be used to identify clusters of similar viral strains easily, and 
to calculate the distances between them, using different approaches to model the 
nucleotide changes.
6.1. Aims of the chapter
PAUP was used in this chapter to compare sequence data, obtained from the pol gene of 
the virus, in patients from the COLATE trial. The phylogenetic analyses were conducted 
on consensus sequences and not on individual clones; so all nucleotide distances are 
calculated between viruses that were sampled through the use of population sequencing. 
As a result, a mutation that is only present in a minority viral strain at baseline, or during
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follow up, will not be accounted for in these comparisons. I will use these data to evaluate 
nucleotide changes in the predominant virus of patients who were receiving cART, and to 
examine the potential benefits of preserving the M1841 A/ mutation in the dominant virus 
population.
6.2. Literature review
HIV drug resistance can have a negative impact on the response to cART in both 
previously naive and in ARV-experienced patients188:189;386. The continued use of an 
antiretroviral, to which an HIV infected patient is harbouring a resistant viral strain, remains 
controversial. Current guidelines recommend that following virological failure at least two 
active ARVs should be started, because resistance mutations to the drugs in the failing 
regimen are likely to be present in the predominant virus33. Alternative strategies are to 
add on an active ARV or switch some ARVs in the regimen, especially in patients with few 
treatment options available (section 1.6.9).
With the recent introduction of integrase inhibitors, CCR5 inhibitors and other new drugs 
from existing classes, there should be other active drugs around for the foreseeable future. 
Yet, resistance to these new drugs and their relationship with the other, older drugs still 
needs to be understood. Given the potential emergence of resistance, patients in need of 
salvage therapy may wish to postpone starting one of these newer drugs until a fully active 
regimen containing at least two and preferably three fully active drugs can be prescribed 
simultaneously.
HIV infected patients are also living for longer due to the improvements in therapy, and this 
has led to the growth of a highly treatment experienced population who have an array of 
resistance mutations in their virus populations. Current UK data suggest that the 
prevalence of triple class resistance is approximately 10% in all patients who have 
resistance testing available. In order to preserve treatment options in patients who have 
high levels of resistance in their virus populations, the need for recycling ARVs that a 
patient has already been exposed to, is likely to persist despite the expanding number of 
antiretroviral drug classes.
Lamivudine (3TC) is a commonly used NRTI, currently used in >65% of patients receiving 
cART in EuroSIDA. Virological failure on a 3TC-containing regimen is associated with the 
emergence of the point mutation M184I or M184V387, both of which confer high-levels of 
resistance to 3TC328:388, but conversely hypersusceptibility to zidovudine, stavudine and
tenofovir38*390. Viruses containing these mutations are associated with >100-fold and 
>500-fold reduced susceptibility to 3TC respectively (i.e. M184V is associated with a 500 
to 1000 fold increase of the 50% inhibitory concentration (IC50) compared to wild-type virus 
-  see 1.6.3.2 for more information on the ICso)38* 391.
Although the largest benefits from cART are seen if a patient has a virus that is fully- 
susceptible to the ARVs in their regimen, it has been hypothesized that retaining 3TC in a 
failing 3TC-containing regimen and consequently retaining the M184V mutation could be 
virologically beneficial27* 389. Evidence from in vitro experiments suggests that viruses 
containing the M184V mutation may have a lower replication capacity and increased 
fidelity compared to wild-type viruses271"278. Alternatively, lamivudine may retain some 
residual activity against a virus containing the M184V mutation.
These results have been confirmed, in part, in clinical studies where plasma HIV RNA has 
remained below baseline values by approximately 0.5 log10 copies/mL in 3TC-treated 
patients despite the detection of M184V391:392. The clinical benefit of adding 3TC to other 
NRTIs was also seen beyond the first few months in CAESAR, i.e. after 3TC resistance 
had emerged94, adding further support to the hypothesis that the presence of M184V may 
lead to better efficacy of other ARVs393.
In the E-184V study, all patients who were on a 3TC containing regimen, in whom the 
M184V mutation was detected by population sequencing, and who requested a treatment 
interruption, were randomised to either interrupt all ARVs or to continue receiving 3TC 
alone. By week 48, 20 (69%) patients in the treatment interruption arm and 12 (41%) 
patients in the 3TC arm had discontinued the study due to immunological or clinical failure 
(i.e. a difference of 28%), illustrating the protective ability of continuing 3TC despite the 
presence of high-level resistance. Further, the mean decline in CD4+ T cell percentage, 
viral rebound and recovery of replication capacity were significantly lower in the 3TC group 
compared to the no-3TC group in this study279.
Although an immunological, virological and clinical benefit associated with the detection of 
the M184V mutation has been shown in vivo in the E-184V study279, these patients were 
highly treatment experienced and received lamivudine mono-therapy. Resistance data 
showed that the continuation of lamivudine preserved viruses with M184V as well as other 
resistance mutations, probably due to their linkage with M184V on the same virus genome.
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Thus the beneficial effects in terms of reduced replication capacity cannot be ascribed 
entirely to the selective pressure on M184V mutants.
The COLATE study (appendix V) was set up to examine the possible beneficial effects of 
maintaining selective pressure on M184V, induced by continuation of 3TC, on virological 
and immunological response in treatment-experienced patients who were receiving cART 
rather than 3TC alone. A study by Miller MD et al, examined intensification trials of 
tenofovir in treatment-experienced patients, in order to determine the effects of resistance 
at baseline on HIV RNA response. In these trials, HIV RNA response to tenofovir was 
reduced among patients with >3 TAMs inclusive of either the M41L or L210W, or in 
patients who had a preexisting K65R mutation, but slightly increased treatment responses 
were observed when the M184V mutation was present.
In this chapter I will report the main results of the COLATE trial (i.e. HIV RNA change 
according to the use of 3TC), and evaluate resistance patterns in patients with viraemia 
during follow-up. The rationale behind COLATE was described in 2.1.2. At screening, 
patients were divided in two strata: stratum A, including only patients who experiencied 
virological failure on their first 3TC-containing cART regimen; and stratum B, including 
those who were failing a second or later 3TC-containing cART regimen. Even if no 
difference in HIV RNA reductions is seen between intervention arms, it remains of interest 
to test whether the repeat detection of M184V over time is associated with a slower 
accumulation of additional mutations in the predominant virus of patients not achieving 
complete viral suppression. If this is the case, maintaining 3TC may be a viable approach 
for preserving future treatment options.
I will use phylogenetic analysis to monitor nucleotide distances over time, and assess 
whether there were accelerated rates of viral evolution amongst patients who discontinued 
3TC (Off-3TC) compared to those who continued on it (On-3TC) as part of COLATE. In 
addition, I will compare nucleotide distances from baseline at each time-point, according to 
the presence of M184V, to evaluate the virological benefit of retaining M184V in the 
predominant virus, through follow-up.
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6.3. Methods
6.3.1. The COLATE study
Details of entry into COLATE have been described in 2.1.2. In brief, all randomised 
patients, irrespective of their treatment status, were followed from baseline (the day of 
starting the optimised regimen plus 3TC in the On-3TC arm and the day of starting the 
optimised regimen alone in the Off-3TC arm) to week 48. Follow-up visits were scheduled 
at weeks 4, 12, 24, 36, and 48. During follow-up, the following procedures were 
performed: clinical evaluation, blood safety analyses, HIV RNA, CD4+ T cell count and 
plasma storage.
6.3.2. PCR and sequencing
Genotypic resistance testing and virological sequencing was performed centrally in 
batches using cryopreserved plasma samples. ABL sequenced the protease gene and the 
first 1005 nucleotides of the reverse transcriptase gene, spanning a total of 1302 
nucleotides. Plasma samples were used for sequencing at baseline and at each visit 
during follow-up if HIV RNA >500 copies/mL.
6.3.3. Statistical methods for this chapter
Similarly to the MaxCmin trials, the per-protocol population for analysis of the main 
COLATE trial included all patients who initiated their assigned treatment. The primary 
efficacy measure was the average-area-under-the-curve-minus-baseline (AAUCMB) 
reduction in log10 HIV RNA after 48 weeks. Observations from patients who withdrew 
consent, were lost to follow-up or died were censored at their last follow-up visit. The 
definition of treatment failure included observed virological failure (see section 2.1.2.2.1), 
patients who withdrew consent, were lost to follow-up or died.
Chi-squared and Fisher’s exact tests were used to compare categorical variables. 
Continuous variables were analysed using Student’s f-tests or Kruskal-Wallis tests 
depending on the distribution. Cox analysis was performed and Kaplan-Meier plots were 
produced for analyses investigating the time to: virological failure (section 2.1.2.2.1); 
virological suppression (i.e. HIV RNA < 50 copies/mL); treatment discontinuation and to a 
CD4+ T cell count increase >100 cells/pl, for comparisons that contained a sufficient 
number of events (n>25). Multivariable models were developed to identify independent 
predictors of virological failure.
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Patients were included in the nucleotide distances sub-study if they had a baseline sample 
and at least one follow-up sample available for sequencing. Sequencing was only 
possible at study visits if a patient had an HIV RNA >500 cps/mL Some patients had an 
HIV RNA <500 cps/mL soon after baseline so follow-up resistance testing could not be 
performed on their virus. This resulted in a different number of sequences coming from 
each patient. I wanted to investigate all nucleotide changes from baseline, so patients with 
resistance data at baseline and at at least one other time point were included in the 
primary comparison (i.e. at the baseline visit and at, at least, one follow-up visit). I also 
performed a sensitivity analysis looking at all nucleotide changes between sequences at 
consecutive time points, irrespective of whether the first sequence in the pair was the 
baseline sequence.
In the main resistance analysis, nucleotide distances from baseline were estimated by 
comparing all available sequences to the baseline sequence for each patient and 
calculating the number of nucleotide changes that occurred, using PAUP. Non-parametric 
tests were used to test whether differences existed in these distances between treatment 
arms at all scheduled visits. Using the Bonferroni correction for multiple testing a p-value 
of £0.01 was considered significant (i.e. 5 tests, one per visit, therefore 0.05/5=0.01).
Generalised linear models (appendix IV) were then used as a more sensitive measure to 
assess the association between treatment arms and nucleotide distances and between the 
presence of M184V and nucleotide distances. Since each patient could have more than 
one observation (i.e. more than one follow-up resistance test so more than one 
measurement of their nucleotide distances from baseline), I used generalised estimating 
equations (GEEs) to account for the non-independence of some observations. I selected 
an autoregressive correlation structure to account for the fact that distances between 
sequences taken close to each other in time (i.e. closer to baseline) are likely to be shorter 
than distances between sequences measured with a long gap between them. GEEs use 
an adjusted standard error to account for non-independence among repeat observations 
(i.e. nucleotide distances) from the same patient. Adjustments were made for other 
confounding factors. All statistical analyses were performed in STATA, version 8.2.
6.3.4. Genetic distances and phylogenetic reconstruction
In order to match sequences from an individual, Jesper Kjaer at CHIP performed pairwise 
genetic distance calculations between all sequences using the following three evolutionary 
nucleotide approaches: Jukes-Cantor394; Kimura 2-parameter methods395; and SynScan396.
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Jukes-Cantor allows us to model substitutions at each nucleotide position assuming an an 
equal rate of substitution for each nucleotide change (i.e. a within purine transition A <--> 
G has the same probability as a within pyrimidine transition T <—> C, and similarly this is 
equal to the rate of transversions (A or G C or T)). For example, if valine (say the 
nucleotide triplet GTC) was present at codon position 184 at baseline, and methionine (say 
the nucleotide triplet ATG) was present in the follow-up resistance test, the change from G 
to A (i.e. a transition) at the first position would be modelled with the same likelihood as the 
nucleotide change from C to G (i.e. a transversion) in the third position.
The Kimura 2-parameter method is a more sensitive approach and measures distances 
after accounting for the transversion/transition ratio. Since transitions are more likely to 
occur than transversions, because transversions cause problems in hydrogen bonds and 
in geometrical structures, they are modelled using different likelihoods using the Kimura 2- 
parameter approach. So, in the previous example the change from G to A at the first 
position would be modelled with a higher likelihood than the nucleotide change from C to 
G in the third position.
The SynScan evolutionary nucleotide model is the most sensitive evolutionary nucleotide 
approach to take for detection of evolution because it uses the approach described by Nei 
and Gobori397 to take into account both synonymous and non-synonymous changes as 
well as accounting for information held by ambiguous nucleotides (i.e. positions that code 
for a mixture of A, C, T and G). A synonymous mutation is a ‘silent’ nucleotide change that 
does not result in an amino acid substitution and always occurs in the third position of a 
codon. A non-synonymous mutation is a nucleotide change that results in an amino acid 
substitution. In the above example, valine may have changed to methionine using two 
different routes: either the synonymous route, GTC -> GTG -> ATG or the non- 
synonymous route GTC -» ATC -> ATG. In the first case the amino-acid has changed 
from valine -> valine -> methionine and in the second case, the substitution route is valine 
-> isoleucine -> methionine. These are accounted for using different weights using the 
SynScan approach.
To build phylogenetic trees we imported pairwise distances into PAUP263. Trees were 
created using Neighbour-Joining distance methods and the robustness of the trees was 
evaluated using bootstrap analysis with 1000 rounds of replication. Sequences from a 
single individual should be closely related to each other therefore they are expected to 
group together rather than sequences from different patients. If the sequences from a
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single individual did not group together, I assumed the sequences were not actually from 
the same patient, so all sequences from these patients were excluded from the analysis.
6.4. Results
6.4.1. Patient characteristics
From May 1999 to May 2002, there were 136 patients who were receiving a lamivudine 
containing regimen and were enrolled into the COLATE trial. Of these, 131 (96.3%) 
initiated their optimised regimen in addition to their randomised treatment: 65 continued 
3TC in the On-3TC arm and 66 discontinued 3TC in the Off-3TC arm. There were a total 
of 124 patients (N=60 in the On-3TC arm and N=64 in the Off-3TC arm) who were 
followed up for the entire 48 weeks of the study or have outcome data available after 48 
weeks of follow-up.
Out of the 131 patients who initiated their randomised regimen there were 17 (13%) who 
permanently discontinued it during follow-up (11 patients stopped 3TC in the On-3TC arm 
and six re-started 3TC in the Off-3TC arm, p=0.18). The primary reason for stopping 3TC 
for patients in the On-3TC arm was due to clinical non-fatal adverse events; similarly 
clinical events due to other drugs in the regimen were amongst the main reasons for re­
initiating 3TC in patients who discontinued it as part of randomisation. These patients are 
not counted as failures when looking at the effect of treatment on viral load. The 
disposition of patients through week 48 is shown in Table 6.4.1.1.
Table 6.4.1.1: Disposition of patients through week 48 in the main COLATE trial
On-3TC
N (%)
Off-3TC
N (%)
Total
N (%)
Randomised: 65 (100) 71 (100) 136 (100)
Initiated assigned treatment (ITT/e population) 65 (100) 66 (93) 131 (96)
Initiated but permanently discontinued treatm ent1> 
Reason:
11 (17) 6(9) 17(13)
Virological failure 3 1 4
Death 0 1 1
Clinical non-fatal adverse event 4 2 6
Patient choice 1 0 1
Lost to follow-up 3 2 5
Patients with an outcome at week 48 60 (92) 64 (97) 124 (95)
1) Discontinuation in the On-3TC arm is equal to stopping 3TC; in the Off-3TC arm it is equal
to starting 3TC
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At baseline, no differences were observed between treatment arms in medical history, 
demographics, clinical and laboratory parameters or in exposure to ARVs prior to baseline, 
with the exception of a higher CD4+ T cell count in patients in the On-3TC arm compared 
to patients in the Off-3TC arm (Table 6.4.1.2; p=0.01).
There were 28 (43%) and 27 (41 %) patients in stratum A who were randomised to the On- 
3TC and Off-3TC arms, respectively. The remaining 76 patients entered the study after 
failing a second or later 3TC-containing cART regimen and were included in stratum B 
(N=37 (57%) in the On-3TC arm and N=39 (59%) in the Off-3TC arm). Due to the entry 
criteria (see 2.1.2.2) patients in stratum A (n=55) had less advanced HIV-disease 
compared to patients in stratum B (n=76); those in stratum B were older and exposure to 
more ARVs prior to baseline. There were no other baseline differences between strata in 
medical history, demographics or in clinical and laboratory parameters (Table 6.4.1.2).
Table 6.4.1.2: Baseline characteristics according to treatment group and strata
Baseline parameter On-3TC 
N =65
Off-3TC 
N =66
Stratum A a 
N =55
Stratum B b 
N =76
P-
valuec
Gender No. male (%) 53 (82) 54 (82) 43 (78) 64 (84) 0.38
Age 42.0 40.0 39.0 42.5 0.005
Median yrs, (IQR) (36.5, 50.0) (36.0, 47.3) (34.0, 43.0) (37.3, 51.8)
HIV exposure group No. (%)
Men who have sex with men 39 (60) 37 (56) 29 (52) 47 (62)
0.48
Heterosexual 18 (28) 20 (30) 19 (35) 19 (25)
Intravenous drug use 2 (3) 1 (2) 2 (4) 1 (1)
Unknown & other 6 (9) 8 (12) 5 (9) 9 (12)
Race No. (%) 
White 55 (85) 53 (80) 43 (78) 65 (86)
0.32
Black 8 (12) 10 (15) 10 (18) 8 (11)
Asian 2 (3) 1 (2) 2 (4) 1 0 )
Other 0 (0) 2 (3) 0 (0) 2 (3)
CDC, Category C No. (%) 23 (35) 20 (30) 14 (25) 29 (38) 0.13
HIV RNA logio cps/mL; median (IQR) 3.9 (3.3, 4.4) 4.0 (3.4, 4.6) 3.5 (3.1, 4.3) 4.1 (3.7, 4.7) 0.002
CD4+ T cell count 360 280 327 300 0.57
106/l; median (IQR) (257,481) (180, 376) (204,451) (199, 425)
Nadir CD4+ T cell count 133 122 150 121 0.92
106/l; median (IQR) (38, 198) (61,200) (53, 208) (43, 193)
ARVs used prior to baseline 5 5 4 7 <0.00
median number (IQR) (4,8) (3, 8) (3, 5) (5, 9) 01
a) Stratum A = patients enrolled following their 1st virological failure on a 3TC-containing regimen
b) Stratum B = patients enrolled following their 2nd or more failure on a 3TC-containing regimen
c) P-value for the comparison between stratum A versus stratum B
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There were no differences in the planned number of ARVs or ARV drug classes between 
treatment arms. Further, patients in each treatment arm initiated a comparable number of 
ARVs at baseline, negating the possibility that clinicians may have prescribed extra ARVs 
in the Off-3TC arm to combat the additional use of 3TC in the On-3TC arm. The mean 
(95% Cl) number of ARVs other than 3TC that were received was 3.5 (3.2 to 3.8) and 3.4 
(3.1 to 3.7) in the On-3TC and Off-3TC arms, respectively. The most common 
combination of NRTIs used at baseline was d4T plus ddl (N=25 (38%) in the On-3TC arm 
and N=27 (41%) in the Off-3TC arm) and ABC plus ddl (N=9 (14%) in the On-3TC arm 
and N=9 (14%) in the Off-3TC arm).
No significant differences were observed between treatment arms in the proportion of 
patients who switched to, or at week 48, received a PI, NNRTI or an abacavir-containing 
regimen. Further, there was no difference in the time to first change of assigned treatment 
between treatment arms with regard to the 3TC component (i.e. the time to stopping 3TC 
in the On-3TC arm and re-starting 3TC in the Off-3TC arm, p=0.20, log rank test).
6.4.2. Virological response
No significant differences were observed between treatment arms in the primary efficacy 
outcome (i.e. the AAUCMB reduction in HIV RNA - Figure 6.4.2.1). Mean HIV RNA 
reductions from baseline were 1.4 (95% Cl: 1.1 to 1.6) log10 cps/mL in the On-3TC arm 
and 1.5 (95% Cl: 1.2 to 1.7) log10 cps/mL in the Off-3TC arm (p=0.51).
Figure 6.4.2.1: AAUCMB analysis according to treatment arm and strata
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Similarly, no differences were seen in the primary efficacy outcome between treatment 
arms within strata (Stratum A: 1.0 (95% Cl: 0.7 to 1.4) log10 cps/mL for On-3TC versus 1.4 
(95% Cl: 1.0 to 1.8) log10 cps/mL for Off-3TC (p=0.21); Stratum B: 1.6 (95% Cl: 1.3 to 1.9) 
log10 cps/mL for On-3TC versus 1.5 (95% Cl: 1.3 to 1.8) log™ cps/mL for Off-3TC 
(p=0.75)). The mean HIV RNA AAUCMB reductions did differ between strata, HIV RNA 
reductions from baseline were 1.2 (95% Cl: 0.9 to 1.5) log10 cps/mL in stratum A and 1.6 
(95% Cl: 1.4 to 1.8) log™ cps/mL in stratum B, (p=0.02). However, there was no evidence 
of a significant interaction between treatment and strata on the AAUCMB reductions (test 
for interaction, p=0.22).
No difference was seen between treatment arms in the time to protocol-defined virological 
failure (p=0.65, log rank test), time to achieving a >1.0 log™ cps/mL reduction in HIV RNA 
from baseline or time to viral suppression for patients who had an HIV RNA above the 
level of detection (>50/>400 cps/mL). The overall proportion of patients with HIV RNA <50 
copies/mL increased from 0% at baseline to 59% in the On-3TC arm and to 46% in the 
Off-3TC arm by week 48 (i.e. 12.6% (95% Cl: -5.1% to 30.3%) more patients had HIV 
RNA <50 cps/mL at week 48 in the On-3TC arm compared to the Off-3TC arm, p=0.17).
6.4.3. Immunological response
The median (IQR) increase from baseline in CD4+ T cell counts was 87 cells/pl (25 to 153) 
in the On-3TC arm and 76 cells/pl (-32 to 186) in the Off-3TC arm (p=0.41). A rise of ;>100 
CD4+ T cells/pl at any time during follow-up was seen in 42 patients in the On-3TC arm 
and 44 patients in the Off-3TC arm with no difference in the time to achieve this increase 
(p=0.86, log rank test).
6.4.4. Clinical non-fatal adverse events (AEs)
Forty-nine (37%) patients experienced a total of 94 AEs of grade 3 and/or 4; 43 in the On- 
3TC arm and 51 in the Off-3TC arm (p=0.25 for the number of AEs experienced). Overall, 
16 (17%) grade 3 and/or 4 AEs were from the gastrointestinal system without difference 
between the treatment arms.
6.4.5. Resistance
As highlighted in chapters 4 and 5, baseline resistance patterns can influence the 
virological response to treatment. In this analysis, I will compare baseline genotypes from 
patients in the On-3TC arm to baseline genotypes from patients in the Off-3TC arm. This
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analysis will highlight any initial differences that occur in the predominant virus populations 
of patients in COLATE that may impact on virological response. Since this analysis is 
restricted to patients who have a baseline sequence available, the availability of a follow- 
up sample is not a necessity for inclusion in these comparisons.
There were a total of 117 patients who were enrolled into COLATE and had a baseline HIV 
RNA >500 cps/mL (N=56 in the On-3TC arm and N=61 in the Off-3TC arm). From these, 
genotypic resistance test results were available from 102 (87%) patients at baseline; 49 
(88%) in the On-3TC arm and 53 (87%) in the Off-3TC arm. Patients who contribute data 
to all of the resistance analyses in this chapter are outlined in Figure 6.4.5.1.
Figure 6.4.5.1: Patient flow through the study
Allocated to discontinue 3TC (N=71) 
Discontinued 3TC (N=66) 
Received 3TC (N=5)
Reasons: screening failure (3), withdrew 
consent (1), lost to follow-up (1)
Allocated to continue 3TC (N=65) 
Received 3TC (N=65)
Did not receive 3TC (N=0)
Randomised
N=136
Patients with HIV RNA >500 cps/mL 
during follow-up 
(N=37)
No. with baseline HIV RNA >500 
cps/mL (N=56)
And with sequencing available 
(N=49)
Patients with HIV RNA >500 cps/mL 
during follow-up 
(N=29)
No. with baseline HIV RNA >500 
cps/mL 
(N=61)
And with sequencing available (N=53)
Patients with HIV RNA >500 at 
baseline and during follow-up (N=31) 
And with sequencing available at 
both time points (N=23)
Patients with HIV RNA >500 at 
baseline and during follow-up 
(N=26)
And with sequencing available at 
both time points (N=19)
6.4.5.1. Baseline resistance patterns
No differences were seen between treatment arms in the number of IAS-USA (September 
2006) resistance mutations to NRTIs, NNRTIs, or primary mutations to Pis at baseline
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(Table 6.4.5.1.1). In addition, the baseline genotypic sensitivity score (GSS) to all of the 
drugs received at baseline was comparable between arms: using the REGA GIS (version 
6.4.0), there was a mean GSS of 1.9 (95% Cl: 1.6 to 2.2) in the On-3TC arm and 2.1 (95% 
Cl: 1.9 to 2.4) in the Off-3TC arm, p=0.34.
All 49 patients harboured M184V in the On-3TC arm, but in the Off-3TC arm M184V was 
only detected in 47 out of 53 (89%) patients, p=0.03. No differences were seen between 
treatment arms in the presence of TAMs at baseline, although marginally more patients in 
the On-3TC arm had the L210W mutation at baseline compared to those in the Off-3TC 
arm, p=0.03. Since these groups make up a sub-group of the COLATE trial, patients are 
no longer randomised in these comparisons, so imbalances may be seen between 
treatment arms.
Table 6.4.5.1.1: Number of mutations to each class of ARVs at baseline
No. of IAS-USA resistance 
mutations
Overall 
N=102 
No, (%)
On-3TC 
N=49 
No, (%)
Off-3TC 
N=53 
No, (%)
P-value
Specific mutations: M184V 96(94) 49 (100) 47 (89) 0.02
NRTIs 0 5(5) 0(0) 5(9) 0.25
1 25 (25) 11 (22) 14(26)
2 8(8) 5(10) 3(6)
3 15(15) 7(14) 8(15)
4 15(15) 8(16) 7(13)
5 9(9) 3(6) 6(11)
& 6 25 (25) 15(31) 10(19)
Primary PI mutations 0 62 (61) 28 (57) 34(64) 0.73
1 20 (20) 11 (22) 9(17)
2:2 20 (20) 10 (20) 10(19)
NNRTls 0 65(64) 31 (63) 34 (64) 0.52
1 20 (20) 8(16) 12(23)
2:2 17(17) 10(20) 7(13)
TAMs M41L 49 (48) 26 (53) 23 (43) 0.33
D67N 41 (40) 22 (45) 19(36) 0.35
K70R 24 (24) 11 (22) 13(25) 0.81
L210W 29 (28) 19(39) 10(19) 0.03
T215Y 42 (41) 22 (45) 20(38) 0.46
K219E/Q 25 (25) 12 (24) 13 (25) 0.99
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6.4.5.2. Nucleotide distances
To see whether the use of 3TC influenced nucleotide changes during follow-up, I 
compared all available sequences to the baseline sequence and calculated the number of 
nucleotide changes that occurred. Patients with a baseline sequence and at least one 
follow-up sequence were included in these comparisons.
There were 57 patients (26 (40.0%) and 31 (47.0%) in the On-3TC and Off-3TC arms 
respectively) with HIV RNA >500 copies/mL at baseline and at some point during follow- 
up. From these, there were 42 (73.7%) patients who had samples that were possible to 
sequence at both baseline and follow-up (19 (73.1%) and 23 (74.2%) in the On-3TC and 
Off-3TC arms respectively) (Figure 6.4.5.1 and Table 6.4.5.2.1).
It was not possible to sequence both baseline and follow-up samples for the remaining 15 
patients due to insufficient plasma concentrations, sample contamination or due to a lack 
of an available sample at either the baseline or follow-up time point.
Table 6.4.5.2.1: Disposition of patients in the nucleotide distances sub-study.
On-3TC
No. (%)
Off-3TC
No. (%)
Total
No. (%)
Patients with HIV RNA >500 c/ml at baseline and at 
£1 follow-up visit:
26 (100) 31 (100) 57 (100)
Patients with baseline and >1 follow-up sequences: 19(73) 23 (74) 42 (74)
Total number of sequences: 67 67 134
Baseline 19 23 42
Week 4 12 10 22
Week 12 9 7 16
Week 24 9 10 19
Week 36 8 7 15
Week 48 10 10 20
Patients included in the final analysis: 18(69) 19(61) 37 (65)
Total number of sequences in the final analysis: 63 54 117
Baseline 18 19 37
Week 4 12 9 21
Week 12 9 6 15
Week 24 8 9 17
Week 36 7 4 11
Week 48 9 7 16
Patients who had a baseline and at least one follow up sequence available (N=42) were 
compared to the remaining patients in COLATE (N=89). Similar proportions of patients 
with sequencing information came from stratum A (N=17, 31%) and stratum B (N=25,
32%). At baseline, patients who had their virus sequenced had a higher HIV RNA (median 
(IQR): 4.1 (3.7 to 4.9) vs. 3.9 (3.2 to 4.4) log10 copies/mL, p=0.005), a lower CD4+ T cell 
count (median (IQR): 203.0 (113.0 to 355.0) vs. 360.0 (247.0 to 458.0) cells/pl, p<0.0001), 
a lower CD4+ nadir (median (IQR): 75.0 (32.3 to 162.5) vs. 140.0 (64.5 to 210.0) cells/pl, 
p=0.002) and were significantly more likely to have an AIDS-defining illness prior to study 
entry (21 (50.0%) vs. 22 (24.7%), p=0.004) compared to patients in COLATE who did not 
have both baseline and follow-up samples available. Since patients who had their virus 
sequenced at both baseline and follow-up were virologically worse off than those who did 
not (i.e. they have an HIV RNA >500 copies/mL during follow-up), a larger number of 
nucleotide substitutions is likely to be detected than in the average patient enrolled into 
COLATE, due to the higher viral replication rates in these patients.
A total of 67 sequences from 19 patients in the On-3TC arm and 67 sequences from 23 
patients in the Off-3TC arm were obtained (Table 6.4.5.2.1). Sequences were analysed 
for each patient using population sequencing. Patients could have a maximum of one 
sequence per follow up visit, resulting in differences between the numbers of sequences 
for each patient. If sequences stemming from each patient did not group together in the 
phylogenetic trees, and grouped more closely with sequences from another patient, I 
suspected that there could be an error in either the matching of the sequences or in the 
sequence itself. This is because all of the sequences stemming from a particular patient 
should be more similar to each other than sequences from other patients, so I would 
expect them to group together in the phylogenetic trees. All patients who had sequences 
that did not group together were excluded from the analyses.
Four sequences from one patient in the On-3TC arm (hollow circles, Figure 6.4.5.2.1A) 
and thirteen sequences from four patients in the Off-3TC arm (diamonds, squares, circles 
and triangles, Figure 6.4.5.2.1B) were suspicious sequences and have been marked in the 
phylogenetic trees. These patients, and all their sequences, were excluded from the 
analyses so that I could study nucleotide distances between viral populations that are 
closely linked without interference from patients who experience major changes to their 
predominant virus (as indicated by a jump in the phylogenetic trees), or more likely, a mix 
up of sequences or sample contamination.
After the exclusions of patients with suspicious sequences, 63 sequences from 18 patients 
in the On-3TC arm and 54 sequences from 19 patients in the Off-3TC arm were included
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in the analysis (Table 6.4.5.2.1). Phylogenetic trees were created for the protease and RT 
genes separately and were similar to the trees for the whole sequence (data not shown).
Figure 6.4.5.2.1: Neighbour-Joining distance trees for sequences in the On-3TC arm (A) 
and Off-3TC arm (B) using distances calculated through the Jukes-Cantor method
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Figure B:
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Legend: The first number in the leaf name indicates the presence of the M184V mutation (1 = 
present, 0 = not present). Leaves marked with a symbol have been excluded from the analysis. 
The number between the two hyphens is the patient identifier. The last two-digit number is the 
week visit to which the sequence belongs: 01 = Baseline; 04 = Week 04; 12 = Week 12; 24 = Week 
24; 36 = Week 36; 48 = Week 48
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6.4.5.2.1. Characteristics of patients in the nucleotide distances sub-study
The 37 patients who were included in this final resistance analysis were primarily male 
(78.4%) and white (78.4%). They had relatively low CD4+ T cell counts (median: 175, IQR: 
111 to 324 cells/pl) with a median (IQR) viral load of 4.1 (3.8 to 4.9) log10 copies/mL. 
There were 15 patients (41 %) who reached virological suppression at some point during 
follow-up. No significant differences were observed in baseline demographics between 
treatment arms, but differences did exist in prior treatment use (Table 6.4.5.2.1.1).
Approximately the same proportions of patients in both treatment arms had previously 
used Pis, 88.9% (On-3TC) and 84.2% (Off-3TC), but patients randomised to On-3TC had 
been exposed to this drug class for longer, a median duration (IQR) of 51.6 (38.2 to 55.5) 
months (On-3TC) vs. 33.7 (18.6 to 49.0) months (Off-3TC), p=0.02. When looking at the 
AAUCMB analysis for patients who had their virus sequenced the results were similar to 
those obtained in COLATE overall: a mean 1.6 (95% Cl: 1.3 to 1.8) log10 cps/mL reduction 
in HIV RNA for patients in the On-3TC arm compared to 1.5 (95% Cl: 1.3 to 1.8) log10 
cps/mL for patients in the Off-3TC arm (p=0.78).
Table 6.4.5.2.1.1: Baseline characteristics of the patients included in the analysis.
Baseline parameter On-3TC 
N =18
Off-3TC 
N =19
Gender No. male, (%) 15 (83) 14 (74)
Age Median years (IQR) 41.5 (32.5,51.3) 39.0 (37.0, 43.0)
CDC, category C No. Yes, (%) 9 (50) 11 (58)
Viral load copies/mL log™ (IQR) 4.4 (3.7, 4.9) 4.0 (3.8, 5.0)
CD4* count 106/l; median (IQR) 170 (111,284) 180 (116,351)
CD4* nadir count 106/l; median (IQR) 42.5 (5.8,97) 80 (39, 180)
HIV exposure group Homosexual/bisexual 11 (61) 11 (58)
Heterosexual 5 (28) 7 (37)
IVDU 1 (6) 0 (0)
Unknown & other 1 (6) 1 (5)
Race: White 14 (78) 15 (79)
Black 3 (17) 3 (16)
Asian 1 (6) 0 (0)
Other 0 (0) 1 (5)
Previous NRTI use No. (%) 18 (100) 19(100)
Median months, (IQR) 56.2 (24.7,99.9) 49.5 (29.3, 77.2)
Previous PI use No. (%) 16 (88.9) 16 (84.2)
Median months, (IQR) 51.6 (38.2,55.5) 33.7 (18.6,49.0)
Previous NNRTI use No. (%) 9 (50.0) 13 (68.4)
Median months, (IQR) 6.9 (5.4, 27.0) 15.2 (0.6,20.5)
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6.4.5.2.2. Nucleotide distances according to treatment arm
For each patient, nucleotide distances from baseline were estimated by comparing all 
available sequences to the baseline sequence and calculating the number of nucleotide 
changes that occurred, using each of the three approaches described in section 6.3.4. 
The patterns observed in Figure 6.4.5.2.2.1 are consistent with the sequences illustrated in 
the phylogenetic trees (Figure 6.4.5.2.1), where samples taken during follow-up are 
progressively more distant from the baseline sample. Distances appear to increase more 
quickly for patients in the Off-3TC arm compared to patients in the On-3TC arm (Figure 
6.4.5.2.2.1). However, due to the small number of patients and consequently low power at 
each visit, no statistically significant differences were observed using Kruskal-Wallis tests. 
At Week 48 the median number of nucleotide changes from baseline was 9.00 (IQR: 5.00 
to 28.38) in the On-3TC arm and 12.00 (IQR: 8.50 to 20.00) in the Off-3TC arm using the 
SynScan approach, p=0.71. A lower number of substitutions was seen using both the 
Jukes-Cantor and the Kimura 2-parameter approaches (Figure 6.4.5.2.2.1).
Figure 6.4.5.2.2.1: The distance between baseline and each follow-up visit using: A) Jukes-Cantor; 
B) Kimura 2-parameter and C) SynScan.
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I then used generalised linear models to assess whether there was a difference between 
treatment arms in the average number of nucleotide changes, averaged over all time- 
points. There were a mean 0.45 (95% Cl: -1.55 to 2.46) more synonymous nucleotide 
substitutions from baseline and 0.74 (95% Cl: -1.05 to 2.52) more non-synonymous 
nucleotide substitutions from baseline in the Off-3TC arm compared to the On-3TC arm; 
albeit these differences were not significant, p=0.66 and p=0.42, respectively. Overall, 
using the SynScan approach, there was a trend for a larger number of substitutions from 
baseline in the Off-3TC arm compared to the On-3TC arm: there were a mean 1.16 (-2.24 
to 4.56) more substitutions, averaged over all time-points, p=0.50. This difference is 
similar to the patterns observed using both the Jukes-Cantor and Kimura 2-parameter 
approaches (Figure 6.4.5.2.2.2).
Nucleotide distances did not differ between strata: there were a mean 0.47 (-2.67 to 3.61) 
more substitutions in stratum A compared to stratum B, averaged over all time-points, 
p=0.77. Patients who experienced increases in HIV RNA experienced significantly larger 
nucleotide distances: 2.42 (0.80 to 4.05) more substitutions for every log10 cps/mL 
increase in HIV RNA over the period (p=0.003).
Figure 6.4.5.2.2.2: Nucleotide distances from baseline between Off-3TC and On-3TC 
Using: Jukes-Cantor (JC); Kimura 2-parameter (K2P); and SynScan.
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6.4.6. Pattern of decline in the prevalence of M184I/V
To investigate whether the lack of a difference in the average number of accumulated 
nucleotide changes between treatment arms could be due to the fact that the M184I/V 
mutation remained present in the dominant viral population of patients who discontinued 
3TC, I decided to look at the prevalence of M184I/V throughout follow-up. By examining 
the proportion of patients with mutations at genotypic testing, the prevalence of M184I/V 
showed a decline over time in the predominant virus of patients who discontinued 3TC 
(Figure 6.4.6.1). By week 24, M184I/V was detected in the predominant virus of four of 
nine (44.4%) patients in the Off-3TC arm; by week 48 this had decreased to 14.3% (i.e. 
one of seven patients in the Off-3TC arm who had resistance tests available at week 48). 
The patient in the Off-3TC arm, in whom the M184I/V mutation was detected by population 
sequencing at week 48, re-started 3TC a week into the trial. This may explain why 
M184I/V remained present in the dominant viral species. In contrast, in patients in the On- 
3TC arm, M184I/V was still detected in the dominant virus of six of eight (75.0%) and 
seven of nine (77.8%) patients at weeks 24 and 48, respectively. Of note, Figure 6.4.6.1 
only reflects the pattern of decline in patients with successful sequencing and, for obvious 
reasons, does not include patients who were virologically suppressed. The characteristics 
of patients in each treatment arm, in whom M184I/V was not detected after 24 weeks of 
follow-up, were comparable to patients in whom M184I/V was detected after 24 weeks of 
follow-up, with respect to baseline NNRTI use and baseline PI use. In addition, similar 
proportions of these patients entered COLATE after failing a first-line regimen (data not 
shown).
Figure 6.4.6.1: Patients in whom M184I/V was detected at each visit: by treatment arm.
6.4.7. Nucleotide distances according to presence of M184I/V
As depicted in Figure 6.4.6.1, there was an appreciable amount of time in the Off-3TC arm 
where the M184I/V mutation remained present even though patients had discontinued 
3TC. Conversely, the 1841/V appeared to have reverted back to 184M in some patients in 
the On-3TC arm even under selection pressure from continued use of 3TC. To account 
for the fact that M 1841/V could be detected in the predominant virus of some patients in the 
Off-3TC arm during follow-up, and M 1841/V could not be detected in the predominant virus 
of some patients in the On-3TC arm, I identified whether the M184I/V mutation was 
present in the predominant virus at each visit and compared nucleotide distances from 
baseline, according to the presence of this mutation.
So, for example, Figure 6.4.7.1 illustrates four possible scenarios for the disappearance 
and re-appearance of the M 1841/V mutation at each of the follow-up visits. The distance 
between baseline and each of the five follow-up time points would contribute data to the 
‘1841/V comparison arm’ for patient 1. Since the 1841/V mutation is continuously detected 
in the predominant virus of this patient, they would not contribute any data to the ‘184M 
comparison arm’. In patient 2 ,1841/V is detected at each visit from baseline until week 36. 
At week 36 the 1841/V mutation is no longer detected, instead it appears to have reverted 
back to 184M. The first three distance calculations (i.e. nucleotide distances from baseline 
to weeks 4, 12 and 24) would contribute data to the ‘1841/V comparison arm’ whereas the 
last two distances (i.e. nucleotide distances from baseline to weeks 36 and 48) would 
contribute data to the ‘184M comparison arm’. The 1841/V mutation disappears from the 
predominant virus of patient 3 after four weeks of follow-up. However, it is detected again 
in the predominant virus afer 48 weeks of follow-up. In this situation, the first and last 
distance calculations (i.e. nucleotide distances from baseline to week 4 and from baseline 
to week 48) would contribute data to the ‘1841/V comparison arm’ whereas the nucleotide 
distances from baseline to week 12 and baseline to week 36 would contribute data to the 
‘184M comparison arm’. Patient 3 would not contribute any data to these comparisons at 
week 24, because no resistance data is available at this time point for this patient.
Of note, only two patients had plasma samples available for sequencing at each of the five 
follow-up time points and at baseline, and, since some of the situations outlined in the 
figure are highly unlikely to occur, this diagram is just provided as a hypothetical example 
to illustrate how this analysis was performed. Patients 4 and 5 are likely to be more 
representative of the patients in our study than patients 1 to 3.
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Figure 6.4.7.1: Hypothetical presence of mutations in the dominant virus, over follow-up
W eek of follow up:
0 4 12 24
- ■ — . ......- ..r ......—i .........i----
36 48
Amino acid detected at codon position 184 in the dominant virus:
1: V l/V l/V l/V l/V l/V
2: V IN l/V l/V M M
3: V l/V M M l/V
4: V l/V M
5: V M
When I modelled nucleotide distances from baseline using this approach, there were a 
mean 10.74 (7.46 to 14.02) fewer nucleotide substitutions from baseline in follow-up 
samples where 1841/V was detected compared to those where 184M was detected, 
averaged over all time-points, using the SynScan method (synonymous and non- 
synonymous combined), p<0.0001 (Figure 6.4.7.2).
Figure 6.4.7.2: Nucleotide distances from baseline between M184I/V and no M184I/V 
Using: Jukes-Cantor (JC); Kimura 2-parameter (K2P); and SynScan.
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Larger nucleotide distances were also seen from baseline in patients who had a follow-up 
virus in which 184M was detected compared to those in which 1841/V was detected, using 
both the Jukes-Cantor and Kimura 2-parameter approaches. Using the Jukes-Cantor 
method there were a mean 6.23 (3.82 to 8.64) fewer nucleotide substitutions from baseline 
if the M184I/V mutation was detected compared to those where it was not, p<0.0001. 
Similarly there were a mean 4.79 (2.94 to 6.64) fewer nucleotide substitutions from 
baseline if the M184I/V mutation was detected compared to those where it was not, using 
the Kimura 2-parameter method, p<0.0001.
6.4.8. The route of disappearance of the M184I/V mutation
In the previous comparisons, there were a significantly larger number of nucleotide 
changes from baseline if the M184I/V mutation was detected in the predominant virus 
during follow-up compared to when it was not, using all three evolutionary nucleotide 
approaches (i.e. from 4.8 to 10.7 nucleotide changes). These differences may arise due to 
the actual loss of the M184I/V mutation (i.e. a back-mutation from isoleucine or valine to 
methionine in the same virus), in combination with a possible increase in viral replication 
and a reduced fidelity of the new virus. Or, potentially, it may be due to other viral 
changes that occur when l/V reverts back to M (i.e. the virus population that was sampled 
at baseline may no longer be the dominant viral species, instead an archived sub-species 
may have outgrown it and become dominant).
In the first case (i.e. assuming that the same virus was sampled at the baseline and follow- 
up tests), the lack of detection of 1841/V at the follow-up test could have occurred as a 
result of this virus undergoing a back-mutation from l/V to M at codon position 184 (i.e. a 
viral “drift” -  a change in the same virus), due to the removal of 3TC and its corresponding 
drug selection pressure from the regimen. Unless other nucleotide changes occur at the 
same time as the disappearance of M184I/V, a back-mutation from l/V to M would only 
account for a maximum of two nucleotide substitutions (i.e. one or two nucleotide changes, 
either in the first or last position of the nucleotide triplet at codon position 184). However, 
in the analysis comparing nucleotide distances according to the presence of M184I/V I 
found a range of between 4.8 nucleotide substitutions according to the Kimura 2- 
parameter method and 10.7 nucleotide substitutions according to the SynScan approach. 
Both of these estimates are larger than what would be expected if only one amino acid 
substitution had occurred.
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Alternatively, and possibly more realistically, the virus that was sampled during follow-up 
may actually come from a different virus population to the one that was sampled at 
baseline (i.e. a viral “shift” -  a change in the dominant virus population). If this was the 
case, the detection of 1841 A/ at baseline followed by a lack of detection of 1841/V at the 
follow-up test, may arise because a virus containing the wild-type 184M amino acid may 
be more Tit* under the conditions at the time of follow-up (for example because lamivudine 
was discontinued) and so it may out-compete the baseline virus that contains the mutant 
1841/V. Under both of these assumptions it would not be possible to detect the M184I/V 
mutation in the predominant virus any longer.
In the case of a viral shift, the number of nucleotide changes would provide an erroneous 
picture of the mutational changes that occur between baseline and follow-up because this 
approach involves comparing the baseline virus to a virus that was only present in minor 
populations at baseline (i.e. a different virus) and so the virus would appear to have 
undergone more nucleotide changes than it actually had. As a result, elevated estimates 
of nucleotide distances would be obtained. The resistance methods in COLATE do not 
allow us to distinguish between viral drifts and viral shifts, with respect to the 
disappearance of M184I/V, in our patients.
6.4.8.1. Distances within samples containing 184M or containing 1841/V
In order to overcome the issue of viral shifts, I designed an alternative analysis. First, I 
assumed that all viruses containing 184M came from the same virus population and that 
all viruses containing 1841/V came from the same virus population. Then, in order to see 
how much of the difference in distances between viruses in which M 1841/V was detected 
compared to viruses where M184I/V was not detected, may be explained by an amino acid 
substitution from l/V to M (i.e. a back-mutation) I excluded information on nucleotide 
changes that occurred at the time of the reversion back to 184M. Instead, I estimated the 
distance-per-unit-time from the first sequence that contained 184M to following samples 
where 184M was present, and compared this distance to the distance-per-unit-time 
between viruses that contained 1841/V (i.e. from baseline to other time points where 1841/V 
was present).
In essence, nucleotide distances were calculated between the first sample containing 
184M to other samples containing 184M, and compared to the nucleotide distances 
between the first sample containing 1841/V (i.e. the baseline sample) and other samples 
containing 1841/V. Patients could contribute sequence data to both arms of this sub­
analysis if they had £1 sequence where 1841/V was present as well as £1 sequence where 
184M was present. The nucleotide changes that occur at the time of the amino acid 
reversion from l/V to M will not contribute to the distance calculations in this analysis 
because distances are not calculated between viruses containing 1841/V and viruses 
containing 184M. Instead, this analysis investigates whether distances among patients 
with a virus containing 184M are different from those with a virus containing 1841/V. Then, 
by definition, only nucleotide changes other than those seen at codon position 184 will be 
accounted for in these comparisons.
So, if I refer back to the example in Figure 6.4.7.1, the distance between baseline and 
each of the five follow-up time points would still contribute data to the ‘184I/V comparison 
arm’ for patient 1 and this patient would not contribute any data to the ‘184M comparison 
arm’. In patient 2, the first three distance calculations (i.e. nucleotide distances from 
baseline to weeks 4, 12 and 24) would contribute data to the ‘1841/V comparison arm’ 
whereas the nucletode distance between the last two samples (i.e. the nucleotide distance 
from week 36 to week 48) would contribute data to the ‘184M comparison arm’. Similarly, 
in patient 3, the first and last distance calculations (i.e. nucleotide distances from baseline 
to weeks 4 and from baseline to week 48) would contribute data to the ‘1841/V comparison 
arm’ whereas the nucleotide distances from week 12 to week 36 would contribute data to 
the ‘184M comparison arm’. Patient 4 would only contribute data to ‘1841/V comparison 
arm’ (i.e. the distance between baseline and week 12), and patient 5 would contribute no 
data to these comparisons. All of the distances were standardised for the time between 
measurements.
Using this approach, there was a mean: 2.58 (-0.49 to 5.64), p=0.10; 1.98 (-0.38 to 4.34), 
p=0.10; and 3.47 (-1.22 to 8.16), p=0.15, fewer nucleotide substitutions in viruses where 
M184I/V was detected compared to those in which it was not, after adjustment for the time 
between measurements, using the Jukes-Cantor; Kimura 2-parameter; and SynScan 
methods, respectively. In this analysis, the magnitude of the difference in the number of 
nucleotide substitutions between samples where 184I/V was detected compared to those 
where 184M was detected, was reduced from 10.74 (7.46 to 14.02) to 3.47 (-1.22 to 8.16), 
using the SynScan approach. This may suggest that the trend for smaller distances 
observed in the main analysis, for patients where 1841/V was detected, can be partly 
explained by the actual loss of the 184I/V mutation (or other mutational changes that occur 
simultaneously). However, there still appears to be a marginal difference in the number of 
nucleotide changes between viruses containing M 1841/V and viruses that do not.
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6.4.8.2. Comparing distances from samples where M 1841/V is present, 
missing or changed (M-> l/V or l/V->M) between visits:
As a further way to try to understand whether the reversion of l/V back to M, or the re- 
emergence of 1841/V, happened as a consequence of a shift to a different viral sub­
population (as opposed to a viral drift) I compared nucleotide distances between patients 
who had a virus with the same mutation at consecutive visits (i.e. either 184M was present 
at both visits or 1841/V was present at both visits) to patients who had a virus that 
underwent an amino acid substitution in between visits.
If I refer back to Figure 6.4.7.1 in this case, patient 1 would still contribute five sets of 
observations to these comparisons, but they now reflect the distance between visits rather 
than the distances from baseline. For patient 1, the data that would now be included in the 
‘1841/V comparison arm’ includes the distance from baseline to week 4, from week 4 to 
week 12, from week 12 to week 24, from week 24 to week 36 and from week 36 to week 
48). In patient 2, the nucleotide distances from baseline to week 4, from week 4 to week 
12 and from week 12 and 24 would contribute data to the ‘1841/V comparison arm’; the 
nucletode distance between week 24 and week 36 would contribute data to the ‘change 
from M to l/V or l/V to M arm’; and the nucletode distance from week 36 to week 48 would 
contribute data to the ‘184M comparison arm’. In patient 3, the nucleotide distances from 
baseline to week 4 would contribute data to the ‘1841/V comparison arm’; the nucleotide 
distances from week 4 to week 12 and from week 36 to week 48 would contribute data to 
the ‘change from M to l/V or l/V to M arm’; and the nucleotide distances from week 12 to 
week 36 would contribute data to the ‘184M comparison arm’. Patient 4 would contribute 
data to ‘1841/V comparison arm’ (i.e. the distance between baseline and week 12) and to 
the ‘change from M to l/V or l/V to M arm’ (i.e. the distance between week 12 and week 
24) and patient 5 would also contribute data to the ‘change from M to l/V or l/V to M arm’. 
Distances were again standardised for the time between measurements.
If the reversion of l/V back to M was due to a shift in the dominant virus population, the 
largest nucleotide distances would be expected to be seen in patients who had a virus that 
underwent an amino acid substitution at position 184. This is because, under our 
assumption, the nucleotide distance would be calculated between two different viruses. In 
fact, I would expect the nucleotide distances in this group to be substantially greater than 
the nucleotide distances in the other two groups.
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Although the trends were in the anticipated direction - patients who had a virus that 
underwent an amino acid change from M to l/V or l/V to M experienced the largest 
distances and patients who retained 1841/V the smallest - I did not find any significant 
differences between the three groups (Figure 6.4.8.2.1).
Using Jukes-Cantor, Kimura 2-parameter and SynScan there were a mean 1.85 (95% Cl: - 
1.29 to 4.98), 1.42 (95% Cl: -0.99 to 3.83) and 2.70 (95% Cl: -2.00 to 7.39) fewer 
nucleotide substitutions in patients who had a virus in which 1841/V was detected at 
consecutive visits respectively, and 3.17 (-1.25 to 7.60), 2.44 (95% Cl: -0.96 to 5.84) and 
5.51 (95% Cl: -0.63 to 11.66) more nucleotide substitutions in patients with an amino acid 
change, compared to patients who had a virus in which 184M was detected at consecutive 
visits.
Figure 6.4.8.2.1: Comparison of distances between samples where M184I/V is present, missing or 
changed (M-> l/V or l/V->M) between consecutive visits
:
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6.4.9. Sensitivity analyses
6.4.9.1. Excluding patients who did not have M184I/V at baseline:
When I excluded the three patients who did not have a virus showing M 1841/V at baseline, 
the results of the main analysis comparing nucleotide distances between treatment-arms 
(section 6.4.5.2.2) did not change substantially. There was still a trend for a larger number 
of substitutions in the Off-3TC arm compared to the On-3TC arm: in the Off-3TC arm a 
mean 0.34 (-2.30 to 2.97) more substitutions were seen according to the Jukes-Cantor 
approach, p=0.80; a mean 0.26 (-1.77 to 2.28) more substitutions according to the Kimura 
2-parameter approach, p=0.80; and a mean 1.39 (-2.28 to 5.06) more substitutions 
according to the SynScan approach, p=0.46, averaged over all time-points.
In this same subset of patients, there were slightly larger differences in the nucleotide 
distance from baseline than that observed in the main analysis, when we grouped patients 
according to the detection of M184I/V instead of the COLATE randomisation group 
(section 6.4.7), after exclusion of the three patients who did not have a virus containing 
M184I/V at baseline. Using the Jukes-Cantor, Kimura 2-parameter and SynScan 
approaches there were a mean 7.65 (95% Cl: 5.04 to 10.26), p<0.0001; 5.88 (95% Cl: 
3.88 to 7.89) p<0.0001; and 12.30 (8.77 to 15.84), p<0.0001 fewer nucleotide substitutions 
from baseline in patients in whom M 1841/V was detected compared to those in whom it 
was not detected, respectively.
6.4.9.2. Excluding outlying sequences only and not the whole patient:
In all of the previous analyses I excluded all patients who had sequences that did not 
group together in the phylogenetic trees. Instead of excluding all sequences from the 
patient I excluded only the suspsicious sequences (i.e. the sequences that did not group 
with the other sequences) to see whether this affected the results. The inclusion of nine 
sequences from three patients resulted in an increase in power, yet similar estimates to all 
of the previous comparisons (data not shown). There were a mean 1.13 (-2.02 to 4.29), 
p=0.48 more substitutions according to the SynScan approach in the Off-3TC arm 
compared to the On-3TC arm, averaged over all time points, and a mean 9.91 (6.88 to 
12.94) fewer nucleotide substitutions from baseline if the M184I/V mutation was detected 
in the predominant virus population compared to those in whom it was not, p<0.0001. The 
results using the Jukes-Cantor and Kimura 2-parameter approaches were consistent with 
the above (data not shown).
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6.5. Discussion 
6.5.1. Summary of main results
The aim of COLATE was to assess whether retaining 3TC in a new regimen after failing 
cART, in patients in whom the M184V mutation was present in their predominant viral 
population, could be virologically or immunologically beneficial in clinical practice. This is 
the first study to address the effect of retaining the M184V mutation during cART in vivo. 
COLATE was designed with the assumptions that i) M184V would be present at baseline 
ii) M184V would gradually disappear in the Off-3TC arm iii) the background cART would 
consist of at least three ARVs throughout follow-up and iv) knowledge of whether each 
patient was receiving 3TC, due to the open-label design of the trial, would not result in 
additional ARVs being added to the pre-selected background regimen or to ARVs used 
during follow-up. All of these expectations were met in this study.
All patients with baseline resistance tests in the On-3TC arm and 89% of patients in the 
Off-3TC arm harboured M184V. In the On-3TC arm this mutation was detected 
throughout the whole of follow-up whereas it gradually disappeared in the Off-3TC arm. 
The mean number of ARVs received other than 3TC was >3 throughout follow-up, with no 
differences in the use of individual drugs between treatment arms.
6.5.2. Interpretation of the results of the COLATE trial
As far as the results of the main trial are concerned, no differences were observed 
between treatment arms in the AAUCMB HIV RNA log10 reductions (On-3TC arm: 1.4 and 
Off-3TC arm: 1.5 log10; p=0.51), in the ability or time to suppress HIV RNA, or in the time to 
or magnitude of CD4+ T cell count increases. Our observations differ from (the 
interpretation of) data from laboratory experiments and non-randomised studies, which 
indicate a postulated benefit of retaining the M184V mutation in the predominant viral 
population272:393:398:390. Several potential explanations exist for this discordance.
Firstly, most clinical studies that have addressed this issue had limited statistical power to 
draw firm conclusions. With a sample size of 160 the COLATE trial was designed with 
90% power to show a difference in HIV RNA reductions between treatment arms of £0.5 
log10 cps/mL. Even though the final sample size was only 131 patients, the trial retained 
>80% power to detect a difference in the primary analysis.
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Secondly, use of different ARVs and/or ARV drug class during follow-up, or different 
baseline resistance patterns in the predominant viral populations of these patients, could 
have influenced the overall outcome of the trial. In this study, no difference was seen in 
use or duration of treatment with individual ARVs or drug class prior to baseline, or during 
follow-up, between patients in the On-3TC and those in the Off-3TC arm. In addition, 
there were no differences at baseline in the number of primary mutations to NRTIs, 
NNRTIs or Pis (Table 6.4.5.1.1) and there were no differences in the baseline GSS 
between treatment arms. However, for all patients in stratum A and the majority of 
patients in stratum B a new regimen consisting of £2 drugs to which the virus was 
susceptible to was initiated at baseline. The residual viral effect of 3TC in the On-3TC arm 
could have been indiscernible because patients were receiving other active drugs. Since 
the predominant virus at baseline was reasonably susceptible to the other ARVs in the 
regimen, it may not have been possible to tease out an added virological benefit of 
continuing 3TC.
The results of the COLATE study can only be applied to patients who have the potential to 
initiate three new ARVs and cannot be extended to patients with multi-drug resistance who 
have few treatment options available. The continued use of 3TC alone has already been 
addressed in the E-184V pilot study279, with results consistent with both an impaired fitness 
of M184V containing viruses or residual activity of 3TC against viruses harbouring the 
M184V mutation, although these results still need to be reproduced using a larger dataset.
One concern about the re-use of drugs, which, in many cases would be an add-on to a 3- 
or 4-ARV regimen, is the potential risk of side effects associated with multi-drug 
regimens399. Lamivudine is a very well tolearated drug and I did not observe any 
statistically significant differences in adverse events leading to premature interruption of 
the assigned treatment strategy between patients in the On-3TC and those in the Off-3TC 
arm.
6.5.3. Interpretation of the results investigating nucleotide distances
In this chapter, I described a sub-group of patients who had genotypic data available at 
baseline and during follow-up. This was done because I wanted to evaluate whether 
patients who discontinue 3TC after failing a 3TC-containing cART regimen experience 
more nucleotide substitutions in their dominant virus population compared to patients who 
maintain it in their regimen. This is the first study that has addressed this question in vivo, 
thereby enabling us to assess whether adding 3TC to a new cART regimen for a patient, in
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whom M184V is detected in their predominant viral population, is likely to be worthwhile in 
clinical practice.
Based on the hypothesis of reduced replication capacity and increased fidelity of viruses 
containing M184V, larger evolutionary distances were expected in patients who 
discontinued 3TC compared to those who retained it over time. I examined nucleotide 
distances for patients with HIV RNA >500 cps/mL and a genotypic test, both at baseline 
and at 1^ visit during follow-up. Although these patients did not reach virological 
suppression and may have different rates of viral evolution compared to those who 
reached virological suppression (and for whom resistance could not be measured), they 
should still reflect the changes that occurred in the predominant virus populations during 
follow-up.
Using the Jukes-Cantor, Kimura 2-parameter and SynScan evolutionary nucleotide 
approaches I found comparable mutation rates through 48 weeks of follow-up in patients in 
both arms of the study. Nucleotide distances increased from baseline throughout follow- 
up (Figure 6.4.5.2.1 and Figure 6.4.5.2.2.1) indicating that the virus population 
progressively evolved away from the population seen at baseline. In the Off-3TC arm a 
large number of nucleotide substitutions occurred between weeks 4 and 12, whereas 
substitutions started to appear later on in the On-3TC arm, although none of the 
differences were statistically significant at any individual time point. When I estimated the 
overall mean difference in nucleotide distances between treatment arms, averaged over all 
time-points, I saw 1.2 more changes in patients who discontinued 3TC. This is consistent 
with our a priori expectations because patients in the Off-3TC arm are expected to lose 
M184V after discontinuing 3TC and this reversion back to wild-type would entail at least a 
one nucleotide non-synonymous change at codon 184 of the reverse transcriptase gene.
Although I did not find an appreciable effect of discontinuing 3TC on nucleotide distances 
in some patients in the Off-3TC arm, M184V was detected in a number of tests for an 
appreciable period of time after stopping 3TC. Therefore, this may have eclipsed the 
detection of an effect associated with the presence of this mutation if it did exist. Using the 
proportion of patients with mutations at genotypic testing, the rates of decline of the 
M184V mutation were in concomitance to the increases in nucleotide distances that we 
saw from baseline. Since I analysed patients who initiated a cART regimen 
simultaneously to their 3TC-protocol strategy, other ARVs may have influenced nucleotide 
distances. Certain drugs could block the evolutionary pathway of the virus or delay the
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loss of M184V, which could explain why, in some patients who discontinued 3TC, M184V 
could be detected throughout follow-up. Adjustment for individual drugs was not possible 
in the multivariable analyses because it would have resulted in groups containing too few 
patients. Four patients in each treatment arm stopped their randomised regimen before 
week 48 and one patient in the Off-3TC arm experienced a treatment interruption.
To account for the fact that, in some patients in the Off-3TC arm, M184V could still be 
detected in the predominant virus during follow-up, and, in some patients in the On-3TC 
arm, M184V could not be detected, I compared evolutionary distances from baseline 
according to whether M 1841/V had been detected or not. I used generalised linear models 
to compare nucleotide distances from baseline between these two groups, and to take into 
account the fact that, on average, the time between tests was longer in patients in whom 
M184V was detected at baseline but not in the follow-up test compared to those where 
M184V was detected at both time points. In these comparisons, I found highly significant 
differences: patients who had a virus showing M 1841/V in their follow-up resistance tests 
had significantly fewer nucleotide substitutions than those in whom the M814V mutation 
had reverted back to M at some point.
It is possible that these differences occur because the loss of M 1841/V results from a viral 
drift (i.e. the reversion of 1841/V back to M in the dominant virus). However, it is more 
likely that this change reflects a shift in the dominant virus population -  from a virus that 
contains M184V to a different virus that does not. In an alternative analysis, I compared 
the distance-per-unit-time among viruses not showing the M184I/V mutation during follow- 
up to viruses where M184I/V was detected during follow-up, under the assumption that 
these sequences stem from the same virus population. Compared to viruses showing the 
M184I/V mutation, I saw larger distances in those without it, but these trends were only 
marginally significant (Jukes-Cantor: p=0.10, Kimura 2-parameter: p=0.10, SynScan: 
p=0.15). If the assumption is true then this would imply that the difference I saw in the 
main analysis may be only partly explained by the actual loss of M184I/V and that other 
changes are occuring.
I then compared nucleotide distances between consecutive tests for patients in whom the 
same mutation was detected at codon position 184 at each visit (i.e. either 184M was 
present at both visits or 184I/V was present at both visits) to those of patients in whom 
1841/V ws detected at one test but not at the following test (or vice-versa). If the same 
mutation is detected at consecutive visits then the distance between sequences from
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these visits is likely to reflect the distance between viruses sampled from the same virus 
population. This comparison was performed to highlight whether the distance between 
consecutive sequences, in which there was an amino acid change, are substantially larger 
than the distance between viruses sampled from the same viral population.
As expected, patients who had a virus that underwent an amino acid substitution between 
visits experienced larger distances, but they were not significantly different to patients in 
whom the same mutation was detected at codon position 184 at consecutive visits. 
Therefore, if our assumptions are correct, a shift to a different viral sub-population is 
improbable. Furthermore, using the SynScan approach, I only saw 10.7 more nucleotide 
changes from baseline in viruses in which the M1841 A/ mutation was not detected 
compared to viruses where M184I/V was detected, so a shift to a different viral sub­
population is unlikely because more than ten nucleotide changes (from 1302 nucleotide 
positions studied) would be expected if a new viral sub-population had become dominant.
I used the Jukes-Cantor, the Kimura 2-parameter and the SynScan approaches to model 
the number of substitutions over 48 weeks of follow-up. Although I saw similar trends in 
nucleotide distances using all three different nucleotide methods, the magnitude of the 
effect size varied according to the method used. The SynScan approach provided 
estimates that were two to three fold higher than either the Jukes-Cantor or the Kimura 2- 
parameter methods for each comparison.
This difference arises because the SynScan approach uses a larger weighting to calculate 
the distance between two sequences if a within-purine or within-pyrimidine (section 1.5) 
substitution has occurred (i.e. a transition). Both the Jukes-Cantor and the Kimura 2- 
parameter approaches estimate the distance between the two purines or between the two 
pyrimidines to be zero whereas the SynScan approach estimates the distance for a 
transition to be 0.5. Similarly, the Kimura 2-parameter approach gives a weight to 
transversions (i.e. a purine to a pyrimidine substitution or vice-versa), whereas the Jukes- 
Cantor method only accounts for nucleotide changes that result in an amino acid 
substitution. In this analysis I consistently found the largest number of nucleotide changes 
using the SynScan approach and the smallest number using the Jukes-Cantor approach. 
This indicates that nucleotide changes are occurring in the viral population of these 
patients, although the changes are likely to be transitions that have not yet resulted in an 
amino acid substitution. These changes may be important for quantifying resistance
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because they may reflect what will happen over the long run, although no study as yet has 
shown any evidence that they are.
6.5.4. Limitations of the analysis
In these comparisons, the observed increases in nucleotide distances over follow-up are 
likely to reflect changes to the predominant viral population as a result of drug pressure 
from the regimen the patient is receiving. In addition, changes may occur as a result of 
natural evolution of the virus population. We only sequenced the reverse transcriptase 
and protease genes, and since both genes are under drug selection pressure it is not 
possible to tell whether the changes identified arise as a result of natural evolution.
Further support could come from an analysis of another gene that is not under drug
pressure and has a naturally high rate of nucleotide substitutions, such as the envelope 
gene, in patients in this study. The hypervariable regions of envelope can change 
significantly even in the absence of cART400, so analysis of envelope sequences, in 
addition to protease and reverse transcriptase, would add support to discerning the effect 
of the M184V mutation.
In this nucleotide distances sub-study I am dealing with consensus sequences rather than 
clones. Although important information on phylogenetic evolution has been obtained from 
consensus sequences recently4011402, use of this method could result in sampling only 
dominant variants in the quasispecies. As a result, some patients may be misclassified as 
not having M 1841/V in their virus when in fact they had it in less than 20% of a mixed virus 
population. The best way to address viral diversity over time is by sequencing multiple 
clones at each time point or using heteroduplex assay systems. Analysis of single 
consensus sequence at each time point only provides limited information.
These data are derived from a randomised controlled trial but since not all patients are
included in the analyses it does not constitute a randomised comparison. Since no
randomisation occurred in this sub-group of patients there may not be a comparable prior 
risk of viral evolution in both treatment arms. As a result unknown factors may have 
influenced the rate of viral evolution and caused imbalances between treatment groups. 
However, the rate of suppression was comparable between the two treatment arms in the 
parent study therefore selecting this group of patients should not induce a selection bias 
and there should be a comparable risk of viral evolution, in terms of known and unknown 
factors, in both treatment arms.
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Because only a small number of sequences could be included in these analyses, there 
may be insufficient power to detect a difference in nucleotide distances between treatment 
arms. If follow-up time had been longer, so that patients in the Off-3TC arm had a longer 
period in which M 1841/V was not present in their dominant viral species, I would have had 
more power to detect an effect on nucleotide changes associated with discontinuing 3TC.
Our study suggests a marginal benefit of retaining M184V in the virus population because 
fewer nucleotide changes occur in viruses that show M 1841/V. However, patients who 
retained 3TC in their regimen are not likely to benefit virologically from this strategy in the 
first 48 weeks of treatment. Larger datasets and a longer follow-up time are needed to see 
if patients who continue 3TC, in order to maintain M184V, have smaller nucleotide 
distances to those who discontinue it and are likely to lose the mutation from their 
dominant virus due to the lack of drug-selection pressure.
6.5.5. Conclusion
Overall, I did not find a difference in nucleotide distances for patients who continued on 
3TC compared to those who discontinued it at any stage during 48 weeks of follow-up, but 
confidence intervals for the difference cannot rule out a moderate effect in favour of 
continuing 3TC. Post-hoc, exploratory analyses looking at the nucleotide distances 
according to whether M184I/V was detected or not produced significant results. This could 
be due to the postulated higher fidelity and lower replication capacity of the mutant reverse 
transcriptase272.
Our analyses do not rule out the possibility that M184V could influence virological 
response alongside less potent cART than is used in our study, or in a minority of patients 
in whom viral suppression is not a realistic goal. Such an effect, however, has limited 
clinical relevance given the recommended and prescribed cART regimens in today’s 
management of HIV infection. At the time of the COLATE trial, lopinavir/r was the most 
recent ARV to enter the market, and since then numerous other ARVs have become 
available (e.g. tipranavir, darunavir, maraviroc and MK0518) for patients with fairly 
extensive resistance. If these new ARVs are used appropriately, these data do not 
suggest that adding 3TC to the regimen will be of any added virological or immunological 
benefit. However, it could still be a relevant treatment strategy for patients who fail to 
achieve viral suppression. The results of this chapter are consistent with the theory of an 
enhanced fidelity of viruses containing the M184V mutation, which should be further 
investigated as a stratey to preserve future drug options in patients with HIV.
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In conclusion, in this randomised open label study no virological or immunological benefit 
was observed in patients who continued 3TC as part of cART, after failing a 3TC- 
containing regimen, compared to those who discontinued it. Even though a virological 
benefit was not observed according to treatment arm, there was a trend for smaller 
nucleotide distances to be seen in patients whose predominant virus showed the M184I/V 
mutation, compared to those in whom M184I/V was not detected. These findings, in a 
heterogeneous study population, support evidence of a beneficial effect of the M184V 
mutation.
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CHAPTER 7: ASSOCIATION BETWEEN RESISTANCE AND CD4+T CELL
COUNT CHANGE IN PATIENTS ON ARVs WITH ONGOING VIREMIA
7. Introduction
In chapter 6, I investigated whether retaining 3TC in a virologically failing 3TC containing 
regimen could be beneficial because 3TC is associated with the emergence of M184V and 
there could be a reduction in the fitness of viruses containing the M184V mutation. In the 
COLATE study there was no significant virological benefit of retaining 3TC throughout 
follow-up because patients were receiving an active cART regimen simultaneously to the 
3TC component. However, there was a trend towards larger nucleotide distances if 
M 1841/V disappeared from the main virus population compared to viruses where M 1841/V 
remained present, which is consistent with the original hypothesis. Current cART 
regimens are potent and successfully reduce viral load if a patient has a virus that is 
sensitive to the ARVs in their regimen. The potency of the other drugs in the regimen may 
have made it difficult to tease out a potential virological benefit of retaining the M184I/V 
mutation in the COLATE trial.
In the present era, with new ARVs still arriving on the market, it is possible to select an 
effective viral load reducing regimen for the majority of patients, although there are still 
some patients at the salvage stage of treatment in whom viral loads cannot be 
suppressed403. The immediate aim of therapy is to suppress viral replication to 
undetectable levels, thereby limiting the emergence and growth of viruses carrying 
resistance mutations109. However, some mutations may lead to a reduced replication 
capacity of the virus or an improvement in fidelity (as partly illustrated in the previous 
chapter for M184I/V)391. Patients who require salvage therapy may actually benefit from 
retaining drugs that preserve these mutations while they wait for other active drugs to 
become available1721284.
7.1. Aims of the chapter
Preserving virologically failing drugs in a regimen that keeps beneficial mutations present 
may improve the clinical prognosis of the patient. If these mutations influence the rates of 
viral replication, they are likely to be reflected by CD4+ T cell count declines, which in turn, 
will be related to clinical progression. Further, preserving “failing” drugs could be 
beneficial because there may still be some residual activity of the ARVs. In this chapter I 
will assess whether the ARVs used and level of resistance present (i.e. specific mutations
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and class of mutations) is associated with CD4+T cell count changes in EuroSIDA and the 
UK CHIC study, in combination with data from the UK HIV drug resistance database.
7.2. Literature review
It has been shown in several studies, most clearly in the large PLATO collaboration, that 
among patients with ongoing viraemia (i.e. two consecutive viral loads > 500 copies/mL) 
CD4+ T cell count changes are more favourable (or less unfavourable) in patients receiving 
ARVs (i.e. they experience smaller CD4+ T cell count declines) compared to patients with 
comparable viral loads who are not on ARVs152. Since all patients have high levels of viral 
replication in these comparisons, it is unclear whether the more favourable CD4+ T cell 
count changes in patients on ARVs is related to the presence of resistance mutations in 
the virus and, if so, whether the effect is greater for certain mutations compared to others.
The presence of resistance mutations may cause a virus to have a reduced capacity for 
inducing CD4+ T cell count declines because it may not be able to infect the T lymphocyte 
cells as efficiently281. A reduction in viral fitness associated with viruses containing some 
resistance mutations has been shown previously281 286, but this reduced fitness may act 
entirely through a reduction in the viral load and not directly impact on the CD4+ T cell 
counts287. In patients on ARVs as well as those off ARVs there is a trend for more 
favourable (or less unfavourable) CD4+ T cell count changes in patients with a lower viral 
load.
In this chapter I will identify patients in EuroSIDA and in the UK CHIC study who have 
linked resistance data in the UK resistance database. All patients who have ongoing viral 
load > 500 cps/mL were included in these comparisons, in order to assess whether the 
level of resistance in the virus (i.e. specific mutations and class of mutations) is associated 
with CD4+ T cell count changes independent of the use of ARVs.
I will also examine the relationship between resistance mutations and CD4+ T cell count 
declines for a given viral load or extent of viral load suppression from the pre-ART level to 
see whether the presence of certain mutations provides information on immunological 
response above-and-beyond what can be derived from the use of viral load testing. 
Patients in these studies contribute observational data where resistance testing is 
performed at varying time points depending on the centre. Retrospective resistance 
testing has also been performed on stored samples for some of the patients.
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7.3. Methods
7.3.1. Patient selection
Patients who appeared in both the UK CHIC study and the UK Drug Resistance database 
were combined with patients from EuroSIDA who had resistance information available. All 
duplicate entries were removed (i.e. patients who had clinical data in both EuroSIDA and 
the UK CHIC study). Patients were included in the final analysis if they had:
1. A pair of consecutive HIV RNA measurements (both >500 cps/mL) 8 to 26 weeks 
apart. If an HIV RNA measurement (>500 cps/mL) was taken within 8 weeks of the 
first recording, the next HIV RNA was included instead, as long as it was also >500 
cps/mL and 8 to 26 weeks after the first measurement.
2. CD4+ T cell counts available at the time each of the above HIV RNA measurements 
was recorded (+/-1 week either side)
3. An available resistance test in the above interval (defined by the pair of HIV RNA 
measurements) or 4 weeks before to 4 weeks after. If more than one resistance 
test was available in the interval, only the first resistance test was included in the 
analysis. If more than one resistance test was performed on the same day these 
test results were merged, so if a mutation had been found using only one test it 
was still considered to be present overall
4. Patients had to be on the same regimen for at least 4 months before the first viral 
load measurement AND up to the second viral load measurement OR off all ARVs 
during this period.
Patients could be included in the analysis on more than one occasion: they could have 
more than one pair of consecutive HIV RNA measurements satisfying the above criteria, 
each with a separate resistance test, or they could have more than one pair of consecutive 
HIV RNA measurements satisfying the above criteria with only one resistance test that 
was used a multiple number of times. No restrictions were made on the time between 
consecutive HIV RNA pairs; consequently the same HIV RNA measurement could be used 
repeatedly in consecutive pairs of measurements. This was also the case for CD4+ T cell 
count pairs. HIV RNA pairs were the unit of analysis in this chapter rather than individual 
patients.
7.3.2. Genotypic interpretation systems
In both EuroSIDA and the UK Drug Resistance Database, each full nucleotide sequence 
was aligned to an amino acid reference sequence (i.e. consensus B) and all of the amino
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acid substitutions were identified. A genotypic sensitivity score (GSS) was calculated for 
each patient using the Stanford (version 4.2.6) genotypic interpretation system (GIS).
7.3.3. Statistical analysis
The use of certain ARVs may lead to the emergence of specific mutations in the virus. 
These will be archived if the selection pressure from the corresponding drug is removed. 
Since there is a strong relationship between the presence of mutations and the ARVs that 
are used, it was not possible to enter both variables into a regression model together. 
Instead, HIV RNA pairs were categorised into groups according to the drugs the patient 
was receiving at the time and the mutations that were present in the associated resistance 
test in a composite variable. The groups were as follows:
1. Patients who were receiving a ritonavir boosted PI in whom £1 primary PI 
resistance mutation was detected (On Pl/r, PI mutations)
2. Patients who were receiving a ritonavir boosted PI but did not have a virus showing 
any primary PI resistance mutations (On Pl/r, no PI mutations)
3. Patients who were receiving an unboosted PI in whom £1 primary PI resistance 
mutation was detected (On PI, PI mutations)
4. Patients who were receiving an unboosted PI who did not have a virus showing 
primary PI resistance mutations (On PI, no PI mutations)
5. Patients who were receiving an NNRTI in whom £1 NNRTI resistance mutation was 
detected (On NNRTI, NNRTI mutations)
6. Patients who were receiving an NNRTI and did not have a virus showing NNRTI 
resistance mutations (On NNRTI, no NNRTI mutations)
7. Patients who were receiving a PI (unboosted or boosted) and an NNRTI in whom 
£1 resistance mutation was detected to both drugs (On PI & NNRTI, mutations to 
both)
8. Patients who were receiving a PI (unboosted or boosted) and an NNRTI and only 
had a virus showing resistance to one or neither of the classes (On PI & NNRTI, 
mutations to 1 or neither)
9. Patients who were receiving NRTIs only in whom >1 mutation was detected to 
NRTIs (On NRTIs only, NRTI mutations)
10. Patients who were receiving NRTIs but did not have a virus showing any mutations 
to NRTIs (On NRTIs only, no NRTI mutations) and
11. Patients who were not receiving any ARVs (Off-ART)
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Patients in all categories except for group 10 could have NRTI mutations present in their 
virus, those in all categories except group 6 could have a virus showing NNRTI mutations 
and those in all categories except groups 2 and 4 could have a virus showing PI 
mutations. The presence of mutations to each of the drug classes was identified by using 
the 2006 IAS-USA drug resistance mutations lists233.
I fit standard linear regression models to the CD4+ T cell count slopes over time (i.e. the 
difference between the pair of CD4+ T cell counts, standardized for the time in between 
them) for patients satisfying the inclusion criteria. All baseline characteristics (i.e.those 
measured at the same time as the first HIV RNA measurement) and follow-up variables 
that were significant (p<0.2) in the unadjusted analysis were entered into a backwards 
selection model. Variables that were still significant (p<0.2) were retained in the final 
model. Variables were assessed for co-linearity prior to any multivariable regression 
analysis. All of the main variables of interest and the most significant predictors in the 
cases of co-linearity were retained for inclusion in the final models. The mutation category 
described above was included in the multivariable models to investigate the relationship 
between the ARV used, the class of mutation and the CD4+ T cell count slopes. All 
possible interactions between variables were also investigated.
The relationship between the number of mutations to each class of ARVs and CD4+ T cell 
count slopes was examined in more detail to see whether there was a linear association, 
or whether individual mutations need to be weighted differently. Individual mutations were 
investigated in separate multivariable models, adjusted for all other variables that 
predicted CD4+ T cell count response in the main analysis.
7.3.4. Sensitivity analysis
I performed a number of different sensitivity analysis on these data. These are described 
over the next few paragraphs:
Patients who have large HIV RNA changes during the interval are likely to experience a 
greater number of mutational substitutions in their virus than those with small HIV RNA 
changes: there is more scope for mutations to emerge in the virus of these patients 
because their virus is undergoing more changes under drug pressure from the regimen 
they are receiving. In one sensitivity analysis, I restricted the comparisons to patients who 
had minimal HIV RNA changes (i.e. AHIV RNA <0.25 log™ cps/mL) in order to reduce the 
amount of noise generated from any mutational changes that occurred to the virus during
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the interval between HIV RNA measurements. This means that any difference in CD4+T 
cell count slopes is likely to be attributed to the mutations that are present in the virus that 
was sampled for the resistance test, rather than unidentified mutations that may have 
evolved over follow-up. Further, if a relationship between resistance mutations and CD4+ 
T cell count slopes was identified in this subgroup of patients, the analysis would already 
be partly controlled for HIV RNA changes during the interval between measurements. So, 
this analysis reflects the association between resistance and immunological response, 
independently of HIV RNA change, in a more controlled setting.
I also considered the effect of restricting the analysis to patients with high viral loads (i.e. 
HIV RNA >10000 cps/mL) at the start and at the end of each interval. This analysis was 
performed to see whether the presence of mutations has a greater impact on CD4+ T cell 
count changes in patients who have high levels of viral replication. These patients are 
failing treatment with extremely high levels of viraemia so any potential benefit of retaining 
certain mutations may be more apparent in this population. These patients reflect patients 
on salvage therapy who could potentially benefit from new strategies that involve retaining 
certain drugs in order to retain certain mutations in their predominant virus population.
Since non-adherence (or sub-optimal adherence) can affect the results of these 
comparisons, in another sensitivity analysis I decided to restrict the population to patients 
who have a GSS <1. Patients with a GSS <1 are assumed to be adherent because they 
have a wide range of mutations present in their virus and, as demonstrated in section 
1.6.1.1, resistance mutations are not likely to emerge in the predominant virus of non­
adherent patients because they will only have limited exposure to treatment. Patients who 
are selected for this sensitivity analysis also reflect those who are in need of salvage 
therapy and may benefit from these strategies, because they have very few treatment 
options available.
In another sensitivity analysis I performed a generalised linear model using generalised 
estimating equations to account for the repeated measurements on some individuals (i.e. 
some patients contribute more than one CD4+ T cell count pair to these analyses). This 
analysis was restricted to patients who had their pairs of CD4+ T cell counts measured at 
least one year apart. If measurements are taken close together it is likely that the last 
CD4+ T cell count in an interval will be the first of the pair of CD4+ T cell counts in the next 
interval, which would result in a negative correlation structure between pairs of CD4+T cell 
counts. Restricting pairs of observations to be at least one year apart ensured that there
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was a positive correlation structure, because each CD4+ T cell count will only contribute to 
one interval so consecutive CD4+ T cell count slopes will no longer be negatively 
correlated.
7.4. Results
7.4.1. Patient characteristics
Overall there were 3047 patients who satisfied criteria 1 to 4 in section 7.3.1. These 
patients had 4812 paired HIV RNA measurements, where 3166 resistance tests were used 
on one occasion and 823 on two occasions (Figure 7.4.1.1).
The characteristics of patients for all time points combined are shown separately for 
patients who were on ARVs and patients who were off ARVs at the time of their viral load 
pair (Table 7.4.1.1). Patients who were receiving ARVs contributed a total of 3220 paired 
HIV RNA measurements to this analysis. In the resistance tests associated with these HIV 
RNA pairs, there were 1678 (52%) with primary PI mutations, 1480 (46%) with NNRTI 
mutations and 2700 (84%) with NRTI mutations. The equivalent numbers of patients who 
were off ARVs and had a virus containing these mutations were 59 (4%), 64 (4%) and 124 
(8%), respectively. In patients who were using ARVs there were 742 (23%) isolates with 
an NNRTI mutation but no primary PI mutation and 940 (29%) isolates with a primary PI 
mutation but no NNRTI mutation. In contrast, there were only 47 (3%) isolates with an 
NNRTI mutation but no primary PI mutation and 42 (3%) with a primary PI mutation but no 
NNRTI mutation in patients who were off ARVs.
The median (IQR) length of time between the first HIV RNA measurement and the second 
HIV RNA measurement was 13 (10 to 17) weeks; this did not differ according to whether 
the patient was on or off ARVs. In patients on ARVs the median (IQR) HIV RNA at the 
start of the episode was 3.93 (3.39 to 4.54) log10 cps/mL with a median increase of 0.08 (- 
0.19 to 0.40) log10 cps/mL during the interval between HIV RNA measurements. In 
patients off ARVs, the median (IQR) viral load at the start of the episode was 4.74 (4.24 to 
5.15) log10 cps/mL with a median increase of 0.06 (-0.20 to 0.32) log10 cps/mL during the 
interval between HIV RNA measurements.
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Figure 7.4.1.1: Patient flow
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* Patients can be classified as being On ARVs AND being Off ARVs if they have paired HIV RNA measurements and an equivalent resistance 
test while they are receiving ARVs and also at a time when they are off ARVs
Table 7.4.1.1: Characteristics of patients at the start of the HIV RNA pair
On ARVs
N=3220
Off ARVs
N=1592
Length of the interval between HIV RNA measurements (weeks): 13 (10, 17) 13 (11, 17)
First CD4+T cell count of the pair (cells/pL): 274 (168,410) 303 (217,410)
Second CD4+T cell count of the pair (cells/pL): 269 (160,404) 279 (189,384)
Change in CD4+T cell counts between the paired values (cells/pL): -7 (-50,38) -22 (-78,28)
First HIV RNA of the pair (log10 cps/mL): 3.93 (3.39,4.54) 4.74 (4.24,5.15)
Second HIV RNA of the pair (log10 cps/mL): 4.04 (3.53,4.63) 4.78 (4.27,5.23)
Change in HIV RNA levels between paired values (log10 cps/mL): 0.08 (-0.19,0.40) 0.06 (-0.20,0.32)
First HIV RNA of the pair below the HIV RNA set point1: 
Number (%)
826 (77.8%) 
(N=1062)
861 (62.1%) 
(N=1386)
Time between resistance test and first HIV RNA of the pair (weeks): 8.0 (0.3, 13.1) 
weeks after start
4.0 (0.0, 13.1) 
weeks after start
Mutation category2: Number (%)
On Pl/r3, PI mutations*
On Pl/r3, no PI mutations*
On PI, PI mutations*
On PI, no PI mutations*
On NNRTI, NNRTI mutations*
On NNRTI, no NNRTI mutations*
On PI & NNRTI, mutations to both*
On PI & NNRTI, mutations to 1 drug or no mutations* 
On NRTIs only, NRTI mutations 
On NRTIs only, no NRTI mutations
426(13.2%) 
184(5.7%) 
704 (21.9%) 
292 (9.1%) 
698 (21.7%) 
142 (4.4%) 
278 (8.6%) 
113 (3.5%) 
326(10.1%) 
57 (1.8%)
NRTI mutations present: Number Y (%) 2700 (83.8%) 124(7.8%)
NNRTI mutations present: Number Y (%) 1480 (46.0%) 64 (4.0%)
Primary PI mutations present: Number Y (%) 1678 (52.1%) 59 (3.7%)
Genotypic Sensitivity Score (GSS4, Stanford): Median (IQR) 1.0 (0.5, 2.0) -
Number of ARVs used: Median (IQR) 3 (3,4) -
ARVs used: Number (%) 
Pis
NNRTIs 
NNRTIs + Pis 
NRTIs only
1606 (49.9%) 
840 (26.1%) 
391 (12.1%) 
383 (11.9%)
-
AZT used: Number Y (%) 1016(31.6%) -
’The viral load set-point is defined as the last HIV RNA recording before commencing cART;
2Refers to any major mutation as defined in the IAS-USA 2006 tables233; 3PI/r: ritonavir-boosted PI; 
4GSS: Calculated using the Stanford 4.2.6 Dec 12 2006 interpretation system; * These groups also 
contain patients receiving NRTIs and patients with NRTI mutations
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7.4.2. CD4+ T cell count changes according to the use of ARVs
Overall, the median (IQR) CD4+T cell count at the start of the episode was 283 (185 to 
410) cells/pL. Patients experienced a median change in CD4+ T cell counts of -10 (-60 to 
34) cells/pL over a median of 13 (10 to 17) weeks. This translates into a monthly CD4+T 
cell count change of -3.4 (-19.3 to 11.3) cells/pL/month (i.e. the mean (95% Cl) of the 
individual CD4+T cell count slopes).
In patients who were on ARVs the median (IQR) CD4+T cell count at the start of the 
interval was 274 (168 to 410) cells/pL and it was 303 (217 to 410) cells/pL for patients who 
were off ARVs. During the interval between CD4+ T cell count measurements, there was a 
median change of -7 (-50 to 38) cells/pL for patients who were on ARVs and -22 (-78 to 
28) cells/pLfor patients who were off ARVs. As expected, less pronounced declines (i.e. 
less of a decline in CD4+ T cell counts) were seen in patients who were receiving 
treatment. From an unadjusted regression model, patients who were off ARVs had a 
mean (95% Cl) 4.48 (2.24 to 6.73) cells/pL greater CD4+T cell count decline per month 
compared to those who were on ARVs, p<0.0001. After adjustment for the time between 
the first HIV RNA measurement of the pair and the resistance test, and also for the HIV 
RNA at the start of the interval, there were still substantial differences in CD4+T cell count 
declines between patients who were on ARVs and those who were off ARVs: mean (95% 
Cl) difference: 5.10 (2.66 to 7.55) cells/pL7month greater CD4+T cell count declines in 
patients who were off ARVs, p<0.0001.
7.4.3. CD4+ T cell count changes, according to the class of mutations
After quantifying the effect of being on ARVs I focussed on patients who were on treatment 
so that I could examine the relationship between mutations and CD4+T cell count 
response in patients who were failing therapy. A test for an interaction between the 
presence of mutations and the use of ARVs for predicting CD4+ T cell count declines 
revealed a marginal effect (p=0.12). This implies that the relationship between mutations 
and immunological response may differ in treated patients compared to patients who are 
off therapy.
When I restricted the analysis to patients who were using ARVs for the duration of the 
interval, the sample size was reduced to 1912 patients. A total of 3220 paired 
measurements satisfied the inclusion criteria, 1960 resistance tests were used on one 
occasion and 630 on two occasions (Figure 7.4.1.1).
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Resistance mutations are generally more prevalent in the virus population of patients who 
are using ARVs. If the presence of certain mutations can be beneficial in patients who are 
failing a cART regimen, it may be worthwhile trying to keep those mutations in the 
dominant viral sub-species by using ARVs that select for those mutations. In patients who 
are off treatment the predominant virus is likely to revert back to wild-type and 
consequently a beneficial effect of the mutations may not be attained.
The mean monthly change in CD4+ T cell counts according to the class of resistance 
mutation and according to the ARV that the patient was using is shown in Table 7.4.3.1 for 
all patients who were receiving ARVs. Patients on NNRTIs had more favourable CD4+T 
cell count changes if they did not have a virus containing an NNRTI-specific mutation. 
Conversely, patients receiving Pis or Pl/rs have more favourable CD4+ T cell count slopes 
if they had a Pl-specific mutation present in their virus.
After adjustment for the time between the first HIV RNA measurement of the pair and the 
resistance test, the genotypic sensitivity score (according to the Stanford interpretation 
system) and the value of the first HIV RNA measurement of the pair, there was little 
evidence for a difference in CD4+T cell count changes according to the IAS-USA 
mutations that were present (Table 7.4.3.1). The adjusted mean (95% Cl) CD4+T cell 
count changes were: -0.7 (-4.4 to 3.0); -3.6 (-9.4 to 2.2); -5.0 (-7.9 to -2.1); and -3.2 (-9.9 
to 3.5) cells/pL/month for patients on Pl/rs with Pl-mutations, on Pl/rs without Pl-mutations, 
on NNRTIs with NNRTI-mutations and on NNRTIs without NNRTI-mutations, respectively, 
p=0.21. Although the global p-value was not significant in this case, patients falling into 
some groups experienced larger CD4+T cell count changes than patients falling into other 
groups. However, these results need to be interpreted with caution due to the issue of 
multiple testing.
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Table 7.4.3.1: CD4+T cell count changes: by class-specific mutations and ARV used
Number (%) Mean CD4 Mean HIV RNA ACD4* T cell Adjusted mean***
count change change count CD4+ T cell count
(N=3220) cells/pWmonth Copies/m L/month cells/pLVmonth change
Mutation category (IAS-USA) (95% Cl) (95% Cl) (95% Cl) relative 
to group 1**
cells/pL/month 
(95% Cl)**
On Pl/r, PI mutations* (group 1) 426 (13.2%) -0.4 (-3.7, 2.9) 0.02 (0.00, 0.04) Ref -0.7 (-4.4, 3.0)
On Pl/r, no PI mutations* 184 (5.7%) -3.7 (-8.8, 1.4) 0.03 (-0.01,0.07) -2.9 (-10.0,4.2) -3.6 (-9.4, 2.2)
On PI, PI mutations* 704 (21.9%) 1.1 (-1.5, 3.6) 0.03 (0.02, 0.05) 1.7 (-2.9, 6.3) 1.0 (-1.9, 3.9)
On PI, no PI mutations* 292 (9.1%) -1.7 (-6.8, 3.3) 0.04 (0.01,0.08) -0.7 (-7.0, 5.5) -1.4 (-6.2, 3.3)
On NNRTI, NNRTI mutations* 698 (21.7%) -5.2 (-8.1,2.3) 0.03 (0.02, 0.05) -4.3 (-8.9, 0.4) -5.0 (-7.9, -2.1)
On NNRTI, no NNRTI mutations* 142 (4.4%) -3.2 (-10.4, 4.0) -0.03 (-0.08, 0.02) -2.5 (-10.4, 5.4) -3.2 (-9.9, 3.5)
On PI & NNRTI, mutations to both* 278 (8.6%) -3.7 (-7.7, 0.2) 0.03 (0.01, 0.05) -3.5 (-9.3, 2.2) -4.2 (-8.9, 0.4)
On PI & NNRTI, muts to 1 class or no muts* 113(3.5%) -5.5 (-11.5, 0.4) 0.02 (-0.02, 0.06) -4.4 (-12.8, 4.0) -5.1 (-12.4,2.2)
On NRTIs only, NRTI mutations 326 (10.1%) -3.4 (-8.7, 1.9) 0.05 (0.03, 0.07) -2.6 (-8.2, 2.9) -3.3 (-7.5, 0.8)
On NRTIs only, no NRTI mutations 57 (1.8%) 1.5 (-7.6, 10.5) -0.06 (-0.15, 0.04) 2.0 (-9.2,13.3) 1.3 (-9.1, 11.7)
* These can also include NRTI mutations
** Adjusted for the time between the first HIV RNA measurement of the pair and the resistance test, the genotypic sensitivity score (according to the 
Stanford interpretation system) and the first HIV RNA measurement of the pair
*** Adjusted means are the predicted values, obtained from a multivariable regression model. Adjusted means were estimated by using the mean values 
of the other covariates in the model (see **)
7.4.3.1. CD4* T cell count changes, including the first CD4* T cell count
I also wanted to quantify the effect of the first CD4+ T cell count of the pair on CD4+ T cell 
count slopes, so I performed a separate multivariable model adjusted for the first CD4+ T 
cell count (Table 7.4.3.1.1). As expected, for every 100 cells/pL higher CD4+T cell count 
there was a 6.02 (5.37 to 6.67) cells/pL/month greater decline in CD4+T cell counts over 
the interval, possibly influenced by regression to the mean404 405. An alternative 
explanation for this trend is that there could be greater variability in the slopes at higher 
CD4+ T cell counts or that the CD4+ T cell count slopes are, in fact, non-linear. Natural 
history studies have shown that CD4+ T cell counts decline approximately exponentially in 
patients who are off-ARVs. Adjusting for the first CD4+ T cell count had a negligible impact 
on the other predictor variables. This variable was excluded from the main model because 
it is highly correlated to CD4+ T cell count slopes and may bias the results looking at the 
relationship between CD4+ T cell count slopes and mutation category.
Table 7.4.3.1.1: CD4+ T cell count changes: adjusted for the first CD4+ T cell count
Unadjusted analysis Multivariable analysis
Variable
ACD4* T cell count 
cells/pL/month P-value 
(95% Cl)
ACD4* T cell count 
cells/pL/month 
(95% Cl)
P-value
First CD4+ T cell count of the pair
(per 100 cells/|iL higher)
-5.44 <0.0001 
(-6.05, -4.83)
-6.02 
(-6.67, -5.37)
<0.0001
First HIV RNA of the pair
(per log10 cps/mL increase)
1.43 0.11 
(-0.31,3.17)
-3.99 <0.0001 
(-5.80,-2.17)
Time between resistance test and 
the first HIV RNA of the pair
(per week longer)
0.14 0.14 
(-0.05, 0.32)
J
0.16 0.08 
(-0.02, 0.33)
Mutation category (IAS-USA):
On Pl/r, PI mutations 
On Pl/r, no PI mutations 
On PI, PI mutations 
On PI, no PI mutations 
On NNRTI, NNRTI mutations 
On NNRTI, no NNRTI mutations 
On PI & NNRTI, mutations to both 
On PI & NNRTI, muts to 1 or no drugs 
On NRTIs only, NRTI mutations 
On NRTIs only, no NRTI mutations
Ref
-3.29 (-9.90,3.33) 
1.45 (-3.16,6.05) 
-1.35 (-7.05, 4.34) 
-4.79 (-9.40,-0.18) 
-2.82 (-10.09,4.44) 
-3.33 (-9.11,2.45) 
-5.14 (-13.08, 2.80) 
-3.05 (-8.57,2.46) 
1.85 (-8.73,12.42)
0.17 Ref
-4.05 (-10.91,2.82) 
0.86 (-3.54,5.27) 
-0.71 (-6.71,5.30) 
-3.65 (-8.09,0.78) 
-0.44 (-8.17,7.29) 
-4.53 (-10.04,0.98) 
-4.35 (-12.44, 3.74) 
-3.02 (-8.31,2.26) 
3.69 (-7.30, 14.67)
0.24
GSS score (Stanford v.4.2.6):
0-0.5
1-2 
>2
Ref
1.57 (-1.34,4.49) 
-1.97 (-5.77, 1.83)
0.17 Ref
1.39 (-1.53,4.31) 
I -4.48 (-9.61,0.64)
0.04
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7.4.3.2. Residual drug activity
I investigated HIV RNA changes within each of the mutation groups to assess whether the 
trend towards a benefit of harbouring a PI mutation was due to residual activity of the Pl(/r) 
(i.e. despite the presence of mutations the drug is still partially active). If residual activity is 
an explanation for why these differences are occurring, it is likely to be reflected in the viral 
load changes before impacting on CD4+T cell count declines. Or instead, viral load 
changes could also be a result of the mechanism by which the mutations lead to more 
favourable CD4+ T cell count declines. Patients in the majority of strata experienced 
similar HIV RNA increases, but patients who were using NNRTIs and did not have any 
NNRTI mutations in their virus experienced marginal HIV RNA declines (Table 7.4.3.1).
To further assess the relationship between residual activity of the Pl(/r) and CD4+T cell 
count changes, I fit a model looking at CD4+ T cell count slopes according to whether the 
patient was on a Pl(/r) (or not) and according to whether a PI mutation was present in the 
virus (or not). In unadjusted analyses, patients in whom a PI mutation was detected in 
their virus had a 2.54 (-0.11 to 5.18) cells/pL/month smaller decline in CD4+T cell counts 
compared to those who had a virus in which a PI mutation was not detected, p=0.06.
Being on a Pl(/r) was associated with a 3.04 (0.32 to 5.77) cells/pLVmonth smaller decline 
in CD4+T cell counts compared to those not on a Pl(/r), p=0.03. In a model that included 
both of these variables, the presence of a PI mutation was associated with a 1.41 (-1.65 to 
4.47) cells/pLVmonth smaller decline in CD4+T cell counts (p=0.37), and being on a Pl(/r) 
was associated with a 2.32 (-0.83 to 5.47) cells/pL/month smaller decline in CD4+ T cell 
counts, (p=0.15), compared to patients who had a virus in which a PI mutation was not 
detected and patients who were not on a PI, respectively.
To assess residual activity in patients on Pl/rs in more detail, I re-categorised the number 
of PI mutations into i) no primary PI mutations; ii) one to three primary PI mutations and iii) 
£ four primary PI mutations. If residual drug activity is an explanation for why there is a 
beneficial effect of retaining PI mutations in patients who are failing a PI containing 
regimen I would expect to see the smallest CD4+ T cell count declines in patients falling 
into group ii (i.e. patients with a virus containing one to three primary PI mutations) and the 
largest declines in patients who have a virus containing £ four primary PI mutations.
In patients who were receiving Pis (either in the boosted or unboosted form) there was a
1.39 (-3.23 to 6.01) cells/pLVmonth smaller CD4+T cell count decline in patients with one to 
three primary PI mutations and a 3.83 (-3.17 to 10.82) cells/pLVmonth greater CD4+T cell
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decline in patients with £ four primary PI mutations compared to patients with no primary 
PI mutations; albeit these differences did not reach statistical significance.
I then examined the relationship between the number of mutations to each drug class and 
CD4+ T cell count slopes to see whether there was a linear relationship or whether 
individual mutations need to be accounted for separately. The relationship between CD4+ 
T cell count slopes and the number of NNRTI mutations was linear: there was a 1.86 (0.31 
to 3.41) cells/pL/month, p=0.02, greater CD4+T cell count decline for each additional 
NNRTI mutation, after adjustment.
The relationship between the number of PI mutations and CD4+ T cell count slopes was 
not linear. By examining the data in more detail, patients with a virus containing one or 
two primary PI mutations experience the smallest CD4+ T cell count declines but once >2 
mutations have emerged there appears to be an increasing negative effect of 
accumulating PI mutations: the more PI mutations that emerge, the greater the decrease 
in CD4+ T cell counts.
7.4.4. CD4+ T cell count changes according to specific mutations
To investigate whether the presence of any specific mutation has a greater impact on 
CD4+ T cell count slopes compared to any other mutation I used separate models to 
examine the IAS-USA mutations that occurred in > 5% of resistance tests overall (i.e. not 
specifically in patients who received drugs that select for those mutations). These 
analyses were also adjusted for the time between the first HIV RNA measurement of the 
pair and the resistance test, the genotypic sensitivity score (according to the Stanford 
interpretation system) and the value of the first HIV RNA measurement.
The presence of any NNRTI-specific mutation was associated with a greater CD4+T cell 
count decline and the presence of most Pl-specific mutations were associated with a 
smaller CD4+ T cell count decline, although most of the comparisons did not reach 
statistical significance. In separate models, the presence of K103N and Y181C in the RT 
gene were associated with a mean (95% Cl) 2.96 (-0.16 to 6.09), p=0.06, and 4.48 (0.74 to 
8.23), p=0.02, cells/pL/month greater CD4+T cell count decline compared to viruses 
without either mutation, respectively. No PI or NRTI mutation alone was associated with 
CD4+T cell count changes (Table 7.4.4.1). Of note, these could be chance findings due to 
multiple testing. In patients who were off ARVs, the presence of K103N and Y181C was 
associated with a mean (95% Cl) 0.71 (-11.00 to 12.42), p=0.91, and 9.41 (-9.29 to 28.11),
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p=0.32, cells/pL/month smaller CD4+ T cell count reduction compared to viruses without 
either mutation, respectively.
Table 7.4.4.1: CD4+T cell count changes: according to specific mutations
ACD4* T cell count for presence 
vs absence of each mutation 
cells/pL/month (9 5% Cl)
P-value
Specific IAS-USA mutations *
NRTI mutations: M41L -0.32 (-3.33,2.69) 0.84
D67N -0.18 (-3.19,2.83) 0.91
K70R -1.21 (-4.36,1.94) 0.45
L74V -1.45 (-6.05,3.16) 0.54
M184V 0.16 (-2.80,3.11) 0.92
M184I/V* -0.13 (-3.12,2.85) 0.93
L210W 0.78 (-2.40,3.96) 0.63
T215Y 0.73 (-2.22,3.68) 0.63
T215F -2.08 (-6.13, 1.96) 0.31
T215Y/F* -0.10 (-3.26, 3.06) 0.95
K219Q -1.84 (-5.84,2.16) 0.37
K219E -1.08 (-5.65,3.49) 0.64
K219E/Q* -1.04 (-4.37,2.28) 0.54
NNRTI mutations: K103N -2.96 (-6.09,0.16) 0.06
Y181C -4.48 (-8.23,-0.74) 0.02
Y181C/I* -4.16 (-7.86,-0.46) 0.03
G190A -1.93 (-5.98,2.12) 0.35
G190A/S* -2.00 (-5.84,1.84) 0.31
PI mutations: M46I 0.86 (-2.78,4.51) 0.64
M46L 3.01 (-1.77,7.79) 0.22
M46I/L* 1.86 (-1.38,5.10) 0.26
V82A 1.55 (-2.01,5.12) 0.39
V82A/F/L/T/S* 0.99 (-2.29,4.28) 0.55
I84V -0.43 (-4.49,3.64) 0.84
L90M -0.53 (-3.64,2.57) 0.74
* Occurring in >5% of the population overall; Mutations in bold indicate the presence of one or the 
other mutation in the virus population. For example, the M184I/V mutation is recorded as being 
present if either 184I or 184V is indentified in the predominant virus at the time of the test.
7.4.5. Sensitivity analysis
7.4.5.1. The extent of viral load suppression
Data from the PLATO collaboration showed an association between the extent of viral load 
reduction from the pre-ART value with the CD4+ T cell count slopes. The pre-ART HIV 
RNA level indicates the maximum level of viral replication for each patient in the absence 
of ARVs and generally in the absence of resistance mutations (although some patients
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may have primary resistance). Therefore, the extent of suppression from this value will 
enable us to assess the effect that prior treatment had on the overall decline in replication 
rates and its subsequent effect on CD4+T cell count slopes.
I repeated the above analysis on the 1062 CD4+T cell count pairs for which the viral load 
reduction from the pre-ART value was known. In our comparisons the extent of viral load 
reduction from the pre-ART value was not a significant predictor of CD4+ T cell count 
slopes (Table 7.4.5.1.1).
Table 7.4.5.1.1: CD4+T cell count changes: patients with a pre-ART HIV RNA value
Unadjusted analysis Multivariable analysis
Variable
ACD4+T cell count 
cells/pU/month 
(95% CQ
P-value
ACD4* T cell count 
cells/pL/month 
(95% CO
P-value
HIV RNA change from pre-ART value
(for every log10 cps/mL greater reduction)
-1.28 
(-3.21, 0.65)
0.19 0.21 
(-2.12, 2.55)
0.86
First CD4+T cell count of the pair
(per 100 cells/pL higher)
-5.70 
(-6.76, -4.63)
<0.0001 -6.37 
(-7.50, -5.24)
<0.0001
First HIV RNA of the pair
(per log10 cps/mL increase)
2.28 
(-0.69, 5.25)
0.13 -1.55 
(-5.33, 2.22)
0.42
Time between resistance test and the 
first HIV RNA measurement of the pair
(per week longer)
0.11
(-0.21,0.44)
0.50 0.10 
(-0.21, 0.40)
0.54
Mutation category (IAS-USA):
On Pl/r, PI mutations 
On Pl/r, no PI mutations 
On PI, PI mutations 
On PI, no PI mutations 
On NNRTI, NNRTI mutations 
On NNRTI, no NNRTI mutations 
On PI & NNRTI, mutations to both 
On PI & NNRTI, mut to 1 or no drugs 
On NRTIs only, NRTI mutations 
On NRTIs only, no NRTI mutations
Ref
-2.73 (-14.66,9.20) 
3.77 (-6.38, 13.92) 
-3.04 (-14.17, 8.09) 
-4.86 (-14.11,4.40) 
-5.64 (-18.01,6.74) 
1.59 (-11.64,14.83) 
-4.31 (-18.53,9.92) 
-2.69 (-13.89,8.51) 
-3.31 (-20.10, 13.47)
0.62 Ref
-3.50 (-15.60,8.61) 
2.36 (-7.24, 11.97) 
0.37 (-10.81, 11.54) 
-8.05 (-16.83,0.73) 
-2.99 (-15.53,9.55) 
-3.94 (-16.55,8.66) 
-1.13 (-15.78, 13.51) 
-8.51 (-19.14,2.13) 
-1.98 (-19.36, 15.41)
0.18
GSS score (Stanford v.4.2.6):
0-0.5
1-2 
>2
Ref
4.06 (-1.39,9.51) 
-4.13 (-10.66,2.41)
0.02 Ref
3.50 (-1.91,8.92) 
-10.35 (-19.26,-1.43)
0.001
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7.4.5.2. Patients with minimal HIV RNA changes
Viral load changes in the interval between HIV RNA measurements are likely to influence 
CD4+T cell count slopes. To quantify the effect of mutations on CD4+T cell count slopes 
without interference from patients who experience large HIV RNA changes, I repeated the 
analysis on patients who experienced minimal viral load changes (i.e. AHIV RNA <0.25 
log10 cps/mL during the interval between HIV RNA measurements). In the 1374 (42.7%) 
paired observations satisfying these criteria, the median (IQR) CD4+T cell count at the 
start of the episode was 275 (173 to 410) cells/pL and patients experienced a CD4+T cell 
count change of -2.0 (-15.6 to 13.0) cells/pL/month. So, overall the CD4+T cell count 
changes were marginally more favourable in this subgroup.
In both patients who received Pl/rs and those who received NNRTIs, patients with a virus 
that harboured resistance mutations had greater CD4+T cell count declines than patients 
who had a virus that did not. CD4+ T cell count increases were observed in both patients 
receiving a Pl/r or an NNRTI instead of the CD4+T cell count declines that were seen in 
section 7.4.3. Since, in the main analysis, the major differences in CD4+T cell count 
slopes were seen between patients who had a virus containing a mutation compared to 
those who had a virus that did not contain a mutation if they were receiving a Pl/r or an 
NNRTI (Table 7.4.3.1 and Table 7.4.3.1.1), I will report the results for patients falling into 
these groups in these sensitivity analyses. The adjusted mean (95% Cl) CD4+ T cell count 
changes were: 0.28 (-8.49 to 9.05); 0.45 (-10.49 to 11.38); 4.63 (-1.54 to 10.80); and 7.18 
(-4.39 to 18.75) cells/pL/month for patients on Pl/rs with Pl-mutations, on Pl/rs without Pl- 
mutations, on NNRTIs with NNRTI-mutations and on NNRTIs without NNRTI-mutations, 
respectively, for these 1374 patients.
7.4.5.3. Patients with high levels of viral replication
Since the effect of a specific mutation may be stronger in patients who are virologically 
failing their treatment regimen with high levels of viral replication I restricted the analysis to 
patients who had a high viral load (i.e. HIV RNA >10000 cps/mL) at both the start and the 
end of the interval. Even though the sample size was reduced down to 1249 (38.8%), the 
estimated benefit from retaining PI mutations was similar to the analysis in 7.4.3. In this 
subgroup analysis, the median (IQR) CD4+T cell count at the start of the episode was 210 
(114 to 322) cells/pL and patients experienced a CD4+T cell count change of -2.7 (-15.1 to 
8.7) cells/pL/month.
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The adjusted mean (95% Cl) CD4+T cell count changes were: -2.63 (-7.67, 2.41); -3.71 (- 
10.95, 3.52); -6.25 (-11.31, -1.18); and -1.88 (-10.52, 6.76) cells/plVmonth for patients on 
Pl/rs with Pl-mutations, on Pl/rs without Pl-mutations, on NNRTIs with NNRTI-mutations 
and on NNRTIs without NNRTI-mutations, respectively.
7.4.5.4. The time between the resistance test and the HIV RNA interval
The entry criteria for all of the patients studied so far (section 7.3.1) includes patients with 
a resistance test performed in the four weeks after the viral load pair as well as patients 
with a resistance test in the four weeks prior to the viral load pair. As a result, mutations 
identified during the test may not have been present during the interval between HIV RNA 
measurements, but may have appeared afterwards. I restricted the analysis to patients 
who had a resistance test taken before the end of the viral load interval in order to reduce 
the possibility of reverse causality between mutation emergence and CD4+ T cell count 
slopes. In addition, removal of the 602 paired HIV RNA intervals in which the resistance 
test was performed after the end of the viral load pair excludes all patients who may have 
started another regimen prior to their resistance test.
The total numbers of paired measurements satisfying these criteria were 2618. The 
median (IQR) CD4+ T cell count at the start of the episode was 276 (169 to 410) cells/pL 
and patients experienced a CD4+T cell count change of -1.7 (-16.2 to 12.6) 
cells/pL/month. The adjusted mean (95% Cl) CD4+ T cell count changes were: 0.86 (-3.24 
to 4.97); -3.34 (-9.68 to 3.00); -5.43 (-8.66 to -2.20); and 1.73 (-5.53 to 8.99) 
cells/pLVmonth for patients on Pl/rs with Pl-mutations, on Pl/rs without Pl-mutations, on 
NNRTIs with NNRTI-mutations and on NNRTIs without NNRTI-mutations, respectively.
7.4.5.5. Exclusion of non adherent patients
Patients who are not adherent to the ARVs in their regimen will have limited exposure to 
therapy. These patients are likely to have a virus that is deemed to be susceptible to the 
ARVs in their regimen because their virus is unlikely to contain many mutations. To 
exclude these non adherent patients, and to see whether clearer differences can be seen 
in adherent patients with limited treatment options available, I restricted the analysis to 
patients with a GSS <1 (N=1267). In these patients, the median (IQR) CD4+T cell count at 
the start of the episode was 210 (114 to 322) cells/pL and patients experienced a CD4+T 
cell count change of -2.65 (-15.09 to 8.71) cells/pLVmonth.
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Table 7.4.5.5.1 shows there are stronger differences in CD4+T cell count slopes between 
patients who are receiving Pis and have a virus containing PI mutations compared to 
patients who have a virus that does not contain such mutations. In the main analysis on 
the whole group of patients, there was a 2.9 (-4.2 to 10.0) cells/pL greater decline in CD4+ 
T cell counts for patients who received a Pl/r and did not have a virus containing a Pl- 
resistance mutation compared to those on a Pl/r who had a virus containing a PI 
resistance mutation. In this subgroup analysis, there was an 18.3 (-4.9 to 41.4) cells/pL 
greater decline in CD4+ T cell counts for patients who received a Pl/r and did not have a 
virus containing a Pl-resistance mutation compared to those on a Pl/r who had a virus 
containing a PI resistance mutation. However, numbers are small in this subgroup 
analysis and no significant differences between mutational categories were observed.
Table 7.4.5.5.1: CD4+T cell count changes: patients with a GSS <1 (N=1267)
Unadjusted analysis Multivariable analysis
Variable
ACD4+T cell count 
cells/pLymonth j P-value 
(95% Cl)
ACD4+T cell count 
cells/pL/month 
(95% Cl)
P-value
First CD4* T cell count of the pair
(per 100 cells/pL higher)
-4.46 <0.0001 
(-5.39, -3.53) !
-5.40 
(-6.40, -4.40)
<0.0001
HIV RNA at start of interval
(per log10 cps/mL increase)
-1.18 0.42 
(-4.07,1.71)
-7.44 ! <0.0001
I
(-10.54,-4.34)
Time between resistance test and 
first HIV RNA measurement of the 
pair (per week longer)
0.16 0.24 
(-0.11,0.44)
I
0.18 0.18 
(-0.08,0.45) ]
|
Mutation category (IAS-USA):
On Pl/r, PI mutations 
On Pl/r, no PI mutations 
On PI, PI mutations 
On PI, no PI mutations 
On NNRTI, NNRTI mutations 
On NNRTI, no NNRTI mutations 
On PI & NNRTI, mutations to both 
On PI & NNRTI, muts to 1 or no drugs 
On NRTIs only, NRTI mutations 
On NRTIs only, no NRTI mutations
|
Ref 0.55 
-11.15 (-35.13, 12.84)
-0.12 (-6.02,5.78) i 
27.16 (-43.70, 98.01) !
-4.57 (-10.46, 1.32) j 
4.93 (-30.70,40.57)
-3.26 (-10.10,3.58)
-35.18 (-85.38, 15.02) j 
-3.58 (-10.93,3.77)
Ref
-18.26 (-41.37,4.86) 
0.49 (-5.65,6.63) 
18.48 (-49.54, 86.49) 
-3.08 (-9.55,3.38) 
-0.89 (-35.18,33.39) 
-3.51 (-10.53,3.51) 
-37.78 (-85.99, 10.44) 
-1.99 (-9.42,5.44)
................ '
0.48
7.4.S.6. Generalised linear models with generalised estimating equations
Some of the patients in these comparisons contribute more than one paired HIV RNA 
interval to the regression models. To take into account these repeated measurements I 
examined the data using generalized linear models (GLMs) with generalized estimating
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equations. In the initial GLM performed on these data, the resulting scale parameter was 
unstable because of a negative correlation structure associated with the data. This is 
because it is possible for successive CD4+ T cell count pairs to use the same CD4+ T cell 
count (i.e. the last CD4+T cell count measurement in the pair may be the first value in the 
subsequent pair). As a result it was not possible to fit generalised estimating equations to 
the whole dataset. Instead, I re-ran the analysis using generalized estimating equations, 
but with viral load pairs restricted to be at least a year apart. This ensured there was a 
positive correlation structure. Patients who were receiving Pl(/r)s and had a virus 
containing PI mutations had more favourable CD4+ T cell count slopes than those who 
were receiving NNRTIs, irrespective of whether mutations to NNRTIs were present (Table 
7.4.5.6.1).
Table 7.4.5.6.1: CD4+T cell count changes: generalised linear models 
Including repeated measures on an individual if they occur >1 year apart, N=2248
Mutation category (IAS-USA)
ACD4* T cell count change 
cells/pL/month (95% Cl) 
relative to group 1
Adjusted mean CD4+ T 
cell count change 
cells/pL/month 
(95% Cl)
On Pl/r, PI mutations (group 1) Ref -0.4 (-4.6, 3.8)
On Pl/r, no PI mutations -3.3 (-10.5, 4.0) -3.7 (-9.6, 2.2)
On PI, PI mutations 0.5 (-4.8, 5.9) 0.1 (-3.2, 3.4)
On PI, no PI mutations -2.1 (-8.6, 4.3) -2.6 (-7.4, 2.3)
On NNRTI, NNRTI mutations -5.6 (-10.9, -0.3) -6.0 (-9.2, -2.8)
On NNRTI, no NNRTI mutations -7.5 (-15.6, 0.6) -7.9 (-14.9, 1.0)
On PI & NNRTI, mutations to both -3.9 (-10.8, 3.0) -4.3 (-9.9, 1.2)
On PI & NNRTI, muts to 1 class or no muts -6.9 (-15.8, 2.0) -7.3 (-15.2, 0.5)
On NRTIs only, NRTI mutations -2.0 (-8.4, 4.5) 2.4 (-7.3, 2.5)
On NRTIs only, no NRTI mutations -0.4 (-11.9, 11.2) -0.8 (-11.5, 9.9)
7.5. Discussion
7.5.1. Summary of main results
Although drug resistant HIV RNA can adversely impact on the virological and clinical 
outcomes of HIV infected individuals1961348,349, the presence of certain mutations could be 
beneficial in patients who have no treatment options available to them279:403:406:407. In this 
chapter I investigated the numbers of mutations, the class of mutation, and the prevalence 
of individual mutations in patients who had continuously high levels of viral replication. I 
did not identify any clear differences in CD4+T cell count slopes for a given viral load level
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(or for a given viral load change from the pre-ART value) according to the presence of 
resistance mutations.
There were noticeable differences in CD4+ T cell count declines for patients who were on 
ARVs compared to patients who were off ARVs: with patients off ARVs experiencing a 5.1 
(2.7, 7.6) cells/pL greater CD4+ T cell count decline per month compared to patients who 
were on ARVs. The association between being off treatment and greater declines in CD4+ 
T cell counts is in keeping with previous findings1541408. To see whether this could be 
attributed to the presence of resistance mutations I investigated CD4+ T cell count slopes 
in the subgroup of patients who were on treatment. In this group, patients who were 
receiving NNRTIs had greater CD4+T cell count declines if NNRTI mutations were present 
in their virus and patients who were receiving Pl(/r)s had smaller CD4+T cell count 
declines if PI mutations were present in their virus; albeit these trends did not reach 
statistical significance. These patterns are expected based on the reported small impact 
of common NNRTI resistance mutations such as K103N on viral fitness. On the other 
hand, PI resistance mutations have been associated with a reduced viral fitness (at least 
until compensatory mutations emerge), so if they are present in the virus they may benefit 
the patient immunologically and virologically28* 409* 10.
7.5.2. Interpretation of results
Investigation into the relationship between the numbers of PI mutations and the CD4+T 
cell count slopes revealed a V-shaped relationship instead of a linear one. When I 
categorised patients according to the number of PI mutations that were present in their 
virus, patients had more favourable CD4+ T cell count declines when a single mutation or 
two PI mutations were present. Patients who had more than two primary PI mutations in 
their virus experienced the greatest CD4+ T cell count declines, possibly indicating a cut-off 
level for the benefit of harbouring PI mutations related to the emergence of compensatory 
mutations.
Alternatively, there could be more residual activity of the Pl(/r) when fewer mutations are 
present, and the high CD4+ T cell count declines that are seen in patients who have no 
mutations in their virus could possibly be due to poor adherence. The V-shaped 
relationship between the numbers of PI mutations and the CD4+ T cell count slopes is 
likely to be due to one or both of the residual activity of the PI and reduced fitness of 
viruses containing certain mutations, as has been previously demonstrated411"414.
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Since I have not been able to distinguish between residual activity of the PI and reduced 
fitness of viruses containing certain mutations, studies that investigate partial treatment 
interruption can help to distinguish between residual drug-activity (i.e. if HIV RNA changes 
are seen as soon as the drug is interrupted) versus reduced viral fitness as a result of the 
mutations that are in the virus (i.e. HIV RNA changes are only seen when mutations to the 
drug disappear). It is likely that residual drug activity is the primary explanation for the 
trends in this chapter because I have been unable to identify a clear effect of any class of 
mutation resulting in a reduced fitness of the virus.
In patients on an NNRTI containing regimen, the relationship between the number of 
NNRTI mutations and CD4+T cell count changes appears to be linear, with a 1.86 (0.31 to 
3.41) cells/pLVmonth greater decline in CD4+T cell counts for each additional NNRTI 
mutation. When I investigated frequently occurring mutations for all patients who were 
receiving ARVs, the only mutations, from any of the drug classes, associated with CD4+ T 
cell count slopes were K103N and Y181C. After adjustment for HIV RNA level at the start 
of the interval, the separate presence of K103N and Y181C was associated with a mean 
(95% Cl) 2.96 (-0.16 to 6.09), p=0.06, and 4.48 (0.74 to 8.23), p=0.02, cells/pUmonth 
greater CD4+T cell count decline compared to viruses without either mutation, 
respectively. This is consistent with the high fitness of the K103N and Y181C mutants that 
has been reported by others415-417. No residual activity or beneficial impact on viral fitness 
has been previously observed with resistance to NNRTIs416 418. In patients who were off 
ARVs, the presence of K103N and Y181C was associated with a mean (95% Cl) 0.71 (-
11.00 to 12.42), p=0.91, and 9.41 (-9.29 to 28.11), p=0.32, cells/pLVmonth smaller CD4+ T 
cell count reduction compared to patients in whom either mutation could not be detected, 
respectively.
7.5.3. Clinical interpretation
In this study, patients who were receiving an NNRTI, in whom an NNRTI mutation was 
detected in their predominant virus, experienced larger CD4+ T cell count reductions 
compared to patients with a virus that did not show any NNRTI mutations. Consequently, 
these patients may perform clinically worse over the long term. Of note, there were only 
142 patients who were on a virologically failing NNRTI-containing regimen who did not 
have an NNRTI mutation present in their virus. The reasons for this are unknown. Since it 
could be harmful to keep patients on a virologically failing NNRTI containing regimen it 
may be better to switch them to a PI containing regimen or reduce to an NRTI containing 
regimen if they cannot tolerate the toxicities associated with Pis419-421. This analysis has
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shown that patients who receive NRTIs, without a PI or NNRTI anchor drug, experience 
similar CD4+T cell count declines to patients who receive NNRTIs and NRTIs together. 
Even though all patients are receiving a virologically failing regimen they still benefit from 
remaining on treatment. As illustrated in this study, and as previously demonstrated, 
patients off ARVs do immunologically worse than patients who are receiving therapy154. Of 
note, patients who are off ARVs in this analysis have a mean (95% Cl) 2.12 (-0.66 to 
4.90), p=0.14, and 5.94 (3.48 to 8.41), p<0.0001, cells/pL/month greater CD4+T cell count 
declines than patients receiving NNRTIs and patients receiving a non NNRTI-containing 
regimen, respectively.
It is hard to quantify the sequential relationships between CD4+T cell count changes, viral 
load levels and individual mutations due to the timing of these measurements in these 
studies. The presence of certain mutations may have had an effect on CD4+ T cell counts 
prior to the interval covered by the pair because some mutations may already be present 
in the virus before the first CD4+ T cell count was taken. In an attempt to account for the 
impact of resistance on CD4+T cell counts just prior to the interval between HIV RNA 
measurements I adjusted for the first CD4+T cell count of the pair in a separate model, but 
not in the main model due to the influence of regression to the mean404,405. Similar results 
were found in this analysis. Exclusion of patients who had their resistance tests taken 
after the CD4+ T cell count pair served to confirm our findings, but the impact of the 
mutations on the absolute CD4+ T cell counts prior to treatment is still partially 
unaccounted for. If the presence of a mutation reduces the CD4+ T cell counts prior to the 
pair then these patients will start with a lower CD4+ T cell count and will have less scope 
for decline.
In the current era, with new drugs becoming available, it is unlikely that patients will be 
maintained on a virologically failing regimen for long. It is more probable that clinicians will 
switch some, or all, of the drugs in the regimen in the case of falling CD4+T cell counts. 
However, patients may still be maintained on the failing regimen if CD4+ T cell counts are 
stable, or if they start to increase. More data is required to assess whether the presence 
of mutations in the virus population has a virological or immunological impact in patients 
who are virologically failing their treatment regimen.
All of the analyses in this chapter have been adjusted for the HIV RNA at the start of the 
interval in an attempt to account for the initial impact of viral replication on CD4+ T cell 
count slopes. Even though adjustments have been performed, they do not fully capture
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the noise generated through patients experiencing large HIV RNA changes during the 
interval between HIV RNA measurements. In a subgroup analysis of patients with stable 
viral loads (i.e. AHIV RNA <0.25 log10 cps/mL), minor CD4+T cell count increases were 
seen among patients on Pis and also among patients on NNRTIs. Even though these 
patients had similar HIV RNA levels and CD4+T cell counts at the start of the interval to 
patients in the main analysis, they still experienced more favourable CD4+ T cell count 
declines. Since these patients have more stable viral replication, their CD4+T cell counts 
are not likely to decline as much as in patients in the main analysis.
In a sensitivity analysis, I did not find the extent of viral load suppression from the pre-ART 
value to predict CD4+ T cell count change, which is in contrast to the results published by 
the PLATO collaboration154. Most patients in PLATO started antiretroviral therapy with 
single or dual therapy, had a higher HIV RNA at the start of the interval, a higher pre-ART 
HIV RNA and a lower CD4+ T cell count at the start of the interval, so they had less scope 
for large CD4+ T cell count reductions compared to patients in our study. In fact, CD4+ T 
cell count increases were seen over time in the PLATO population instead of the CD4+ T 
cell count declines seen in this analysis because their analysis was also restricted to 
patients experiencing minimal HIV RNA changes (i.e. AHIV RNA <0.3 log10 cps/mL). In 
PLATO, the level of decline in viral replication from the pre-ART value is a strong 
indication of further CD4+T cell count deterioration, but PLATO patients have truly 
exhausted all of their treatment options and are more severely immunocompromised than 
patients in our study. Patients in our study are failing their cART regimen, but at a lower 
HIV RNA and with fairly low levels of mutation emergence. The combination of residual 
drug activity and a reduced fitness of viruses containing certain mutations might play a 
stronger role in our study because our patients have greater, albeit still limited, 
susceptibility to the drugs they are receiving.
In patients with few treatment options available (i.e. a GSS <1) the magnitude of the effect 
size comparing CD4+T cell count slopes between patients on a Pl(/r) who have a virus 
containing PI mutations, compared to those on a Pl(/r) who do not have a virus containing 
a primary PI resistance mutations, was greater than that seen in the main analysis (section 
7.4.3). This could be partly due to the way GISs ascribe resistance levels. As discussed 
previously (see chapter 4 and chapter 5) GISs do not capture viral sensitivity precisely; 
there are differences between systems in how resistant the virus is deemed to be and so 
these GISs may not reliably judge how effective the whole regimen is. As a result some 
patients may be classified as having a GSS<1, whereas in fact they had a virus that was
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susceptible to more drugs in their regimen. Residual drug activity is likely to be weaker in 
this population than in the main analysis because these patients will have a virus 
containing more mutations and so the drugs should have even less activity, but greater 
differences were observed between patients with and without PI mutations in this 
subgroup.
The exclusion of patients who had resistance tests taken after the viral load pair and the 
use of generalised linear models with generalised estimating equations confirmed our 
findings of a difference in CD4+T cell count slopes in patients who were using Pl(/r)s and 
had Pl-specific mutations compared to patients who did not. Overall, however, there were 
no remarkable differences in CD4+ T cell count slopes for a given viral load according to 
the presence of resistance mutations.
7.5.4. Limitations of the analysis
Our analysis has several limitations: we do not have a measure of adherence in our 
patients and since some mutations disappear fairly quickly in the absence of treatment a 
good adherence rate is required to keep the drug levels high so that mutations are 
retained and the virus does not revert back to wild-type422. I performed a sensitivity 
analysis in which was restricted to patients who had several mutations in their virus (i.e. a 
GSS <1) and found confirmatory results to the analysis in 7.4.3. Since all of these patients 
have mutations in their virus they must have been exposed to treatment and so can 
probably be considered to have intermediate to high rates of adherence.
These analyses have not been adjusted for the presence of NRTI mutations or other 
mutations that are present in the predominant virus. A patient falling into any of the 
mutational categories (excluding patients on NRTIs with no NRTI mutations) may have 
had a virus containing NRTI mutations even if they did not have a virus with mutations to 
the main drug class they were receiving. As a result NRTI mutations may have influenced 
the relationship between CD4+ T cell count slopes and the mutational category. When I 
looked at the relationship between the presence of NRTI mutations and CD4+T cell count 
slopes overall, there was a 1.97 (-1.62 to 5.56) cells/pLVmonth smaller decline in patients 
with NRTI mutations present compared to patients without these mutations, but this did not 
reach statistical significance.
The CD4+ T cell count slopes in this study were calculated on the basis of two values and 
so were highly variable. If there was enough data available to include another CD4+ T cell
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count measurement in this calculation it would improve the estimate and decrease the 
variability of the slopes. However, such slopes are of limited use in clinical practice. In 
addition, use of a third CD4+ T cell count measurement would mean it is possible to 
calculate the slope over a time-period that is more distant to the time of the resistance test.
One of the main limitations to this analysis is the inability to separate out the pure 
treatment effect from the effect of mutations. Since these two variables come arm-in-arm 
(i.e. certain treatments are needed to retain certain mutations) it was not possible to 
investigate these two variables separately. Instead I used a composite variable to 
estimate the relationship between the drug, the presence of mutations and CD4+T cell 
count slopes. Because of a high correlation between covariates, our current analysis 
cannot establish definitively whether these differences are attributed to the drugs 
themselves rather than the mutations present.
7.5.5. Conclusion
In conclusion, there was little evidence of a difference in CD4+T cell count slopes for a 
given HIV RNA level (or a given HIV RNA change from the pre-ART value) according to 
the presence of mutations. Certain NNRTI mutations may be associated with greater 
CD4+ T cell count declines, but since this analysis has limited power due to the high 
variability of CD4+ T cell count slopes, further analyses on a larger number of patients is 
required before any firm conclusions can be drawn.
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CHAPTER 8: VIRAL RE-SUPPRESSION AND DETECTION OF DRUG
RESISTANCE FOLLOWING INTERRUPTION OF A SUPPRESSIVE NNRTI- 
CONTAINING REGIMEN 
8. Introduction
As I have discussed throughout this thesis, HIV infected individuals may experience 
resistance evolution in their virus populations as a result of the treatment they are 
receiving. In chapter 6, I showed that there may be an improvement in fidelity and a 
reduction in the replication capacity of viruses containing the M184I/V mutation, because 
presence of this mutation was associated with fewer nucleotide changes in the virus over 
follow-up.
Although there is a postulated reduction in the replication capacity of viruses containing 
some of the rarer NNRTI mutations, the highly resistance-conferring NNRTI mutations 
have little impact on reducing the replication capacity of the virus and are commonly 
selected in clinical practice423. If an NNRTI resistance mutation emerges in the 
predominant virus of a patient who is receiving either efavirenz or nevirapine, the NNRTI 
component of the cART regimen will no longer have any activity against viral replication 
and so there will be no added benefit of retaining the NNRTI in the treatment regimen. 
This is in accordance with the interpretation of most genotypic interpretation systems 
(GISs). Most GISs rule out the use of NNRTIs when certain NNRTI mutations are present 
because of a lack of residual activity of these drugs and the amount of cross-resistance 
within this drug class (section 1.6.2.1 )33:215:220:221:424:425.
Patients who are on a virologically failing NNRTI containing regimen and have an NNRTI 
mutation in their predominant virus population experience steeper CD4+ T cell count 
declines than those who do not show any NNRTI mutations in their predominant virus, as 
demonstrated in chapter 7. If NNRTI mutations are present, the patient may wish to switch 
the NNRTI component of the regimen to a PI or an NRTI in order to restore susceptibility 
to an NNRTI, even if they have a virus containing resistance mutations to these other 
classes of ARVs. If NNRTI mutations are not present, the patient may still wish to interrupt 
the NNRTI component of a regimen for reasons such as virological failure (although this is 
usually indicative of resistance emergence), toxicity, or because they were only using the 
NNRTI in order to avoid mother-to-child HIV transmission.
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Patients with low levels of HIV RNA replication, who wish to switch the NNRTI to an ARV 
from a different drug class, should not be at an elevated risk of experiencing the 
emergence of resistance mutations if they remain on therapy at the time of switching, 
because replication levels should continue to remain relatively low. However, if a patient 
wishes to interrupt all of the drugs in their regimen, and undergo a treatment interruption, 
then resistance emergence may be an issue due to the differing half-lives of ARVs from 
different classes. The best way to interrupt an NNRTI containing regimen and avoid 
resistance emergence has yet to be identified.
8.1. Aims of the chapter
In this chapter I analyse data from a large trial of treatment interruptions (SMART) and 
examine the rates of viral re-suppression among patients who interrupt an NNRTI- 
containing regimen with HIV RNA <400 copies/mL and re-start ARVs in line with the 
protocol -  which mandated re-initiation after experiencing a CD4+ T-cell count drop to 
<250 cells/pL in the SMART trial.
I also describe drug resistance mutations that were observed in the two months following a 
treatment interruption, for patients who were virologically suppressed (i.e. HIV RNA< 400 
copies/mL) on an NNRTI-containing regimen at entry into SMART and discontinued it in 
line with the protocol.
8.2. Literature review
Interruption of cART is associated with an increased risk of AIDS and other conditions 
typically thought to be associated with treatment (i.e. kidney, heart and liver disease) 
compared to continuous therapy, as recently demonstrated in the SMART study426. In 
SMART, patients who were randomised to the discontinuation arm were advised to stop 
therapy when their CD4+ T cell count was >350 cells/pL and re-initiate it again when it was 
<250 cells/pL. Time-guided interruption strategies or strategies using a higher CD4+ T cell 
count threshold may be a safer way to interrupt treatment than the approach used in 
SMART427.
Even though patients are at a higher risk of developing treatment associated events if they 
discontinue cART426, there are still occasional circumstances where a patient may want, or 
need, to interrupt some or all of the ARVs in their regimen. For example, women who take 
ARVs during pregnancy, in order to prevent mother-to-child HIV transmission, may choose
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to discontinue therapy if their CD4+T cell counts or HIV RNA levels prior to treatment 
initiation were not sufficient to lead to a recommendation for continued cART after delivery. 
In addition, in research, trials of interventions such as therapeutic vaccinations have 
employed short-term interruptions as means of measuring the effect of the intervention on 
the viral load upon interrupting. Further, in developing countries there may be 
interruptions in drug supply and this may necessitate an interruption of ARVs.
ARVs have different plasma and intracellular half-lives to each other428: the plasma 
elimination half-lives of nucleoside reverse transcriptase inhibitors (NRTIs) vary from two 
to six hours, although the half-life of FTC is estimated to be approximately ten hours and 
the half-life of TDF approximately 17 hours. Protease inhibitors (Pis) also have short 
plasma elimination half-lives, which are generally less than eight hours, even if they are 
used with ritonavir boosting. Although the newest PI, darunavir, has a marginally higher 
half-life of approximately 15 hours. On the other hand, efavirenz and nevirapine have 
longer elimination half-lives than the other classes of drugs, estimated to be between 30 to 
45 hours.
Given the prolonged half-life of current NNRTIs, there is a concern that simultaneous 
interruption of the drugs in an NNRTI-containing regimen may lead to a period in which the 
patient carries only a single drug. Monotherapy with an NNRTI can lead to viraemia as it 
is unlikely to be sufficient to maintain virological suppression, and consequently there will 
be an elevated risk of drug resistance emergence (section 1.6.1).
The NNRTIs nevirapine and efavirenz have a low genetic barrier, in that only one mutation 
is required in order to confer high-level resistance to the drug, so the consequences of 
resistance development for these drugs are particularly serious. Since the key NNRTI 
mutations are the same for each NNRTI (e.g. the K103N mutation results in resistance to 
all currently approved NNRTIs), it would compromise future use of all NNRTIs if mutations 
to these drugs occurred. This has led to the suggestion that the NNRTI component of a 
regimen could be stopped earlier than other ARVs in the regimen, with or without 
replacement with a protease inhibitor, to avoid the potential for NNRTI monotherapy295.
Although the long half-lives of NNRTIs is an advantage in cART (because less frequent 
dosing is required), these attributes also make them susceptible to the emergence of 
resistance if an NNRTI-containing regimen is not stopped in a manner that minimizes the
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risk of resistance emergence. Limited data are available on the best way to stop an 
NNRTI in order to avoid monotherapy and the potential emergence of drug resistance.
Stopping the NNRTI component of the regimen 5 to 7 days prior to the nucleoside 
backbone has been shown to prevent resistance emergence to NNRTIs427*29. Other 
regimen-switching or cycling studies have also shown a greater virological benefit if an 
alternative method of stopping an NNRTI is used compared to stopping all ARVs 
simultaneously430. Another factor to consider is that the pathway for selecting NNRTI 
resistance mutations differs according to the drug levels just prior to the treatment 
interruption; where drug concentrations close to the lower limit of the therapeutic range are 
associated with resistance emergence of major NNRTI-resistant variants431.
BHIVA (British HIV Association) guidelines recommend that HIV-infected women who stop 
an NNRTI-containing regimen that was started in order to prevent mother-to-child 
transmission, should either continue their nucleoside backbone for another week, or switch 
the NNRTI to a PI and use three ARVs with similarly short half-lives432. Similarly, the U.S. 
Department of Health and Human Services (DHHS) recommend that women who stop an 
NNRTI-containing regimen that was started in order to prevent mother-to-child 
transmission, should continue their nucleoside backbone for a week after interrupting the 
NNRTI component of the regimen433.
The SMART study provided clinicians with guidelines to consider utilising one of two 
different approaches when interrupting a suppressive NNRTI-based regimen as an 
alternative to interrupting all drugs simultaneously (simultaneous-interruption). They could 
prescribe a staggered-interruption (i.e. an interruption of the NNRTI while maintaining 
NRTIs for a longer period); or initiate a Pl-substitution for the NNRTI or as a substitution 
for the entire regimen (switched-interruption). The decision of which approach to adopt 
was done at the discretion of the prescribing local clinician. Clinicians were encouraged to 
employ either a staggered- or switched-interruption over a simultaneous-interruption: 
however, there were still a number of patients who interrupted all ARVs simultaneously. 
Patients who underwent a simultaneous-interruption were compared to patients who 
interrupted an NNRTI using either of the other strategies to increase the power of these 
comparisons.
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8.3. Methods
8.3.1. Study population
Details of entry into the SMART study have been described in 2.1.3. In SMART, 5472 
patients were randomised to either CD4+ T cell count guided treatment interruptions 
(N=2720, the drug conservation (DC) arm), or to continuous therapy (N=2752, the viral 
suppression (VS) arm). The trial was stopped prematurely on 11th January 2006 after the 
an interim analysis showed that not only were more deaths and AIDS-related events 
occurring in the DC arm, but that serious non-AIDS events (cardiovascular, hepatic, renal) 
were also occurring more frequently.
This subgroup analysis investigates patients with HIV RNA <400 copies/mL, who were on 
an NNRTI-containing regimen at their baseline visit and were randomised to the DC arm of 
SMART. Resistance test data prior to study entry was not mandatory for entry so 
information on archived resistance was not available. I assumed that patients with viral 
suppression on a regimen containing an NNRTI at baseline had no NNRTI resistance 
mutations in their virus at baseline. However, this assumption may be flawed, because 
drug-resistant viruses can be selected and replicate during suppressive antiretroviral 
therapy434.
The resistance analysis was restricted to patients who were virologically suppressed at 
baseline, had an elevated HIV RNA (i.e. HIV RNA >1000 copies/mL) in the two months 
following a treatment interruption and had a plasma specimen stored at the the one-month 
or two-month visit. Where available the plasma sample at the one month visit was used, if 
this was not available the two month plasma sample was used instead.
The one to two month time point was selected because, in the presence of monotherapy, 
NNRTI resistance mutations are likely to emerge relatively quickly (section 1.6.S)435. I did 
not choose a longer time point because there would be a greater likelihood that resistance 
mutations which may have emerged during the ‘NNRTI monotherapy period’ might have 
been out-selected by a virus that did not show any resistance mutations. In addition, there 
is a greater chance that patients will have re-started ARVs if a later time point had been 
studied, in which case resistance mutations in the dominant viral species would not be 
directly related to the mutations that emerged during the time of the treatment interruption.
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8.3.2. Laboratory methods
Follow-up visits in SMART were scheduled to take place after one month, two months and 
every two months thereafter for the first year and every four months in the second and 
subsequent years of follow-up. At each visit, patients had their treatment history recorded 
and their CD4+ T cell counts and plasma HIV RNA levels measured. Plasma samples were 
collected for a subset of patients and were used for nucleotide sequencing if HIV RNA 
£1000 copies/mL Sequence data was translated into amino acid substitutions (full or as 
part of a mixture) from a reference clade B strain (i.e. HXB2) for both RT and protease.
8.3.3. Statistical analysis
Baseline and pre-baseline characteristics were examined and compared between patients 
who stopped an NNRTI according to each of the strategies (i.e. stopped all ARVs 
simultaneously (simultaneous-interruption), experienced a staggered stop (staggered- 
interruption) or switched the NNRTI to a PI before interrupting all ARVs (switched- 
interruption)). Baseline covariates include the mode of infection, gender, CDC category, 
race, age, CD4+ T cell count, CD4+ T cell nadir and HIV RNA level. The four categorical 
variables were compared between stopping categories using Chi-squared and Fisher’s 
exact tests. To compare the distribution of normally distributed continuous variables 
between strategies I used ANOVA models, and for skewed continuous variables I used 
Kruskal-Wallis non-parametric tests.
I used two measures of viral load response in these comparisons: 1) whether the first HIV 
RNA that was measured four to eight months after re-starting therapy was <400 
copies/mL; and 2) the time to first HIV RNA < 400 copies/mL. In the first comparison, I 
included all patients who had an HIV RNA measurement taken four to eight months after 
re-starting an NNRTI containing regimen. The proportion of patients with HIV RNA <400 
copies/mL four to eight months after the re-start of therapy was investigated through 
logistic regression analysis.
All patients who re-started an NNRTI containing regimen were included in the second 
comparison, irrespective of whether they had an HIV RNA measurement in the four to 
eight month window. Kaplan-Meier plots were produced and Cox proportional hazards 
analyses were used to investigate the time to viral re-suppression (i.e. HIV RNA <400 
copies/mL) after the re-start of therapy, according to the method of interrupting the NNRTI 
and also according to the NNRTI that was re-started. Patients who did not have an HIV
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RNA measurement in the eight months following the re-start of therapy were treated as not 
having reached an HIV RNA <400 copies/mL
The number and type of resistance mutation (i.e. specific mutations and class of mutation) 
that were observed in patients who had resistance data available was then examined. 
Since the absolute number of specific mutations observed in the predominant virus 
populations of these patients was small, I used Fisher’s exact tests to compare the 
occurrence of new mutations according to the NNRTI-interruption strategy. Unadjusted 
logistic regression analysis was also used. This analysis had limited power so I could not 
perform any multivariable analysis. It should therefore be interpreted as a descriptive 
analysis of the mutations one can expect to see in patients who stop an NNRTI and should 
indicate whether certain mutations are more likely to arise if the NNRTI component of their 
regimen is interrupted in a certain way. All statistical analyses were performed using 
STATA.
8.4. Results
8.4.1. Patient characteristics
Out of the 2720 patients who were randomised to the DC arm of SMART there were 1131 
(41.5%) who discontinued an NNRTI; and 984 (87.0%) of these had an HIV RNA <400 
copies/mL at the start of their treatment interruption. The 984 patients were primarily male 
(76%) and 27% had a CDC category stage C prior to entry in SMART. At baseline, 
patients had high CD4+ T cell counts (median: 649; IQR: 491 to 835 cells/pL) as required 
for study entry, and low HIV RNA levels (median: 1.7; IQR: 1.7 to 2.0 log10 copies/mL) 
(Table 8.4.1.1).
Overall, 719 of the 984 (73.1%) patients re-started an NNRTI-containing regimen during 
follow-up. From these, there were 688 (95.7%) who had at least one HIV RNA 
measurement four to eight months after the re-start (Figure 8.4.1.1). Out of the 719 
patients who re-started an NNRTI containing regimen after a treatment interruption, 670 
(93.2%) re-started a regimen containing the same NNRTI they interrupted: 427 of 434 
(98.4%) patients who interrupted efavirenz re-started with efavirenz; 240 of 281 (85.4%) 
patients who interrupted nevirapine re-started with nevirapine; and three (75.0%) of the 
four patients who interrupted delavirdine re-started with delavirdine.
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The analysis described in this report mainly focuses on patients who interrupted an NNRTI 
and have their means of stopping recorded, because I wanted to investigate the virological 
impact of stopping an NNRTI using different strategies. There were 717 of 984 (72.9%) 
patients who were virologically suppressed when they interrupted an NNRTI-containing 
regimen and have their interruption strategy recorded. There were no differences in 
baseline characteristics between these patients and those who stopped an NNRTI (with an 
HIV RNA <400 copies/mL) but do not have the method of stopping recorded (data not 
shown). Out of the 717 patients who have their interruption strategy recorded, 515 
(71.8%) re-started an NNRTI after their treatment-interruption and have HIV RNA data 
available four to eight months after re-starting therapy (Figure 8.4.1.1).
Baseline characteristics for the 717 patients who had their treatment interruption strategy 
recorded are outlined in Table 8.4.1.1. The only noticeable difference in baseline 
characteristics between stopping strategies was that patients with simultaneous- 
interruption tended to have a higher HIV RNA levels immediately prior to the interruption 
compared to patients in the other interruption arms, p=0.001, even though these 
comparisons were already restricted to patients with HIV RNA <400 copies/mL at baseline.
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Table 8.4.1.1: Baseline characteristics, according to NNRTI interruption strategy
Patients 
with HIV 
RNA<400 
N=984
Patients with interruption strategy recorded (N=717) Patients with resistance data available ( M=141)
Simultaneous
-interruption
N=145
Staggered-
interruption
N=419
Switched-
interruption
N=153
P-vaiue Simultaneous
-interruption
N=61
Staggered-
interruption
N=56
Switched-
interruption
N=24
P-value
Risk group
Same sex 
IVDU
Opposite sex 
Blood products 
>1 risk factor 
Other/Unknown
460 (47%) 
34 (3%) 
339 (34%) 
11 (1%) 
111 (11%) 
29 (3%)
67 (46%) 
2(1%) 
47 (32%) 
3 (2%) 
20 (14%) 
6 (4%)
182 (43%) 
19 (5%) 
163 (39%) 
7 (2%) 
34 (8%) 
14 (3%)
79 (52%) 
1 (1%) 
56 (37%) 
1 (1%) 
13 (9%) 
3 (2%)
0.09 31 (51%) 
0 (0%) 
17 (28%) 
1 (2%) 
10(16%) 
2 (3%)
22 (39%) 
3 (5%) 
21 (38%) 
1 (2%) 
6(11%) 
3 (5%)
11 (46%) 
0 (0%)
4 (17%) 
0 (0%)
8 (33%) 
1 (4%)
0.19
Gender No. Male, (%) 743 (76%) 110(76%) 311 (74%) 123 (80%) 0.31 47 (77%) 41 (73%) 21 (89%) 0.38
CDC category No. C, (%) 268 (27%) 32 (22%) 113(27%) 42 (27%) 0.47 11 (18%) 21 (38%) 7 (29%) 0.06
Race No. (%) 
Black 
White
Other/unknown
231 (23%) 
622 (63%) 
131 (13%)
38 (26%) 
93 (64%) 
14(10%)
74 (18%) 
293 (70%) 
52 (12%)
26 (17%) 
105 (69%) 
22 (14%)
0.17 19(31%) 
36 (59%) 
6 (10%)
26 (46%) 
21 (38%) 
9 (16%)
9 (38%) 
11 (46%) 
4 (17%)
0.22
Age
Mean (95% Cl)
45 
(44, 45)
44
(43, 46)
44
(43, 45)
44
(42, 45)
0.83 45 
(43, 48)
46
(44, 48)
47 
(43, 51)
0.66
CD4+ (cells/pL)
Med (IQR)
649
(491,835)
660 
(492, 923)
648 
(490, 803)
640
(481,823)
0.43 624 
(471, 834)
614 
(462, 750)
643 
(522, 757)
0.61
CD4+ nadir (cells/pL) 
Med (IQR)
230 
(140, 342)
229 
(134, 366)
229 
(150, 323)
223 
(140, 340)
0.84 208
(101,326)
177 
(57, 277)
209
(71,290)
0.26
HIV-1 RNA (log10 cps/mL) 
Med (IQR)
1.7 
(1.7, 2.0)
1.7 
(1.7, 2.3)
1.7 
(1.7, 1.9)
1.7 
(1.7, 1.8)
0.001 1.9 
(1.7, 2.6)
1.7 
(1.7, 2.3)
1.7 
(1.7, 1.9)
0.25
Figure 8.4.1.1: Overview of patients in the DC arm of SMART
Patients in the DC arm of SMART 
N=2720
Not receiving an NNRTI-containing regimen: N=1589
HIV RNA >=400 cps/mL at baseline: N=147
Interrupted an NNRTI-containing regimen: N=1131
With the method of stopping noted: N=777 
(N=174 - all at once; N=445 - staggered stop; N=158 - switched)
With the method of stopping noted: N=717 
(N=145 - all at once; N=419 - staggered stop; N=153 - switched)
HIV RNA <400 cps/mL at baseline: N=984
VIRAL RE-SUPPRESSION ANALYSIS
Re-started an NNRTI under follow-up: N=719 
With method of stopping noted: N=536
i
HIV RNA measurement taken 4-8 months after the re-start: N=688 
With method of stopping noted: N=515
RESISTANCE ANALYSIS
HIV RNA >1000 cps/mL in the two months following a treatment- 
interruption, with the method of stopping noted: N=550 
(N=117 - all at once; N=312 - staggered stop; N=121 - switched)
Follow-up resistance test available: N=141 
(N=61 - all at once; N=56 - staggered stop; N=24 - switched)
8.4.2. Viral re-suppression after re-starting NNRTIs (all patients)
Out of the 688 patients who re-started an NNRTI and have an HIV RNA measurement 
available four to eight months after resuming therapy, there were 601 (87.4%) who 
reached an HIV RNA <400 copies/mL A total of 404 of the 449 (90.0%) patients who re­
started on an efavirenz-containing regimen, 194 of the 236 (82.2%) patients who re-started 
on a nevirapine-containing regimen and all three (100%) of the patients who re-started on 
a delavirdine-containing regimen, reached viral load re-suppression, p=0.012.
Overall, there were 356 (79.3%), 172 (72.9%) and 3 (100.0%) patients who were still on 
efavirenz, nevirapine and delavirdine, respectively, at the time of viral load re-suppression. 
There were 93 (13.5%) who underwent a treatment change between re-starting the NNRTI 
and the four to eight month HIV RNA measurement (defined as a change to any ARV in 
the regimen). Among patients who changed ARVs, 70 (75.3%) achieved an HIV RNA 
<400 copies/mL compared to 531 of 595 (89.2%) patients who continued on the same 
regimen. The OR of an HIV RNA <400 copies/mL was 0.37 (0.21, 0.63) for patients who 
underwent a treatment change compared to patients who continued on the same regimen,
p<0.0001.
When we focus on the 515 patients who had their initial interruption strategy recorded, 
there were differences in the proportion of patients with HIV RNA <400 copies/mL in the 
four to eight months after re-starting therapy. The OR for achieving HIV RNA re­
suppression was 2.22 (1.19 to 4.15) for patients with a staggered- or switched-interruption 
compared to patients with a simultaneous-interruption, p=0.01, indicating a benefit of either 
or both of these two strategies.
In a multivariable logistic regression model adjusted for the presence of a CDC stage C 
disease at baseline, the relationship between interruption strategy and the proportion of 
patients with viral re-suppression was still apparent. The OR for achieving HIV RNA re­
suppression was: 2.00 (1.25 to 3.19) for patients with a staggered- or a switched- 
interruption compared to patients with a simultaneous-interruption, p=0.004; and 0.54 
(0.30 to 0.97) for patients with a CDC stage C disease prior to entry compared to patients 
without, p=0.04.
This was consistent with the results from a Cox proportional hazards analysis exploring the 
time to viral load re-suppression in the eight months after re-starting therapy according to 
the initial method of stopping an NNRTI. In this analysis, the hazard ratio (HR) for
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achieving HIV RNA re-suppression was 1.27 (1.03 to 1.57) for patients with a staggered- 
or switched-interruption compared to patients with a simultaneous-interruption, p=0.03 
(Figure 8.4.2.1). For 21 of 536 (3.9%) patients, an HIV RNA measurement was not 
available in the eight months after re-starting therapy, so these patients were assumed not 
to have an HIV RNA ^t00 copies/mL for the eight months following the re-start of therapy, 
but were still included in the analysis.
In a multivariable Cox model adjusted for gender, the presence of a CDC stage C disease 
at baseline and age, the relationship between interruption strategy and the time to viral re­
suppression was still apparent. The HRs for achieving HIV RNA re-suppression were:
1.29 (1.04 to 1.59) for patients with a staggered-interruption or a switched-interruption 
compared to patients with a simultaneous-interruption, p=0.02; 1.29 (1.06 to 1.57) for 
females compared to males, p=0.01; 0.80 (0.66 to 0.95) for patients with a CDC stage C 
disease prior to entry compared to patients without, p=0.01; and 1.05 (1.01 to 1.10) for 
every five years older at baseline, p=0.01.
Figure 8.4.2.1: Kaplan Meier plots illustrating the time to viral re-suppression according to 
the interruption strategy
Re-supression rates
>x
5 N- 
S °
Baseline 2 months 4 months 6 months 8 months
Analysis time (months)
artdisc = Simultaneous-interruption 
artdisc = Staggered- or switched-interruption
Interruption strategy (No. at risk)
Simultaneous: 101 66 19 12 9
Staggered/switched: 435 231 60 18 10
In the multivariable Cox model, an interaction effect existed between the NNRTI re-started 
and the interruption strategy, suggesting that a relationship between the interruption 
strategy and the time to viral re-suppression only existed in patients who re-started
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efavirenz, p=0.01. From a multivariable model, among patients who re-started efavirenz, 
the HR for achieving HIV RNA re-suppression was 1.74 (1.28 to 2.39) for patients with a 
staggered- or switched-interruption compared to patients with a simultaneous-interruption, 
p<0.0001; whereas among patients who re-started nevirapine, the HR for achieving HIV 
RNA re-suppression was 0.89 (0.62 to 1.26) for patients with a staggered- or switched- 
interruption compared to patients with a simultaneous-interruption, p=0.51.
8.4.3. Detection of drug resistance mutations
There were 141 (18.1%) patients, with HIV RNA <400 copies/mL at baseline, who have 
resistance data available (Figure 8.4.1.1): 61 of these underwent a simultaneous- 
interruption, 56 had a staggered-interruption and 24 had a switched-interruption (Table 
8.4.1.1). This is because plasma was only collected at every visit for a subset of patients 
from the U.S. The remaining patients in SMART had blood samples collected annually.
When I focussed on these 141 patients, there were no significant differences in baseline 
characteristics according to the method of interrupting the NNRTI. Marginally more 
patients with a staggered-interruption had an AIDS defining event prior to entry compared 
to those using other strategies, but this did not reach statistical significance.
At the time of the treatment interruption, there were no differences in risk group, gender, 
the proportion of patients with CDC category stage C or baseline CD4+ T cell count for the 
141 patients who met eligibility for inclusion in the analysis of resistance compared to all 
other patients who interrupted an NNRTI with an HIV RNA <400 copies/mL, although they 
were more likely to be black (i.e. 38% versus 21%), p<0.0001. The CD4+ nadir was also 
lower in the 141 patients who were included in these comparisons (a median (IQR) of 200 
(78, 299) versus 237 (149, 348), p=0.0004) compared to those who were not included.
In the two months following a treatment-interruption, 23 (16%), 18 (13%) and 11 (8%) of 
the 141 patients with resistance data available had an NRTI, NNRTI and/or Pl-specific 
mutation detected, respectively (August/September 2007 IAS-USA mutations lists)436. No 
significant differences were observed in the proportion of class-specific mutations that 
were detected according to the method of stopping the NNRTI (Table 8.4.4.1).
NNRTI mutations were marginally more likely to be detected in the dominant virus of 
patients who had a simultaneous-interruption compared to those who had a staggered- or 
switched-interruption (Odds ratio for the detection of an NNRTI mutation: OR (95% Cl):
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0.57 (0.21 to 1.53) for staggered- or switched-interruption versus simultaneous- 
interruption, p=0.29). In contrast, NRTI mutations were marginally more likely to be 
detected in the predominant virus of patients who had a staggered- or switched- 
interruption compared to patients with a simultaneous-interruption, potentially due to the 
sole use of NRTIs after the NNRTI component of the regimen had been interrupted in 
patients with a staggered-interruption (OR for the detection of an NRTI mutation (95% Cl): 
1.23 (0.49 to 3.05) for staggered- or switched-interruption versus simultaneous- 
interruption, p=0.66). However, neither of these trends reached statistical significance. In 
contrast to expectations, Pl-specific mutations were no more likely to be seen in the 
predominant virus of patients who used a switched-interruption strategy compared to 
patients using other approaches (data not shown).
8.4.4. Detection of specific and class-specific mutations
I then explored the detection of specific resistance mutations and investigated how many 
drugs classes were compromised by the presence of resistance in these patients. No 
significant differences were seen in these comparisons, but the number of mutations that 
were detected overall was small, so I only have limited power to illustrate any differences if 
they truly exist (Table 8.4.4.1). Of note, the 188C/H/L and the 190S/A mutations were 
more commonly seen in patients who stopped all ARVs simultaneously, yet this difference 
did not reach statistical significance.
Table 8.4.4.1: Detection of resistance, according to NNRTI interruption strategy
All patients 
N=141
Stopped all 
ARVs at 
once 
N=61
Staggered
stop
N=56
Switched
before
stopping
N=24
P-value
Follow-up resistance mutations (N, %): 
NRTI mutations 
NNRTI mutations 
PI mutations
23 (16.3%) 
18(12.8%) 
11 (7.8%)
9 (14.8%)
10 (16.4%) 
3 (4.9%)
11 (19.6%) 
7 (12.5%) 
6(10.7%)
3 (12.5%)
1 (4.2%)
2 (8.3%)
0.72
0.35
0.49
Follow-up resistance mutations (N, %):
0 classes
1 class
2 classes
3 classes
102 (72.3%) 
28(19.9%) 
9 (6.4%)
2 (1.4%)
45 (73.8%) 
11 (18.0%) 
4 (6.6%)
1 (1.6%)
37 (66.1%) 
15 (26.8%) 
3 (5.4%)
1 (1.8%)
20 (83.3%) 
2 (8.3%)
2 (8.3%)
0 (0.0%)
0.57
Number of mutations overall (N, %): 
0 
1 
2 
£3
102 (72.3%) 
18 (12.8%) 
6 (4.3%) 
15 (10.6%)
45 (73.8%) 
7 (11.5%) 
3 (4.9%)
6 (9.8%)
37 (66.1%) 
10(17.9%) 
2 (3.6%) 
7(12.5%)
20 (83.3%) 
1 (4.2%)
1 (4.2%)
2 (8.3%)
0.72
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All patients 
N=141
Stopped all 
ARVs at 
once 
N=61
Staggered
stop
N=56
Switched
before
stopping
N=24
P-value
Number of NRTI mutations (N, %):
0 118(83.7%) 52 (85.3%) 45 (80.4%) 21 (87.5%) 0.97
1 6 (4.3%) 2 (3.3%) 3 (5.4%) 1 (4.2%)
2 6 (4.3%) 3 (4.9%) 3 (5.4%) 0 (0.0%)
>3 11 (8.3%) 4 (6.6%) 5 (8.9%) 2 (8.3%)
Number of PI mutations (N, %):
0 130 (92.2%) 58 (95.1%) 50 (89.3%) 22 (91.7%) 0.33
1 8 (5.7%) 1 (1.6%) 5 (8.9%) 2 (8.3%)
>2 3 (2.1%) 2 (3.3%) 1 (1.8%) 0 (0.0%)
NRTI mutations (N, %):
41L 6 (4.3%) 2 (3.3%) 4(7.1%) 0 (0.0%) 0.41
62V 2 (1.4%) 2 (3.3%) 0 (0.0%) 0 (0.0%) 0.65
65R 1 (0.7%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0.99
67N 6 (4.3%) 3 (4.9%) 2 (3.6%) 1 (4.2%) 0.99
69 insertion 1 (0.7%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0.99
70R 8 (5.7%) 2 (3.3%) 4 (7.1%) 2 (8.3%) 0.50
74 V 2 (1.4%) 2 (3.3%) 0 (0.0%) 0 (0.0%) 0.65
75I 1 (0.7%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0.99
116Y 1 (0.7%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 0.57
151M 1 (0.7%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 0.57
1841N 13 (9.2%) 5 (8.2%) 5 (8.9%) 3 (12.5%) 0.86
210W 5 (3.6%) 1 (1.6%) 4(7.1%) 0 (0.0%) 0.20
215Y/F 9 (6.4%) 2 (3.3%) 5 (8.9%) 2 (8.3%) 0.35
219Q/E 5 (3.6%) 2 (3.3%) 2 (3.6%) 1 (4.2%) 0.99
NNRTI mutations (N, %):
103N 5 (3.6%) 2 (3.3%) 3 (5.4%) 0 (0.0%) 0.72
1081 5 (3.6%) 1 (1.6%) 3 (5.4%) 1 (4.2%) 0.49
181 C/I 2 (1.4%) 2 (3.3%) 0 (0.0%) 0 (0.0%) 0.65
188C/H/L 4 (2.8%) 3 (4.9%) 1 (1.8%) 0 (0.0%) 0.52
190S/A 4 (2.8%) 3 (4.9%) 1 (1.8%) 0 (0.0%) 0.52
PI mutations (N, %):
30N 3 (2.1%) 1 (1.6%) 2 (3.6%) 0 (0.0%) 0.78
46I/L 4 (2.8%) 1 (1.6%) 2 (3.6%) 1 (4.2%) 0.67
50L7V 1 (0.7%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0.99
54M/L 1 (0.7%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 0.57
82A/F/U/T/S 1 (0.7%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 0.57
84V 2 (1.4%) 1 (1.6%) 1 (1.8%) 0 (0.0%) 0.99
90M 3 (2.1%) 2 (3.3%) 0 (0.0%) 1 (4.2%) 0.39
Any IAS-USA mutation that is not listed in the above table was not detected in the predominant virus 
populations of patients in our comparisons (i.e. NRTI: 77L, 115F; NNRTI: 1001, 106A/M, 225H, 236L; and PI: 
32I, 33F, 47V/A, 48V, 76V, 88S).
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8.4.5. Pair-wise comparisons
I performed pair-wise comparisons between the three stopping strategies to see whether 
there were differences between any two stopping methods in the overall numbers of 
mutations or the numbers of mutations that were detected to each drug class individually. 
I also investigated the number of drug classes the virus was resistant to using pair-wise 
comparisons. These comparisons did not highlight any significant differences (Figure 
8.4.5.1).
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Figure 8.4.5.1: Pair-wise comparisons between NNRTI stopping strategies
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8.4.6. Virological re-suppression after re-starting NNRTIs (N=141)
Out of the 141 patients with resistance data available, there were 101 (71.6%) who re­
started an NNRTI according to protocol recommendations and have HIV RNA data 
available four to eight months after resuming therapy (42 patients with simultaneous- 
interruption, 40 patients with staggered-interruption and 19 patients with switched- 
interruption): 83 (82.2%) of these patients reached an HIV RNA <400 copies/mL a 
maximum of eight months after the re-start.
Among patients who re-started an NNRTI, significantly fewer patients who had a 
mutation detected in their resistance test (18 of 26 (69.2%)) achieved viral re­
suppression compared to those who did not have any mutations in their resistance 
tests (65 of 75 (86.7%)), p=0.05. The proportion of patients who reached virological re­
suppression after re-starting therapy did not differ according to the type of resistance 
mutations that were present in the resistance test. Six out of 9 (66.7%) patients with a 
virus showing NRTI mutations only, 7 out of 9 (77.8%) patients with a virus showing 
NNRTI mutations and 5 out of 8 (62.5%) patients with a virus showing PI mutations, 
achieved viral load re-suppression four to eight months after re-starting therapy.
8.5. Discussion
8.5.1. Summary of main results
To the best of my knowledge, the SMART study provides the largest database of 
patients who were virologically suppressed on an NNRTI-containing regimen and 
stopped their ARVs according to one of three pre-defined strategies. These data 
enable us to examine the presence of resistance and rates of viral re-suppression 
among patients who re-started an NNRTI following interruption from a suppressive 
NNRTI-containing regimen.
Limited data are available on the best way to stop an NNRTI-based regimen in order to 
avoid monotherapy and the potential emergence of drug resistance. As described in 
section 8.2, stopping the NNRTI component of the regimen 5 to 7 days prior to 
stopping the nucleoside backbone may minimize the risk of resistance emergence to 
NNRTIs427 429.
When I explored virological re-suppression in patients who resumed therapy following a 
treatment interruption the odds ratio for achieving HIV RNA re-suppression was: 2.00 
(1.25 to 3.19) for patients with a staggered- or a switched-interruption compared to 
patients with a simultaneous-interruption, p=0.004. This model was adjusted for the 
presence of a CDC stage C disease at baseline. In a survival analysis, there was also
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a trend for a difference in the time to viral re-suppression according to the interruption 
strategy: fewer patients with simultaneous-interruption reached viral re-suppression 
compared to patients using either a staggered- or switched-interruption, log rank
p=0.02.
8.5.2. Interpretation of results
In the vast majority of cases the NNRTI that was re-started was the same as the 
NNRTI that was interrupted. Therefore, the patterns I observed according to the 
NNRTI re-started can be considered to reflect those of the NNRTI that was interrupted. 
In a multivariable Cox proportional hazards analysis, there was an interaction between 
the NNRTI interruption strategy and the NNRTI that was re-started. Among patients 
who re-started with an efavirenz-containing regimen, those who used either a 
staggered- or switched-strategy to interrupt their NNRTI initially had a higher chance of 
reaching viral re-suppression than patients who used a simultaneous-interruption 
approach. Of note, fewer patients who re-started on a nevirapine-containing regimen 
reached HIV RNA re-suppression compared to patients who re-started on efavirenz, 
irrespective of the interruption strategy.
In general, I have shown that interruption from an NNRTI containing regimen does not 
always result in HIV RNA re-suppression once therapy is resumed. This study has 
provided some evidence that, if a patient is interrupting an efavirenz-containing 
regimen, it is particularly important not interrupt all ARVs simultaneously, but to 
undergo a staggered- or switched-interruption instead. This could well be the case for 
nevirapine as well, even though it was not highlighted as strongly in this study.
Drug resistant variants have been shown to emerge during periods of increased HIV-1 
replication, when drug concentrations are suboptimal295:437'440. Although the absolute 
number of mutations detected in this chapter was small, NNRTI mutations were 
observed in a relatively high proportion of patients two months after a treatment- 
interruption. Even though we cannot exclude the possibility that these mutations were 
present before therapy interruption, these results emphasise the need for treatment- 
interruptions to be performed with caution (and only when essential), in order to avoid 
the emergence of NNRTI-specific mutations and compromise future treatment options.
Among patients who re-started therapy, significantly fewer patients who had a mutation 
in their resistance test achieved viral re-suppression (18 of 26 (69.2%)) compared to 
those who did not have any mutations in their resistance test (65 of 75 (86.7%)), 
p=0.05, re-emphasising the need to interrupt NNRTI-based regimens wisely.
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Overall, the absolute number of reverse transcriptase and protease mutations that 
were detected in this population was small for patients interrupting an NNRTI using 
each interruption method. NNRTI-mutations were less likely to arise after a staggered- 
or switched-interruption compared to patients with a simultaneous-interruption, but the 
number of patients in whom resistance mutations were detected was too small for any 
of the differences to reach statistical significance. Although the trend was not 
significant, a staggered or switched-interruption was still associated with nearly half the 
odds of detecting an NNRTI mutation in the predominant virus population compared to 
a simultaneous-interruption: OR (95% Cl): 0.57 (0.21 to 1.53).
Patients who underwent a staggered- or switched-interruption experienced higher 
levels of PI mutation detection than patients with a simultaneous-interruption, yet still 
Pl-specific mutations were only seen in the predominant virus of only two patients who 
switched to a Pl-containing regimen. It is not known if this is attributable to the 
occurrence of new mutations or to the re-appearance of previously existing PI 
mutations that emerged as a result of re-using a Pl-containing regimen.
Patients who withdraw consent to continue in trials or become lost to follow up are 
likely to remain off treatment until they return to clinical care. These data give us some 
insight into the risk of mutation-development (and hence, the prevalence of resistance) 
in patients who drop out of ARV programmes in developing as well as developed 
countries. They also indicate the likelihood that these patients will experience 
virological suppression if a similar regimen is re-started.
8.5.3. Limitations of the analysis
NNRTI resistance emergence has been associated with NNRTI drug levels prior to the 
treatment-interruption, with drug concentrations close to the lower limit of the 
therapeutic range associated with more resistance emergence431. Additional 
information on drug concentrations as a result of different methods of treatment- 
interruption in the SMART study would help to identify the impact of these strategies on 
drug exposure, but these data were not available in this study. In contrast to the 
observations by Darwich etal it is possible that patients with high NNRTI drug 
concentrations at the time of stopping all of their ARVs simultaneously are at higher 
risk of NNRTI drug resistance mutations emerging than patients with drug 
concentrations that are closer to the lower limit of the therapeutic range.
This analysis only looks at the risk of resistance emergence after a first treatment- 
interruption in SMART. Detailed information on treatment interruptions prior to
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enrolment in SMART is not available for these patients. Repeat interruptions of the 
same regimen could increase the risk of resistance emergence437. Some patients 
show little evidence of resistance emergence in their predominant virus population 
during a first interruption, but an elevated risk after a second or third interruption of the 
same regimen437. Conversely, Arnedo-Valero et al showed that the number of 
mutations did not increase with the number of interruptions441. In SMART, patients 
could re-initiate the same regimen after their treatment-interruption, but since the study 
was terminated prematurely, it was not possible to examine the relationship between 
mutation emergence and further interruption-cycles in more detail.
It is not known whether the mutations observed in this study are attributable to the 
occurrence of new mutations or to the re-appearance of previously existing mutations 
that emerged as a result of a previous regimen. Since all of these patients had a virus 
that was virologically suppressed at baseline it was not possible to perform genotypic 
resistance testing at entry and so there is no information on what mutations were 
present prior to enrolment. The use of highly sensitive assays suggests that drug- 
resistant viruses can be selected and replicate during suppressive antiretroviral 
therapy434, so mutations may already be present in the virus at baseline. As a result 
mutations that emerge during follow-up may already be present in more minor sub­
species at baseline; alternatively, they may be newly developed mutations.
In a similar way to all of the comparisons I have performed so far, this study used 
population sequencing rather than more sensitive methods for identifying mutants that 
are present as minority viral strains, for assessing drug resistance. If ultra-sensitive 
genotyping (e.g. real time PCR, clonal or single genome sequencing) analyses had 
been used, more NNRTI mutations (i.e. low frequency drug resistant variants) may 
have been detected442. Patients may appear to have wild-type strain at the time of their 
resistance test even if mutations in proviral DNA are present439. It is, therefore, 
possible that our data under-estimate the incidence of resistance mutations as a result 
of the treatment interruption439.
Viral re-suppression may be a better indicator of whether resistance has emerged 
during the treatment interruption compared to directly looking for resistance. While, 
theoretically, there is a period of time after the interruption when NNRTI resistance can 
emerge and grow, the wild-type virus is often likely to take over instead. It may take a 
while for the wild-type virus to be suppressed in order to allow the resistant virus to 
become dominant after the same regimen is re-started.
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8.5.4. Conclusion
To conclude, the method of terminating an NNRTI and the NNRTI re-started may 
impact on the chances of viral re-suppression on an NNRTI-containing regimen after a 
treatment-interruption. NNRTI mutations were observed in a relatively high proportion 
of patients two months after a treatment-interruption. While no significant differences 
were observed between stopping strategies in the number, type or class of mutation 
that emerged, there was a consistent trend for more mutations to emerge when a 
simultaneous-interruption strategy was used.
The simultaneous-interruption of all ARVs in a suppressive NNRTI/NRTI containing 
regimen may negatively impact on the response to the future use of ARVs due to the 
emergence of resistance mutations. These data provide further evidence for negative 
consequences of interrupting an NNRTI-containing cART regimen and further support 
the recommendation to avoid interruption entirely. Where such interruptions are 
essential, these data suggest that a staggered- or switched- approach when 
interrupting an NNRTI may reduce the risk of resistance emergence compared to a 
simultaneous strategy.
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CHAPTER 9: CONCLUDING REMARKS
9. General discussion
Current treatment regimens are highly effective at reducing viral replication, improving 
the immune function and extending the life-expectancy of individuals infected with HIV. 
Since 1996 the us\e of combination therapy has led to a dramatic decline in the risk of 
HIV-related morbidity and mortality. As a result, in areas where this therapy is 
available, HIV is now considered to be a chronic condition rather than a fatal disease. 
Yet, over 25 years since the discovery of HIV, we have still not found a cure for it. This 
is because HIV cannot be expunged from latently infected cells - there are continual 
low levels of viral replication and HIV remains present in the pro-viral DNA of resting 
CD4+T cells. So, HIV infected patients are likely to remain infected for the rest of their 
lives
Even though UNAIDS reduced its estimates of global infections by over six million 
(from 39.5 million to 33.2 million) between November 2006 and November 2007, the 
latest figures reflect improvements in country data collection and analysis, as well as a 
better understanding of the natural history and distribution of HIV infection, rather than 
an actual decrease in the global prevalence rates of HIV infection. The total number of 
people living with HIV is still increasing because the number of new HIV infections is 
rising and individuals who are infected with HIV are surviving for longer. Since access 
to treatment is continuing to improve in many areas of the world, resistance emergence 
to available drugs and the transmission of resistance-containing viruses are two key 
public health concerns related to how best to manage HIV-infected populations globally 
in the future.
9.1.1. Summary of main findings
In chapter 3 I examined the emergence of new PR mutations in the virus population of 
patients who were failing a Pl/r containing regimen. Regimens that included a ritonavir 
boosted PI were increasing in popularity when this thesis was started. At the time, it 
was thought that ritonavir boosting would ensure successful viral suppression so large 
amounts of resistance emergence would be prevented. New PI mutations associated 
with reduced viral efficacy emerged in the predominant virus of patients who failed a 
regimen containing any of the Pl/rs studied in the MaxCmin and COLATE trials (i.e. 
IDV/r, SQV/r and LPV/r), but this analysis was substantially under-powered to identify 
any clinically meaningful differences in the rates of mutation emergence if they truly 
existed. Although only nine patients had a virus that acquired a new primary PI 
mutation, the odds of acquiring a new mutation was nearly four-fold higher if a patient 
already had a primary PI mutation present in their virus at baseline.
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In this analysis 59% of the patients were Pl-experienced prior to study entry and so 
may have had PI mutations present in their baseline virus, even if they were not 
identified in their baseline resistance test (i.e. they may have been present in more 
minor species). In addition, Pl-nai've patients with HIV RNA <500 copies/mL at 
baseline may have also had unidentified resistance mutations in their protease gene 
because the gene could not be sequenced due to the low viral load. The mutations 
that were identified in the follow-up resistance tests may be new mutations that occur 
due to sub-optimal use of their treatment regimen, or they may reflect the re- 
emergence of a previously existing mutation. This chapter highlighted some of the 
problems of dealing with viral sub-species that are present in low levels (including virus 
circulating in plasma), which is a problem with the resistance testing methods used in 
all of the chapters.
In chapters 4 and 5 I examined baseline resistance mutations for predicting viral load 
response in patients who were recruited to the MaxCmin and COLATE trials and 
EuroSIDA. I assumed that mutations that were sampled in the majority virus at 
baseline reflected the virus over the first 12 weeks of follow-up. In chapter 3 ,1 
investigated resistance emergence in the predominant viral population of patients who 
were failing a Pl/r containing regimen. Since these patients are patients who have the 
highest risk of experiencing resistance emergence and showed little resistance 
emergence between baseline and the time of failure, the assumption that baseline 
resistance mutations reflect mutations over the short-term (in chapters 4 and 5 where 
patients are at a lower risk of mutation emergence) is likely to be valid.
GISs are used to translate genotypic data into a resistance score that can be applied in 
clinical practice. Many GISs have been created, and there are disagreements between 
them on what mutations confer resistance to certain ARVs, especially for Pl/rs443. In 
these trials I found moderate concordance between the baseline Pl/r resistance levels 
ascribed by four GISs. By comparing different GISs it is possible to improve our 
knowledge on the relationship between specific mutations and viral load response 
under drug pressure from a particular ARV. This analysis highlights that there are 
some mutations which are incorporated into certain GISs but omitted by others. 
However, although there were differences in the interpretation of the genotypic data by 
each of the GISs, there were negligible differences in their abilities to predict HIV RNA 
response after four and 12 weeks follow-up. GISs need to be continually updated with 
the latest developments on resistance emergence to existing ARVs and to new ARVs 
that enter clinical practice.
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In chapter 6 ,1 investigated nucleotide distances over follow-up in the COLATE study. 
Nucleotide distances were compared: between patients who received 3TC and those 
who stopped 3TC; and also according to the presence of the M184V mutation. The 
presence of this mutation was associated with a decrease in the number of nucleotide 
changes that occurred in the major virus population over follow-up, which was not likely 
to be explained by a shift to an archived sub-population. These findings add support to 
other studies that have found a decrease in the replication capacity and an increase in 
the fidelity of viruses containing the M184V mutation. However, it is not possible to say 
with certainty that the results in this chapter reflect the same virus evolving over time. 
This is partly due to the sampling methods that were used in this chapter and the 
changes that occurred in the viral populations over follow-up (such as a shift to an 
archived sub-species). Even though slight differences in nucleotide distances were 
observed between viruses containing M184V compared to viruses in which this 
mutation was not present, the short-term virological benefit of retaining this mutation 
was not apparent in these patients, possibly because they were also receiving several 
active antiretroviral drugs during follow-up. Current treatment guidelines recognise that 
continued use of lamivudine in patients harbouring viruses containing 184V may be of 
benefit, and this is usually done in clinical practice.
In chapter 7 I investigated the relationship between resistance mutations (specific 
mutations and the class of mutation) and immunological response in patients with 
ongoing viraemia, after adjusting for HIV RNA levels and HIV RNA changes. In this 
analysis there was a trend towards more favourable CD4+ T cell count responses if a PI 
mutation was present in the virus and less favourable CD4+T cell count responses if an 
NNRTI mutation was present. One important limitation of this analysis is that it was not 
possible to differentiate between the residual effects of the antiretroviral drug that may 
have selected for the specific mutation. However, since NNRTIs have a lower genetic 
barrier to resistance emergence than Pis, the emergence of a single NNRTI mutation is 
likely to be more virologically and immunologically damaging than the emergence of a 
PI mutation in patients who are using the corresponding drugs.
Patients who cannot tolerate their current cART regimen well may wish to switch one or 
more components or interrupt treatment completely before they experience virological 
failure. Patients who fail a first-line NNRTI containing regimen are significantly more 
likely to experience drug resistance emergence than patients who fail a first-line 
regimen that contains a Pl/r318. In patients who wish to interrupt their treatment 
regimen, interrupting in a way that minimises the risk of prolonged exposure to one 
drug alone, and hence a raised risk of resistance emergence, is important for
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preserving future treatment options. Interrupting NNRTIs using different strategies (i.e. 
a simultaneous interruption strategy, a staggered interruption strategy or by switching 
the NNRTI to a PI before interrupting treatment) was related to resistance emergence 
and viral re-suppression rates in patients who re-started therapy, in chapter 8. No 
significant differences were observed between stopping strategies in the number, type 
or class of mutation that emerged, although there was a trend for more NNRTI 
mutations to appear in the virus of patients who stopped all ARVs simultaneously 
compared to all other strategies.
Overall, treatment interruptions are not recommended, even if they are only used in 
patients who are failing their treatment regimen in order to allow the majority virus to 
revert back to wild-type. In HIV-infected patients who have had multiple virological 
failures and have no therapeutic options available to them, it has been shown that 
significant reversion of resistance mutations after a treatment interruption fails to 
restore antiviral efficacy of a salvage regimen, and is actually clinically harmful173. In a 
study conducted on heavily pre-treated patients, all baseline resistance mutations that 
disappeared during the interruption re-occurred after treatment resumption444.
Although this thesis has highlighted some of the benefits of analysing sequence data, 
resistance data needs to be interpreted with caution. I have already discussed the 
presence of archived resistance species and how erroneous sampling methods can 
lead to incorrect interpretation of the data. An additional problem with interpreting 
resistance data concerns patients who are eligible for resistance testing. Since 
resistance testing is generally only possible if a patient has an HIV RNA >500 
copies/mL (preferably 1000 copies/mL), the results of resistance testing cannot be 
extended to all patients infected with HIV. Resistance tests are usually performed on a 
sub-group of individuals who are starting a new treatment regimen and so will only be 
generalisable to a select group of individuals.
9.1.2. Resistance emergence in relation to new therapy
This thesis evaluates resistance data from observational studies and randomised trials 
in order to increase our understanding about the occurrence and role of drug 
resistance in HIV infection. With the recent introduction of fusion inhibitors, CCR5 
inhibitors, integrase inhibitors and maturation inhibitors there are likely to be new drugs 
available for the foreseeable future. These can be used in patients who have high 
levels of resistance to the three main classes of ARVs because they have different 
resistance pathways and act on the virus at different stages of its replication cycle.
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Raltegravir is the latest ARV to have been approved by the FDA. It was approved by 
the FDA in October 2007 and is the first integrase inhibitors to receive such approval.
In the last two years two new Pl/rs have been approved -  tipranavir (TPV) was 
approved for use in HIV infected individuals in June 2005, which was followed by the 
approval of darunavir (DRV) exactly a year later. Patients with high levels of resistance 
emergence and no treatment options available still have good virological and 
immunological responses on regimens containing these new drugs3231445*448.
A recent study, performed on HIV-1-infected individuals who had no treatment options 
available, showed positive virological and immunological responses over 24 weeks of 
follow-up on a regimen containing both etravirine (the newest NNRTI to enter the 
market) and DRV449. In another study, patients with up to three mutations conferring 
resistance to DRV still had a 50% chance of achieving an undetectable viral load after 
six months of treatment with DRV450, indicating that these newer drugs may be more 
resilient against mutations that occur along the pol gene than the older ARVs. Further, 
these newer drugs also appear to be well tolerated451.
A question that still needs to be addressed is whether Pl/rs, especially with the 
introduction of DRV, should be used in first-line therapy or reserved for later regimens. 
The virological impact of incorporating these new ARVs into regimens containing older 
ARVs or into regimens containing other new ARVs still needs to be evaluated. 
Resistance patterns also need to be documented.
The pursuit of new and novel treatment regimens is ongoing, in particular there is a 
drive to reduce the toxicity and simplify regimens, in order to reduce poor adherence 
and consequent resistance emergence. Single-tablet, fixed dose regimens are likely to 
become the treatment of choice for patients who start therapy452.
9.1.3. Plans for future work
Although only a few mutations emerged in the predominant viral population of patients 
who contributed resistance data to chapter 3, there could be other areas of the HIV 
genome that reflect resistance to these drugs and compromise response to therapy. 
There is growing evidence that gag cleavage site (CS) mutations emerge under PI 
pressure. Already several mutations have been well characterized, and among these, 
the S373P mutation and the I437V mutation have been proposed as independent 
predictors of PI failure. Currently analyses are being performed on the combined 
MaxCmin and COLATE data to assess the emergence of CS mutations and whether
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they have an impact on virological response in these patients. Early analysis suggests 
that CS mutations emerged in 25% of patients who experienced virological failure on 
Pl/r, including 7% who did not experience the emergence of a PR mutation. In line 
with other reports453, these results support the idea of introducing some mutations in 
the gag CS into the GISs used for the interpretation of genotypic data, although the 
relationship between CS mutations and virological failure still needs to be explored in 
more detail in this study.
At the moment there is only marginal concordance between GISs for predicting the 
degree of resistance to the newly approved ARVs. In a recent analysis I investigated 
concordance between GISs in their ascribed resistance levels to both TPV and DRV.
In these analyses, concordance between GISs was fair-to-moderate for determining 
resistance to TPV, but it was poor for DRV; possibly reflecting the longer use of TPV 
and the converging of opinions on resistance mutations for this drug. The level of 
agreement between GISs was also shown to vary by subtype for TPV. The resistance 
levels ascribed by each GIS for TPV and DRV still need to be related to viral load 
changes in patients receiving these drugs. Longer follow-up time is required in order to 
provide enough power for these comparisons.
There has been little change in the frequency of resistant viral strains over time; 
however, there has been an increasing prevalence of non-B subtypes overall and 
among Caucasian individuals454. Because of differences in natural polymorphisms, PI 
resistance could be enhanced in particular subtypes once the relevant major 
substitutions are selected455.
9.1.4. Summary and concluding remarks
Resistance emergence to HIV drugs is a vast area that has only been touched upon in 
this thesis. Although this thesis is not a comprehensive analysis of all aspects of 
resistance emergence, it has highlighted some of the benefits and some of the major 
problems associated with resistance emergence. I hope this thesis will contribute to 
research investigating resistance emergence to new ARVs, and help to understand the 
relationship between different mutations and viral replication further.
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Appendix I: The International AIDS Society (IAS-USA) mutation lists
Volume 1S Issue 4 August/September 2007
Update of the Drug Resistance Mutations in HIV-1:2007
Victoria A. Johnson, MD, Franqoise Brun-Vezinet, MD, PhD, Bonaventura Clotet, MB, PhD, 
Huidrych F. Gunthard, MD, Daniei R. Kurrtzkes, MD, Beenan Pillay, MD, PhD, Jonathan M. 
Schapiro, MD, and Douglas D. Richman, MD
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Appendix IV: Statistical Methods
Regression models 
Linear regression:
Linear regression models are used when we wish to predict the value of a continuous 
variable, y, known as the dependent or outcome variable, from a set of explanatory or 
independent variables; xu x2,x3, ..., xn. We estimate the magnitude of the effect of the 
independent variables on the dependent variable using a sample of observations from 
the population of interest. We assume that the association takes the following form:
y  = or + j8,x , + P2X2 + P3X3 + ... +PnX„ + £
The random error term, e, for each observation is assumed to be independent of all 
other error terms and comes from a normal distribution with expected value (mean) of 
zero, and a variance of a2; i.e. e are mutually independent and are all ~N(0, a2).
Estimates of the parameters a, ft, ft, , ft, are usually obtained using the method of 
least squares or the maximum likelihood methods456. The parameter estimate of a 
predicts the value of y for an observation where all independent variablesxr, x2, ..., xn 
are equal to zero. The parameter estimate for ft gives the impact of a unit increase in 
x, on y when all other independent variables are kept constant.
The impact of the explanatory factor x, on the outcome variable y can be formally 
tested. Here, the null hypothesis is that there is no association between x, and y, i.e. ft 
is equal to 0. A Wald test statistic is calculated by dividing the estimate of ft by its 
standard error. We compare this test statistic to the standard normal distribution to 
obtain a p-value. Furthermore, a 95% Cl for ft can be calculated by adding and 
subtracting 1.96 multiplied by the estimate’s standard error to the estimate of ft.
Censored regression analysis:
A censored variable has a large proportion of its observations at the minimum or 
maximum. In this thesis I have modelled HIV RNA reductions and since, in most 
cases, the HIV RNA value cannot be measured below the lower limit of quantification of 
the assay (i.e. 50 copies/mL), patients with a follow up HIV RNA measurement at the 
lower limit of quantification may have a greater HIV RNA decline than can be 
calculated.
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So, to estimate the magnitude of the effect of the independent variables on the 
(censored) dependent variable using a sample of observations from the population of 
interest, we assume that the association takes the following form:
y* = a  + + p2x2 + P3X3 +•■■ +PnXn + e
This is the same model that is used in simple linear regression analysis, but now y* can 
represent censored observations. So, in the case of HIV RNA reductions, y* is not 
completely observed when y* < 50  copies/mL, yet we still know that y* <50 copies/mL
Because the censored variable is not measured over its entire range, the mean and 
variance of a censored variable will be biased. In addition, ordinary least squares 
estimates of y on x will be biased. Instead maximum likelihood estimates of the 
parameters a, fa, (52, ■■, /3„, can be obtained using other methods. Tobit models allow 
estimation of linear regression models when y has been subject to left censoring, right 
censoring or both457.
Generalised Linear Models
Generalised linear models are a family of regression models that include linear 
regression and logistic regression. Similarly to linear regression, we wish to investigate 
the impact of a set of independent variables on a dependent variable y. However, y no 
longer has to be a continuously distributed variable. Generalised linear models take 
the following form:
/J = a  + /]lxl + P 2x2 + /?3*3 + . . . +  Pnxn + £ 
where
jli  =  linear predictor
a = m
f  (6)  = link function
The random error term, e, for each individual observation is assumed to be 
independent of all other error terms, each has an expected value of zero and the same 
variance.
In the linear regression model, described in the previous section, the link function is 
simply equal to the value of the dependent variable, y, and the error terms are normally 
distributed.
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Logistic regression:
The logistic regression model has been used frequently in the analyses presented in 
this thesis. This section will give a short summary of the statistical ideas that form the 
basis of the model.
Logistic regression models are used when the dependent variable, y, is binary (i.e. it 
can only take the values 0 or 1). Here, the link function is logit(0), where 0 is the 
probability that y is equal to one and logit(0) is the log odds of 0 given by the formula 
loge(0/[1-0]). The estimates of ft obtained from the model give the log odds of the 
impact of a unit increase in x, on the probability that y=1, and the exponential of this 
gives the odds ratio. So, the final model would take the form
logit (0) = loge (0/1-0) = a + f r X i  + p2x2 + •■■PnXn where
0 is the proportion of patients with the outcome
exp(a) is the odds of the outcome in patients without any of the predictors
exp(pj) is the odds ratio of virological failure in patients with the predictor Xj compared to
those without the predictor Xj
The reason for modelling the log odds of the outcome rather than just the proportion of 
patients with the outcome is that log odds can take any value, positive or negative, 
whereas proportions are constrained to lie between 0 and 1. When using statistical 
models it is better to model a quantity that is unconstrained to avoid the possibility of 
predicting impossible values (like proportions that are <0 or >1).
Wald tests and 95% CIs can be calculated in the same way as the linear regression 
case. A Wald test is simply constructed by dividing by the standard error of fy. The 
value of the test is then compared with a standard normal distribution to obtain a p- 
value. If the p-value is <;0.05, it is conventionally accepted that there is enough 
evidence to reject the null hypothesis of no association between Xj and the outcome of 
interest.
The standard error of ft can also be used to construct a 95% Cl around the log odds 
ratio as follows:
95% C.l. for log odds of outcome = ± 1.96 x standard error of ft
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Cox proportional hazards regression models:
We are often interested in calculating the time to the occurrence of an event. When 
some individuals do not experience the event (and perhaps have different lengths of 
follow-up) then we have censored data, as individuals are still at risk of experiencing 
the event in the future. We use survival methods to account for these censored 
data458.
For each individual, we can calculate a hazard, h(t), which is the instantaneous rate of 
having an event at any point in time, t, given that the individual has not experienced the 
event of interest up until this time point. However, we may not be interested in the 
value of the hazard itself, we are often interested in the hazard ratio -  the multiplicative 
effect that a unit increase in a factor of interest has on the hazard. Cox proportional 
hazard regression models take the following form:
h(t) = h0(t)exp(/?1x1 + +...finxn) t >  0
Here, ho(t) is the baseline or underlying hazard. Cox proportional hazard regression 
models make no assumptions on the form of this hazard (and thus the models are 
semi-parametric). However, the models make the proportional hazards assumption; the 
multiplicative impact of factor xr on the hazard remains constant, regardless of the 
current time point.
The parameters /3?, /?2,... /?„, are estimated by maximising the partial likelihood. The 
estimate of exp((3) gives the hazard ratio for factor x,. We can construct hypothesis 
tests to assess the impact of factor x, on the hazard and 95% confidence intervals 
similarly to that described for linear regression models.
Generalised Estimation Equations
Generalized Estimation Equations (GEE) are methods of parameter estimation for 
correlated data. In chapter 6, each patient could have more than one measurement of 
their nucleotide distances from baseline because a baseline resistance test, and more 
than one follow-up resistance test, may have been available. When data are collected 
on the same patient across successive points in time, these repeated observations are 
correlated over time. If this correlation is not taken into account then the standard 
errors of the parameter estimates will not be valid and hypothesis testing results will not 
be reproducable.
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GEE was introduced by Zeger and Liang459 as a method of estimating regression 
model parameters when dealing with correlated data. In addition to specifying the 
distribution of the dependent variable (which must be a member of the exponential 
family), the link function and the independent variables, to define a regression model 
using the GEE methodology one needs to specify the covariance structure of the 
repeated measurements.
In GEEs, the random error terms, z, for each observation are no longer normally 
distributed with an expected value (mean) of zero, and a variance of a2. Instead z are 
correlated using one of the following matrices460:
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Appendix V: Relevant papers
The ability of four genotypic interpretation systems to 
predict virological response to ritonavir-boosted 
protease inhibitors
Zoe V. Foxa,b, Anna Maria Gerettic, Jesper Kjaer3, Ulrik Bak Dragsted3, 
Andrew N. Phillips1*, Jan Gerstoftd, Schlomo Staszewski6, 
Bonaventura Clotet, Viktor von Wyl8 and Jens D. Lundgren3
Background: Limited information exists on the prognostic value of genotypic interpret­
ation systems (GISs) for ritonavir-boosted protease inhibitors (Pl/rs). W e  compared Pl/r 
resistance levels ascribed by four GIS and examined their abilities to predict H IV -R N A  
reductions after starting a Pl/r-based regimen (baseline).
Methods: Data on viraemic (H IV -R N A  >  500 copies/ml) patients starting a Pl/r with a 
baseline resistance test were combined from an observational cohort study (EuroSIDA) 
and three randomized trials (M axC m in l; MaxCmin2 and COLATE). The GIS surveyed 
were ANRS, D M C , REGA and Stanford. Factors associated with H IV -R N A  change were 
identified through censored regression analysis.
Results: W e  included 744 patients, of whom 67%  were PI experienced. At baseline 
1 2 -2 8 %  (depending on the GIS) patients had a virus with predicted resistance/ 
intermediate resistance to the Pl/r initiated. Concordance between GISs on ascribed 
Pl/r resistance levels was moderate: kappa values ranged from 0.01 to 1.00, with the 
lowest kappas seen for amprenavir. The median (interquartile range) baseline H IV -R N A  
was 4.4  (3 .5 -5 .1 )  log10 and was reduced by 2.2 (2 .1 -2 .3 ) lo g 10 12 (9 -1 3 )  weeks after 
baseline. GIS consistently showed greater H IV -RN A reductions as the ascribed level of 
sensitivity to the Pl/r increased. Conversely, the number of other active drugs in the rest 
of the regimen, according to each GIS did not predict H IV -R N A  reductions consistently.
Conclusion: Despite large variations in how GIS classify H IV  susceptibility to Pl/r, all 
GIS predicted H IV -R N A  reductions of a similar magnitude. The ascribed level of 
susceptibility to other drugs in the regimen did not predict H IV -R N A  decline.
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Antiviral Therapy 11:761-770
A randomized trial to evaluate continuation versus 
discontinuation of lamivudine in individuals failing 
a lamivudine-containing regimen: The COLATE trial
Zoe Fox’, U lrik B Dragsted1*, Jan G ersto ft2, Andrew N Phillips3, Jesper Kjaer1, Lars M ath iesen\ 
Mike Youle5, Christine Katlam a6, Andrew H ill7, Johan N Bruun8, Nathan Clumeck9, Pierre Dellamoniea10 
and Jens D Lundgren1 on beha lf o f  the The COLATE study group
’Copenhagen HIV Programme (CHIP), Hvidovre University Hospital, Copenhagen, Denmark
2Rigshospitalet, Copenhagen, Denmark
3Royal Free and University College Medical School, London, UK
4Hvidovre University Hospital, Copenhagen, Denmark
sRoya! Free Centre for HIV Medicine, London, UK
6Hopital de la Pitie-Salpetriere, Paris, France
7Pharmacoiogy Research Laboratories, Liverpool University, Liverpool, UK 
8Ullevai Hospital, Oslo, Norway 
9C.H.U. Saint-Pierre, Brussels, Belgium 
,0H6pital de I'Archet, Nice, France
fSee additional web file for a full list o f The COLATE study group
Background: Lamivudine (3TC) therapy can cause the 
emergence of M184I/V. Previous studies suggest a higher 
fidelity of the mutant reverse transcriptase and lower 
replication capacity of the mutant virus. No data exist 
from clinical comparative studies evaluating the benefit 
of M 184I/V  in patients receiving combination antiretro­
viral therapy (cART).
Methods: H IV -1-infected adults failing a 3TC-containing 
regimen were randomized to continue (0n-3TC) or 
discontinue 3TC (Off-3TC) whilst receiving cART. The 
primary efficacy measure was the log10 average-area- 
under-the-curve-minus-baseline reduction in HIV RNA 
over 48 weeks. Cryopreserved plasma samples from 
patients with baseline and ;*1 follow-up sample with HIV 
RNA >500 copies/ml were sequenced for a nucleotide 
distances substudy. Evolutionary distances were 
compared between treatment arms and between viruses 
with and without M l84 I/V .
Results: The overall 48-week log10 HIV RNA change was 
-1 .4  (950/o Cl: -1 .6 , -1 .1 ) for On-3TC (n=65) and -1 .5  
(95% Cl: -1 .7 , -1 .2 ) for Off-3TC (n=66; P=0.51). No 
difference was seen in the magnitude o f the CD4+ T-cell 
count increases (median increase: 87 vs 76 cells/ml for 
3TC vs 0ff-3TC, respectively). Thirty-seven patients had 
baseline and follow-up sequencing. Overall, there were 
1.2 (95%  Cl: -2 .2 , 4.6) more nucleotide substitutions 
from baseline for Off-3TC patients (P=0.50), and 10.7 
(95%  Cl: 7.5, 14.0) fewer nucleotide changes in viruses 
containing M 184I/V  (P<0.0001).
Conclusion: This study found no added virological or 
immunological benefit of continuing 3TC in patients on 
cART harbouring M184I/V. Evolutionary distances from 
baseline were larger in viruses that did not contain 
M184I/V. More discernable benefits may be seen in 
patients with fewer drug options as potent cART may 
eclipse a benefit o f M 184I/V  in COLATE.
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